{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "#CONVERT PDF TO PLAINTEXT FILES https://euske.github.io/pdfminer/programming.html\n",
    "import pdfminer\n",
    "from six import StringIO\n",
    "import re\n",
    "import sys\n",
    "import os\n",
    "sys.path.append(\"/usr/local/lib/python3.7/site-packages/pdfminer/\")\n",
    "\n",
    "from pdfminer.pdfparser import PDFParser\n",
    "from pdfminer.pdfdocument import PDFDocument\n",
    "from pdfminer.pdfpage import PDFPage\n",
    "from pdfminer.pdfpage import PDFTextExtractionNotAllowed\n",
    "from pdfminer.pdfinterp import PDFResourceManager\n",
    "from pdfminer.pdfinterp import PDFPageInterpreter\n",
    "from pdfminer.pdfdevice import PDFDevice\n",
    "from pdfminer.layout import LAParams\n",
    "from pdfminer.converter import PDFPageAggregator\n",
    "from pdfminer.layout import LAParams, LTTextBox, LTTextLine\n",
    "\n",
    "#CHANGE THESE PATHS TO THE FOLDER WHERE YOU STORE THE DATA\n",
    "Path = \"/Users/phuong/Documents/JBI_paper/Fulltext_Papers_PDFs/\"\n",
    "Output_Path = \"/Users/phuong/Documents/JBI_paper/Fulltext_Papers_Plaintexts/\"\n",
    "\n",
    "#read the PDF files to get plain text full-text\n",
    "filelist = os.listdir(Path)\n",
    "for i in filelist:\n",
    "    if i.endswith(\".pdf\"):\n",
    "        # Open a PDF file.\n",
    "        fp = open(Path + i, 'rb')\n",
    "        # Create a PDF parser object associated with the file object.\n",
    "        parser = PDFParser(fp)\n",
    "        # Create a PDF document object that stores the document structure.\n",
    "        # Supply the password for initialization.\n",
    "        document = PDFDocument(parser)\n",
    "        # Check if the document allows text extraction. If not, abort.\n",
    "        if not document.is_extractable:\n",
    "            raise PDFTextExtractionNotAllowed\n",
    "        # Create a PDF resource manager object that stores shared resources.\n",
    "        rsrcmgr = PDFResourceManager()\n",
    "        # Set parameters for analysis.\n",
    "        laparams = LAParams()\n",
    "        # Create a PDF page aggregator object.\n",
    "        device = PDFPageAggregator(rsrcmgr, laparams=laparams)\n",
    "        interpreter = PDFPageInterpreter(rsrcmgr, device)\n",
    "        extracted_text = ''\n",
    "        for page in PDFPage.create_pages(document):\n",
    "            interpreter.process_page(page)\n",
    "            layout = device.get_result()\n",
    "            for lt_obj in layout:\n",
    "                if isinstance(lt_obj, LTTextBox) or isinstance(lt_obj, LTTextLine):\n",
    "                    extracted_text = extracted_text + \" \"\n",
    "                    extracted_text += lt_obj.get_text()\n",
    "\n",
    "        outputFile = Output_Path + i.replace(\"pdf\",\"txt\")\n",
    "\n",
    "        with open(outputFile,\"wb\") as txt_file:\n",
    "            txt_file.write(extracted_text.encode(\"utf-8\"))\n",
    "            \n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "#GET THE METHODS SECTIONS TO PLAINTEXT FILES\n",
    "from io import BytesIO as StringIO\n",
    "import re\n",
    "import sys\n",
    "import os\n",
    "\n",
    "#CHANGE THESE PATHS TO THE FOLDER WHERE YOU STORE THE FULL-TEXT PLAINTEXT DATA\n",
    "Output_Path = \"/Users/phuong/Documents/JBI_paper/Fulltext_Papers_Plaintexts/\"\n",
    "#Get the text between Methods & Results section \n",
    "filelist_2 = os.listdir(Output_Path)\n",
    "start_pattern = [\" METHODS\",\" Methods\",\" Subjects and methods\",\" Subjects and Methods\",\n",
    "                 \" MATERIALS AND METHODS\",\" Materials and methods\",\n",
    "                 \" METHODS AND MATERIALS\",\" PATIENTS  AND  METHODS\",\n",
    "                 \" PARTICIPANTS AND METHODS\",\n",
    "                 \" SUBJECTS AND METHODS\",\n",
    "                 \" Materials and Methods\"]\n",
    "stop_pattern = [\" RESULTS\",\" Results\",\" RESULTS AND DISCUSSION\"]\n",
    "for i in filelist_2:\n",
    "    if i.endswith(\".txt\"):\n",
    "        with open(Output_Path + i, 'r') as article_plaintext_file:\n",
    "            file_path = Output_Path + i\n",
    "            text_between_Methods_Results = []\n",
    "            recording = False\n",
    "            output_section = []\n",
    "            \n",
    "            for line in article_plaintext_file:\n",
    "                line = line.replace(\"\\n\", \"\")\n",
    "                if recording is False:\n",
    "                    #If the line contains \"METHODS\" header, start record the text, change the flag to \"TRUE\"\n",
    "                    if line in start_pattern:\n",
    "                        recording = True\n",
    "                        output_section.append(line.strip())\n",
    "                elif recording is True:\n",
    "                    #If the line contains \"RESULTS\" header, stop record the text, change the flag to \"FALSE\"\n",
    "                    if line in stop_pattern:\n",
    "                        recording = False\n",
    "                    else:\n",
    "                        output_section.append(line.strip())    \n",
    "                        \n",
    "            #Save the methods section into a text file\n",
    "            #CHANGE THESE PATHS TO THE FOLDER WHERE YOU STORE THE DATA\n",
    "            methods_section_path = '/Users/phuong/Documents/JBI_paper/MethodsSections_Papers_Plaintexts/'\n",
    "            methods_section_file_name = methods_section_path + \"methods_section_\" + i\n",
    "            methods_section_file = open(methods_section_file_name,'w')  \n",
    "            for line in output_section:\n",
    "                line = line.strip()\n",
    "                line = line.replace(\"\\n\", \" \")\n",
    "                line = line + \" \"\n",
    "                methods_section_file.write(line)           \n",
    "            methods_section_file.close()\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "#PREPROCESS TEXT OF THE METHODS SECTION\n",
    "\n",
    "#remove stopword in \"Methods section\" text files:         \n",
    "from nltk.corpus import stopwords \n",
    "from nltk.tokenize import word_tokenize \n",
    "#word_tokenize accepts a string as an input, not a file. \n",
    "stop_words = set(stopwords.words('english')) \n",
    "\n",
    "#CHANGE THESE PATHS TO THE FOLDER WHERE YOU STORE THE DATA\n",
    "Methods_Section_Path = \"/Users/phuong/Documents/JBI_paper/MethodsSections_Papers_Plaintexts/\"\n",
    "filelist_3 = os.listdir(Methods_Section_Path)\n",
    "for i in filelist_3:\n",
    "    if i.endswith(\".txt\") and i.startswith(\"methods\"):\n",
    "        with open(Methods_Section_Path + i, 'r') as file1:\n",
    "            #Preprocess the text from Methods section: eliminate stop words, eliminate numbers.\n",
    "            line1 = file1.read()# Use this to read file content as a stream\n",
    "            line1 = line1.replace(\"- \",\"\")\n",
    "            line1 = re.sub(' +', ' ',line1)\n",
    "            words = line1.split() \n",
    "            methods_section_file_name_filtered = Methods_Section_Path + \"methods_section_filtered_\" + i\n",
    "            for word in words:\n",
    "                word = re.sub(r'\\W+', ' ', word)\n",
    "                word = word.lstrip()\n",
    "                word = word.rstrip()\n",
    "                if not word in stop_words: \n",
    "                    if not re.match(\"^[0-9 ]+$\", word):\n",
    "                        appendFile = open(methods_section_file_name_filtered,'a') \n",
    "                        appendFile.write(\" \"+ word) \n",
    "                        appendFile.close()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to\n",
      "[nltk_data]     /Users/phuong/nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Methods Study quality standards After approval responsible Ethics Committee Federal Institute Drugs Medical Devices BfArM Bonn Germany study EudraCT conducted Clinical Research Center Department Clinical Pharmacology Pharmacoepidemiology University Heidelberg certified according DIN EN ISO9001 2008 It followed standards Good Clinical Practice Declaration Helsinki specific legal requirements Germany Written informed consent obtained participant inclusion Population The participants screened presence functional SLCO1B1 15 haplotype CYP2C9 2 alleles Four groups healthy volunteers enrolled classified follows carriers wild type alleles CYP2C9 extensive metabolizers SLCO1B1 EM wt ii carriers wild type CYP2C9 deficient SLCO1B1 EM def iii poor metabolizers CYP2C9 wild type SLCO1B1 PM wt iv deficient PM def None participants regular drug treatment past months study except oral contraceptives females none taking drugs substances known induce inhibit drug metabolizing enzymes transporters within period less times respective elimination half life Grapefruit juice allowed preceding days start study The participants ascertained good state health basis medical history physical examination routine laboratory testing including screening illicit drugs Women required nonlactating negative pregnancy test use two independent effective contraceptive methods Participants following conditions excluded intolerance study drugs regular smoking excessive alcohol drinking condition could modify pharmacokinetics study drugs investigation allergies except mild forms hay fever hypersensitivity reactions participation another clinical trial within month study moderate severe liver renal impairment blood donation within weeks prior study pulmonary arterial hypertension inability give written informed consent communicate well investigator During whole study smoking alcohol beverages containing grapefruit juice allowed Twenty four hours study day participants allowed drink caffeinated beverages Participants fasted study days received standardized lunch dinner Study design This open monocentre fixed sequence multiple dose study assessing effect clarithromycin bosentan pharmacokinetics dosed steady state relationship CYP2C9 SLCO1B1 genotypes Concurrently intraindividual changes CYP3A4 activity monitored Study conduct The study conducted bosentan steady state account auto induction metabolism Participants started oral bosentan mg daily day Tracleer Actelion Pharmaceuticals Freiburg Germany maintained mg twice daily day day Additionally day day oral clarithromycin _ mg day_1 Klacid Pro Abbott Wiesbaden Germany co administered bosentan On study days plasma samples collected h day also h administration bosentan determine pharmacokinetics bosentan Prior study study days CYP3A activity monitored oral doses mg midazolam using validated limited sampling strategy Genotyping CYP2C9 SLCO1B1 For genotyping CYP2C9 2 rs1799853 CYP2C9 3 rs1057910 SLCO1B1 15 rs2306283 rs4149056 used hybridization format LightCycler480 Roche Applied Sciences Mannheim Germany primers probes published previously Analytical assays Quantification bosentan major metabolites performed validated liquid chromatographyÐtandem mass spectrometry method details see supplementary material The lower limit quantification ng ml_1 bosentan ng ml_1 desmethyl bosentan ng ml_1 hydroxy desmethyl bosentan ng ml_1 hydroxy bosentan Calibration drugs linear coefficients correlation r2 always The within day day to day accuracy precision data quality control bosentan metabolites always within The plasma concentrations midazolam determined validated chromatographyÐtandem mass spectrometry method previously described The calibrated range 0 525Ð150 ng ml_1 midazolam correlation coefficient The lower limit quantification ng ml_1 The accuracies always within corresponding precision coefficient variation Pharmacokinetic analysis statistical evaluation Data presented point estimates confidence intervals CIs unless indicated otherwise Standard pharmacokinetic parameters bosentan midazolam determined using Kinetica Thermo Fisher Scientific Waltham MA USA Peak concentration Cmax directly obtained individual data Area plasma concentrationÐtime curve dosing interval AUC0Ð_ AUC time dosing extrapolated infinity AUC0Ð determined using linear trapezoidal rule The terminal slope concentrationÐtime curve _ calculated linear regression time vs log concentration data The metabolic ratio plasma calculated molar ratio AUC0Ð AUC0Ð_ bosentan divided sum AUC0Ð AUC0Ð_ metabolites The apparent oral clearance bosentan Cl F first repetitive administration calculated dose bosentan divided plasma AUC0Ð AUC0Ð_ respectively Midazolam clearance estimated using partial AUC values previously described The relationship midazolam bosentan clearance changes induced clarithromycin analysed using Spearman rank correlation The nonparametric MannÐWhitney U test used evaluate differences two samples independent observations using Prism GraphPad Software La Jolla CA USA A P value considered significant Assuming impact clarithromycin similar cyclosporine five participants enough detect mean AUC difference power applying t test paired observations unequal variances two sided significance level Due multiplicity issues confirmatory power calculation used assessment influence haplotypes bosentan pharmacokinetics\n",
      "Subjects methods Subjects The subjects eight healthy male volunteers aged 48_years weighing 52Ð78_kg All volunteers gave written informed consent study conducted accordance Declaration Helsinki The subjects negative anti_H pylori immunoglobulin G antibodies SRL Inc Tokyo Japan confirmed 13C_urea breath test Ubit_IR200 Ohtsuka Electronics Tokyo Japan CYP2C19 genotyping DNA samples obtained eight individuals The samples analysed polymerase chain reaction_restriction fragment length polymorphism PCR_RFLP method detect CYP2C19 genotype according previously reported technique 15 It reported two point mutations CYP2C19 gene The wild_type allele G position exon G position exon CYP2C19 One m1 allele mutated alleles A position exon Another mutated allele m2 allele A position exon 4 16 _17 Four individuals genotyped homozygous extensive metabolizers homo_extensive metabolizers two wild_type alleles Another four individuals genotyped heterozygous extensive metabolizers hetero_extensive metabolizers one wild_type allele one m1 allele SRL Inc Tokyo Japan Study protocol The first 24_h intragastric pH monitoring subjects represented pre_treatment period Rabeprazole 10_mg Pariet Eisai Co Ltd Tokyo Japan lansoprazole 30_mg Takepron Takeda Co Ltd Osaka Japan omeprazole 20_mg Omepral Fujisawa Pharmaceutical Co Ltd Osaka Japan administered following day 30_min evening meal agent administered days around time The order administration test agents subject randomized crossover manner The washout periods studies least 2_weeks subject completed study three test drugs within 4_month period Subjects instructed take three meals day dinner 19 00_h breakfast 07 30_h lunch 12 30_h Meals standardized subjects asked keep contents meal similar possible 48_h pH_metry The pH electrode inserted transnasally local anaesthesia positioned fluoroscopically electrode located body stomach 5_cm distal cardia Monitoring performed continuously 48_h 17 00_h time pH electrode changed within 40_min monitoring continued 48_h The gastric pH measured 10_s intervals portable pH meter attached glass pH electrode Chemical Instrument Co Ltd Tokyo Japan The pH electrode calibrated recording using standard buffer solutions pH_1 68 pH_7 00 At end recording data transferred personal computer stored analysed software Chemical Instrument Co Ltd Tokyo Japan The 24_h monitoring period divided daytime 07 00Ð23 00_h night_time 23 00Ð07 00_h periods Statistical analysis A 24_h profile intragastric pH obtained subject baseline days 1Ð3 dosing The mean percentage time intragastric pH_ _3 pH_³_3 holding time calculated subject dosing session suitable intervals daytime 07 00Ð23 00_h night_time 23 00Ð07 00_h All numerical data listed Table_1 given mean_ _s d range Differences pH_³_3 holding time day drug administration compared baseline data using paired t_test Bonferroni method correct multiplicity A P value less _0 05 3 considered statistically significant Statistical calculations performed using SAS software system Table Intragastric pH_³_3 holding time  administration proton pump inhibitors 3_days\n",
      "Methods Ethics study design The study conducted phase clinic Cetero Research Fargo ND March May compliance International Conference Harmonization Good Clinical Practice Health Insurance Portability Accountability Act The protocol informed consent form reviewed approved PRACS Institutional Review Board Fargo ND All subjects informed nature purpose study gave written informed consent screening The study open label randomized four treatment crossover design evaluate effects salt form acetaminophen food single dose pharmacokinetics phenylephrine healthy adults Subjects admitted clinic evening treatment period remained site last blood urine samples collected 24_h dosing Given short half life phenylephrine periods separated least 3 day washout dose Site personnel administered study drug following four treatment sequence randomization During treatments subjects abstained caffeine containing products 24_h study start discharge Standardized beverages meals free grapefruit xanthine containing products Subjects Men women ages years body mass index approximately 18Ð29_kg m2 total body weight 50_kg lb eligible participate deemed healthy medical history physical examination clinical laboratory profile blood chemistry profile hematology urinalysis vital signs 12 lead electrocardiogram ECG Prospective nonsmoking subjects excluded history clinically significant systemic conditions hepatitis B C antibodies human immunodeficiency virus taken prescription nonprescription medications monoamine oxidase inhibitors within days half lives whichever longer dose administration history excessive alcohol use positive urine drug screen known sensitivity allergy phenylephrine Women pregnant nursing excluded Treatments investigational products Commercially available drug products supplied clinic original packages For Treatments A B D subjects administered dose 250_mL water fasting overnight least 10_h remained fasted 4_h dosing These three fasting treatments A single dose 25_mg phenylephrine tannate equivalent phenylephrine HCl 10_mg administered one combination tablet SINA 12X MedPointe Healthcare Inc Somerset NJ phenylephrine tannate 25_mg guaifenesin 200_mg per tablet B single dose 10_mg phenylephrine HCl administered two combination caplets Tylenol Sinus Congestion  Pain Daytime McNeil PPC Lancaster PA phenylephrine HCl 5_mg acetaminophen 325_mg per caplet D single dose 10_mg phenylephrine HCl administered one tablet Sudafed PE Pfizer Inc Morristown NJ For Treatment C following overnight fast least 10_h subjects administered single dose 10_mg phenylephrine HCl one tablet Sudafed PE 250_mL water 30_min start standard high fat breakfast Guidance Industry Pharmacokinetics Sample collection assays Fifteen blood samples 5_mL pharmacokinetic evaluation phenylephrine treatment collected direct venipuncture tubes containing tripotassium ethylenediamine tetra acetic acid anticoagulant Because Treatment A included long acting tannate salt phenylephrine Treatment C would access potential food effects blood sampling times scheduled 8_h dose predose 60_min 8_h Based previous studies phenylephrine HCl rapidly absorbed eliminated blood collections adjusted earlier times Treatments B D predose 60_min 5_h Plasma harvested blood samples stored frozen _70_ C assayed For urine metabolite evaluation subjects completely voided bladders within 20_min dosing treatment period predose aliquot urine collected volume All urine collected throughout 24_h beginning immediately dose administered ending final scheduled void For 24 h interval urine pooled covered container stored refrigerated The total amount collected measured weight thorough mixing aliquots transferred frozen _70_ C assayed Bioanalytical assays conducted PPD Inc Madison WI Plasma samples analyzed phenylephrine unconjugated free base using commercial validated liquid chromatographyÐtandem spectrometry LC MS MS method quantification limits 2500_pg mL PPD Bioanalytical Laboratory The interassay accuracy ranged interassay variability ranged quality control samples run sample analysis Urine samples analyzed phenylephrine unconjugated free base total phenylephrine unconjugated plus enzyme digested conjugates phenylephrine glucuronide 3 hydroxymandelic acid 3 HMA using commercial validated LS MS MS methods PPD Bioanalytical Laboratory 2008a PPD Bioanalytical Laboratory 2008b PPD Bioanalytical Laboratory 2008c The quantification limits 2 0Ð200_ng mL phenylephrine phenylephrine glucuronide 100Ð5000_ng mL total phenylephrine 3 HMA The interassay precision accuracy quality control samples respectively phenylephrine respectively phenylephrine glucuronide respectively total phenylephrine respectively 3 HMA Pharmacokinetic statistical analysis No specific sample size calculation applied study exploratory A sample size subjects considered sufficient describe phenylephrine pharmacokinetics metabolism adequately Phenylephrine pharmacokinetic parameters derived observed individual plasma concentration time data included maximum concentration Cmax time maximum concentration Tmax area plasma concentration time curve extrapolated infinity AUC terminal exponential half life t_ Data analyzed actual sampling times using WinNonlin Version PharSight Mountain View CA noncompartmental methods e g linear log trapezoidal method AUC Concentrations lower limit quantitation occurred Cmax imputed zero missing respectively For urine pharmacokinetic analysis total amounts phenylephrine unconjugated total phenylephrine two metabolites phenylephrine glucuronide 3 HMA excreted urine 24_h quantified Because sulfate metabolite could synthesized assayed directly urine amount excreted estimated indirectly described previously using amount total phenylephrine Gelotte Zimmerman The excreted amounts Ax expressed percentages administered phenylephrine dose PDx using following equation PDx _ _ Ax _mol free base dose _mol x Statistical analyses conducted using SAS Version SAS Institute Inc Cary NC Pharmacokinetic parameters summarized descriptive statistics natural logarithmic transformed AUC Cmax analyzed using mixed effect analysis variance ANOVA The general linear model procedure SAS used ANOVA four treatment crossover design Four factors ANOVA tested effects treatment treatment sequence subjects within sequence study period The ratios least squares geometric means phenylephrine AUC Cmax comparing Treatments A B C Treatment D reference associated confidence intervals __ _0 05 determined Safety For safety monitoring vital signs measured screening study period completion study Safety assessed observed spontaneously reported treatment emergent adverse events throughout study review vital signs blood pressure pulse measurements laboratory values physical examinations\n",
      "Methods Study design This prospective placeboand active controlled open label blinded evaluation randomized three way crossover study The study assessed influence rabeprazole mg day days omeprazole mg day days antiplatelet effects pharmacokinetics clopidogrel mg day days CYP2C19 genotyped non smoking healthy Caucasian male subjects normal basal platelet aggregation testing  aggregation _g mL collagen 1Ð2 mmol L arachidonic acid _M adenosine diphosphate ADP platelet count complete blood count prothrombin time Subjects gave written informed consent participate CYP2C19 genotyping selected basis genotype protocol approved Committee Protection Human Subjects ële de France II French Medicine Agency Subjects randomized based Latin square design receive clopidogrel mg day morning fasting state days three study periods separated drug free period 2Ð3 weeks together placebo mg rabeprazole mg omeprazole given time clopidogrel Platelet function evaluation pharmacodynamics performed day dosing D1H0 day hours last intake study drugs D7H0 D7H4 respectively The pharmacokinetics clopidogrel inactive carboxylic acid metabolite active metabolite determined blood samples taken H0 various times administration last dose clopidogrel concomitant drug either placebo PPI Additional blood samples determination omeprazole 5 hydroxyomeprazole rabeprazole rabeprazole thioether plasma concentrations taken hours postdose day confirm proper exposure PPIs Pharmacodynamic evaluations The primary test assess platelet function based VASP phosphorylation level measured whole blood using flow cytometric assay Platelet VASP Diagnostica Stago Biocytex Asni res France FACScan flow cytometer Becton Dickinson Le Pont de Claix France Results expressed platelet reactivity index PRI calculated mean fluorescence intensity MFI samples incubated prostaglandin E1 PGE1 alone PGE1 ADP simultaneously using following formula MFIPGE1ÐMFIPGE1 ADP MFIPGE1 _ previously described This test Ð also referred VASP index Ð specifically assesses activity P2Y12 receptor target clopidogrel antiplatelet action widely used monitoring responsiveness clopidogrel The percentage change PRI study day last administration study drugs relative baseline i e prior drug administrations percentage change _PRI  D7H0 used primary study endpoint _PRI  relative day also calculated D7H4 Platelet aggregation determined time points used VASP phosphorylation level assessments ADP induced platelet optical aggregometry Biopool Ventura CA USA ADP _M using platelet rich plasma adjusted _ 109 L Inhibition platelet aggregation IPA induced ADP calculated MPA day Ð MPA day 7 MPA day _ MPA maximal platelet aggregation induced ADP Platelet aggregation tests performed TA 8 V optical platelet aggregometer Soderel Medical Heillecourt France within hours sampling subjects Pharmacodynamic evaluations performed blind study period CYP2C19 genotype Pharmacokinetic evaluations Blood samples clopidogrel assay collected mL ethylenediaminetetraacetic acid EDTA vials stored C _L 2 bromo 3_ methoxyacetophenone mM acetonitrile added within seconds sampling stabilize active metabolite Blood samples centrifuged C within minutes stored _80 C assay Clopidogrel clopidogrel carboxylic acid clopidogrel active metabolite omeprazole 5 hydroxyomeprazole rabeprazole rabeprazole thioether extracted plasma solid phase OASIS HLB cartridge mg 1 mL Waters SAS Milford MA USA Chromatographic separation detection compounds performed YMCÐUltraHT Pro C18 analytical column YMC Dinslaken Germany using ultra high performance liquid chromatography coupled tandem mass spectrometry system UPLC Acquity TQD Waters SAS Milford MA USA Limits quantification ng mL clopidogrel clopidogrel active metabolite ng mL rabeprazole rabeprazole thioether ng mL clopidogrel carboxylic acid ng mL omeprazole 5 hydroxyomeprazole Pharmacokinetic variable values calculated using WinNonlin Professional version higher Pharsight Corp Mountain View CA USA The maximum plasma concentration Cmax time occurrence Tmax obtained observed values The area concentration time curve AUC sampled matrix dosing interval calculated linear up log trapezoidal summation The apparent terminal rate constant _z multiple dosing 1 hour determined linear regression terminal points log linear concentration time curve The apparent terminal half life multiple dosing hours determined ln2 _z CYP2C19 genotyping activity The loss of function CYP2C19 variants rs4244285 rs4986893 tested using polymerase chain reaction PCR based specific probe hybridization single base extension 681G A 636G A comprise two common reduced functional variants CYP2C19 2 CYP2C19 3 respectively Subjects CYP2C19 1 1 genotype designated CYP2C19 extensive metabolizer EM subjects The molar omeprazole 5 hydroxyomeprazole metabolic ratio plasma samples hours calculated index CYP2C19 activity In one EM subject ratio calculated blood sample taken hours 5 hydroxyomeprazole detectable hours Statistical analyses Sample size calculated assumption approximately subjects would good antiplatelet responders defined subjects VASP index study day relative study day would decrease ³ expected intrasubject standard deviation differences _PRI ² PRI value day cut off value recently proposed clopidogrel mg daily maintenance dose With assumptions subjects sufficient conclude non inferiority rabeprazole placebo _PRI limit non inferiority  power true difference treatment means equal Pharmacodynamic analyses first performed good antiplatelet responders defined subjects Mixed effect models fitted _PRI data dependent variable sequence treatment period factors subject random effect Ninety percent confidence intervals CIs calculated difference means rabeprazole versus placebo Non inferiority concluded upper limit CI fell This non inferiority limit chosen represents difference omeprazole placebo reported Gilard et al absolute value relative value prompted US Food Drug Administration s warning interaction PPIs clopidogrel Additional post hoc analyses performed compare change VASP index study day relative study day omeprazole rabeprazole relative placebo using Wilcoxon signed rank test good antiplatelet responders Post hoc correlation analyses performed using Pearson s correlation A linear mixed effects model suitable three way crossover design fitted log transformed pharmacokinetic variables CIs ratio mean pharmacokinetic variables clopidogrel constructed using least square means intrasubject variance model The analysis performed clopidogrel active metabolite clopidogrel major carboxylic acid metabolite Bioequivalence considered demonstrated CIs ratios AUC0Ð24 Cmax placebo PPI study periods fell range 80Ð125\n",
      "Methods Clinical Study Procedures Healthy volunteers recruited described Supplemental Material In open label two phase crossover study equal number volunteers completed metformin alone followed metformin plus famotidine treatment sequence n 6 completed treatments reverse order i e metformin plus famotidine followed metformin alone n 6 See Clinical Study Design Fig The interval treatment phases set minimum 7days allow complete elimination study drugs Study day procedures described Metformin Alone Phase Volunteers reported Clinical Research Center CRC San Francisco General Hospital SFGH three day carbohydrate controlled diet 200Ð250 g day overnight fast 10h remained duration visit 48h Vital signs obtained inclusion exclusion criteria confirmed 3h oral glucose tolerance test OGTT g performed morning Day Subjects administered mg immediate release tablet IRT metformin evening Day followed mg IRT 12h later Day On Day fasting 10h second OGTT administered 2h second dose metformin Fig 1b A normal meal schedule standardized carbohydrate controlled meal resumed study days completion OGTT For 12h following second dose metformin volunteers asked drink oz water every 2h maintain urine flow pH A series venous blood samples drawn 2h first metformin dose 24h second metformin dose pharmacokinetic analysis metformin Blood samples collected minutes glucose administration pharmacodynamic analysis glucose concentrations Each blood sample collected heparinized tubes kept ice centrifugation rpm min 4 C Urine samples collected following time intervals pre dose 0Ð12h first metformin dose 0Ð2 2Ð4 4Ð6 6Ð8 8Ð12 12Ð24h second metformin dose Urine volume pH recorded interval Aliquots plasma urine specimens stored _80 C pending bioanalysis Metformin Plus Famotidine Phase Procedures Metformin Plus Famotidine Phase repeated described addition six oral doses famotidine mg total administered course 48h visit A single dose famotidine mg administered 1h prior OGTT Day Multiple dosing famotidine mg given hourly intervals beginning hours second dose metformin morning Day See Study Design Fig 1b Eight additional blood draws mL taken 4h Day single dose pharmacokinetic analysis famotidine Analytical Methods Metformin famotidine concentrations plasma urine concomitantly quantified using liquid chromatographyÐ tandem mass spectrometry LC MS MS The assay included modifications previously reported method follows aliquot clinical sample plasma urine mixed volumes acetonitrile containing internal standards i e metformin d6 metformin phenformin famotidine The mobile phase consisted acetonitrile double distilled water mM ammonium formate mM formic acid v v The assay validated range calibration curve plasma 5Ð2000 ng mL urine 40Ð4000 ng mL famotidine metformin Both intra day inter day assay coefficients variation less analytes Glucose concentrations plasma creatinine concentrations plasma urine determined CLIA certified Clinical Laboratory SFGH For vitro methodology see Supplemental Material Clinical Pharmacokinetics The pharmacokinetic parameters metformin 0Ð24h second dose mg total famotidine 0Ð4h 12h single mg dose evaluated using non compartmental analysis previously described Phoenix WinNonlin Pharsight Certara Company St Louis MO USA Participants treatment periods missing inaccurate urine volumes excluded statistical analysis Since inhibition MATE1 known alter creatinine concentrations famotidine affect glomerular filtration CKD EPI creatinine equation used calculate creatinine clearance CLCR estimate glomerular filtration rate GFR Metformin renal secretion clearance CLRS calculated based estimated GFR using equation CLRS  CLR _ fu á GFR fu fraction unbound metformin plasma Metformin total renal clearance calculated using total amount metformin excreted urine Ae36 divided total area curve AUC36 two doses The plasma AUC36 determined population approach using population pharmacokinetic parameters model previously developed healthy volunteers similar study conditions together integration techniques NONMEM Bioavailability calculated total amount metformin excreted urine estimated infinity divided total dose metformin mg assuming metformin eliminated entirely kidney fe 1 For description pharmacometric modeling simulation methodologies famotidine creatinine see Supplemental Material Statistical Analysis The size study population n 12 calculated allow detection true difference AUC3 glucose power significance level Data presented mean  SEM unless otherwise specified Paired nonparametric StudentÕs t tests used analyze differences metformin pharmacokinetic pharmacodynamic parameters metformin alone versus metformin plus famotidine well genotypes using GraphPad Prism GraphPad Software Inc San Diego CA USA Geometric mean ratios GMR confidence interval CI GMR calculated using Stata StataCorp LP College Station Texas USA estimate clinically relevant differences metformin pharmacokinetic parameters standard bioequivalence boundaries 80Ð125 \n",
      "Methods Subjects Sixteen healthy male subjects aged 20Ð31 years body weight range 51 7Ð72 3 kg eligible participate study The subjects considered healthy based medical interview physical examination vital signs clinical laboratory tests electrocardiogram Written informed consent obtained subject upon entering study Subjects required abstain taking medication without prior consent investigator drinking alcohol smoking consuming food beverages containing grapefruit St John s wort caffeine Study design The study conducted accordance good clinical practice GCP single center Kan nondai Clinic Ibaraki Japan open label randomized two way crossover study The study protocol informed consent documents documents approved institutional review board Kan nondai Clinic Subjects received two treatment regimens random order least 7 day washout period treatments In treatment A subjects received single mg dose pranlukast standard breakfast day This treatment regime designed evaluate pharmacokinetics pranlukast without clarithromycin In treatment B mg clarithromycin Clarith tab 200 Taisho Toyama Pharmaceutical Co Ltd Tokyo Japan administered twice daily morning evening days On day clarithromycin pranlukast coadministered morning standard breakfast The pharmacokinetics pranlukast evaluated day clarithromycin pharmacokinetics evaluated days The pranlukast capsule manufactured accordance Good Manufacturing Practice The capsules containing mg pranlukast manufactured Ono Pharmaceutical Co Ltd Osaka Japan The dose clarithromycin used study maximum dose sinusitis patients according Japanese label Pharmacokinetic sampling On day pharmacokinetic evaluation blood samples mL collected hours postpranlukast administration order measure plasma concentrations pranlukast metabolites HM 1 HM 2 M 1 M 1 S Blood samples mL used measure clarithromycin plasma concentrations collected hours post treatment In addition clarithromycin blood samples collected drug administration days Samples collected tubes containing sodium heparin centrifuged plasma harvested stored _209C analysis Assays pranlukast four metabolites plasma Plasma concentrations pranlukast metabolites except M 1 S measured simultaneously using validated LC MS MS analytical procedure Briefly mL plasma transferred glass tubes mL internal standard IS solution mL mol L potassium dihydrogen phosphate added The analytes extracted mL ethyl acetate After centrifugation g min organic layer transferred new glass tube evaporated dry 409C gentle nitrogen stream The solution reconstituted mL mmol L ammonium acetate acetonitorile v v filtered mm membrane type W MR Kurabo Osaka Japan mL aliquot injected LC MS MS The LC MS MS system consisted separation module Waters Milford USA API4000 Applied Biosystems Foster USA Discovery RP Amide C16 mm 2 1_150 mm Supelco Bellefonte USA used separation kept 309C The flow rate mL min acetonitorile mmol L ammonium acetate used mobile phase A B respectively step gradient separation The ratio mobile phase A follows 0Ð4 5 min 4 5Ð5 5 min 5 5Ð10 min A negative MRM detection mode used MRM transitional pairs follows pranlukast 480Ð424 M 1 496Ð292 HM 1 496Ð292 HM 2 494Ð292 IS 494Ð438 The retention time analyte min pranlukast min M 1 min HM 1 min HM 2 min IS The calibration curves pranlukast metabolites linear concentration range ng mL Intraand inter day precision CV analyte within accuracy RE within To examine M 1 S mL plasma incubated sulfatase Type H 1 Helix pomstia Sigma 379C min hydrolyze M 1 S M 1 After hydrolysis M 1 concentration measured described The plasma levels M 1 S calculated subtracting M 1 concentration obtained without hydrolysis hydrolysis Assays clarithromycin plasma A validated LC MS MS method used examine clarithromycin plasma Briefly mL plasma mL IS roxithromycin solution mL methanol acetonitorile v v mixed After centrifugation mL supernatant transferred polypropylene tube containing mL vol acetic acid A mL aliquot injected LC MS MS consisting autosampler SIL HTc Shimadzu Kyoto Japan pump LC 10ADvp Shimadzu column oven CTO 10ASvp Shimadzu API4000 ZORBAX Extend C18 mm 2 1_50 mm Agilent technologies Palo Alto USA column used kept 409C vol acetic acid acetonitrile methanol v v used mobile phase A B respectively step gradient separation The ratio mobile phase A follows 0Ð1 min 1Ð4 min 4Ð7 min The flow rate set mL min min min mL min min mL min min A positive MRM detection mode used MRM transitional pairs follows clarithromycin 748Ð158 roxithromycin 838Ð158 The calibration curves clarithromycin linear concentration range ng mL Intraand inter day precision CV within accuracy RE within Pharmacokinetic analysis The area plasma concentration versus time curve hours infinity AUC0Ð12 clarithromycin AUC0Ð pranlukast estimated using linear trapezoidal rule The peak plasma concentration Cmax values time associated maximal concentration tmax obtained data The elimination rate constant lz calculated slope linear regression log transformed concentration values versus time terminal phase The elimination halflife t1 2 calculated 0 693 lz These parameters calculated using WinNonlin Professional Ver software Pharsight Mountain View USA Statistical methods A power analysis performed calculate number subjects necessary show change AUC0Ð Cmax pranlukast power significance level p¼0 05 The reference test treatments pranlukast alone pranlukast clarithromycin respectively An ANOVA performed pranlukast logtransformed AUC0Ð Cmax treatment fixed effect subject random effect The results expressed test reference ratio geometric means confidential interval CI All statistical analyses performed using SAS software program version SAS Institute Japan Tokyo Japan Safety tolerability The following safety assessments performed prior dosing regular intervals post treatment adverse event reports clinical laboratory tests hematology blood chemistry urinalysis vital signs blood pressure heart rate respiration rate body temperature physical examination body weight 12 Lead ECG continuous Lead II ECG monitoring\n",
      "Methods Subjects We conducted pharmacokinetic study approved University Pittsburgh Institutional Review Board healthy subjects men women ³ years age body mass index  kg m2 provided informed consent Exclusion criteria abnormal bone marrow function renal dysfunction proteinuria estimated creatinine clearance  mL min 1 73 m2  impaired hepatic function liver enzymes bilirubin  normal upper limit QTcF  msec screening ECG using QTcF formula electrolyte abnormality e g hypokalemia hypomagnesemia hypophosphatemia hyperkalemia hypocalcemia hyponatremia pregnancy breast feeding use medications including over the counter products herbal products mineral supplements within two weeks start study use investigational new drug within days start study Daily multivitamin preparations oral contraceptives women allowed Study design The study 2 period open label randomized cross over fixed sequence design power detect difference nilotinib AUC type I error assuming within subject variability In one phase subject received Tawbi et al Page Cancer Chemother Pharmacol Author manuscript available PMC November NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript mg nilotinib Tasigna Novartis Pharmaceuticals Corp East Hanover NJ p o mL water phase mg calcium carbonate X Tums Ultra administered p o minutes prior nilotinib dose The two nilotinib doses separated wash out period least days On treatment days subjects fasted midnight night dosing hour dosing approximately AM time received light breakfast At approximately AM subjects given light snack approximately PM subjects could eat per normal schedule Water allowed ad libitum While participating study subjects could consume alcoholic caffeine containing beverages h prior screening visit h prior day dosing end PK sampling Also subjects could consume grapefruit grapefruit juice star fruit h prior dosing end PK sampling Pharmacokinetic sampling bioanalysis Venous blood samples N 13 per subject mL drawn indwelling catheter heparinized Vacutainer tubes h nilotinib administration Blood samples centrifuged C x g min resulting plasma aspirated stored _20 C analyzed Plasma samples analyzed nilotinib using FDA validated LC MS method stable isotope internal standard previously developed validated laboratory range 5Ð5000 ng mL 12 Pharmacokinetic data analysis The nilotinib plasma pharmacokinetic parameters determined standard noncompartmental methods PK Solutions Summit Research Services Montrose CO www summitPK com The maximum concentration Cmax time reach maximum concentration tmax determined visual inspection plasma concentration versus time curves The nilotinib elimination rate constant ke  obtained using nonlinear least square regression terminal concentration versus time data The nilotinib area concentration versus time curve AUC calculated trapezoidal rule extrapolation infinity AUC0Ð The percentage AUC0Ð extrapolated beyond last sample time Clast indicating fraction AUC0Ð based plasma determinations calculated Ideally percentage extrapolated Statistical analysis Whether calcium carbonate significant effect pharmacokinetics nilotinib determined SPSS Windows SPSS Inc Chicago IL Pharmacokinetic parameters day day compared using two tailed exact Wilcoxon signed rank test Data considered significantly different p  The presence sequence effect assessed Wilcoxon rank sum test R version We also performed analysis bioequivalence calculating confidence intervals nilotinib AUC ratio Cmax ratio based log transformed data Equivalence limits defined 80Ð125\n",
      "Methods Patients Samples After parental permission obtained DNA isolated whole blood saliva available children participating pharmacokinetic study pharmacogenetic analysis adequate post dose PK data PK visit available subjects female male included population PK analysis Figure DNA isolated using QIAamp DNA Mini Kit Qiagen Valencia CA Division Clinical Pharmacology Toxicology Therapeutic Innovation Children s Mercy Kansas City Quality assessed agarose gel electrophoresis DNA concentration determined spectrophotometrically NanoDrop instrument time isolation Genotyping DNA samples genotyped Canadian Pharmacogenomics Network Drug Safety CPNDS British Columbia Children s Hospital Research Institute Vancouver BC Canada SNPs using customized Illumina GoldenGate SNP genotyping assay Illumina San Diego CA designed capture genetic variation key genes involved drug absorption distribution metabolism excretion ADME including phase I II drug metabolism enzymes drug transporters drug targets drug receptors transcription factors ion channels disease specific genes All SNP genotype data manually clustered using GenomeStudio software Illumina The SNPs could clustered excluded analyses leaving total SNPs The ADME panel consisted coding SNPs identified literature review database queries cause nonsynonymous synonymous amino acid changes associated changes enzyme activity function The panel also consisted tag SNPs identified using ldSelect algorithm select maximally informative set tag SNPs assay candidate genes The tag SNP selection performed using data International HapMap project included four populations CEU CHB JPT YRI threshold LD statistic r2 minor allele frequency The concordance genotype calls replicate genotyped samples greater n  If call rate sample sample excluded analysis genotyping repeated samples failing threshold first attempt The average genotyping call rate samples Of SNPs passing quality control deviated Hardy Weinberg equilibrium p 0 05 excluded analysis leaving total analysis statistical associations PK drug response outcome variables Pharmacokinetic Outcome Measures Estimates uncorrected apparent oral baclofen clearance CL F apparent oral baclofen clearance corrected body weight L h kg population PK analysis provided primary outcome measures exploratory pharmacogenetic investigation For cohort n 49 mean  SD uncorrected CL F  L h median L h range L h weight corrected CL F varied approximately 5 fold L hr kg mean  SD  L h kg median L h kg Allometrically scaled apparent oral clearance data also provided mean  SD  L h kg0 529 median L h kg0 529 range L h kg0 529 6 Clinical Outcome Measures Spasticity primarily assessed baseline follow up PK visit using Modified Tardieu Scale MTS The severity resistance stretch evaluated using Tardieu scale score TSS angle spastic catch R1 evaluated using manual electronic goniometers clear catch TSS 2 found Improvement Ashworth Scale also assessed Hamstring measurements available subjects Assessment genetic variants associated clinical response determined using following clinical endpoints improvement mean hamstring MTS score baseline visit PK study visit improvement mean hamstring MTS angle spastic catch R1 baseline visit PK study visit measured degrees using manual electronic goniometer To calculate improvement original visit mean change scores rescaled positive improvements indicate reduction spasticity baseline Statistical Analysis A univariate analysis conducted determine association outcome variable corrected oral clearance drug response SNP Continuous outcome variables analyzed analysis variance testing compare means variables genotype Categorical variables analyzed Fisher s exact test compare percentage risk outcomes genotype Multiple tests adjusted false discovery rate FDR Tests adjusted p value FDR less considered statistically significant Statistical analyses conducted SAS software version JMP version SAS Institute Inc Cary NC\n",
      "Methods Subjects Healthy non smoking men women within ideal body weight height gender Metropolitan Life Scale regarded eligible participate study Subjects excluded met one following criteria pregnancy breast feeding history hypersensitivity reactions protease inhibitors quinine similar agents mefloquine chloroquine quinidine quinolones serum creatinine times upper limit normal liver function test three times upper limit normal evidence history physical examination gastrointestinal psychiatric cardiovascular neurological disorders Electrocardiograms also recorded All subjects gave written informed consent study protocol received approval Obafemi Awolowo University Teaching Hospitals Research Ethics Board Radiation Safety Committee Six men four women certified healthy doctor A R O team completed study The mean  SD age weight subjects  years range 22Ð29  kg range 60Ð71 respectively None received drugs least month study Study design drug administration blood sampling This open label three period pharmacokinetic nonrandomized sequential design study A scheme depicting study design presented Figure In period overnight fast single oral doses mg quinine sulphate two tablets mg quinine sulphate Wockhardt UK Ltd Wrexham UK given volunteers Blood samples ml withdrawn venepuncture forearm subject prior h drug administration heparinized tubes baseline quinine pharmacokinetics evaluation The blood samples immediately centrifuged g min separate plasma stored _20 C analysis quinine 3 hydroxyquinine In period wash out period weeks volunteers received oral doses mg ritonavir two capsules Medavir mg Cipla Ltd Mumbai India every h doses Blood samples ml taken 13th dose i e day h h within dosing interval ritonavir baseline pharmacokinetics The blood samples drawn heparinized tubes centrifuged g min plasma stored _20 C analysis ritonavir In period without allowing wash out period subjects continued mg ritonavir every h five additional doses A single 600 mg quinine sulphate oral dose given concurrently 15th ritonavir dose day subjects blood samples collected h evaluation pharmacokinetics quinine ritonavir presence No drugs alcohol allowed taken throughout duration study Drug analysis The concentrations ritonavir quinine major metabolite 3 hydroxyquinine plasma determined using new ion pair reversed phase high performance liquid chromatographic method recently developed laboratories simultaneous analysis three compounds human plasma This involved simple extraction diethyl ether alkaline conditions Chromatographic separation achieved 5 µm particle size C 18 column _ mm i d using mobile phase consisting methanol acetonitrile 0 02 M potassium dihydrogen phosphate containing mmol l_1 perchloric acid pH pumped column flow rate ml min_1 Retention times ritonavir 3 hydroxyquinine quinine internal standard pyrimethamine min respectively The limits detection validated lower limits quantification ng ml_1 ritonavir corresponding values ng ml_1 quinine 3 hydroxyquinine respectively The coefficients variation intraday interday analysis ranged quinine 3 hydroxyquinine ritonavir The absolute recovery three compounds Our laboratory participate external quality assessment programme ritonavir quinine Data statistical analysis The peak plasma concentrations Cmax time reach peak concentration Tmax noted directly concentration vs time profiles quinine 3 hydroxyquinine ritonavir Other pharmacokinetic parameters calculated individual plasma concentration vs time profiles employing standard noncompartmental methods For example total area plasma concentration vs time curve AUCT determined using linear trapezoidal rule last datum extrapolation infinity The area last datum point Ct infinity obtained Ct _ _ elimination rate constant calculated linear regression analysis terminal phase log concentrationÐtime profile The elimination half life T1 2_ oral plasma clearance CL F evaluated ratios 0 693 _ dose AUCT respectively The pharmacokinetic calculations done using pharmacokinetic program package WinNonlin Standard Edition Version Scientific Consultant Inc Apex NC USA In model option noncompartmental analysis linear trapezoidal rule used calculation area curve AUC The Wilcoxon matched pairs signed ranked test used evaluate difference pair data i e effects quinine ritonavir pharmacokinetics effect ritonavir 3 hydroxyquinine disposition Results recorded mean  SD In value P  considered statistically significant\n",
      "Methods The study design enrollment criteria clopidogrel PK PD statistics described detail Online Appendix To eliminate variables known influence clopidogrel and or PPI metabolism homozygous CYP2C19 extensive metabolizer genotype healthy subjects enrolled confined clinical research unit\n",
      "Methods Clinical trial The current investigation independent part omeprazole dose_finding study Caucasian infants gastroesophageal reflux This study designed accordance legal requirements Declaration Helsinki The study protocol approved Ethics Committee Comit de Protection des Personnes H pital Saint Louis Paris France registered ClinicalTrials gov registry No NCT01657578 Informed consent forms obtained patients parents guardians Omeprazole administered daily morning According Bayesian approach five doses omeprazole initially selected 1Ð3 mg kgÐ1 dayÐ1 Pharmacokinetic samples obtained h administration first dose Analytical method omeprazole metabolites The analytical method omeprazole metabolites adapted Rezk et al Briefly plasma concentrations omeprazole 5_hydroxy_omeprazole omeprazole sulfone determined high_performance liquid chromatography ultraviolet detection The calibration curve ranged ng mlÐ1 omeprazole ng mlÐ1 5_hydroxy_omeprazole omeprazole sulfone The interday intraday coefficients variation CVs controls omeprazole 5_hydroxy_omeprazole omeprazole sulfone respectively The lower limits quantification LOQ associated interday intraday CVs ng mlÐ1 omeprazole ng mlÐ1 5_hydroxy_omeprazole ng mlÐ1 omeprazole sulfone Genotyping DNA extracted using QIAmp DNA Blood Mini Kit Qiagen Chatsworth CA USA whole blood sample A Nanodrop spectrophotometer Labtech Palaiseau France used quantify DNA concentration TaqMan allelic discrimination technique 3__minor groove binding quencher probes ABI Prism Applied Biosystems Foster City CA USA used perform CYP2C19 http www guidetopharmacology org GRAC FamilyDisplayForward familyId 152 768 genotyping For CYP2C19 polymorphisms primers probes obtained Applied Biosystems CYP2C19 2 rs4244285 CYP2C19 17 rs12248560 For ABCB1 polymorphisms C3435T rs28365046 G2677T A rs2032582 C1236T rs1045642 design primers probes determination technical conditions carried laboratory previously reported Population pharmacokineticÐpharmacogenetic modelling omeprazole metabolites Nonlinear mixed effects modelling program NONMEM V Icon Development Solutions USA used pharmacokinetic analysis The estimation pharmacokinetic parameters variabilities carried using first_order conditional estimation method interaction option An exponential model selected estimate interindividual variability pharmacokinetic parameter could expressed follows _i  _mean e_i _i represent individual pharmacokinetic parameter value ith subject _mean _i typical value parameter population variability subjects assumed follow normal distribution respectively Covariate analysis used forward backward selection method The stepwise covariate modelling likelihood ratio test used evaluate potential impact variable pharmacokinetic parameter During forward selection step covariate included model significant P  _2 distribution one degree freedom decrease reduction objective function value OFV base model achieved Then significant covariates added simultaneously full model At backward selection step contribution significant covariate removed one one full model retained final model significant increase OFV obtained Both graphical statistical criteria used model validation Goodness_of_fit plots including observed DV vs population PRED individual prediction IPRED conditional weighted residuals CWRES vs time PRED generalized based model parameters diagnostic purposes The stability performance final model also evaluated nonparametric bootstrap re_sampling replacement times using PsN v2 30 Then estimated parameters bootstrap procedure compared estimated original data set The final model also assessed normalized prediction distribution errors NPDE One thousand simulation performed using final model parameters NPDE results shown graphically NPDE R package v1 2 including QQ_plot histogram NPDE The NPDE assumed follow normal distribution The predictive performance final model evaluated external validation independent group neonates young infants n  number samples  The individual concentration patient predicted Bayesian estimation method ÔMAXEVAL  0Õ ESTIMATION step using NONMEM Prediction error PE calculated using following equation PE  individual predicted concentrationÐmeasured concentration measured concentration Nomenclature targets ligands Key protein targets ligands article hyperlinked corresponding entries http www guidetopharmacology org common portal data IUPHAR BPS Guide PHARMACOLOGY permanently archived Concise Guide PHARMACOLOGY\n",
      "Methods Study site The study conducted January June Infectious Diseases Institute IDI Uganda Heart Institute Mulago Hospital Kampala Uganda Study design population This two arm parallel study assess pharmacokinetics single dose artemether lumefantrine co administered without lopinavir ritonavir based ART HIV infected patients without malaria Patients eligible participate older years evidence systemic illness indication medications known potential drug interactions study drugs Patients abnormal cardiac liver renal function positive blood smear malaria pregnant mothers reported use herbal medication excluded Ethical considerations The study approved Uganda National HIV AIDS Research Committee ARC Uganda National Council Science Technology HS registered ClinicalTrials gov NCT Study procedures explained participants local languages Each participant received information leaflet take home All participants provided written informed consent prior study entry Study procedures conducted accordance principles Good Clinical Practice Study procedures Patients screened enrolled consecutively cohort patients attending IDI The artemether lumefantrine plus lopinavir ritonavir arm consisted HIV positive patients stable mg lopinavir ritonavir plus two nucleoside reverse transcriptase inhibitors NRTIs taken twice daily least month The artemether lumefantrine arm consisted HIV positive ART naive patients started ART yet eligible ART according national guidelines Patients arms took co trimoxazole daily prophylaxis opportunistic infections Adherence study drugs assessed using self report pill count clinical visit On evening prior study day participants reminded study day appointment given detailed instructions eat food lopinavir ritonavir arm reminded administer ART pm arrive hospital fasting state On morning study day patients admitted Heart Institute Blood smears malaria parasites performed patients found positive smears given standard six dose course artemether lumefantrine excluded study A 12 lead electrocardiograph ECG monitor attached continuous cardiac function monitoring An indwelling intravenous catheter inserted following aseptic techniques blood samples drawn determination pre dose concentrations artemether dihydroartemisinin lumefantrine A standardized breakfast added fat cater fat requirement artemether lumefantrine absorption administered 21 The intake breakfast study drugs directly observed study staff All patients took single dose four tablets equivalent mg artemether lumefantrine Coartem Novartis Pharma AG Basel Switzerland Batch number F0660 water immediately breakfast Patients lopinavir ritonavir arm took mg lopinavir ritonavir Aluvia Abbott Laboratories USA plus two NRTIs study artemether lumefantrine dose The NRTI combination consisted zidovudine plus didanosine tenofovir plus emtricitabine Sampling performed h post artemether lumefantrine dosing An aliquot mL blood collected per sampling time lithiumÐheparin tubes Samples centrifuged immediately min plasma separated stored immediately _70 C shipment dry ice Clinical Pharmacology Laboratory Mahidol Oxford Tropical Medicine Research Unit Mahidol University Bangkok Thailand measurement artemether dihydroartemisinin lumefantrine plasma concentrations Safety assessment Medical history physical examination routine clinical laboratory tests ECG urine screens pregnancy performed screening On study day medical history physical examination blood smears malaria parasites performed Standard 12 lead ECGs recorded screening immediately prior dosing continuously h post dose artemether lumefantrine daily days thereafter Participants monitored adverse events weeks post sampling onset duration severity relationship trial drugs noted Artemether dihydroartemisinin lumefantrine plasma concentration measurement Artemether dihydroartemisinin concentrations measured using solid phase extraction liquid chromatography mass spectrometry 22 Total assay coefficients variation dihydroartemisinin artemether analysis less quality control levels The lower limit quantification ng mL limit detection ng mL drugs 22 Lumefantrine concentrations determined using solid phase extraction liquid chromatographic assay ultraviolet detection 23 The coefficient variation less quality control levels The lower limit quantification ng mL limit detection ng mL 23 Analytical pharmacokinetic methods Non compartmental analysis performed using WinNonlin Professionalª software version Pharsight Corp Mountain View CA USA Pharmacokinetic parameters included observed maximum concentration Cmax time Cmax Tmax area plasma concentrationÐtime curve zero last observation AUC0 last area plasma concentration time curve zero extrapolated infinity AUC0 elimination clearance CL F apparent volume distribution V F elimination half life t1 2 absorption lag time Tlag The trapezoidal rule linear up log down used estimate AUC All parameters calculated using actual blood sampling times Drug concentrations lower limit quantification bioanalytical assays treated missing data The median values ranges pharmacokinetic parameters recorded two groups Statistical analysis Data analysed using STATA version StataCorp College Station TX USA Baseline characteristics summarized mean CI compared using independent t test The Wilcoxon rank sum test used compare pharmacokinetic parameters two groups A P value considered statistically significant\n",
      "Materials methods Materials reagents Ilaprazole ilaprazole sulfone ilaprazole thiol ether standards obtained Livzon Pharmaceutical Group Inc purity Zhuhai China Omeprazole standards obtained Sigma Chemical Company purity USA Ilaprazole tablets obtained Livzon Pharmaceutical Group Inc Zhuhai China HPLC grade acetonitrile methanol methyl tert butyl ether MTBE purchased Dikma Comp Guangzhou China HPLCgrade water obtained using Milli Q system Millipore USA All reagents analytical grade Subjects This study conducted approval Xiangya institutional review boards informed consent subjects Twelve healthy Chinese Han male volunteers normal hepatic renal hematologic function selected study All results within normal limits see Table 1S The age participants ranged years mean SD years weight ranged kg kg height ranged cm cm The exclusion criteria included use medication within weeks prior commencement study use tobacco alcohol study clinically significant illness within months prior study A physical examination performed common laboratory parameters hematological hepatic renal functions determined study monitor safety drug treatment Study protocol This randomized open labeled self controlled 3 way crossover study Twelve subjects randomized groups ilaprazole mg clarithromycin mg ilaprazole mg clarithromycin mg amoxicillin g combination therapy All drugs administered twice daily consecutive days 7th After h fasting volunteers given drugs mL tap water morning 7th Then mL mL blood samples collected h drug administration The whole blood sample centrifuged immediately upper layer serums transferred polyethylene tubes stored C analysis After 7 d drug elimination period dose subjects proceeded next phase Measurement serum drug concentration The quantitative determination ilaprazole two metabolites based improved LC MS MS method published Zhou et al 16 Briefly chromatographic condition included Thermo HyPURITY C18 column mm_2 1 mm _m mobile phase consisting mmol L ammonium formate water acetonitrile solution v v flow rate mL min The API4000 triple quadruple mass spectrometer Applied Biosystems USA operated multiple reactions monitoring mode via positive electrospray ionization interface This method displayed linearity concentration range 0 23Ð2400 00 ng mL ilaprazole 0 05Ð105 00 ng mL ilaprazole thiol ether 0 06Ð45 00 ng mL ilaprazole sulfone The lower limits quantification ng mL ilaprazole ilaprazole sulfone ilaprazole thiol ether respectively The intraand interday precisions less terms relative standard deviation RSD accuracy within terms relative error RE ilaprazole ilaprazole sulfone ilaprazole thiol ether The concentration clarithromycin plasma determined using HPLC MS MS Separation analytes internal standard IS roxithromycin performed Waters Xterra MS C18 column mm_50 mm µm mobile phase consisting mmol L ammonium acetate water acetonitrile solution v v flow rate mL min The API4000 triple quadruple mass spectrometer operated multiple reactions monitoring mode via positive electrospray ionization interface The standard www chinaphar com Cao S et al Acta Pharmacologica Sinica npg curves displayed excellent linearity systematic bias The lower limit quantification clarithromycin ng mL intraand inter day precisions less medium high concentrations less low concentration terms relative standard deviation RSD accuracy within terms relative error RE clarithromycin concentrations Pharmacokinetic analysis Pharmacokinetic parameters calculated according non compartmental model using Winnonlin Pharsight Corporation ver Mountain View CA USA The peak concentration Cmax time peak concentration Tmax directly analyzed visual inspection plasma concentration time profile The elimination rate constant _ obtained least square fitted terminal log linear portion slope plasma concentration time profile elimination half life t1 2 evaluated according 0 693 _ The area plasma concentration time curve AUC evaluated linear trapezoidal rule extrapolated infinity dividing last measurable concentration _ according following equation AUC AUC0Ðt Clast _ Statistical analysis All data expressed mean SD Statistical comparisons mean values different groups performed using paired t test AVONA The data analyzed using statistical program SPSS Statistical Package Social Sciences Windows SPSS Chicago IL USA Differences considered statistically significant P 0 05 The confidence intervals log values AUC Cmax determined bio equivalence test The resulting data beyond 70 Ð143 Cmax 80 Ð AUC single treatment groups considered significantly different\n",
      "Methods An open label two period fixed sequence crossover study conducted healthy male volunteers Each volunteer gave written informed consent enrolled The study protocol approved Institutional Review Board Seoul National University Hospital Subjects received single 100 mg oral dose udenafil day overnight fasting maintained fasting state h drug administration A 400 mg dose ketoconazole administered day morning days Subjects kept eating food h drug administration days On day overnight fasted subjects received mg udenafil approximately h ketoconazole dosing Following single dose udenafil blood samples collected h dosing Following second dose udenafil administered co administration ketoconazole additional blood sample drawn h udenafil dosing ensure complete characterization pharmacokinetic profile udenafil even co administration ketoconazole increased t1 2 udenafil Udenafil DA 8164 concentrations plasma determined using liquid chromatographyÐtandem mass spectrometry The lower limit quantification ng ml_1 method validated range 2Ð2000 ng ml_1 The accuracy withinand between runs ranged respectively precision withinand between runs ranged Pharmacokinetic parameters determined noncompartmental methods using WinNonlin Version Pharsight Corp Mountain View CA USA The metabolic AUC ratio udenafil calculated AUClast DA 8164 divided udenafil correcting AUC values molecular weights udenafil MW DA 8164 MW The log transformed Cmax AUClast AUC pharmacokinetic variables compared values two treatments using paired t test These differences estimated geometric mean confidence interval CI Tmax examined using Wilcoxon signed rank test based matched pairs All statistical analyses performed using SPSS software SPSS Seoul Korea Adverse events AEs monitored asking general health related questions subjects self reporting Physical examinations 12 lead ECGs laboratory tests including clinical chemistry haematology urinalysis performed predetermined intervals\n",
      "Methods Study design This open_label two_period fixed_sequence study conducted single centre Healthy subjects received single oral dose neratinib mg alone Period combination multiple doses oral lansoprazole mg Period Figure Pharmacokinetic sampling neratinib performed h following neratinib dose The washout period neratinib dose least days The primary objective study evaluate effect multiple doses lansoprazole absorption pharmacokinetics single dose neratinib healthy subjects The secondary objective assess safety tolerability neratinib administered lansoprazole The study protocol approved Chesapeake Research Review Columbia MD USA IRB registration number IRB 00_000_790 The study performed accordance ethical principles Declaration Helsinki subsequent amendments Written informed consent obtained subjects prior study enrollment The study registered ClinicalTrials gov identifier NCT02334501 Study participants Healthy men women aged 18Ð55 years body mass index within range 18 5Ð32 0 kg m_2 eligible Study participants required medically healthy clinically significant medical history based physical examination laboratory profiles vital signs 12_lead electrocardiograms ECGs Nonsmokers moderate smokers cigarettes day least months prior screening eligible Women childbearing potential required use acceptable method birth control sexually inactive days prior first dose study drug least days following last dose study drug Nonvasectomized men required use acceptable form contraception study days last dose study drug Consumption foods beverages containing following substances prohibited xanthines caffeine h neratinib administration end sample collection alcohol h Day period end sample collection grapefruits Seville oranges juice days Period throughout study Medications including over_the_counter products herbal products vitamin supplements prohibited days prior first dose study drug days cytochrome P450 and or P_glycoprotein inducers throughout study Treatment During Period subjects received single oral dose neratinib mg six mg tablets Excella GmbH Feucht Germany lot P114127_0001 L002 following standard breakfast During Period subjects received oral lansoprazole mg one delayed_release capsule USP Natco Pharma Limited Hyderabad India lot 404_133 administered approximately every h days prior standard breakfast single oral dose neratinib mg morning Day following standard breakfast All study drugs administered approximately ml water supervision clinic personnel Subjects ambulatory seated upright h neratinib administration Pharmacokinetics Noncompartmental pharmacokinetic parameters calculated plasma neratinib concentrationÐtime data using Phoenix WinNonlin Version Certara USA Inc Princeton NJ USA Actual sample times used calculations Cmax determined directly observed plasma concentration data tmax computed blood draw time date medication time date Area plasma concentrationÐtime curve time last quantifiable nonzero concentration AUC0Ðt calculated linear trapezoidal method linear interpolation Area plasma concentrationÐtime curve time extrapolated infinity AUC0Ðinf calculated sum AUC0Ðt plus ratio last quantifiable plasma concentration apparent first_order terminal elimination rate constant _z _z calculated linear least_squares regression analysis terminal log_linear phase plasma concentrationÐtime curve The percentage AUC0Ðinf extrapolated AUC extrap calculated Ð AUC0Ðt AUC0Ðinf _ Apparent first_order terminal elimination half_life t_ calculated 0 693 _z Apparent total plasma clearance oral extravascular administration CL F calculated Dose AUC0Ðinf Apparent volume distribution terminal elimination phase oral extravascular administration V_z F calculated Dose AUC0Ðinf x _z Sample collection analytic methods For quantification neratinib plasma concentrations 2_ml venous blood samples collected blood collection tubes containing potassium ethylenediaminetetraacetic acid prior neratinib dosing h Day 1 Period Day 5 Period h Day 2 Period Day 6 Period h Day 3 Period Day 7 Period h Day 4 Period Day 8 Period following neratinib dosing Collection tubes centrifuged within min collection approximately 5 C Duplicate plasma aliquots transferred labelled storage tubes stored within min collection approximately _70 C Samples shipped Covance Bioanalytical Services LLC Indianapolis IN USA analysis Neratinib internal standard neratinib extracted samples using protein precipitation analysed using liquid chromatography tandem mass spectrometric detection The validated range assay 3 00Ð250 ng ml_1 The presence lansoprazole affect quantification neratinib blank samples spiked lansoprazole contain significant peaks retention time neratinib internal standard data shown For low ng ml_1 medium ng ml_1 high ng ml_1 quality control samples interassay accuracy respectively interassay precision expressed relative standard deviation respectively corresponding biases _0 8 _1 5 respectively All study samples n  analysed within known stability period days storage _60 C _80 C Safety Safety endpoints included adverse events physical examinations vital signs 12_lead ECGs clinical laboratory tests i e haematology coagulation haemolysis serum chemistry urinalysis Safety monitored throughout study repeated clinical laboratory evaluations All adverse events coded using Medical Dictionary Regulatory Activities MedDRA version A treatment_emergent adverse event defined event started worsened time study drug administration days last dose For purposes reporting adverse events Period separated two parts lansoprazole alone i e postdose Day predose neratinib Day lansoprazole plus neratinib i e postdose neratinib Day end study Statistical methods Descriptive statistics calculated pharmacokinetic parameters neratinib without lansoprazole To assess effect lansoprazole pharmacokinetics neratinib log_transformed neratinib parameters i e AUC0Ðt AUC0Ðinf Cmax compared performing analysis variance anova included treatment fixed effect subject random effect model The inferential results models i e least_square means differences least_square means standard errors exponentiated original scale obtain geometric least_square means geometric mean ratios GMR confidence intervals CIs intrasubject coefficient variations The GMR point estimates AUC0Ðt AUC0Ðinf Cmax neratinib plus lansoprazole vs neratinib used assess magnitude drugÐdrug interaction confidence intervals CIs outside 80 00Ð125 00 limits Allowing type I error approximately power assuming intrasubject coefficient variability Cmax reported study A1Ð1117_US true GMR Cmax within range 95Ð105 estimated sample size required subjects An additional two subjects enrolled allow possible drop_outs giving total study population subjects Analyses performed Phoenix WinNonlin Version SAS Version\n",
      "Cytochrome P450 CYP enzymes comprise major drug metabolizing enzyme system humans Genetic polymorphisms environmental factors dietary components toxins drugs affect activity enzymes result interindividual variations drug concentrations In addition metabolizing enzymes drug influx efflux proteins P glycoprotein P gp important sources pharmacokinetic variability drug response underlined recently 1 The pharmacokinetic variability modifications activities CYP and or P gp cause various pharmacological toxicological consequences It therefore important precisely reliably evaluate vivo activity phenotyping A cocktail approach involving administration multiple CYPor P gp specific probe drugs used simultaneously assess activities enzymes transporter Many phenotyping cocktails developed used past decades 2 3 4 5 6 7 The use cocktails limited fact probe drugs mephenytoin6 debrisoquine 2 6 longer available many countries Another limitation use therapeutic doses insufficiently validated probes might provoke side effects 8 especially used clinical practice vulnerable population This limitation may overcome use lower probe doses alternative requires development sensitive analytical methods Several currently available phenotyping procedures require tedious multiple venous blood sampling 2 4 For cocktails limited sampling strategies phenotyping indexes proposed cocktails require collection plasma urine samples 3 5 6 Moreover phenotyping indexes established based normal CYP function often unknown whether chosen indexes reliable case altered CYP activity A novel promising approach CYP P gp activity phenotyping use dried blood spots DBSs sampling procedure This sampling method successfully applied therapeutic drug monitoring pharmacokinetic studies 9 10 11 Recent studies shown DBS sampling could also used individual cytochrome phenotyping CYP2C9 ref CYP3A13 activities The purpose study evaluate usefulness effectiveness DBS sampling simultaneous assessment activities six CYP isoforms P gp using low dose phenotyping cocktail composed caffeine CYP1A2 bupropion CYP2B6 flurbiprofen CYP2C9 omeprazole CYP2C19 dextromethorphan CYP2D6 midazolam CYP3A fexofenadine P gp The reliability method assessment modulation CYP P gp activities examined administration cocktail alone presence known CYP P gp inhibitors inducer\n",
      "Methods Subjects The study conducted nine healthy normoglycaemic nondiabetic male female subjects nonreproductive potential 22Ð44 years age weighing approximately 60Ð92 kg Prior start dosing subjects normoglycaemic levels estimated creatinine clearance ³80 ml min_1 history Type diabetes considered generally good health assessed basis medical history physical examination including vital signs 12 lead electrocardiogram ECG routine laboratory tests haematology blood chemistry urinalysis Furthermore unless allowed investigator minor ailments subjects permitted take prescription nonprescription medications within days start dosing throughout study In particular subjects explicitly instructed take herbal remedies St John s Wort oral hypoglycaemic agents oral parenteral contraceptives drugs inhibitory inductive potential CYP3A4 CYP2C9 CYP2C19 Study design This randomized open label two period crossover study Subjects received single 1 25 mg doses glyburide alone one period period sitagliptin mg daily days glyburide dose also co administered sitagliptin day Administration study drug witnessed medical staff clinical research unit glyburide administered clock time periods During treatment regimens days glyburide administered subjects remained clinical research unit completion 24 h postdose study procedures Since glyburide taken food standardized breakfast subject provided periods glyburide administered control potential effects pharmacokinetics Food demonstrated meaningful effect sitagliptin pharmacokinetics Both periods separated wash out interval least days subjects crossed treatment regimen Safety assessments included physical examination 12 lead ECG vital signs rest systolic diastolic blood pressure pulse rate respiratory rate body temperature routine laboratory tests haematology blood chemistry urinalysis performed prestudy screening predose first dose day first period 12 lead ECG laboratory safety tests h postdose vital signs glyburide alone period vital signs 12 lead ECG day co administration period h postdose glyburide alone period day co administration period except 12 lead ECG vital signs collected h postdose glyburide alone period day co administration period These safety evaluations also repeated poststudy visit occurred approximately days administration last dose study drug Glucometer measurements conducted monitor signs symptoms hypoglycaemia predose specified time points h postdose glyburide alone period day co administration period Clinical adverse experiences also monitored throughout study prestudy screening poststudy visit This study conducted ProMedica Clinical Research Center according provisions Declaration Helsinki written informed consent obtained subject prior conducting protocol related procedure The study approved independent institutional review committee Western Institutional Review Board Pharmacokinetic assessments Blood samples glyburide assay collected following time points 48 h period glyburide administered alone day co administration period predose h At collection ml blood drawn one ethylenediamine tetraaceticacid spray dried lavender top Vacutainer tube The tubes placed ice refrigerated immediately collection centrifuged r p m min 4 C The plasma transferred 4 5 ml polypropylene NUNC tubes stored freezer _20 C analysis The NUNC tubes sent PPD Development Morrisville NC USA dry ice drug assay Plasma samples assayed glyburide using high performance liquid chromatography  methanol  nM ammonium acetate mobile phase hypersil BDS C18 _ mm _m particle size analytical column tandem mass spectroscopy MS MS detection glyburide d11 internal standard Liquid liquid extraction performed  ethyl acetate hexane The lower limit quantification glyburide ng ml_1 coefficient variation CV assay linear calibration range 0 100Ð50 0 ng ml_1 The CV ranged conduct assays The software used integrate chromatograms Sciex Analyst PPD Development Plasma concentrations actual sampling times relative dose used determine pharmacokinetic parameters exception Tmax subject The onset apparent terminal log linear portions individual plasma concentrationÐtime profiles determined inspection The apparent terminal rate constant _ estimated regression terminal log linear portion plasma concentrationÐtime profile t1 2 calculated quotient ln2 _ AUC last time point calculated using linear trapezoidal method ascending concentrations log trapezoidal method descending concentrations AUC0Ð estimated sum AUC last measured concentration extrapolated area given quotient last measured concentration _ Cmax Tmax obtained inspection plasma concentration data Provided actual observed time Tmax differ meaningful way nominal plasma sampling time nominal plasma sampling times used determine Tmax Statistical analysis Since efficacy safety related integrated glycaemic control h including fasting glucose overall drug exposure i e AUC considered relevant pharmacokinetic parameter study The single dose glyburide pharmacokinetic parameters AUC0Ð Cmax Tmax apparent t1 2 following co administration glyburide  sitagliptin relative glyburide alone compared The AUC0Ð Cmax following single 1 25 mg dose glyburide alone co administrated mg sitagliptin analysed using analysis variance anova model appropriate two period crossover design terms sequence subject within sequence period treatment A confidence interval CI AUC0Ð geometric mean ratio GMR glyburide  sitagliptin glyburide glyburide calculated compared prespecified comparability bounds For evaluation sitagliptin s effect glyburide pharmacokinetics wider CI chosen study instead sometimes used drug interaction studies The reasoning wider CI follows Given potential dose related hypoglycaemia glyburide GMR AUC0Ð vs without sitagliptin would considered potentially clinically meaningful might warrant dose adjustment higher doses glyburide used clinic treatment T2DM Similarly reduction plasma glyburide exposure might warrant dose increase maintain optimal glycaemic lowering effect The pharmacokinetic parameters Tmax apparent t1 2 following single 1 25 mg dose glyburide alone co administered mg sitagliptin also analysed using anova model described Prior statistical analysis log transformation applied AUC0Ð Cmax data rank transformation applied Tmax data inverse transformation applied apparent t1 2 data The ShapiroÐWilk Levene s test statistics used check normality homogeneous variance anova model For power calculation true AUC0Ð geometric means glyburide alone vs co administered sitagliptin i e true GMR sample size n  subjects treatment group provided probability yielding CI AUC0Ð GMR within interval If true AUC0Ð GMR within interval study provided least power getting CI within\n",
      "Materials Methods Patient selection Japanese patients histologically cytologically confirmed malignant solid tumors refractory conventional chemotherapy tumors effective therapy available candidates study Eligibility criteria included following age years World Health Organization WHO performance status 0Ð1 life expectancy ³ months absolute leukocyte count ³ 4000 µL  000 µL absolute neutrophil count ³ 2000 µL hemoglobin level ³ g dL platelet count ³ 000 µL serum creatinine level mg dL creatinine clearance ³ mL min arterial partial pressure oxygen torr Additional entry criteria serum bilirubin ² mg dL serum aspartate aminotransferase AST alanine aminotransferase ALT ² IU L Before study entry 6_week interval required patients previously treated mitomycin C nitrosoureas 4_week interval required chemotherapy endocrinotherapy surgery radiation therapy immunotherapy treatments investigational agents 2_week interval blood transfusion administration granulocyte_colony stimulating factor G_CSF Patients ineligible study symptomatic central nervous system metastases active infection non_malignant disease considered incompatible protocol Patients receiving corticosteroids coumarin anticoagulants less weeks prior administration E7070 excluded study The protocol approved institutional review boards National Cancer Center patients gave written informed consent prior study entry Dosage dose escalation E7070 provided lyophilized powder 500_mg vials Eisai Co Tokyo Japan The starting dose E7070 set mg m2 mild moderate grade grade toxicity observed doses mg m2 lower previous phase I study 5 Subsequent doses escalated mg m2 E7070 dissolved mL distilled water added mL normal saline injection solution administered intravenous infusion h doses mg m2 Injection site reaction observed one three patients mg m2 three three patients mg m2 Therefore E7070 given mL normal saline h mg m2 Patients hospitalized first course E7070 remained hospitalized close observation days thereafter Subsequent courses could administered outpatient basis weekly patient evaluations investigator Patients enrolled cohorts three patients per dose level observed days observation period extended days longer recovery period needed If one three patients experienced DLT three additional patients treated dose If two three six patients experienced DLT dose level regarded MTD If none first three patients demonstrated DLT next three patients treated next higher dose level Individual patients demonstrate DLT showed evidence disease progression could receive E7070 originally assigned dose After MTD determined dose MTD evaluated total six patients identification proposed recommended dose phase II study The recommended dose highest dose less treated patients experienced DLT Definition dose_limiting toxicity The DLT defined occurrence following events cycle attributable E7070 National Cancer Institute Common Toxicity Criteria NCI CTC version grade non_hematological toxicity except nausea vomiting effectively managed symptomatic treatment alopecia grade leukopenia grade neutropenia accompanied fever ³ 38 5 C persisted ³ days platelet count  000 µL Prophylactic use colony_stimulating factors permitted first cycle however patients neutropenia met criteria DLT permitted receive concomitant treatment G_CSF Evaluation patients Safety evaluated basis physical findings vital signs adverse events laboratory parameters obtained baseline periodically throughout study During first cycle hematology studies performed least twice week vital signs physical examinations including evaluation performance status serum biochemistry measured days Toxicity evaluations subjective objective findings performed according NCI CTC version days For second subsequent cycles vital signs laboratory tests toxicity evaluations based subjective objective findings performed days cycle Blood glucose monitored dose E7070 end infusion Blood coagulation studies carried dose cycles also day first cycle Efficacy assessed physician basis antitumor effect according Response Evaluation Criteria Solid Tumors RECIST 11 If antitumor effect observed disease site re_evaluated least weeks later confirm response Pharmacokinetics Pharmacokinetic studies performed first cycle treatment On day blood samples mL drawn indwelling intravenous cannula arm contralateral bearing infusion line Samples collected heparinized tubes preinfusion min start infusion end 1_ 2_h infusion min h infusion The samples centrifuged 1500_g min 5 C resulting plasma samples stored _20 C analysis Urine samples collected start E7070 infusion three 24_h intervals h start infusion The concentrations E7070 plasma urine analyzed Eisai Co means validated high_performance liquid chromatography methods UV detection HPLC_UV The lower limit quantification ng mL N_ 3_Chloro_7_indolyl _4_ N_methylsulfamoyl benzenesulfonamide ER_67771 12 used internal standard Plasma internal standard mol L phosphate buffer pH vortexed After adding ethyl acetate mixture shaken centrifuged The organic layer collected transferred glass tube evaporated nitrogen flow drying block The residue dissolved CH3CN_6 7 mmol L phosphate buffer pH solution injected HPLC apparatus Chromatographic separation achieved using column switching method Asahipak C8P_50 Showa Denko Tokyo Japan separation column YMC_pack ODS_AM_312 YMC analytical column Mobile phases CH3CN mmol L phosphate buffer pH v v separation CH3CN mmol L phosphate buffer pH v v analysis E7070 monitored UV detection nm Pharmacokinetic parameters E7070 single dose administration first cycle determined non_compartmental analysis using WinNONLIN Pharsight Corporation CA USA The apparent elimination rate constant terminal phase _z estimated linear regression analysis terminal log_linear declining phase last quantifiable concentration The elimination half_life t1 2 calculated t1 2  ln 2 _z The area plasma concentrationÐtime curve zero last quantifiable sampling time AUC 0Ðtn obtained log trapezoidal rule The AUC zero infinity calculated AUC 0Ðtn Cn _z Cn last quantifiable concentration The clearance calculated dose AUC The mean residence time MRT estimated AUMC AUC AUMC first moment curve The volume distribution calculated MRT _ clearance Genotyping procedures CYP2C9 CYP2C19 Genotyping conducted using Invader assay BML Tokyo Japan Genomic DNA isolated whole blood QIAamp DNA Blood Kit Qiagen CA USA The primary probes wild type mutant probes used detect C430T A1075C mutations CYP2C9 G681A G636A CYP2C19 respectively The invader assay fluorescent resonance energy transfer FRET _detection 96_well plates Third Wave Technologies WI USA contained Cleavase enzyme FRET probes MOPS buffer polyethylene glycol Eight microliters mixtures consisting appropriate primary probe Invader oligonucleotide MgCl2 added wells followed addition µL heat_denatured genomic DNA overlaid µL mineral oil For CYP2C9 2 C430T detection dilution CYP2C9_specific polymerase chain reaction PCR product used instead genomic DNA CYP2C9 2 C430T detection point sequence CYP2C19 The plates incubated 63 C h genomic DNA h PCR product The fluorescence intensities measured Cytofluor fluorescence plate reader Applied Biosystems CA USA excitation nm wavelength bandwidth emission nm FAM dye detection excitation nm emission nm RED dye detection Subjects either allele defined hetero extensive metabolizers hetero EM two mutated alleles poor metabolizers PM mutated alleles homo EM\n",
      "Methods Eight normal healthy male volunteers agreed participate study providing written informed consent This study approved local Institutional Review Board All subjects nonsmokers self reported healthy confirmed medical history physical examination blood chemistries urinalysis Subjects instructed abstain caffeine alcohol containing products least two days study visit none subjects receiving counter prescription medications Subjects received probe drug chlorzoxazone 250_mg three occasions prior disulfiram administration second daily disulfiram dose eleventh daily disulfiram dose Subjects also received combination chlorzoxazone probe drugs caffeine 100_mg dapsone 100_mg debrisoquine 10_mg mephenytoin 100_mg prior disulfiram administration eleventh daily dose Subjects received disulfiram 250_mg orally morning doses administered clinic personnel All probe drugs given orally eight ounces water morning overnight fast The five probe drugs administered simultaneously cocktail previously shown devoid interaction doses used In session heparinized plasma samples collected prior drug administration 10_h probe administration Urine collected 0 8_h container ascorbic acid preservative unstable dapsone hydroxylamine metabolite Plasma harvested centrifugation urine aliquots stored frozen _20_ _C analysed Analytical techniques The following drugs metabolites measured high performance liquid chromatographic techniques described previously caffeine paraxanthine plasma chlorzoxazone 6 hydroxychlorzoxazone plasma 6 hydroxychlorzoxazone urine dapsone DDS dapsone hydroxylamine HDA urine dapsone monoacetyldapsone plasma debrisoquine DB 4 hydroxydebrisoquine HDB urine 4_ hydroxymephenytoin HMP urine The within between day coefficients variation assays ²10 All assay procedures utilized study tested probe drugs metabolites ensure analytical interference would occur simultaneous administration Data analysis Chlorzoxazone 6 hydroxychlorzoxazone pharmacokinetic data presented detail previously In report chlorzoxazone metabolic ratio calculated concentration ratio 6 hydroxychlorzoxazone chlorzoxazone 4_h plasma sample used index CYP2E1 activity The concentration paraxanthine dimethylxanthine divided concentration caffeine 8_h plasma sample used assess CYP1A2 activity The ability N hydroxylate dapsone CYP mediated estimated urinary recovery ratio equation image HDA urinary recovery dapsone hydroxylamine 8_h urine sample DDS 8_h urinary recovery dapsone Acetylator phenotype defined ratio monoacetyldapsone dapsone 8_h plasma sample subjects acetylation ratio greater classified rapid acetylators The area concentration time curve AUC monoacetyldapsone dapsone 10_h dapsone administration calculated trapezoidal rule The activity CYP2D6 estimated using debrisoquine recovery ratio equation image HDB DB urinary recoveries 4 hydroxydebrisoquine debrisoquine 8_h respectively The total urinary recovery 4_ hydroxymephenytoin µmol used phenotypic measure CYP2C19 activity Statistical analysis Data presented median range Statistical test values Hodges Lehmann estimates median differences exact confidence intervals Computations performed using StatXact Cytel Software Corporation USA Differences considered statistically significant confidence intervals excluded zero\n",
      "Materials Methods Individuals Twenty_two healthy male Korean subjects carrying CYP2C9 1 1 n_ _8 CYP2C9 1 3 n_ _8 CYP2C9 1 13 n_ _6 genotypes included study These volunteers randomly recruited among unrelated Korean volunteers genotyped CYP2C9 alleles polymorphisms For genotyping genomic DNA isolated peripheral blood leucocytes using Wizard Genomic DNA kit Promega Madison WI USA according manufacturerÕs instructions Genotyping CYP2C9 2 alleles performed using polymerase chain reaction_restriction fragment length polymorphism analysis described previously There significant differences demographic parameters genotype groups table Medical histories physical examinations routine laboratory tests blood chemistry haematology urine analysis revealed abnormalities The individuals asked refrain taking medication caffeine grapefruit products tobacco alcoholic beverages least 1_week throughout study period All individuals provided verbal written informed consent This study followed guidelines Declaration Helsinki institutional ethics committee School Pharmacy Sungkyunkwan University Suwon Korea approved protocol Table Individual demographic characteristics according CYP2C9 genotype healthy Korean individuals Genotype Number individuals Age year Height cm Weight kg Body mass index kg m2 CYP2C9 1 1 23 5_ _2 8 175 4_ _4 4 67 5_ _4 7 21 9_ _1 0 CYP2C9 1 3 23 3_ _1 7 173 6_ _4 1 66 1_ _4 1 21 9_ _0 9 CYP2C9 1 13 23 0_ _1 8 175 5_ _2 9 68 0_ _3 7 22 1_ _1 4 Each value represents mean_ _S D Study protocol On day study individuals received oral dose 8_mg lornoxicam Zefo Hyundaipharm Co Ltd Seoul Korea 240_ml water overnight fast The individuals maintained fasting state 4_hr drug administration Venous blood samples 10_ml obtained 24_hr lornoxicam administration The blood samples centrifuged immediately plasma samples stored _70 C needed Determination plasma lornoxicam 5__hydroxylornoxicam concentrations Plasma lornoxicam determined using validated high_performance liquid chromatography HPLC Waters HPLC System Milford MA USA assay ultraviolet detection Model Waters Briefly 1_ml plasma spiked 10__l internal standard piroxicam 40__g ml acidified 100__l 5_M H2SO4 extracted 6_ml dichloromethane The organic phase evaporated 40 C constant flow nitrogen gas The residue reconstituted 500__l mobile phase A 65__l aliquot injected analytical column Capcell Pak C18 UG120 5__m 4 6_mm___250_mm Shiseido Tokyo Japan The mobile phase consisted mixture 20_mM phosphate buffer_acetonitrile_methanol V V V adjusted pH NaOH The flow rate 1 0_ml min column oven temperature 30 C The effluents detected ultraviolet light 371_nm The lower limit quantification lornoxicam 4_ng ml The standard curves lornoxicam linear 1200_ng ml plasma r2_ _0 9999 mean accuracy 96 18Ð111 53 The coefficients variation within_day between_day precision lornoxicam measurements plasma 1 16Ð13 64 5__Hydroxylornoxicam concentrations expressed arbitrary units U relative peak area 5__hydroxylornoxicam peak area internal standard ___100 Pharmacokinetic analysis The pharmacokinetic parameters lornoxicam 5__hydroxylornoxicam estimated using non_compartmental methods BA calc KFDA Seoul Korea Actual blood sampling times used maximum plasma concentration Cmax time reach Cmax tmax presented observed values The area plasma concentration_time curve AUC calculated using linear trapezoidal rule The elimination rate constant ke estimated least_squares regression slope terminal plasma concentration The AUC infinity AUCinf calculated AUCinf_ _AUC_ _Ct ke Ct recently measured plasma concentration The half_life t1 2 calculated ln_2 ke apparent oral clearance CL F lornoxicam calculated CL F_ _dose AUCinf Statistical analysis The number individuals genotype group estimated sufficient detect difference AUCinf lornoxicam two genotype groups statistical power least _ level The power sample size calculated Power Sample Size Program PS version All pharmacokinetic data expressed mean_ _S D except tmax presented median value range Differences pharmacokinetic parameters genotype groups assessed using StudentÕs t_test MannÐWhitney rank sum test normality equal variance tests Data analysed using SigmaStat Windows version Systat Software Inc Chicago IL USA p Values_ _0 05 considered statistically significant\n",
      "Methods Study Design All procedures performed studies involving human participants accordance ethical standards institutional and or national research committee Helsinki declaration later amendments comparable ethical standards Informed consent obtained individual participants included study Approval study granted Chesapeake Research Review This open label single dose three period randomized study healthy adult subjects Cysteamine bitartrate DR capsules Procysbi Horizon Pharma Inc Lake Forest Illinois USA supplied 75 mg capsules Omeprazole supplied 20 mg delayed release capsules Mylan Pharmaceuticals Canonsburg PA USA A single branded orange juice SUNCUPª used subjects Any PK effects cysteamine PPIs would expected similar acting drugs similar effects gastric pH therefore PPIs studied All study drugs administered orally following overnight fast subjects instructed crush split chew capsules Study Population Healthy adult nonsmokers including males females non childbearing potential aged 18Ð55 years body mass index BMI kg m2 screening considered suitable inclusion Key exclusion criteria included clinically significant medical psychiatric conditions illnesses might confounded results study posed additional risk subject Subjects free withdraw study time reason may withdrawn study principal subinvestigator adverse events AEs difficulties blood collection protocol violation Treatment Protocol Subjects randomly assigned receive following treatments A B C one two sequences three periods ABC BAC Fig Subjects received treatment one occasion Treatment A Cysteamine bitartrate mg _ 75 mg DR capsules hour day approximately mL orange juice Treatment B Cysteamine bitartrate mg _ 75 mg DR capsules hour day approximately mL water Treatment C Omeprazole mg approximately mL water every h consecutive days within  h dosing time day co administered cysteamine bitartrate mg hour day approximately mL water An external file holds picture illustration etc Object name 12325_2018_661_Fig1_HTML jpg Fig Study design Treatment A single dose cysteamine bitartrate delayed release capsules mg orange juice day Treatment B single dose cysteamine bitartrate delayed release capsules mg water day Treatment C omeprazole mg water daily days  single dose cysteamine bitartrate delayed release capsules mg water day On days omeprazole administered within  h dosing time day Additional water and or orange juice maximum mL administered needed subject capsule dosing completed within min scheduled time The 600 mg oral dose cysteamine bitartrate DR selected study dose used previous healthy subject studies well tolerated well dose US prescribing information A dose mg omeprazole daily within recommended dose prescribed US labeling In addition multiple doses consecutive days ensured maximum inhibition acid secretion omeprazole pharmacodynamic response reaches plateau days dosing Study Procedures On day period subjects randomized one two treatment sequences ABC BAC On day periods single oral dose cysteamine bitartrate DR administered orange juice treatment A water treatment B followed blood sampling h determination plasma cysteamine levels In period multiple oral doses omeprazole water administered daily consecutive days days 1Ð5 co administered single oral dose cysteamine bitartrate DR water treatment C day Blood samples determination plasma cysteamine levels taken h following cysteamine bitartrate DR dosing Day There washout period days first dosing period Subjects followed approximately days last study drug administration determine whether AE occurred since last dose study drug s Outcome Measures The following primary PK parameters assessed area concentrationÐtime curve time time last observed measured non zero concentration AUC0Ðt area concentrationÐtime curve time extrapolated infinity AUC0Ð maximum observed concentration Cmax time reach Cmax tmax In addition percent AUC0Ð extrapolated AUC extrap apparent first order terminal elimination rate constant kel apparent first order terminal elimination half life t_ apparent total plasma clearance extravascular administration CL F apparent volume distribution terminal elimination phase extravascular administration Vz F calculated All PK parameters calculated using Phoenix WinNonlin v 6 3 24 h plasma cysteamine concentrationÐtime data Blood samples determining plasma cysteamine concentrations obtained following time points pre dose h h post dose Safety assessed via evaluation AEs classified Medical Dictionary Regulatory Activities MedDRA v 19 0 physical examination 12 lead electrocardiograms vital signs including systolic diastolic blood pressure pulse rate temperature respiratory rate body weight clinical laboratory tests Only treatment emergent AEs TEAEs summarized Statistical Analysis A sample size subjects calculated using power least alpha error The power defined probability confidence interval CI detect ratio within acceptance criteria 80 00Ð125 00 A true ratio assumed intra subject coefficient variation CV  obtained previous data used A total subjects dosed allow possible dropouts Summary statistics calculated nominal concentrationÐtime points plasma cysteamine PK parameters In addition geometric means geometric CVs calculated Cmax AUC parameters For PK parameters analysis variance performed log transformed AUC0Ðt AUC0Ð Cmax sequence treatment fixed effects subject nested within sequence random effect Period considered statistical model third treatment period confounded treatment C The linear model included calculation least squares means LSM difference treatment LSM standard error associated difference Ratios LSM calculated using exponentiation difference treatment LSM analyses log transformed AUC0Ðt AUC0Ð Cmax These ratios expressed percentage relative appropriate reference treatment treatment A treatment B depending comparison interest Consistent two one sided tests CIs ratios derived exponentiation CIs obtained difference treatment LSM resulting analyses log transformed AUC0Ðt AUC0Ð Cmax expressed percentage relative treatment A treatment B depending following comparisons interest Cysteamine bitartrate DR capsules  water treatment B compared cysteamine bitartrate DR capsules  orange juice treatment A Omeprazole  cysteamine bitartrate DR capsules  water treatment C compared cysteamine bitartrate DR capsules  water treatment B Omeprazole  cysteamine bitartrate DR capsules  water treatment C compared cysteamine bitartrate DR capsules  orange juice treatment A Nonparametric analysis Wilcoxon signed rank test performed tmax included calculation median CIs differences among treatments All plasma cysteamine concentrations and or PK parameter descriptive statistics generated using SAS v 9 3 Cary NC USA\n",
      "Methods This Phase crossover study ClinicalTrials gov Identifier NCT01517399 open_label single_sequence design conducted three sites United States South Texas Accelerated Research Therapeutics START San Antonio TX Duke University Medical Center Durham NC Vanderbilt University Medical Center Nashville TN The study conducted accordance principles Declaration Helsinki Good Clinical Practice guidelines The protocol approved local institutional review board centre START IRB00001035 IRB00003657 IRB00004920 IRB00006075 Duke University Pro00032884 Vanderbilt University written informed consent obtained patient undergoing study procedure Patients Male female adults aged ³18 years histologically cytologically confirmed advanced solid tumours screening eligible study In addition eligible patients required Eastern Cooperative Oncology Group performance status ²2 adequate bone marrow haemoglobin ³9 0 g dl_1 platelet count ³100 _ 109 l absolute neutrophil count ³1 5 _ 109 l hepatic alanine aminotransferase aspartate aminotransferase ²3 _ upper limit normal ULN ²5 _ ULN patients liver metastases total bilirubin ²1 5 _ ULN clotting international normalized ratio ² renal function serum creatinine ²1 5 _ ULN Excluded patients hepatocellular carcinoma chronic liver cirrhosis history active coronary artery disease within previous months i e myocardial infarction unstable angina coronary artery bypass graft stenting and or evidence uncontrolled symptomatic bradycardia grade ³ according National Cancer Institute NCI Common Terminology Criteria Adverse Events CTCAE version cardiac arrhythmia uncontrolled hypertension Patients receiving known inducer inhibitor CYP1A2 CYP2C9 CYP2C19 CYP3A4 P_gp and or received nondrug agent systemic gastric pH modifiers i e ranitidine proton pump inhibitor etc within previous days ineligible Treatment protocol A modified version Cooperstown  cocktail used study probe CYP2D6 dextromethorphan omitted vitro assessment demonstrated tivantinib inhibit CYP2D6 All patients received study drugs fixed sequence probe drugs administered twice tivantinib without tivantinib On day patients received simultaneous single oral doses warfarin mg vitamin K mg caffeine mg meal followed close succession single intravenous infusion midazolam mg Approximately h later patients received single oral dose omeprazole mg Vitamin K also given days prevent anticoagulant effects warfarin On day patients received single oral dose digoxin mg meal Digoxin administered approximately h administration CYP probes avoid antisecretory effect omeprazole may affect bioavailability digoxin On day patients started treatment oral tivantinib mg BID food continued tivantinib day total duration days The tivantinib dose mg BID selected highest dose evaluated clinical studies After days treatment tivantinib probe drugs vitamin K administered sequence warfarin vitamin K caffeine midazolam omeprazole day vitamin K days digoxin day After completion DDI study patients could continue tivantinib treatment cycles  days The efficacy results extension phase reported Blood sampling PK analyses Blood sampling times optimized probe drug using information published literature reduce number site visits volume blood collection avoid blood sampling late night Table Blood samples collected venipuncture using dipotassium EDTA tube Plasma prepared within min extraction centrifugation 1500g min stored _10 C whole blood stored _20 C analysis Blood samples collected PK analyses within min first doses warfarin caffeine min end midazolam infusion h postdose days min digoxin dosing h postdose digoxin days min morning dose tivantinib h dosing days Additional samples collected determination trough tivantinib concentrations tivantinib dosing days predose samples collected days also used determine S_warfarin concentrations h postdose predose samples collected days used determine digoxin concentrations h postdose S_warfarin concentrations h postdose Plasma concentration assays Plasma samples assayed caffeine S_warfarin omeprazole 5_hydroxyomeprazole midazolam digoxin tivantinib metabolites HPM4 HPM5 HPM6 HPM8 prevalidated high_performance liquid chromatographyÐtandem mass spectrometry Table S1 Calibration standard data quality control sample data incurred sample reproducibility data chromatograms indicated assay methods performed acceptably sample analysis Assay sensitivity specificity analyte stability assessed successfully validated All assays performed within relative standard deviation precision sensitivity ²20 mean accuracy 80Ð120 lower limit quantitation Blood sampling pharmacogenomic analyses genotyping A blood sample ml collected patients day used DNA preparation CYP2C9 CYP2C19 genotyping conducted Cancer Genetics Inc Raleigh NC USA genotype data used predict metabolizer phenotypes PK analyses The PK parameters included maximum plasma concentration C max time C max T max AUC time zero last quantifiable concentration AUC last time zero extrapolated infinity AUC 0Ðinf calculated probe substrate using SAS SAS Institute Cary NC USA The ratio omeprazole 5_hydroxyomeprazole calculated C max AUC PK parameters included AUC 0Ð12 tivantinib metabolites HPM4 HPM5 HPM6 HPM8 also calculated administration single multiple doses tivantinib The linear trapezoidal rule used calculate AUC AUC last calculated omeprazole 5_hydroxyomeprazole least three time points measurable plasma concentrations available AUC 0Ðinf calculated concentrationÐtime profile exhibited elimination phase met requirements estimation elimination rate constant R  portion AUC extrapolated time last quantifiable concentration infinity exceed Safety monitoring Safety monitored assessing adverse events physical examinations vital signs electrocardiograms clinical laboratory tests Adverse events graded according NCI CTCAE version Statistical analyses Assuming test_to_reference ratio intra_patient coefficient variation one_sided type I error rate bioequivalence range 0 80Ð1 25 sample size evaluable patients would provide ³80 probability establish equivalence drug interaction effect C max AUC test treatment tivantinib combination omeprazole warfarin caffeine midazolam digoxin reference treatment omeprazole warfarin caffeine midazolam digoxin without tivantinib The PK_evaluable set drug included patients compliant took prohibited concomitant medications Patients predose drug concentrations C max compliant certain drug excluded PK_evaluable set drug PMs CYP2C9 excluded PK analyses S_warfarin PMs CYP2C19 excluded PK analyses omeprazole For primary end point statistical analysis linear mixed_effects model fitted log_transformed PK parameters treatment without tivantinib fixed effects patient random effect The point estimate treatment difference corresponding confidence interval CI calculated antilogged obtain point estimate CI linear scale ratio geometric means test treatment probe drug  tivantinib compared reference treatment probe drug alone The absence DDI concluded CI test_to_reference ratio PK parameter within effect boundaries 0 80Ð1 25 The interpretation apparent difference considered clinical significance CI test_to_reference ratio PK parameter fell outside effect boundaries Nomenclature targets ligands Key protein targets ligands article hyperlinked corresponding entries http www guidetopharmacology org common portal data IUPHAR BPS Guide PHARMACOLOGY permanently archived Concise Guide PHARMACOLOGY\n",
      "METHODS Subjects The Ethics Committee University Medicine Pharmacy ÒIuliu HatieganuÓ Cluj Napoca Romania reviewed approved clinical protocol In addition subject gave written informed consent prior study procedure The study conducted accordance principles Helsinki amendments Tokyo Venice Hong Kong Good Clinical Practice GCP rules Twenty healthy volunteers included study Caucasian non smoking males females aged years whose health status established based medical history physical examination clinical laboratory tests considered eligible subjects They history alcohol substance abuse Study design This open label non randomized sequential clinical study two period design During Period I Reference single oral dose mg atomoxetine administered subject whereas Period II Test healthy volunteers received single oral dose mg atomoxetine coadministered mg bupropion Between two study periods subjects treated daily dose mg bupropion days respectively mg bupropion another days order quickly reach desired concentration On days subjects remained clinical research unit hours drug administration received standardized meals hours drug intake Water intake restricted hour two hours atomoxetine dosing All drugs administered morning fasted state least mL water No consumption alcohol beverages foods containing methylxanthines coffee tea cola etc permitted hours prior first drug administration collection last blood sample respective study period Drugs study medication except oral contraceptives smoking alcohol allowed taken course trial Alcohol smoking intake J Pharm Pharm Sci www cspsCanada org 200medication except study drugs oral contraceptives allowed throughout trial The pharmaceutical products used Strattera atomoxetine hydrochloride mg capsules Lilly USA LLC Indianapolis USA Elontril bupropion hydrochloride mg tablets Glaxo Wellcome GmbH  Co Bad Oldesloe Germany Blood plasma samples collection analysis Venous blood ml drawn heparinized tubes first Reference last day study Test prior drug administration well h separated plasma stored frozen 20oC analysis A validated high throughput liquid chromatography mass spectrometry HPLC MS method used determine plasma concentrations atomoxetine glucuronidated form active hydroxylated metabolite The chromatographic system Agilent series binary pump autosampler thermostat Agilent Technologies Santa Clara CA USA coupled Brucker Ion Trap SL Brucker Daltonics GmbH Bremen Germany Also chromatographic column used Zobrax SB C18 mm x mm i d _l Agilent Technologies mobile phase consisted mM ammonium formate solution acetonitrile mixture elution gradient  acetonitrile start minutes The flow rate mL min thermostat temperature set 48 C The mass spectrometry detection single ion monitoring mode positive ions using electrospray ionization source The ions monitored m z atomoxetine m z glucuronidated metabolite The retention times parent drug 4 hydroxyatomoxetine O glucuronide min min respectively Furthermore calibration curves compounds linear ng mL The analytical method validated terms specificity linearity intraand inter day precision accuracy analyte recovery The calibration curves compounds linear ng mL correlation coefficients r  mean  S D n  atomoxetine  glucuronidated metabolite For atomoxetine intraand inter day precision less accuracy bias less recovery ranged respectively For 4 hydroxyatomoxetine O glucuronide intra inter day precision less accuracy less recovery ranged respectively Pharmacokinetic analysis A noncompartmental approach used determine pharmacokinetic parameters atomoxetine glucuronidated form 4 hydroxyatomoxetine active metabolite For atomoxetine metabolite parameters calculated Period I Reference atomoxetine administered alone well Period II Test atomoxetine administered concurrently bupropion pretreatment regimen enzymatic inhibitor The maximum plasma concentration Cmax ng ml corresponding time reach concentration tmax h obtained directly observed concentration time data The area concentration time curve AUC0 t estimated using linear trapezoidal rule The area extrapolated infinity AUC0 addition Ct k AUC0 t Ct represents estimated concentration time k elimination rate constant The latter estimated least square regression plasma concentration time data points lying terminal region using semi logarithmic dependence corresponds first order kinetics The elimination half life calculated using following equation t1 2  0 693 k Phoenix WinNonlin version Pharsight Co Mountain View CA USA software used order determine pharmacokinetic parameters Phenotype analysis The AUC0 metabolic ratio atomoxetine 4 hydroxyatomoxetine O glucuronide used identify potential PMs exclude final analysis This performed subject subsequently lower values attributed EM phenotype whereas higher values associated PM phenotype STATISTICAL ANALYSIS The analysis variance ANOVA applied compare pharmacokinetic parameters atomoxetine active metabolite glucuronidated form two treatment periods Test Reference General linear model J Pharm Pharm Sci www cspsCanada org 201procedures used sources variation subjects period treatment This statistical approach employed pharmacokinetic parameters except tmax For latter one non parametric alternative Friedman test performed test differences values corresponding study period The existence potential clinical consequences following concomitant administration atomoxetine bupropion assessed using bioequivalence methodology The confidence intervals CIs Test Reference period ratios Cmax AUC0 t AUC0 log transformed calculated using SchuirmannÕs two one sided test considering bioequivalence range Regarding analysis tmax equivalence range expressed untransformed data significance established using non parametric Friedman test Phoenix WinNonlin version Pharsight Co Mountain View CA USA also software used statistical analysis A p value less considered statistically significant\n",
      "METHODS Study popuZution Fourteen healthy volunteers participated trial Group consisted six extensive metabolizers group two intermediate metabolizers group six poor metabolizers sparteine debrisoquin Groups matched sex age weight CYP2D6 phenotype evaluated use single oral dose mg sparteine sulfate lÕ subjects classified according urinary metabolic ratio MR sparteine 2and 5 dehydrometabolites shows clear trimodal distribution following groupslÕ l MR extensive metabolizer l  MR  intermediate metabolizer l MR I poor metabolizer In addition phenotyping Xba I restriction fragment length polymorphism RFLP polymerase chain reaction PCR used genotyping deoxyribonucleic acid peripheral leukocytes volunteers PCR procedures performed detect A B C D E F J mutations CYP2D6 gene 2o 25 The characteristics volunteers shown Table I The study protocol approved ethics committee Robert Bosch Hospital Stuttgart Germany Before study participants informed physician aim course possible risks study written informed consent obtained A detailed physical examination laboratory tests performed completion study Study design A single oral dose mg dihydrocodeine hydrogentartrate Paracodin administered volunteers fasted overnight Blood samples wer obtained first dose l 2 l 2l 2 3l 2 hours Urine collected hours Urine serum samples stored 20Ó C analysis Analytic methods determination dihydrocodeine dihydrocodeine metabolites Dihydrocodeine dihydromorphine serum determined gas chromatography tandem mass spectrometry GS MS MS 26 In brief ng morphine ng codeine added internal standards ml serum After pH adjusted serum samples extracted ml vol vol mixture dichloromethane 2 propanol The organic phase evaporated dryness gentle stream nitrogen pentafluoropropionyl derivatives prepared treatment l rl pentafluoropropionyl acid minutes 60Ó C The derivatizing reagent removed nitrogen residue dissolved acetonitrile Aliquots injected GC MS MS system consisted II gas chromatograph Hewlett Packard Waldbronn Germany TSQ mass spectrometer Finnigan MAT Bremen Germany The limits quantification rig ml serum dihydrocodeine pg ml serum dihydromorphine Quality control samples dihydrocodeine rig ml dihydromorphine rig ml routinely assayed intraassay coefficient variation less interassay coefficient variation less Dihydromorphine nordihydrocodeine urine determined dilution water described The total amounts dihydromorphine unconjugated conjugated nordihydrocodeine measured dilution l l urine water acid hydrolysis p l hydrochloric acid 100Ó C minutes Dihydrocodeine bitartrate obtained Merck Darmstadt Germany dihydromorphine hydrochloride nordihydrocodeine hydrochloride gifts Mundipharma Limburg Ger v Pharmacokinetic evaluation The maximum serum concentration C time C obtained visual inspection serum concentrationtime curves dihydrocodeine dihydromorphine The area serum concentration time curves AUC dihydrocodeine AUC dihydromorphine AUC nM calculated trapezoidal rule segment infinity determined last concentration measured divided elimination rate constant Elimination half life estimated linear regression log transformed serum concentrations terminal elimination phase Apparent oral clearance CL dihydrocodeine obtained following equation CLral  Dose AUC Partial metabolic clearance CL dihydromorphine calculated following Ae total amount conjugated unconjugated dihydromorphine excreted urine hours Renal clearance CL dihydromorphine derived equation Statistical analysis All data presented mean  SD Pharmacokinetic parameters extensive poor metabolizers compared MannWhitney U test A Spearman rank correlation calculated urinary metabolic ratio sparteine AUC nc AUC ratio urinary metabolic ratio dihydrocodeine Ae Ae respectively p Values considered statistically significant\n",
      "Methods Conduct study This open_label nonrandomized single_sequence study registered ClinicalTrials gov NCT01766050 Institutional Review Board Independent Ethics Committee approval obtained study conducted accordance Good Clinical Practice principles Declaration Helsinki All participants provided written informed consent Subjects Eligible subjects men women aged 18Ð45 years body mass index 18Ð30 kg m_2 healthy determined medical history physical examination electrocardiogram ECG clinical laboratory findings Women childbearing potential participating men sexual partners category required continue contraception days last dose study medication Exclusion criteria included known suspected infection risk factors developing infection autoimmune disorders history strong family history malignancy Prior exposure belatacept abatacept leucocyte_depleting agents e g rituximab prohibited The washout period months hormonal contraceptive agents weeks five half_lives whichever longer prescription drugs St John s wort live vaccine administration weeks over_the_counter drugs herbal preparations week aspirin Concomitant medications permitted study unless initiated investigator treat adverse events Subjects abstained foods beverages containing caffeine well known inhibit induce CYP1 A2 CYP2C9 CYP2C19 CYP2D6 CYP3 A4 Tables Table Study design Screening enrolment IC IC belatacept IC IC Clinical furlough Follow_up End study Days _21 _1 Day Day Day Day Day Day Day  Day  IC Inje cocktail Table Inje cocktail components Cytochrome P450 enzyme Probe substrate Inje cocktail Metabolite 1A2 Caffeine mg Paraxanthine 2C9 Losartan mg E_3174 2C19 Omeprazole mg 5_hydroxyomeprazole 2D6 Dextromethorphan mg Dextrorphan 3A4 Midazolam mg 1__hydroxy_midazolam Study design treatment Table summarizes study sequence Participants admitted clinical pharmacology unit Day _1 screening remained clinic furlough Day subsequently returning two follow_up visits All subjects received drug regimen In morning Days fasting least h subjects administered oral doses Inje cocktail consisted caffeine 200_mg tablet losartan 50_mg tablet omeprazole 40_mg delayed_release capsule dextromethorphan 30_mg capsule midazolam 5_mg oral syrup probe substrates CYP1 A2 CYP2C9 CYP2C19 CYP2D6 CYP3 A4 respectively In morning Day fasting least h belatacept administered single 10_mg kg_1 intravenous infusion min closely followed within approximately min Inje cocktail doses listed Belatacept mg kg_1 selected dose approved use initial phase kidney transplant During dosing Inje cocktail oral dispenser used administer midazolam re_filled twice ml water administered subject In addition time Inje cocktail dosing ml water administered subject along study medication A physician site day dosing remained site least h midazolam dose Compliance assessed mouth check Table Disposition subjects Data Set Subjects n  Enrolled Dosed Completed study Did complete study Adverse event Withdrew consent Lost follow_up Safety analysis Pharmacokinetic analysis 100 0 a Reduced pharmacokinetic data set dextromethorphan aA reduced pharmacokinetic data set defined dextromethorphan dextrorphan one poor CYP2D6 metabolizer excluded Table details Inje cocktail components metabolites together relevant CYP subtype Each drug Inje cocktail sourced single commercially available lot Table Effect belatacept pharmacokinetics Inje cocktail components Day Day Day Omeprazole C max AUC 0Ðt AUC 0Ð Caffeine C max AUC 0Ðt AUC 0Ð Losartan C max AUC 0Ðt AUC 0Ð Dextromethorphan C max AUC 0Ðt AUC 0Ð Midazolam C max AUC 0Ðt AUC 0Ð Data point estimates geometric mean ratio test day vs Day confidence interval AUC area plasma concentration_time curve Cmax maximum concentration Pharmacogenomics Using blood sample collected Day _1 genotyping performed polymorphic CYP2C9 CYP2C19 CYP2D6 identify poor metabolizers Inje cocktail components effort guide data interpretation Pharmacokinetic analysis study end points Blood samples serum belatacept pharmacokinetics taken pre_ post_dose Day Days Blood samples assessment plasma concentrations Inje cocktail components caffeine losartan omeprazole dextromethorphan midazolam metabolites paraxanthine E_3174 5_hydroxyomeprazole dextrorphan 1__hydroxy_midazolam respectively collected h Days 24_h postdosing The primary end point maximum serum concentration Cmax area plasma concentrationÐtime curve AUC time zero time last quantifiable concentration AUC0Ðt AUC time zero infinity AUC0Ð Inje cocktail component without administration belatacept Cmax AUC0Ðt AUC0Ð metabolites well molecular weight_corrected metabolite_to_drug ratio parameters secondary end points Point estimates geometric mean ratios calculated Inje cocktail components metabolites metabolite_to_drug ratios compare Days Day respectively evaluable pharmacokinetic population All reported results belatacept Inje cocktail data conducted compliance applicable standard operating procedures place time analysis For summaries belatacept Inje cocktail plasma concentrationÐtime data concentrations less lower limit quantification LLOQ treated missing summary tables plots For pharmacokinetic calculations predose concentrations concentrations prior first quantifiable concentration less LLOQ set zero All concentrations less LLOQ set missing Pharmacokinetics parameters derived plasma concentration vs time data using noncompartmental analysis WinNonlin Professional Network Edition Version Pharsight Corp St Louis MO USA Pharmacokinetic assay performance A liquid chromatography tandem mass spectrometry method developed validated simultaneously determine concentrations dextromethorphan losartan major active metabolites losartan carboxylic acid E_3174 midazolam 1__hydroxymidazolam omeprazole major active metabolite 5_hydroxyomeprazole caffeine major active metabolite 1 7_dimethylxanthine paraxanthine support pharmacokinetic analyses All reported results caffeine losartan omeprazole dextromethorphan midazolam paraxanthine E_3174 5_hydroxyomeprazole dextrorphan 1__hydroxy_midazolam concentrations plasma generated using appropriate calibration curves quality control samples met pre_established acceptance criteria conducted compliance applicable standard operating procedures place time analysis A summary assay performance caffeine losartan omeprazole dextromethorphan midazolam paraxanthine E_3174 5_hydroxyomeprazole dextrorphan 1__hydroxy_midazolam concentrations plasma presented Table Table Summary bioanalytical assay performance components Inje cocktail metabolites Analyte Matrix LLOQ ng ml _1  ULOQ ng ml _1  Between_run CV Within_run CV Mean  deviation nominal concentration Caffeine Plasma ²8 17 ²35 1 Losartan Plasma ²8 60 ²20 6 Omeprazole Plasma ²7 74 ²17 0 Dextromethorphan Plasma ²9 50 ²22 9 Midazolam Plasma ²3 65 ²4 90 Paraxanthine Plasma ²8 14 ²36 1 E_3174 Plasma ²8 37 ²20 9 5_hydroxyomeprazole Plasma ²6 41 ²15 5 Dextrorphan Plasma ²11 5 ²23 8 1__hydroxymidazolam Plasma ²6 47 ²11 2 aMaximum value analytical quality controls CV coefficient variation LLOQ lower limit quantitation ULOQ upper limit quantitation Exploratory biomarker analyses Serum samples measuring cytokine levels collected Days _1 samples taken prior dosing Days Tumour necrosis factor__ IFN__ IFN__ IL_2 IL_6 IL_10 quantified validated multiplex immunoassay Luminex platform Whole_blood samples collected Days predose predose Pharmacokinetic modelling omeprazole accumulation A physiologically based pharmacokinetic model omeprazole 5_hydroxyomeprazole developed using SimCYP v 13 Certara St Louis MO USA This model developed initial clinical study used evaluate hypothesis observed increase omeprazole AUC observed decrease 5_hydroxyomeprazole AUCm AUCp caused omeprazole_mediated time_dependent inhibition CYP_mediated elimination rather belatacept The regimen omeprazole used healthy volunteer study used model excluded belatacept model predicted accumulation repeated doses omeprazole mg alone Days study population Full model development methodology model parameter values provided supplemental material Safety Safety tolerability secondary objectives Blood urine haematology chemistry urinalysis assessment collected screening Days _1 study discharge Day  visits Subjects required fast nothing eat drink except water least h prior specimen collection clinical laboratory testing All laboratory assessments reviewed investigator prior dosing Day The incidence adverse events significant laboratory abnormalities recorded study changes ECGs vital signs physical examinations monitored Statistical methods The sample size based statistical power considerations Data evaluable subjects required provide least confidence estimated ratios geometric mean values AUC0Ð Inje cocktail component without belatacept within true ratios i e confidence interval CI test reference ratio would given true ratio To estimate effect concomitant belatacept Inje component drugs linear mixed models fitted log_transformed pharmacokinetic parameters Point estimates CIs treatment differences log scale exponentiated obtain estimates Cmax AUC0Ðt AUC0Ð ratios calculated using geometric means Inje cocktail  belatacept Days vs reference value Day No adjustments made multiple comparisons Statistically significant differences defined CI geometric mean ratio falling\n",
      "Methods Study Design All clinical study protocols approved Institutional Review Board study site cyclosporine sirolimus tacrolimus studies Independent Investigational Review Board Inc Plantation Florida mycophenolate mofetil prednisone studies Aspire IRB LLC Santee California The studies conducted accordance ethical principles origin Declaration Helsinki Good Clinical Practice International Conference Harmonisation guidelines applicable laws regulations Signed Institutional Review BoardÐapproved written informed consent obtained subjects prior study_related procedures The studies phase single_center open_label drug_interaction trials conducted healthy subjects evaluate effects isavuconazole administered isavuconazonium sulfate CRESEMBA oral capsules Astellas Pharma US Inc Northbrook Illinois PK coadministered cyclosporine NEORAL oral capsules Novartis Pharmaceuticals Corp East Hanover New Jersey trial conducted November January Covance Madison Wisconsin NCT01494597 MMF CELLCEPT oral tablets Genentech USA Inc South San Francisco California trial conducted March April PAREXEL International LLC Glendale California NCT01711489 prednisolone generic oral capsules prodrug prednisone trial conducted February March PAREXEL International LLC Glendale California NCT01711827 sirolimus RAPAMUNE oral tablets Pfizer Inc Philadelphia Pennsylvania trial conducted December January Covance Dallas Texas NCT01809860 tacrolimus PROGRAF oral capsules Astellas Pharma US Inc Northbrook Illinois trial conducted December January Covance Madison Wisconsin NCT01535547 Healthy medication_free adult male female subjects aged 18_55 years old weighed ³45 kg body mass index 18_32 kg m2 included studies Dosing Sampling Schedules Dosing information expressed isavuconazole equivalent prodrug oral capsules contained isavuconazonium sulfate mg equivalent isavuconazole mg The clinically targeted oral dose isavuconazonium sulfate mg equivalent isavuconazole mg times day loading dose TID followed mg daily QD used studies Only active metabolite isavuconazole referred hereafter Cyclosporine Subjects screened days Ð28 Ð2 checked study center day Ð1 remained day days Subjects returned study center day days follow_up assessment On day subjects received single oral dose cyclosporine mg Following 10_day washout subjects received oral loading dose isavuconazole mg TID days followed mg QD days Figure _ Figure1A 1A A single oral dose cyclosporine mg also administered subjects day Subjects administered doses cyclosporine fasting least hours prior dosing hours dosing Isavuconazole administered immediately following cyclosporine day Blood samples collected PK analysis cyclosporine days predose hours postdose Samples collected PK analysis isavuconazole day predose hours postdose well day predose hours postdose Mycophenolate Mofetil After screening day Ð28 Ð2 subjects checked study center day Ð1 remained day day day Subjects returned study center day days follow_up assessment On day study subjects received single oral dose MMF g followed 7_day washout period Subjects received oral loading dose isavuconazole mg TID days followed mg QD days Figure _ Figure1B 1B On day subjects received single oral dose MMF g concurrently isavuconazole Subjects administered doses MMF fasting least hours prior dosing hours dosing Isavuconazole administered immediately following MMF day Blood samples collected PK analysis MPA metabolite mycophenolic acid phenyl glucuronide MPAG days predose hours postdose Samples also collected PK analysis isavuconazole days predose hours postdose Prednisolone Subjects screened day Ð28 Ð2 checked study center day Ð1 remained day A follow_up visit conducted study center day days On day subjects received single oral dose prednisone mg prodrug prednisolone Following 4_day washout period subjects received oral loading dose isavuconazole mg TID days followed mg QD days Figure _ Figure1C 1C On day subjects received single oral dose prednisone mg isavuconazole Subjects administered doses prednisone fasting least hours prior dosing hours dosing Isavuconazole administered immediately following prednisone day Blood samples collected PK analysis prednisone active metabolite prednisolone days predose hours postdose Samples also collected PK analysis isavuconazole days predose hours postdose Sirolimus Following screening day Ð28 day Ð2 subjects checked study center day Ð1 remained day day day Subjects returned follow_up assessment day days On day subjects received single dose oral sirolimus mg After 21_day washout subjects received loading dose oral isavuconazole mg TID days followed mg QD days Figure _ Figure1D 1D On day subjects received single dose oral sirolimus mg addition isavuconazole Subjects administered doses sirolimus fasting least hours prior dosing hours dosing Isavuconazole administered immediately following sirolimus day Blood samples collected PK analysis sirolimus days predose hours postdose Samples collected PK analysis isavuconazole day predose hours postdose well day predose hours postdose Tacrolimus Subjects screened days Ð28 Ð2 checked study center day Ð1 Following check_in subjects remained study center day days Subjects returned study center day days follow_up assessment On day subjects received single oral dose tacrolimus mg Following 15_day washout subjects received oral loading dose isavuconazole mg TID days followed mg QD days Figure _ Figure1E 1E A single oral dose tacrolimus mg also administered subjects day Subjects administered doses tacrolimus fasting least hours prior dosing hours dosing Isavuconazole administered immediately following tacrolimus day Blood samples collected PK analysis tacrolimus days predose hours postdose Samples collected PK analysis isavuconazole day predose hours postdose well day predose hours postdose Pharmacokinetic Assessments Plasma whole_blood concentrations analytes measured liquid chromatographyÐmass spectrometry mass spectrometry see Supplementary Data S1 methods The primary PK variables immunosuppressive agents area concentration_time curve AUC time infinity AUC0Ð AUC time dosing time last measurable concentration AUClast maximum drug concentration Cmax Secondary variables included time Cmax tmax apparent volume distribution Vz F apparent body clearance dosing CL F elimination half_life t1 2 Because reversible conversion prodrug prednisone prednisolone results wide interindividual variability Vz F CL F parameters measured prednisolone Cyclosporine sirolimus tacrolimus parameters measured whole blood Prednisone prednisolone MPA MPAG measured plasma For isavuconazole area plasma concentration_time curve dosing interval AUC_ Cmax tmax calculated Safety Assessments Treatment_emergent adverse events TEAEs assessed throughout studies Other safety assessments included vital_sign measurements 12_lead electrocardiograms clinical laboratory testing hematology chemistry urinalysis physical examinations Statistics Descriptive statistics used summarize demographics baseline characteristics TEAEs patients received ³1 dose study drug Pharmacokinetics assessed subjects received ³1 dose study drug PK data sufficient calculation ³1 primary PK parameter Levels analyte level quantification entered calculations For PK assessments log_transformed AUC Cmax values analyzed using mixed_effects model treatment fixed effect subject random effect Treatment defined coadministration immunosuppressive agent plus isavuconazole administration immunosuppressive agent alone Results presented confidence intervals CIs constructed around geometric least_squares mean ratios PK parameters measured dosing immunosuppressive agent plus isavuconazole vs dosing immunosuppressive agent alone Pharmacokinetics assessed using noncompartmental analysis Phoenix WinNonlin version higher Certara USA Inc Princeton New Jersey All data processing summarization analyses performed using SAS version Statistical Analysis Software Cary North Carolina Statistical analysis isavuconazole prednisone PK prespecified performed prednisone study\n",
      "Methods Study Design This phase open label one sequence crossover study 1517 CL 0527 EudraCT conducted single center PAREXEL Early Phase Clinical Unit Berlin Germany consisting screening period Day Ð22 Day Ð2 followed two treatment periods separated ³_7 day washout phase During Period subjects admitted clinic Day Ð1 received single oral dose mg roxadustat ASP1517 Astellas Pharma Inc Day Subjects remained clinic discharged Day Blood samples roxadustat pharmacokinetic assessments collected Days 1Ð4 The starting doses current phase studies patients CKD dialysis range mg three times weekly upor down titrated range 20Ð300 mg three times week Therefore selected dose mg roxadustat truly represents medium range widely used therapeutic dose This dose level present DDI study allowed potential increases roxadustat exposure due presence omeprazole without safety concerns After a_³_7 day washout period subjects re admitted clinic Day Ð1 Period During Period subjects received daily oral doses mg omeprazole Antra MUPS AstraZeneca Days 1Ð9 single oral dose mg roxadustat Day Blood samples roxadustat pharmacokinetic assessments collected Days 7Ð10 blood samples omeprazole pharmacokinetic assessments collected Days 7Ð10 Subjects discharged Day returned clinic end study visit 5Ð9 days later safety assessments Since recommended dose omeprazole treatment gastroesophageal reflux disease peptic ulcer disease 20Ð40 mg daily regimen daily administration high doses omeprazole mg Days 1Ð7 administration single oral dose mg roxadustat Day chosen maximize interaction potential closely mimic real life treatment conditions Blood samples pharmacokinetic analyses roxadustat collected preand post dose prefixed intervals Period Period This study conducted accordance clinical study protocol Good Clinical Practice International Council Harmonisation guidelines applicable regulations guidelines governing clinical study conduct ethical principles Declaration Helsinki The protocol approved Independent Ethics Committee Landesamt f r Gesundheit und Sociales Ethik Kommission des Landes Berlin subjects provided written informed consent Study Objectives The primary objective determine effect multiple daily oral doses mg omeprazole pharmacokinetics single oral dose mg roxadustat The secondary objective evaluate safety tolerability single oral dose mg roxadustat alone combination multiple daily oral doses mg omeprazole Study Population Healthy male female subjects aged 18Ð55 years body mass index 18 5Ð29 9 kg m2 enrolled study Female subjects either non childbearing potential must negative serum pregnancy test Day _1 agree use two forms highly effective birth control time screening days final dosing Male subjects female partners childbearing potential agree use two highly effective forms birth control male subjects agree donate sperm screening days final dosing Key exclusion criteria included pregnancy within months breastfeeding within months screening liver function tests 1 5___the upper limit normal use prescription nonprescription drugs including oral contraceptives occasional paracetamol g day weeks prior administration study drug end study visit history drinking_ _21 units male subjects or_ _14 units female subjects alcohol unit_ _10 g pure alcohol mL beer mL spirits mL wine per week drugs abuse months admission use drugs induced metabolism within months prior admission A complete list inclusion exclusion criteria available Online Resource Study Drug Administration On Day Period roxadustat provided single mg tablet mL water overnight fast least h first meal provided h dosing On Days 1Ð6 Days Period omeprazole provided dose 2___20 mg tablets daily total daily dose mg mL water overnight fast least h min breakfast On Day Period omeprazole dosed first roxadustat dosed h later first meal Day provided h roxadustat administration Study Assessments Pharmacokinetic Assessments Blood sampling roxadustat conducted predose min h postdose Days 1Ð4 Period Days 7Ð10 Period Blood sampling omeprazole conducted predose Days min h postdose Days predose Days Blood samples obtained via peripherally placed intravenous cannula via direct venipuncture collected 3 mL tubes sodium heparin Blood samples shipped Astellas Drug Discovery Research Bioanalysis Europe concentrations roxadustat human Na heparin plasma measured using liquid chromatography tandem mass spectrometry method validated according European Medicines Agency bioanalytical method validation guidance July A stable isotope label 13C2 D3 roxadustat used internal standard Roxadustat internal standard extracted µl plasma solid phase extraction separated reversed phase liquid chromatography C18 column using gradient water acetonitrile formic acid used mobile phase Detection performed via tandem mass spectrometry QTrap mass spectrometer using positive Turbo ion spray ionization The method linear range 1Ð1000 ng mL lower limit quantification ng mL The method selective show evidence carryover The inter run accuracy varied _4 6 inter run precision ranged Concentrations omeprazole human Li heparin plasma also measured using liquid chromatography tandem mass spectrometry method A stable isotope labeled omeprazol D3 used internal standard Omeprazole internal standard extracted µl plasma liquidÐliquid extraction separated reversed phase liquid chromatography C18 column Detection performed via tandem mass spectrometry API mass spectrometer using positive Turbo ion spray ionization The method linear range 1Ð500 ng mL lower limit quantification ng mL The method selective show evidence carryover The inter run accuracy varied _1 8 inter run precision ranged Pharmacokinetic parameters calculated using Phoenix Certara LP St Louis MO USA non compartmental methods used calculate values pharmacokinetic parameters Pharmacokinetic Endpoints Primary endpoints area concentrationÐtime profile time dosing extrapolated infinity AUCinf maximum concentration Cmax roxadustat plasma Secondary endpoints included area concentrationÐtime profile last measurable concentration AUClast time reach maximum concentration tmax t_ Safety Safety assessed evaluation nature frequency severity treatment emergent adverse events TEAEs vital signs blood pressure pulse clinical laboratory tests hematology biochemistry urinalysis routine 12 lead electrocardiogram ECG TEAEs graded according National Cancer Institute Common Terminology Criteria Adverse Event guidelines version coded using Medical Dictionary Regulatory Activities MedDRA Statistical Methods Based previous food effect study data file showed within subject coefficient variation sample size determined provide power NQUERY demonstrate absence effect omeprazole roxadustat pharmacokinetics The absence effect concluded confidence intervals CIs ratio geometric means i e roxadustat_ _omeprazole roxadustat alone AUCinf Cmax within no effect boundaries A total subjects enrolled allow dropouts The safety analysis set SAF comprised subjects received least one dose roxadustat The pharmacokinetic analysis set used pharmacokinetic analysis included subjects received least one dose study drug plasma concentration data available determine least one pharmacokinetic parameter Descriptive statistics used summarize demographic baseline data pharmacokinetic parameters i e number subjects arithmetic mean standard deviation  coefficient variation median range Frequencies percentages used categorical data To assess impact omeprazole pharmacokinetics roxadustat log transformed AUCinf Cmax roxadustat analyzed using linear mixed effects model treatment fixed effect subject random effect No imputation missing data performed\n",
      "Methods Patients data collection A single_centre prospective clinical study conducted March January Department Urological Organ Transplantation Second Xiangya Hospital Central South University The study approved Ethics Research Committee Second Xiangya Hospital Central South University yxlb_lcys_201_501 A signed informed consent participate study obtained patients All RTRs receiving intravenous oral VRC prevention treatment IFIs hospitalization eligible enrol study Routine TDM CYP2C19 genotyping performed The initial dose route administration determined based VRC manufacture package insert The subsequent dose adjusted surgeons according clinical response TDM results All patients received tacrolimus cyclosporine primary immunosuppressive agent The exclusion criteria follows age years ii absence VRC plasma concentration CYP2C19 genotyping iii concomitant drugs known large effect VRC pharmacokinetics e g rifampin strong inducer CYP2C19 iv incomplete important dosing information clinical data Patients medical records reviewed individually using standardized data collection form From start VRC therapy researchers tracked accurately recorded dosing information indication therapy route administration dose administration time sampling time concomitant drugs taken VRC therapy proton pump inhibitors PPIs including omeprazole esomeprazole pantoprazole lansoprazole ilaprazole glucocorticoid methylprednisolone In addition demographic data age gender weight laboratory test results blood liver kidney function index time transplantation completed collected blood samples obtained analyse CYP2C19 alleles CYP2C19 2 CYP2C19 3 CYP2C19 17 Blood sampling analytical assays Blood_samples_were_taken h every patient least 2Ð3 samplings receiving first intravenous oral VRC dose Plasma concentrations considered steady state day later following loading doses day later treatment without loading doses At steady state Cmin samples collected min next dose As described previous paper VRC plasma concentrations measured automatic two_dimensional high_performance liquid chromatography Demeter Instrument Co Ltd Hunan China The first dimensional chromatographic column ASTON FRO C18 mm _ mm _m ANAX column second dimensional chromatographic column ASTON HD C18 mm _ mm _m ANAX column DNA purification CYP2C19 genotyping Blood samples 1Ð3 ml genotype detection obtained every enrolled patient DNA purified using E Z N A SQ Blood DNA Kit II Omega Bio_Tek Inc Norcross GA USA method CYP2C19 genotyping carried using Sanger dideoxy DNA sequencing method ABI 3730XL DNA Analyzer ABICo BioSune Biotechnology Co Ltd Shanghai China CYP2C19 phenotypes classified five categories ultrarapid metabolizer UM CYP2C19 17 17 rapid metabolizer RM CYP2C19 1 17 extensive metabolizer EM CYP2C19 1 1 intermediate metabolizer IM CYP2C19 1 2 CYP2C19 1 3 CYP2C19 2 17 poor metabolizer PM CYP2C19 2 2 CYP2C19 2 3 CYP2C19 3 3 PPK analysis A nonlinear mixed_effects model NONMEM developed using first_order conditional estimation_extended least_squares FOCE ELS method performed using Phoenix NLME software Version Pharsight A Certara Company Princeton NJ USA Structural model One_ two_compartment models first_order oral absorption linear nonlinear MichaelisÐMenten elimination intravenous oral administration investigated determine optimal structural model The clearance CL volume distribution V oral bioavailability F VRC characterized estimated The absorption rate constant fixed h_1 based literature report Statistical model The interindividual variability VRC pharmacokinetic parameters described using exponential models Pij  Ppop _ exp _ij Pij jth pharmacokinetic parameter estimation ith individual Ppop population typical value jth parameter _ij random variable distributed mean zero variance _2 Residual variability evaluated comparing following models Additive error model Cobs  Cpred  _Proportional error model Cobs  Cpred _  _ Combined error model Cobs  Cpred _  _  _ÕExponential error model Cobs  Cpred _ exp _ In four equations Cobs Cpred observed predicted concentrations _ _Õ random variables distributed mean zero variances _2 _Õ2 respectively The optimal residual variability model determined balancing objective function value OFV percentage coefficient variation CV RetCode value Covariate model The correlations pharmacokinetic parameters covariates preliminarily inspected linear plots continuous variables box plots categorical variables Subsequently covariates screened forward addition followed backward elimination steps stepwise method establish full model final model including gender _age _body_weight WT white blood cell WBC count haemoglobin HGB level platelet PLT count alanine aminotransferase ALT aspartate aminotransferase AST albumin ALB total bilirubin TBIL direct bilirubin DBIL serum creatinine SCr levels CYP2C19 phenotype PM IM EM postoperative time POT well concomitant medications including lansoprazole ilaprazole methylprednisolone A significant covariate retained final model following criteria met decrease OFV P  included forward addition steps increase OFV P  significant backward elimination steps approximate _2 distribution _2  _2  ii clinical plausibility parameterÐcovariate relationship iii confidence interval CI parameter estimates include zero Model evaluation validation Goodness_of_fit GOF plots used evaluate adequacy fitting The stability final model precision parameter estimation assessed bootstrap method One thousand resamples original data performed The parameters median CI obtained bootstrap analysis compared estimates final model Model_based simulations In order recommend optimal dosing regimens RTRs IFIs specific clinical scenarios various dosing simulations based established final model performed using Phoenix NLME Version The parameter estimates VRC CL V oral F well interindividual variability used simulate steady_state Cmin replicates following different intravenous oral maintenance doses _A VRC Cmin least _gáml_1 critically ill patients poor prognosis recommended British Society Medical Mycology Considering IFI devastating infection RTRs lower end therapeutic Cmin range targeted _gáml_1 dosing simulations The supratherapeutic threshold defined _gáml_1 based recent report Statistical analysis The KruskalÐWallis test DunnÐBonferroni post hoc test applied check differences VRC Cmin among CYP2C19 phenotype groups well among different periods renal transplantation P  considered statistically significant Statistical analysis performed using SPSS version IBM Corporation Armonk NY USA Nomenclature targets ligands Key protein targets ligands article hyperlinked corresponding entries http www guidetopharmacology org common portal data IUPHAR BPS Guide PHARMACOLOGY permanently archived Concise Guide PHARMACOLOGY\n",
      "Materials methods Study design This phase Ib open label four arm parallel design multicenter multiple dose study healthy female subjects non childbearing potential Subjects randomly assigned treatment arms ratio stratification according AAG concentration low 0 5Ð0 73 g L medium 0 74Ð0 96 g L high 0 97Ð1 2 g L Arm A received oral vismodegib mg QD days 1Ð7 Arm B received oral rabeprazole mg QD days 1Ð4 followed rabeprazole mg administered h prior dosing vismodegib mg QD days 5Ð11 Arm C received oral itraconazole mg QD administered h prior dosing vismodegib mg QD days 1Ð7 Arm D received fluconazole mg two 200 mg tablets QD administered h prior dosing vismodegib mg QD days 1Ð7 Subjects admitted clinical research unit day preceding first day study drug administration day_1 confined study completion day Study treatments administered morning approximately mL water overnight fast including water least h During study administration concomitant medications prohibited without prior approval investigator thyroid hormone replacement therapy stable dose least months Additionally prior check in subjects refrain use investigational drug biologic agent half lives days whichever longer H2 receptor antagonists month antacids month medications products vaccines including seasonal flu H1N1 vaccines days monoamine oxidase inhibitors thioridazine pimozide antidepressants month weeks antibiotics narcotics pain weeks over the counter nonprescription medications including vitamins minerals phytotherapeutic herbal plant derived preparations tryptophans St JohnÕs wort days half lives whichever longer PPIs months During study h prior check in subjects abstained consuming alcohol grapefruit caffeine containing foods beverages received standardized diet scheduled times confined clinical research unit Ethical approval The study protocol approved independent Institutional Review Board study conducted accordance provisions Declaration Helsinki Good Clinical Practice guidelines Informed consent obtained individual participants included study This trial registered ClinicalTrials gov identifier NCT01772290 Subjects Eligible subjects females non childbearing potential postmenopausal least year surgically sterile aged 18Ð70 years body mass index 18 0Ð35 0 kg m2 good health based medical history physical examination 12 lead electrocardiogram laboratory test results The acceptable range serum AAG levels 0 5Ð1 2 g L within days prior first dose Subjects excluded significant medical history clinical manifestation metabolic allergic dermatologic hepatic renal hematologic pulmonary cardiovascular endocrine gastrointestinal urologic neurologic psychiatric disorder determined investigator ZollingerÐEllison syndrome BarrettÕs esophagus cancer PK assessments analysis Blood samples collected PK analysis vismodegib prior dosing h postdose days days vismodegib  rabeprazole arm within h prior dosing days 2Ð6 days 6Ð10 vismodegib  rabeprazole arm The primary PK parameters interest average plasma concentration Css ave vismodegib AUC0Ð24h steady state day day vismodegib  rabeprazole arm Exploratory PK parameters included vismodegib maximum plasma concentration Cmax AUC0Ð24h time maximum concentration single dose day day vismodegib  rabeprazole arm time steady state tss defined earlier consecutive days difference vismodegib concentrations  vismodegib vismodegib  rabeprazole arms average unbound plasma concentration steady state Css ave u using values h postdose day day vismodegib  rabeprazole arm PK parameters calculated using noncompartmental methods WinNonlin Pharsight Corporation Mountain View CA Version PK analysis used actual times recorded case report form Total vismodegib plasma concentrations determined Covance Laboratories Inc Õs Bioanalytical Department Madison WI using validated high performance liquid chromatography tandem mass spectrometric detection HPLCÐMS MS analytical procedure Unbound plasma concentrations vismodegib determined Covance Laboratories Inc Õs Bioanalytical Department Madison WI using validated HPLCÐMS MS analytical procedure following equilibrium dialysis performed QPS Newark DE Safety assessments Safety tolerability vismodegib assessed collection adverse events AEs incidence nature severity also changes clinical laboratory results vital signs electrocardiograms physical examination findings Statistical analysis A total subjects planned enrollment order provide least subjects evaluable PK results four treatment arms This sample size estimated sufficient point estimate geometric mean ratio GMR AUC0Ð24h two arms results would fall within  true value  confidence assuming true ratio based standard deviation natural log transformed AUC0Ð24h obtained prior PK studies vismodegib To evaluate relative effect interacting drugs PK vismodegib statistical model built compare parameters Css AUC0Ð24 post day day vismodegib  rabeprazole arm dose control arm Arm A study arms rabeprazole Arm B itraconazole Arm C fluconazole Arm D The values Css AUC0Ð24 natural log transformed prior statistical analysis The statistical model treatment arm fixed effect four levels A B C D follows log PK parameter  treatment  random error The GMR estimated Css AUC0Ð24 Arms A B Arms A C Arms A D A  confidence interval CI calculated GMR Css AUC0Ð24 statistical model All parameters summarized descriptive statistics Steady state defined earlier consecutive days predose time points difference vismodegib concentrations  To evaluate relative effect rabeprazole Arm B time to reach steady state daily dosing vismodegib tss post day day vismodegib  rabeprazole arm calculated control arm Arm A descriptive statistics tss provided Arms A B The PK population included subjects received seven doses vismodegib evaluable PK data The safety population comprised subjects received least one dose vismodegib\n",
      "Method Study design This study open label prospective single centre single arm fixed order interventional pharmacokinetic interaction study The study performed Tuberculosis Centre Beatrixoord All study subjects received standard care MDR TB comorbidities Treatment MDR TB based WHO guidelines individualised patient included The primary objective quantify linezolid area concentrationÐtime curve h AUC0Ð12 without clarithromycin mg mg clarithromycin daily Secondary objectives compare pharmacokinetic parameters linezolid clarithromycin different dosing combinations describe tolerability safety co administration clarithromycin linezolid MDR TB patients All patients gave written informed consent The study protocol approved medical ethical review committee University Medical Centre Groningen Groningen Netherlands The study registered clinicaltrials gov identifier number NCT01521364 Subjects All study subjects aged ³18 years diagnosed MDR TB confirmed using standard microbiological culture methods The criteria exclusion based contraindications known drugÐdrug interactions mentioned summary product characteristics linezolid clarithromycin Subjects excluded study pregnant lactating previously shown hypersensitivity linezolid macrolide antibiotics excipients linezolid clarithromycin hypokalaemia concomitantly received P glycoprotein modulators Drug sensitivity testing DST performed Dutch National Mycobacterial Reference Laboratory National Institute Public Health Environment RIVM Bilthoven The Netherlands using Middlebrook 7H10 agar dilution method Treatment All patients received linezolid mg every h In previous studies showed dose resulted seemingly effective serum concentrations median interquartile range IQR AUC0Ð12 mgáháL_1 38 5Ð64 2 mgáháL_1 AUC0Ð12 MIC ratios 343Ð513 Clarithromycin added therapy dosage mg mg daily consecutively weeks fixed order fig From three cases Tuberculosis Centre Beatrixoord one case published expected mg clarithromycin would result approximately doubled linezolid exposure matching exposure linezolid labelled dose mg twice daily Figure 1Ð Download figureOpen new tabDownload powerpoint Figure 1Ð Study design showing dosing sampling schedules linezolid LZD clarithromycin CLR Before study patients received standard medical care treatment multidrug resistant tuberculosis Full linezolid pharmacokinetic curves recorded baseline week linezolid without clarithromycin receiving linezolid mg clarithromycin weeks linezolid mg clarithromycin weeks fig A trough sample obtained washout period week patients received linezolid besides standard treatment clarithromycin Sample size derived AUCs previous study MDR TB patients relative large increase exposure observed three cases two cases unpublished To reach desired power sample size least five patients calculated using G Power Heinrich Heine Universit t D sseldorf Germany A dropout rate estimated based previous studies Tuberculosis Centre Beatrixoord To compensate estimated dropout seven patients included Experimental procedures The baseline linezolid pharmacokinetic curve trough 1 week washout period obtained steady state reached _3 days Pharmacokinetic curves co administration linezolid clarithromycin assessed steady state weeks allowing pharmacokinetic interaction develop fully Blood samples collected h intake medication The second dose linezolid given directly last blood sample The patients receive standardised meals allowed eat regular breakfast reflecting common clinical practice since food influence linezolid exposure Adherence ensured directly observed inpatient treatment programme Serum concentrations Blood samples drawn centrifuging serum samples stored 20 C analysis Linezolid clarithromycin serum concentrations analysed using validated high performance liquid chromatography tandem mass spectrometry methods Tolerability safety The patients clinically observed nurses attending physicians Routine checks including blood tests carried least weekly part continued standard care including monitoring hyperlactataemia haematological abnormalities thrombocytopaenia anaemia All patients received epoetine _ Eprex Janssen Cilag Leiden The Netherlands pre emptively dose IU twice week prevent anaemia part standard care Gastrointestinal side effects determined using common toxicity criteria CTC scored grades 0Ð4 Routine testing neurotoxic adverse events electromyogram vibration sense monitoring carried 6 week study since effects reported occur median range weeks 10Ð111 weeks In case clinical suspicion peripheral neuropathy neurologist consulted common practice Tuberculosis Centre Beatrixoord Furthermore patients receiving linezolid examined ophthalmologist monthly also common practice centre Pharmacokinetic statistical analysis The main study parameter linezolid AUC0Ð12 secondary study parameters clearance elimination constant elimination half life calculated using trapezoidal rule Kinfit software MWPharm Mediware Groningen Netherlands The pharmacokinetic parameters linezolid clarithromycin described The maximal serum concentration Cmax defined highest observed serum concentration Cmin defined concentration intake medication The hypothesis median differences AUC0Ð12 linezolid baseline compared AUC0Ð12 co administration either mg mg clarithromycin equal zero tested using related samples Wilcoxon signed rank test Secondary pharmacokinetic parameters three curves compared using related samples Wilcoxon signed rank test The nonparametric ANOVA Friedman test used test dose dependency effect clarithromycin linezolid exposure All statistical evaluations performed using SPSS SPSS Chicago IL USA\n",
      "Materials methods Subjects Eight healthy subjects phenotyped EM women men aged healthy subjects phenotyped PM women men aged participated study The subjects phenotyped according sparteine test EM sparteine metabolic ratio MR less PM MR The volunteers given consent participate basis verbal written information protocol approved regional Ethics Committee National Board Health Each volunteer took single oral dose mg quinidine free base gelatine capsule purified dihydroquinidine structural formula purity confirmed NMR mass spectroscopy elemental analysis Blood samples obtained via heparinised intravenous catheter Venflon placed heparinised Venoject tube h hourly h h Additional blood samples 5O2 obtained h drug administration Urine collected intervals h 10_24 h 24M8 h Plasma urine kept frozen 20 C analysis Quantitation quinidine metabolites Quinidine 3S 3OH quinidine quinidine N oxide assayed recently developed HPLC method using fluorescence detection The level quantitation nM plasma n mol1 1 urine three compounds The coefficient variation range tool1z plasma range tmol 1  urine three compounds Pharmacokinetic analysis Pharmacokinetic parameters quinidine metabolites calculated described The area plasma concentration curve quinidine AUCq calculated using trapezoidal method extrapolation infinity The total oral clearance quinidine CL f calculated Dose CL f  AUCq The partial clearances via 3S 3 hydroxylation CLqm 3s _3OH l  N oxidation CLq q N renal excretion CLR metabolism CLM calculated 3S 3OH quinidine urine h CLq 3s 3 tt AUCq h CLq q N  quinidine N oxide urine h AUCq h quinidine urine h CLR  AUCq h CL M  CL f CL R 3S 3Ot1 quinidine urine h quinidine N oxide urine h quinidine urine h arc amounts excreted urine h AUCq h AUC quinidine h For two partial clearances via 3S 3 hydroxylation N oxidation assumed formation rate metabolites appearance urine For calculation CL v assumed biliary excretion take place quinidine absorbed following oral intake The renal excretion clearance 3S 3OH quinidine quinidine N oxide 3S 3OH quinidine urine h CLR 3sl 3oH q  AUCf3s _3o q h quinidine N oxide urine h CLR q_N_o  AUCq_N_o h AUC 3s 3oH q h AUCq_N h h AUCs 3S 3OH quinidine quinidin N oxide calculated trapezoidal method The terminal elimination half life quimdine calculated ln2 A terminal log linear sIope plasma concentration time curve calculated linear regression measurements h E L v tO D Mean conc  n 8   Quinidine 3S 30H quinidine    ide I I  I I I Time  h  A E tO  l I I I I b Time  h  Fig la b Mean plasma concentrations quinidine El 3S 3OH quinidine O quinidine N oxide A eight poor eight extensive metabolisers sparteine b intake mg quinidine free base For pharmacokinetic parameters difference medians EM PM confidence interval median difference calculated MEDSTAT program version Astra Group A S Albertslund Denmark A confidence interval comprising zero considered statistically insignificant\n",
      "METHODS AND MATERIALS This open_label three_period fixed_sequence study Merck Protocol No MK_5172_072_00 conducted accordance principles Good Clinical Practice approved Chesapeake Institutional Review Board Columbia MD All subjects provided written informed consent Subjects Healthy male female subjects ages years inclusive body mass index ³19 ²32 kg m2 screening enrolled Key exclusion criteria history clinically significant medical psychiatric condition infection human immunodeficiency virus hepatitis B virus HCV creatinine clearance mL min history alcoholism drug abuse use substances known significant inducers cytochrome P450 enzymes and or P_glycoprotein days prior study history hypersensitivity study drugs ingredients related compounds pregnancy lactation recent participation another clinical trial Treatments This three_period study minimum 10_day washout study period On day period following overnight fast subjects received single oral dose EBR mg GZR mg FDC In period subjects received FAM single 20_mg oral tablet _10 h evening day _1 h morning day prior receiving EBR GZR FDC day EBR GZR FDC administered single oral dose following overnight fast In period subjects received PAN single 40_mg oral tablet daily days 1Ð5 within h dosing time day On day following overnight fast single oral dose EBR GZR FDC administered _2 h PAN dosing This study conducted fasted subjects eliminate potential confounding effect food Assessments Previous studies shown GZR EBR time maximum drug concentration tmax 2Ð4 h apparent terminal half_life t_ _20 h In study plasma samples determination EBR GZR PKs collected predose h following administration EBR GZR FDC treatment period Safety assessed monitoring adverse events AEs physical examinations vital signs electrocardiograms laboratory safety tests Plasma EBR GZR concentrations determined using validated liquid chromatography tandem mass spectrometry methods lower limit quantitation ng mL EBR ng mL GZR Plasma EBR GZR concentrations actual sampling times used determine area curve AUC maximum drug concentration Cmax 24_h drug concentration C24 tmax t_ EBR GZR Cmax tmax values determined directly observed EBR GZR plasma concentration_time data AUC 0 calculated using noncompartmental analysis linear trapezoidal method ascending concentrations log trapezoidal method descending concentrations The AUC 0 EBR GZR calculated AUC 0 last  Cest last _z Cest last estimated concentration time last quantifiable concentration For subject _z calculated regression terminal log_linear portion plasma concentration time profile apparent terminal t_ calculated quotient natural log _z Statistics The sample size determined based evaluation completers would provide adequate precision estimate geometric mean ratios GMRs according within_subject variability EBR GZR PK parameters observed previously conducted studies A total subjects enrolled account potential dropouts Demographics safety data summarized using descriptive statistics Individual values exposure parameters AUC 0 Cmax C24 EBR GZR natural log_transformed analyzed linear mixed_effects model containing fixed_effect term treatment An unstructured covariance matrix used allow unequal treatment variances model correlation three treatment measurements within subject The two_sided confidence intervals CIs differences least_squares means constructed natural log_scale two comparisons EBR GZR FDC  FAM EBR GZR FDC  PAN vs EBR GZR FDC These differences least_squares means CIs exponentiated obtain estimated GMRs associated CIs The least_squares means corresponding CIs exponentiated obtain estimates population geometric means corresponding CIs original scale treatment As estimation study bounds specified various treatment comparisons evaluations EBR GZR\n",
      "Materials methods The study performed accordance relevant articles Declaration Helsinki revised Tokyo Venice Hong Kong Somerset West Before enrolled clinical study volunteer consented participate writing nature scope possible consequences trial explained physician Before start study protocol appropriate documents approved ethics committee University Hospital Queen Giovanna So a Bulgaria Thirty six unrelated healthy male Caucasians screened CYP2D6 genotype polymerase chain reaction PCR Ten millilitres blood obtained individual DNA isolated peripheral leukocytes described Nietzel For allele speci c ampli cation set primers nested PCR Heim Meyer used For reaction ng DNA used The rst step ampli cation two fragments A B CYP2D6 gene containing mutation sites They served template second PCR reaction avoid false positive results The rst PCR reaction carried volume containing ng DNA template mmol  dNTP lmol  primer mmol  l MgCl2 mmol  l Tris HCl pH mmol  l KCl Triton X 100 U Taq Polymerase Promega An initial denaturation C min cycles followed C C C Ten microlitres sample tested agarose gel Only products rst reaction used template two parallel allele speci c reactions one wild type mutationspeci c primer The second primer nested PCR reaction one primers already used rst reaction The conditions rst PCR except initial denaturation min C cycles followed C C C nally min C Again sample tested agarose gel The combined results four reactions allowed determination alleles subjects  CYP2D6 1 wild type mutant CYP2D6 3 CYP2D6 A Del A2637 exon CYP2D6 4 CYP2D6 B Splice site defect G1934A The rst volunteers genotype suggestive rapid hydroxylator phenotype enrolled bioequivalence trial received randomized cross over fashion one three formulations compared Metohexal slow release tablets Hexal Germany Lopresor Retard Ciba Ciba Switzerland Lopressor L P Ciba mg Ciba France Each formulation contained mg metoprolol tartrate per tablet In three periods trial one formulations administered fasting conditions morning consecutive days Blood quanti cation metoprolol drawn immediately last dose selected time intervals h h thereafter Resting heart rate blood pressure measured daily administration metoprolol A sensitive speci c high performance liquid chromatography HPLC method øuorescence detection applied quanti cation metoprolol The method used extraction metoprolol human plasma based publications Rutledge Garrick To plasma 10 ml glass tube internal standard solution propranolol concentration lg  ml 1 methanol added vortexed The sample alkalized mol  l NaOH vortexed After addition ml diethyl ether 1 min vortexing mixture centrifuged rpm min The organic phase transferred another glass tube mol  l H3PO4 added The mixture vortexed min centrifuged rpm min The upper layer discarded Complete removal ether achieved N2 stream The acid phase transferred autosampler injection vial injected onto analytical column Reversed phase chromatography performed using mobile phase consisting bu er acetonitrile v v The bu er consisted M ortho phosphoric acid adjusted pH triethylamine The øow rate ml  min 1 injection volume A Superspher RP18 analytical column used lm mm Hewlett Packard The Pre column Perisorb RP lm mm Hibar Merck Column heater C Fluorescence detection excitation wavelength  nm emission wavelength  nm The retention times min metroprolol anc min internal standard The lower limit quanti cation method ng  ml 1 The pharmacokinetic evaluation carried means pharmacokinetic software TopFit The following parameters determined subject preparation AUC course one dose interval h AUCs half value duration HVD  per cent peak trough øuctuation PTF minimum steady state concentration Css min average steady state concentration Css av elimination half life t1 2 mean residence time MRT All parameters listed determined model independent way HVD de ned time span within dosing cycle serum concentration deviated maximum concentration less The PTF calculated follows PTF  Css max Ø Css min Cav whereby Cav  AUC The pharmacokinetic parameters metoprolol homozygous heterozygous individuals compared means Wilcoxon rank sum test di erence medians relatively small number observations per group\n",
      "The pharmacokinetic evaluation carried means pharmacokinetic software TopFit The following parameters determined subject preparation AUC course one dose interval h AUCs half value duration HVD  per cent peak trough øuctuation PTF minimum steady state concentration Css min average steady state concentration Css av elimination half life t1 2 mean residence time MRT All parameters listed determined model independent way HVD de ned time span within dosing cycle serum concentration deviated maximum concentration less The PTF calculated follows PTF  Css max Ø Css min Cav whereby Cav  AUC The pharmacokinetic parameters metoprolol homozygous heterozygous individuals compared means Wilcoxon rank sum test di erence medians relatively small number observations per group The pharmacokinetic evaluation carried means pharmacokinetic software TopFit The following parameters determined subject preparation AUC course one dose interval h AUCs half value duration HVD  per cent peak trough øuctuation PTF minimum steady state concentration Css min average steady state concentration Css av elimination half life t1 2 mean residence time MRT All parameters listed determined model independent way HVD de ned time span within dosing cycle serum concentration deviated maximum concentration less The PTF calculated follows PTF  Css max Ø Css min Cav whereby Cav  AUC The pharmacokinetic parameters metoprolol homozygous heterozygous individuals compared means Wilcoxon rank sum test di erence medians relatively small number observations per group\n",
      "Subjects methods Study subjects Healthy Korean male volunteers aged years body mass index kg m2 enrolled study Volunteers went following screening procedures taking medical history physical examination 12 lead electrocardiography ECG assessment clinical laboratory parameters including haematology blood chemistry urine drug screening voluntarily signed informed consent form The participants allowed consume alcohol caffeinated beverage grapefruit products smoke study period Any ethical drugs herbal medicines prohibited weeks study drug administration Study design treatments administration This randomised open label one way crossover two parallel sequences study A total subjects randomised assigned one two parts Subjects assigned part received single dose ilaprazole Noltec Tab IL YANG Pharmaceutical Co mg first period Then washout period days clarithromycin Klaricid Film Coated Tab Abbott Korea mg amoxicillin Amoxicillin Cap mg Chongkundang Chong Kun Dang Pharmaceutical Co Korea mg administered twice daily days second period Ilaprazole mg coadministered clarithromycin amoxicillin day second period Subjects assigned part received single doses clarithromycin mg amoxicillin mg first period washout period days ilaprazole mg administered twice daily days second period Clarithromycin mg amoxicillin mg coadministered ilaprazole day second period Fig All study drugs administered via oral route dosage drug determined based results previous ilaprazole phase study treatment guidelines H pylori eradication labels clarithromycin amoxicillin 22Ð27 The study approved Institutional Review Board Severance Hospital Yonsei University College Medicine Seoul Korea conducted accordance principles Declaration Helsinki Good Clinical Practice Blood sample collection analysis Serial blood samples collected anti coagulated EDTA K2 tubes pre dose h dosing ilaprazole part The PK sampling points part pre dose h dosing clarithromycin amoxicillin Blood sampling points determined considering time reach peak concentration Tmax elimination half life t1 2 ilaprazole clarithromycin amoxicillin Plasma concentrations ilaprazole clarithromycin amoxicillin analysed using liquid chromatography tandem mass spectrometry LC MS MS Samples centrifuged min C 2000_g stored __70 C analysis For analysis ilaprazole _L plasma added polypropylene tubes mixed _L internal standard omeprazole solution mL acetonitrile The mixture vortexed min centrifuged min 11 337_g The supernatant _L collected reconstituted _L mobile phase The supernatant _L injected LC MS MS system An LC system Shiseido Nanospace SI 2 Shiseido Tokyo Japan used mobile phase mM ammonium formate acetonitrile  v v C Chromatographic separation performed flow rate mL min The transition ilaprazole detected m z using MS MS system API4000 AB SCIEX Washington DC USA multiple reaction monitoring MRM mode positive electrospray ionisation ESI source The calibration curve linear range 5Ð1000 ng mL correlation coefficient r _0 995 For analysis clarithromycin _L plasma added polypropylene tubes mixed _L internal standard clarithromycin N methyl 13C d3 solution _L acetonitrile The mixture vortexed min centrifuged min 11 337_g The supernatant _L collected reconstituted _L acetonitrile The supernatant _L injected LC MS MS system The LC system used mobile phase mM ammonium formate acetonitrile_ _20 80 v v C Chromatographic separation performed flow rate mL min The transition clarithromycin detected m z using MS MS system 4000QTRAP AB SCIEX Washington DC USA MRM mode positive ESI source The calibration curve linear range 10Ð7000 ng mL correlation coefficient r _0 995 For analysis amoxicillin _L plasma added polypropylene tubes mixed _L internal standard amoxicillin d4 solution _L acetonitrile The mixture vortexed min centrifuged min 11 337_g The supernatant _L collected reconstituted _L acetonitrile The supernatant _L injected LC MS MS system The LC system used mobile phase deionised water acetonitrile formic acid  v v v C Chromatographic separation performed flow rate mL min The transition amoxicillin detected m z using MS MS system 4000QTRAP AB SCIEX Washington DC USA MRM mode positive ESI source The calibration curve linear range 0 1Ð50 _g mL correlation coefficient r _0 995 The coefficient variation CV represents overall precision assay three study drugs _20 0 lower limit quantification LLOQ upper concentrations calibration PK assessment PK parameters evaluated using non compartmental model Phoenix WinNonlin software version Certara St Louis MO USA The peak concentration Cmax Tmax determined directly observed values The area curve time dosing last measurable concentration AUClast calculated using linear trapezoidal rule The terminal elimination rate constant _z estimated linear regression analysis terminal portion log transformed plasma concentration to time profile The elimination half life t1 2 apparent plasma clearance CL F apparent volume distribution Vd F calculated using following equations t1 2_ _ln 2 _z CL F_ _dose AUCinf Vd F_ _dose _z á AUCinf respectively The AUC last dosing time extrapolated infinity AUCinf calculated using formula AUClast_ _Clast _z Clast represents last measurable concentration The PK drug interactions triple therapy evaluated comparing plasma concentration time profiles PK parameters drug Safety assessment Safety tolerability evaluated throughout study The assessments included monitoring adverse events AEs based physical examinations vital signs 12 lead ECG routine haematology serum chemistry urinalysis The subjects instructed notify study physicians nurses AEs occurred study All AEs reported subjects detected assessments recorded investigators determined relationship treatment The severity AEs evaluated based Common Terminology Criteria Adverse Events CTCAE version Statistical analysis Because study explorative sought evaluate PK interactions study drugs deemed preferable use minimum number subjects Considering power parallel study design would insufficient compared crossover design minimum number subjects estimated consisting subjects per part total number subjects subjects part assumption potential drop out rate Descriptive statistics calculated baseline demographics PK parameters safety data part Baseline demographics treatment sequences evaluated using StudentÕs test using SAS statistical software version SAS Institute Inc Cary NC USA To compare PK parameters Cmax AUClast AUCinf treatments general linear mixed effects model constructed using log transformed data treatment fixed effect variance within subjects random effect The geometric least squares mean ratio GMR confidence interval CI Cmax AUClast AUCinf two different treatments part determined All statistical analyses conducted using SAS version All statistical tests two sided P_ _0 05 considered statistically significant\n",
      "Imatinib novel tyrosine kinase inhibitor significant activity chronic myeloid leukemia CML gastrointestinal stromal tumors GIST 1Ð3 There doseÐsystemic exposure relationship imatinib conventional dose range fourfold interpatient variation systemic exposure given dose dose required achieve specific target level reported 2 4 Variation drug disposition especially plasma clearance may result excessive toxicity suboptimal anticancer effect due inadvertent overdose underdosage respectively 5 The main toxicities imatinib frequently dose related consist neutropenia superficial edema nausea muscle cramps rashes 2 3 Clinical reports reduced efficacy imatinib linked low drug exposure patients CML 2 Approximately imatinib absorbed oral administration half life approximately h 2 The major mechanisms elimination hepatic metabolism biliary fecal excretion unchanged drug metabolites 6 There evidence cytochrome P450 CYP 3A accounts metabolism imatinib active metabolite CGP74588 7 Imatinib also substrate ABC transporter ABCB1 P glycoprotein MDR1 8 9 biliary pump probably mediates substantial elimination parent drug Given potentially substantial interindividual variation activity mechanisms 10 may major determinant variable drug exposure Single nucleotide polymorphisms SNPs CYP3A ABCB1 genes potential alter protein function hence influence efficiency elimination pathways Identifying influential SNPs may allow prediction drug disposition individual patients therefore facilitate dose optimization In exploratory study performed screen drug elimination characteristics using combination vivo tests phenotype genotype elimination pathways relevant imatinib compared day steady state pharmacokinetics well toxicityrelated dosage adjustments The aim understand better relationship drug elimination mechanisms interpatient variation drug exposure\n",
      "Methods This single centre randomized open label two period crossover study Fig enrolled healthy male female subjects aged 18Ð45 years weighing within  ideal body weight height frame size according Metropolitan height weight tables Subjects required non smokers refraining tobacco usage including smokeless tobacco nicotine patches etc month prior screening visit In addition subjects abstain caffeine containing food beverages hours prior dosing alcohol containing food beverages hours prior dosing Seville oranges e g orange marmalade grapefruit grapefruit juice days prior dosing products throughout study This crossover study AB_BA sequence design subjects completing two crossover periods Fig Due long half life trospium chloride XR consequently requiring long drug washout period sequence effect trospium chloride XR could determined combination treatment always administered trospium chloride XR alone treatment The protocol designed washout time long acting trospium chloride XR formulation kept reasonable length time appreciably altering interpretation DDI study The study design consistent US Food Drug Administration guidance long half life DDI studies Subjects received oral metformin Glucophage Bristol Myers Squibb Princeton NJ USA oral trospium chloride XR Sanctura XR Allergan Inc Irvine CA USA according study protocol Fig Subjects instructed take trospium chloride XR daily empty stomach hour breakfast metformin twice daily pm standardized meal calories day  fat Overnight fasting required scheduled clinic attendance Days Group A Days Group B The concomitant medications permitted study hormonal contraceptives paracetamol acetaminophen ²2 g day Pharmacokinetic Evaluation For measurement plasma urine concentrations trospium metformin serial blood urine samples collected subject Collection time points metformin alone treatment pre dose h post dose plasma samples pre dose 0Ð4 4Ð12 12Ð24 h post dose pooled urine samples Day Group A Day Group B Collection time points trospium chloride XRÐalone treatment pre dose h post dose plasma samples pre dose 0Ð4 4Ð12 12Ð24 h post dose pooled urine samples Day Group B Day Group A Collection time points following coadministration trospium chloride XR metformin pre trospium chloride XR dose h post trospium chloride XR dose plasma samples pre metformin dose 0Ð4 4Ð12 12Ð24 h post metformin dose pooled urine samples Day Group B Day Group A The final plasma pharmacokinetic sample collected Day h post dose Group A h post dose Group B Plasma urine samples analysed Prevalere Life Sciences LLC Whitesboro NY USA Plasma urine trospium concentrations measured using fully validated liquid chromatographyÐtandem mass spectrometry LCÐMS MS method lower limit quantitation LLQ ng mL ng mL respectively Plasma urine metformin concentrations measured using validated LCÐMS MS method LLQ ng mL _g mL respectively Safety Tolerability Evaluation Adverse events AEs recorded throughout study period Clinical laboratory evaluations haematology biochemistry urinalysis performed screening final day two treatment periods Day Group A Day Group B Vital signs heart rate blood pressure respiration rate oral body temperature measured 12 lead standard electrocardiograms ECGs performed screening final day two treatment periods Day Group A Day Group B final study exit Day Physical examinations performed screening Day Group A Day Group B study exit Day Body weight measured screening study exit Day Statistical Methods Sample Size Calculation The sample size required power study steady state bioequivalence trospium chloride XR metformin driven within subject variability measured coefficient variation trospium chloride XR  With sample size sequence total subjects crossover design would yield  power reject null hypothesis ratio test mean standard mean null hypothesis ratio test mean standard mean i e test standard bioequivalent favour alternative hypothesis means two treatments bioequivalent Accounting  drop out rate anticipated approximately subjects would need enrolled study order subjects complete study Pharmacokinetic Analyses The calculation pharmacokinetic parameters performed using WinNonlin Enterprise Version IVIVC Toolkit Pharsight Corporation Mountain View CA USA SAS Windows Version SAS Institute Inc Cary NC USA The summary statistics pharmacokinetic parameters calculated using SAS SAS also used data management statistical analyses S Plus TIBCO Software Inc Seattle WA USA formerly Insightful Corporation used graphing pharmacokinetic data Plasma Trospium Metformin A model independent approach used calculate plasma urine pharmacokinetic parameters trospium metformin subject Plasma pharmacokinetic parameters including steady state area plasma concentrationÐtime curve AUC within dosing interval AUC time zero hours AUC12 metformin AUC time zero hours AUC24 trospium maximum peak drug concentration Cmax time peak plasma concentration tmax following drug administration oral clearance half life calculated applicable Descriptive statistics determined pharmacokinetic parameters calculated Pharmacokinetic DDIs evaluated calculating  confidence interval CI ratio estimated geometric means plasma AUC12 metformin AUC24 trospium Cmax values obtained following administration alone combination Administration alone used reference respective drug Urine Trospium Metformin The cumulative amount unchanged drug excreted urine Ae 12or 24 h dosing interval Ae time zero hours metformin Ae time zero hours trospium calculated subject The percentage dose excreted urine determined ratio Ae administered dose Renal clearance drug plasma CLR determined dividing Ae plasma AUC corresponding dosing interval drug A paired StudentÕs test performed compare parameters administration alone combination compound significance level Safety Analyses All randomized subjects received least one dose study medication included safety analyses AE data summarized frequency tables Summary statistics calculated SAS change baseline laboratory parameters ECG parameters vital signs Post hoc Efficacy Analysis To determine clinical implications reduced trospium exposure concomitant metformin administration post hoc analysis performed efficacy data reported two multicentre randomized double blind placebo controlled Phase III trials Comparison primary efficacy outcomes average number toilet voids urinary urge incontinence UUI episodes per day conducted subjects received metformin trospium chloride XR equal number subjects metformin received trospium chloride XR i e matching Sensitivity analyses also performed using twice number control subjects i e matching Additionally primary efficacy outcomes compared subjects metformin subjects receive metformin treatment without matching Control subjects selected propensity score matching propensity scores estimated using logistic regression metformin yes vs dependent variable age sex race OAB duration years baseline urinary frequency baseline urgency severity baseline UUI episodes per day independent variables Ethics The study conducted accordance applicable Good Clinical Practice regulations guidelines Institutional Review Board IRB regulations The study approved Aspire IRB La Mesa CA USA September All subjects provided written informed consent prior enrollment\n",
      "Subjects methods Subjects Fourteen EMs PMs sparteine comparable respect age body weight sex Table recruited among approximately healthy subjects previously phenotyped respect sparteine oxidation polymorphism Department Clinical Pharmacology Odense University A metabolic ratio 12 h urinary recovery sparteine dehydrosparteines higher defined PM phenotype metabolic ratio lower defined EM phenotype In EMs median metabolic ratio range 0 17Ð1 5 The volunteers healthy according history clinical examination treated drug except females taking oral contraceptives Alcohol analgesics allowed h within study days experiments The present sample size chosen reference previous studies detecting analgesic effect different drugs pain models Design medication Each phenotype investigated separate group The study design group randomized double blind three way cross over single oral dose codeine single oral doses placebo negative control morphine positive control Randomization group carried blocks six including six possible treatment sequences Thus EM group three subjects treated treatment sequences codeine placebo morphine placebo codeine morphine whereas two subjects treated four sequences For PM group treatment sequences codeine morphineplacebo placebo morphine codeine included three subjects All study sessions started hours Volunteers weighing kg given mg codeine mg morphine whereas volunteers weighing less kg given mg codeine mg morphine Table A double dummy technique used since codeine mg Nycomed DAK Copenhagen identical codeine placebo tablets different morphine mg Nycomed DAK Copenhagen identical morphineplacebo tablets The number tablets four codeine codeine placebo tablets plus three morphine morphine placebo tablets volunteers weighing less kg three two tablets given three study days Pain tests described performed h medication blood drug level measurements collected series pain measurements The post medication period observation adverse effects h The study days separated least week washout Pain tests Cold pressor test tonic pain The left hand immersed ice chilled water 0 3 C continuously stirred pump After min immersion sooner pain considered intolerable subjects removed hand water Pain intensity continuously rated electronic visual analog scale coupled pen recorder From printouts obtained peak pain intensity score area pain intensity time curve determined Immediately test subjects rated discomfort experienced i e overall feeling unpleasantness test use visual analog scale Heat pain thresholds phasic pain Heat pain detection heat pain tolerance thresholds volar aspect right detection left tolerance wrist determined use computerized version Thermotest Somedic AB Stockholm Sweden method described Brennum et al The thermode consisted series coupled Peltier elements measured _ mm For determination heat pain detection heat pain tolerance baseline Table Demographic details drug doses fro extensive EM poor PM metabolizers sparteine participating study E M P M Number Male female Agea years 20Ð28 21Ð25 Body weighta Kg 50Ð78 5 54Ð88 Drug dose Morphine mg codeine mg Morphine mg codeine mg Median range temperature 35 C 1 Cás 1 rate change cutoff limit 52 C applied By pressing button subject indicated pertinent threshold reached Each threshold calculated average five determinations performed intervals stimulations Pressure pain thresholds  phasic pain Pressure pain detection pressure pain tolerance thresholds determined middle phalanx second detection third tolerance finger right hand electronic pressure algometer Somedic AB Stockholm Sweden method described Brennum et al A 28 mm2 circular probe loaded Nás 1 subject indicated pertinent threshold reached The cutoff limit kPa Each threshold calculated average five determinations intervals stimulations Adverse effects Each symptom sedation dry mouth dizziness nausea headache relaxation euphoria experienced 5 h observation period noted volunteers onset duration severity At end observation period severity symptom rated  present  mild  moderate  pronounced investigator basis interview volunteer Plasma drug concentrations The plasma concentrations codeine morphine morphine 6 glucuronide determined two separate HPLC methods The analysis codeine performed using reversed phase HPLC method fluorometric detection The limit quantitation nmolál 1  At spiked concentrations nmolál 1  accuracy coefficient variation  respectively Morphine morphine 6 glucuronide assayed on line sample clean up electrochemical detection The limit quantitation nmolál 1  respectively At morphine concentrations nmolál 1  accuracy coefficient variation respectively At morphine 6 glucuronide concentrations nmolál 1  accuracy coefficient variation respectively Data analysis statistics The peak change premedication value placebo codeine morphine identified compared use WilcoxonÕs test paired differences Analysis differences area concentration time curves time h AUC 0 4 5 h carried use Mann Whitney phenotypes within drugs WilcoxonÕs within phenotypes drugs tests The frequency subjects experiencing side effects compared use McNemar change test within phenotypes drugs For side effect severity score multiplied duration obtain overall measure pertinent side effect Further total side effect burden subject calculated sum severity score times duration seven different adverse effects registered The differences measure drugs compared phenotype WilcoxonÕs test paired differences The study approved regional Ethics Committee counties Vejle Fyn  j no Danish National Board of Health  j no 2740Ð181Ð1991 The subjects gave written consent participation basis verbal written information\n",
      "SUBJECTS AND METHODS Subjects CYP2C19 genotypes Blood samples taken healthy Japanese subjects receiving written informed consent The DNA extracted individual s leucocytes using commercially available kit Genomix Talent Trieste Italy The genotyping procedure identifying CYP2C19 wild_type wt gene two mutated alleles CYP2C19m1 m1 exon CYP2C19m2 m2 exon performed polymerase chain reaction_restriction fragment length polymorphism method using allele_specific primers described de Morais et_al 23 _24 minor modifications made Kubota et_al 25Helicobacter pylori infection screened using serological test HMáCAP Kit Enteric Product Inc NY USA A total H pylori_negative healthy volunteers invited approved participation study Their negativity H pylori infection confirmed 13C_urea breath test Seven homozygous wt alleles exons wt wt classified homEM group Another five heterozygous m1 mutation without m2 mutation wt m1 heterozygous m2 mutation without m1 mutation wt m2 classified hetEM group The remaining three heterozygous m1 mutation m2 mutation m1 m2 homozygous m1 mutation without m2 mutation m1 m1 classified PM group The groups differ sex age body weight Table_1 None subjects consumed extensive amounts alcohol smoked None taken drugs least 1_week study Written informed consent obtained subjects participation study The protocol approved advance Human Institutional Review Board Hamamatsu University School Medicine Hamamatsu Japan Table  Demographic characteristics Helicobacter pylori_negative subjects enrolled study different S_mephenytoin 4__hydroxylase CYP2C19 genotypes Study protocol All subjects first given placebo dose order obtain control baseline 24_h intragastric pH data described later participated double_blind crossover study either lansoprazole famotidine Subjects given either once_daily dose 30_mg lansoprazole Takeprone Takeda Chemical Industries Ltd Osaka Japan twice_daily dose 20_mg famotidine Gaster Yamanouchi Pharmaceutical Co Ltd Tokyo Japan randomized crossover manner two separate 8_day periods Lansoprazole taken day 08 00_h famotidine taken twice day 08 00_h 20 00_h These dosing schemes i e dosages dosing intervals lansoprazole famotidine chosen according drug formulary approved Japan There washout period least 14_days two study periods The 24_h intragastric pH monitoring measurement plasma levels lansoprazole famotidine performed post_dose day Nocturnal blood sampling conducted sleeping healthy subjects disturbed ethical point view Three standard meals noon 17 00_h 08 00_h prepared hospital provided subjects Mineral water allowed ad libitum beverages permitted Intragastric pH measurements After overnight fasting antimony pH electrode Synectics Medical AB Stockholm Sweden inserted transnasally placed 5_cm cardia fluoroscopic guidance The pH electrode calibrated standard buffer solutions pH_1 07 Synectics Medical Inc Texas USA initiating recordings The pH values recorded Digitrapper MKIII Synectics Medical AB Stockholm Sweden Intragastric pH recordings started soon administration placebo lansoprazole famotidine 08 00_h continuously monitored 24_h period Blood sample collection Blood samples collected heparinized tubes 24_h morning dose i e 08 00_h once_daily 30_mg lansoprazole twice_daily 20_mg famotidine post_dose day Immediately collection blood samples centrifuged 3000_r p m 10_min stored Ð_20_ C assayed Blood sample collection made night_time last evening dose 20_mg famotidine administered 20 00_h avoid disturbing sleep healthy individuals Assays lansoprazole famotidine Plasma concentrations lansoprazole determined high_performance liquid chromatography 26 In brief assay consisted following procedures After 100__L isobutyl p_hydroxybenzoate 25__g mL dichloromethane internal standard added 0 5_mL samples extraction conducted twice shaking 3_mL diethyletherÐdichloromethane 7_ _3 v v After centrifugation 0 5_mL propyleneglycol solution added supernatant solvent evaporated nitrogen stream The residue dissolved 0 5_mL waterÐacetonitrileÐn_octylamine 620_ _380_ _1 v v mobile phase adjusted pH_7 phosphoric acid A 100__L portion solution subjected high_performance liquid chromatography assay The high_performance liquid chromatography system consisted Shimadzu LC_4A LC_6A equipped autosampler cooling device Ishido Chiba Japan A reversed_phase column TSK gel ODS_120T particle size 5__m 250_mm___4 6_mm internal diameter Tosoh Tokyo Japan used The column temperature flow rate mobile phase 40_ C 1 0_mL min respectively Lansoprazole internal standard detected UV absorption 285_nm The intra_assay interassay coefficients variation less Plasma concentrations famotidine also determined high_performance liquid chromatography 27 To 1_mL plasma sample 10_mL centrifuge tube equipped stopper added 1_mL 0 2_M carbonate buffer pH_10 containing 500_ng YAS_423 3_ 2_ diaminomethylene _amino _methyl thio _N2_methylsulphonylpropionamidine 6_mL ethylacetate The tube shaken 10_min centrifuged 500___g 5_min organic solvent aspirated Part aqueous layer introduced high_performance liquid chromatography system consisting LC_6A pump Shimadzu Tokyo Japan SIL_6B autosample injector Shimadzu column 25_cm___4 6_mm internal diameter packed TSK gel ODS_80_Tm Tosoh Tokyo Japan The column maintained 50_ C CTO_6A column oven Shimadzu A mixture 100_mM phosphoric acid containing 10_mM sodium dodecylsulphate acetonitrile 65_ _35 v v used mobile phase flow rate 1 0_mL min Effluent monitored using SPD_6A UV detector Shimadzu wavelength 266_nm The intra_assay interassay coefficients variation less Data analysis Intragastric pH values areas plasma concentrationÐtime curves AUCs famotidine lansoprazole given median mean_ S E M respectively Median intragastric pH values every hour 24_h obtained raw pH values Whether intragastric pH values differed among different CYP2C19 genotype groups determined MannÐWhitney U_test significant difference observed KruskalÐWallis test Statistically significant differences values intragastric pH placebo famotidine placebo lansoprazole famotidine lansoprazole trial phases determined Wilcoxon s signed rank test The values 24_h post_dose AUCs famotidine lansoprazole calculated using linear trapezoidal method Statistically significant differences AUCs famotidine lansoprazole among three different CYP2C19 genotype groups determined one_way analysis variance ANOVA Scheffe s multiple comparison test Statistical calculations performed SAS software SAS Institute Inc Cary NC USA All P values two_sided P_ _0 05 taken indicate statistical significance\n",
      "Methods Study population Healthy Korean male volunteers 20Ð50 years age 80Ð120 ideal body weight enrolled present study without marked past medical medication history based physical examination vital signs 12 lead electrocardiogram clinical laboratory tests Subjects dyscoria uveitis cataract excluded conditions might obstruct interfere ophthalmological examination Study design This study conducted open label fixed sequence three treatment three period crossover design random assignment HM30181 dose period Because HM30181 known long half life 75 7Ð169 3 h single oral dose fixed sequence design used present study HM30181 administered period Eligible subjects admitted Clinical Trials Center Seoul National University Hospital day prior period In period subjects received single oral dose loperamide mg In period single oral dose quinidine mg administered followed single oral dose loperamide mg h later In period subjects randomly received single oral dose HM30181 mg ratio single oral dose loperamide mg h later Each period separated day washout enough ensure full clearance loperamide given previous period P gp inhibition quinidine HM30181 investigated periods respectively period used treatment control Quinidine chosen positive control proven P gp inhibitor 13Ð16 The effects P gp inhibition assessed using pharmacodynamic changes pupil size alertness oxygen saturation pharmacokinetic oral bioavailability loperamide endpoints Food drinks containing caffeine grapefruit alcohol permitted throughout study Smoking allowed study either The Institutional Review Board Seoul National University Hospital approved study protocol IRB No H 0711 014 224 informed consent obtained subjects prior study enrolment All procedures performed accordance recommendations Declaration Helsinki Furthermore study conducted compliance current Good Clinical Practices applicable laws regulatory requirements South Korea Pupil size measurement Trained study personnel measured horizontal pupil diameter using photo slit lamp FS 3 Nikon Tokyo Japan i e pre dose h loperamide administration keeping illuminance room constant lux Before measurement ³2 min allowed subjects adapt lighting conditions room To stabilize accommodation subjects asked see point cm away front The average three measurements taken apart regarded pupil size measurement time All measurements carried eye subject Changes pupil size pre dose plotted vs time loperamide administration area effectÐtime curve AUEC calculated using trapezoidal rule The interand intra day precisions 4 6Ð7 4 7 0Ð16 9 respectively Alertness measurement Alertness measured h loperamide administration using visual analogue scale VAS Subjects asked indicate degree alertness level using scale full alertness extreme drowsiness Measurement oxygen saturation Oxygen saturation measured blood h loperamide administration using bedside cardiac monitor Solar GE Healthcare Little Chalfont Buckinghamshire UK Phamacokinetic blood sampling In period blood samples ml obtained h loperamide administration In periods additional blood samples ml taken time analysis quinidine HM30181 respectively Blood samples loperamide HM30181 collected sodium heparin tubes quinidine collected serum separator tubes Plasma analysis loperamide HM30181 serum analysis quinidine obtained centrifugation g stored polypropylene tubes _20 C concentrations determined Determination concentrations Plasma concentrations HM30181 determined using validated liquid chromatography tandem mass spectrometry LC MS MS method docetaxel internal standard Briefly plasma _l methyl tert butyl ether MTBE ml docetaxel _l ng ml_1 mixed thoroughly centrifuged g min Supernatant ml evaporated residue reconstituted _l acetonitrile injected LC MS MS system The lower limit quantification LLOQ HM30181 ng ml_1 linear calibration range 0 5Ð50 ng ml_1 Each analytical batch six quality control QC samples known values i e two low intermediate high concentrations respectively The analytical results accepted concentrations four six QC samples determined within known values Intraand inter day accuracy 90_108 intraand inter day precision varied CV Plasma concentrations loperamide determined using validated LC MS MS method glipizide internal standard Briefly plasma _l acetonitrile _l glipizide _l ng ml_1 mixed thoroughly centrifuged g min The supernatant injected LC MS MS system LLOQ loperamide ng ml_1 linear calibration range 0 05Ð20 ng ml_1 The QC criteria described HM30181 used determination loperamide concentrations Intraand inter day accuracy 94 2Ð103 2 intraand inter day precision varied CV Serum concentrations quinidine determined using TDxFLx Abbott laboratories IL USA Pharmacokinetic analysis A non compartmental pharmacokinetic analysis performed using WinNonlin version Pharsight Corporation Mountain View CA USA The peak plasma concentration Cmax time Cmax i e tmax directly obtained observed values The terminal elimination rate constant _z estimated linear regression using log linear decline portion individual plasma concentration time data The terminal elimination half life t1 2 calculated natural log divided _z The area concentrationÐtime curve AUC time last measurable time AUC 0 tlast calculated using trapezoidal rule AUC extrapolated infinity AUC 0 calculated adding Clast _z AUC 0 tlast Clast last measurable concentration Statistical analysis Baseline demographic characteristics compared among HM30181 dose groups using KruskalÐWallis test Repeated measures anova used compare differences periods treatments pharmacodynamic endpoints To compare AUC 0 72 h loperamide period i e loperamide alone baseline periods performed mixed effects analysis subject random effect dose period interaction dose period fixed effects SAS SAS Institute Inc NC USA used statistical data analysis level statistical significance two sided unless specified otherwise adjusted multiplicity statistical tests\n",
      "Methods Study design This open_label two_period randomized crossover trial healthy subjects Subjects randomized treatment sequences AB BA Treatment A reference consisted mg metformin twice daily BID days Metformin HCL Actavis mg Aurobindo Pharma _ Milpharm Ltd Middlesex United Kingdom The dose increased mg BID days 3Ð8 This gradual dose step_up chosen limit adverse events AEs subjects used metformin without food days Treatment B test consisted mg metformin BID days 1Ð2 mg metformin BID days 3Ð8 From day day mg daclatasvir daily added Daklinza Bristol_Myers Squibb Uxbridge United Kingdom Between treatments washout period days To study metformin daclatasvir exposure day treatment steady_state blood samples PK curve obtained h h intake metformin daclatasvir respectively To study metformin excretion 12_h urine collected determination metformin renal clearance The PD metformin studied using oral glucose tolerance test OGTT also performed day treatment During 2_h test venous blood withdrawn determine plasma concentrations glucose lactate insulin Study participants Healthy males females included Subjects eligible inclusion 18Ð55 years age body mass index BMI 18Ð36 kg mÐ2 Subjects good age_appropriate health condition physical examination electrocardiography biochemical haematological urinalysis testing No concomitant medication allowed except acetaminophen mg dayÐ1 Main exclusion criteria positive HIV hepatitis B HCV test pregnancy estimated glomerular filtration rate eGFR ml minÐ1 Dosing adherence During study visits days medication administered h supervised study personnel In study visits subjects took medication home adherence assessed follows tablets counted trial nurses ii Medication Event Monitoring System MEMS caps Aardex Ltd Zug Switzerland used monitor opening metformin_containing bottles iii subjects instructed record time medication intake AE diary PK sampling oral glucose tolerance test The study conducted Clinical Research Centre Nijmegen Radboud university medical center Nijmegen Netherlands At steady_state day blood samples withdrawn measure plasma concentrations metformin A B daclatasvir B Drugs taken concomitantly overnight fast blood withdrawn ethylenediamine tetra_acetic acid tubes  predose h metformin intake During treatment B daclatasvir additional sample collected h Blood samples stored refrigerator centrifuged min g Plasma transferred polypropylene tubes stored _40 C bioanalysis To study metformin excretion steady_state assess renal clearance metformin urine collected h intervals h Prior start collection morning urine voided administration metformin Participants asked drink ml water every h The volume pH urine noted stored _40 C bioanalysis For OGTT participants instructed avoid strenuous exercise follow carbohydrate_controlled diet least 200Ð250 g carbohydrates per day days prior day The OGTT performed overnight fast least h At h subjects drank g glucose mL water Following glucose intake venous blood withdrawn  predose min determine plasma concentrations glucose lactate insulin Data collected using Castor EDC Castor Electronic Data Capture Ciwit BV Amsterdam Netherlands Bioanalytical methods Metformin daclatasvir analysed laboratory Department Pharmacy Radboud university medical center Nijmegen Netherlands Metformin plasma urine determined using two different validated ultra_performance liquid chromatography UPLC assays ultraviolet UV detection nm Metformin extracted _l plasma using _l M sodium hydroxide ml 1_butanol n_ hexane v v This solution vortexed min rpm centrifuged min g The aqueous phase frozen min Ð40 C organic phase poured vial Metformin back_extracted organic phase adding _l phosphoric acid This solution vortexed min rpm centrifuged min g Metformin extracted _l urine following procedures adding _l blank plasma After back_extraction _l water phase diluted _l water injection Chromatography performed using Acquity UPLC HSS T3 analytical column _m _ mm Waters Milford MA USA mobile phase M phosphate buffer pH The flow rate set ml minÐ1 After every injection column rinsed combination eluent acetonitrile v v equilibrating back initial eluent Accuracy across five metformin quality_control samples measured three runs n  days ranged plasma urine Interday precision ranged plasma urine n  Intraday precision ranged plasma urine n  For metformin plasma calibration range 0 01Ð5 00 mg lÐ1 urine range 2 0Ð2100 mg lÐ1 Daclatasvir measured using validated UPLC method UV detection nm Daclatasvir extracted _l plasma using _l acetonitrile methanol v v formic acid This solution vortexed min rpm centrifuged min g The supernatant _l poured vial centrifuged min g _l injected onto Acquity UPLC BEH C18 analytical column _m _ mm Waters Milford MA USA The flow rate set ml minÐ1 daclatasvir eluted using gradient M phosphate buffer M phosphate buffer acetonitrile v v Accuracy across five daclatasvir quality_control samples measured three runs days ranged Interday precision ranged intraday precision ranged The calibration range method 0 03Ð10 mg lÐ1 Insulin samples collected lithiumÐheparinized tubes determined clinical chemistry laboratory Radboud university medical center Nijmegen Netherlands random access analyzer Roche E170 modular immunoassay Roche Diagnostics International Ltd Rotkreuz Switzerland Glucose lactate blood gas tube blood gas tube Pro_Vent 4646E lithium_heparin coating Smiths Medical MN USA determined directly sampling using glucose enzymaticÐamperometric method Biosen C_line GP EKF_diagnostic GmbH Barleben Germany PK analysis A noncompartmental approach used WinNonlin Phoenix version Pharsight Corporation St Louis MO USA assess area time curve h h AUC0Ð12 12_h plasma concentration C12 metformin h h AUC0Ð24 24_h plasma concentration C24 daclatasvir In addition maximum plasma concentration Cmax time reach Cmax apparent elimination half_life metformin daclatasvir determined Metformin renal clearance calculated dividing total amount metformin excreted 0Ð12 h AUC0Ð12 The secretion metformin calculated subtracting metformin clearance creatinine clearance calculated using Chronic Kidney Disease Epidemiology Collaboration CKD_EPI formula eGFR mL min 1 73 m2  _ minimum Scr _ _ _ maximum Scr _ 1 _1 209 _ 0 993Age _ female _ black With Scr standardized serum creatinine mg dL _ females males respectively age years In addition geometric mean ratios GMRs confidence intervals CIs treatment B vs treatment A metformin secretion eGFR calculated PD analysis The plasma concentrations glucose lactate insulin used calculate area concentrationÐtime curve h h AUC0Ð2 WinNonlin Phoenix used The insulin glucose concentrations also used calculate homeostatic model assessment insulin resistance HOMA_IR score used quantify insulin resistance HOMA_IR  glucose _ insulin 22 5 Statistical analysis The AUC0Ð12 values metformin treatments A B compared using bioequivalence approach recommended European Medicines Agency EMA evaluate PK drug interactions GMRs CIs AUC0Ð12 Cmax C12 calculated metformin comparing treatment B treatment A We used linear mixed_effect model fixed parameters calculate GMR CI Fixed parameters treatment period sequence subjects within sequence according EMA guidelines For bioequivalence treatments A B AUC0Ð12 GMR CI fall within range 80Ð125 Based previously observed intersubject coefficient variation CV metformin AUC0Ð12 expected intrasubject CV lower For sample_size calculation used power calculation SAS SAS Institute Inc Cary NC USA using paired t_test lognormal distribution showing equivalence For power prove bioequivalence sample size subjects included study To account possible dropouts subjects included Metformin renal clearance log_transformed compared treatments using paired t_test Glucose lactate insulin AUC0Ð2 values log_transformed compared treatments using paired t_test All statistical analyses performed IBM SPSS Statistics IBM Corp Released IBM SPSS Statistics Windows Version Armonk NY IBM Corp Safety tolerability During study visits AEs laboratory safety biochemistry haematology monitored study nurses physicians AEs graded using Division AIDS Table Grading Severity Adult Pediatric Adverse Events ÔDAIDS AE Grading TableÕ version December clarification August Ethics The trial approved Investigational Review Board Radboud university medical center Nijmegen Netherlands The trial conducted accordance Good Clinical Practice Declaration Helsinki registered ClinicalTrials gov NCT02565862 All participants signed informed consent forms screening evaluations\n",
      "Methods Subjects The study conducted single centre Aster Cephac Paris France December February according principles Declaration Helsinki Good Clinical Practice The study protocol reviewed approved independent ethics committee Comit consultatif de Protection des Personnes dans la Recherche Biomedicale Broussais HEGP France All subjects informed aim design risks study declared consent writing Sixteen healthy male Caucasian subjects years age body mass index BMI kg m_2 included study They good health clinically relevant medical psychiatric abnormalities Known suspected hypersensitivity particular study medication history atopic eczema and or active skin disease concomitant medication within weeks prior first dosing led exclusion Study design The investigation designed open label randomized single site two way crossover study two groups participants received two different treatments treatment A rotigotine transdermal patch mg h _1 cm2 total drug content mg rotigotine applied daily days 1Ð4 mg domperidone administered orally t i d days 1Ð5 treatment B rotigotine transdermal patch mg h _1 cm2 total drug content mg rotigotine applied daily days 1Ð4 randomized sequence AB BA wash out period ³7 days treatments A screening examination carried days prior randomization eligibility based physical examination vital signs 12 lead ECG safety laboratory parameters medical history drug alcohol screening serology hepatitis B C human immunodeficiency virus results Subjects hospitalized treatment periods day _1 day Eligibility confirmed day _1 first period subjects randomized either treatment sequence using computer generated scheme They remained fasting least h night first dosing day h sequences Rotigotine transdermal patch Schwarz Biosciences GmbH Monheim Germany applied daily h 24 h patch on period mg domperidone Motilium Janssen Cilag Issy les Moulineaux France administered orally t i d The patch applied abdomen morning administration morning domperidone dose treatment period A Subjects stay bed ³2 h patch application A treatment duration days ensured PK analysis steady state conditions rotigotine treatment periods During confinement paracetamol maximum daily dose mg permitted concomitant treatment A follow up visit performed 5Ð10 days end second treatment period included recording adverse events AEs physical examination vital signs ECG safety parameter assessment Sampling drug analysis Blood samples collected treatment periods lithium heparinized Monovettes venous puncture indwelling venous catheter day prior first patch application days h last patch application treatment Plasma separated stored _20 C analysed Urine samples collected predose day two intervals day h h patch application The total amount urine collected within interval accurately determined aliquot ml stored _20 C analysed Concentrations rotigotine metabolites plasma urine determined validated liquid chromatography tandem mass spectrometry LC MS MS Fentanyl citrate used internal standard overall accuracy precision calibration standards quality controls well within concentrations The lower limit quantification LOQ plasma pg ml_1 unconjugated rotigotine In urine LOQ pg ml_1 pg ml_1 unconjugated total rotigotine respectively pg ml_1 pg ml_1 unconjugated total N desthienylethyl rotigotine respectively pg ml_1 pg ml_1 unconjugated total N despropyl rotigotine respectively Total rotigotine concentrations determined preincubation _ glucuronidase Helix pomatia Sigma Munich Germany ml undiluted enzyme preparation per ml plasma convert conjugates back unconjugated moiety This enzyme preparation contains _ glucuronidase sulphatase activity Pharmacokinetic parameters The primary parameters PK evaluation unconjugated rotigotine area concentrationÐtime curve steady state AUC 0Ð24 ss peak plasma concentration steady state Cmax ss time reach Cmax ss tmax ss terminal half life unconjugated rotigotine t1 2 cumulative amount unconjugated rotigotine excreted urine Ae0Ð24 Cmax ss tmax ss determined directly plasma concentrationÐtime curves unconjugated rotigotine AUC 0Ð24 ss calculated means linear trapezoidal rule The terminal rate constant _z determined h time patch removal last patch treatment last measurable concentration log linear regression The terminal half life calculated t1 2  ln 2 _z Ae sampling interval determined multiplying drug concentration urine volume Summation Ae determined collection interval resulted cumulative amount Ae0Ð24 unconjugated rotigotine within 24 h dose interval The secondary parameters minimum average plasma concentrations unconjugated rotigotine steady state Cmin ss Cave ss Cave ss calculated AUC 0Ð24 ss divided h Additional parameters included renal clearance CLR unconjugated rotigotine calculated Ae0Ð24 AUC 0Ð24 ss Ae0Ð24 total rotigotine main metabolites unconjugated total N despropyl rotigotine N desthienylethyl rotigotine The peak trough fluctuation plasma concentration profile calculated using following equation PTF  Cmax ss _ Cmin ss Cave ss x Cave ss  AUC 0Ð24 ss 24 Total rotigotine total metabolites sum unconjugated conjugated rotigotine metabolites Apparent rotigotine doses evaluated last 24 h patches removed day difference initial drug content patch residual drug amount used patches Safety tolerability assessments Safety tolerability evaluated regular intervals throughout study vital signs measurements supine blood pressure pulse rate 12 lead ECG physical examination clinical laboratory tests skin assessments AEs recorded monitored Patch adhesiveness documented h application patch removal assessed according scoring system range lift 80Ð100 lift Skin assessment performed h h patch removal day patch day patch period It evaluated erythema score reddening slight reddening evident reddening papular reaction vesiculation oedema score visible reaction marginal oedema barely recognizable slight oedema area well defined recognizable elevation evident oedema elevation mm severe oedema elevation mm extending outside patch area Statistical analysis Owing exploratory nature study formal sample size calculation undertaken Data analysis carried using WinNonlin software version Pharsight Mountain View CA USA SAS software version SAS Institute Cary NC USA Calculations peak trough fluctuation done SAS version Descriptive statistics performed SAS procedure SUMMARY All treated subjects complete data sufficient patch adhesiveness without major protocol deviations completed study included analysis PK parameters PK set The primary variables evaluated statistically derive treatment ratios differences rotigotine treatment without domperidone comedication Log transformed AUC 0Ð24 ss Cmax ss t1 2 data unconjugated rotigotine subjected analysis variance ANOVA sequence subject within sequence group period treatment effect using general linear models The residuals ANOVA examined normally distributed random error For log transformed parameters geometric mean ratios rotigotine plus domperidone rotigotine alone corresponding confidence intervals CIs calculated comparison Nonparametric Wilcoxon signed rank test used compare differences tmax ss Secondary PK parameters analysed using descriptive statistics without formal statistical comparison treatments All subjects received least one patch application rotigotine included safety tolerability analysis AEs encoded according modified World Health Organization Adverse Reaction Terms dictionary Safety tolerability data assessed descriptively\n",
      "Methods Study Design Participants The study approved Colorado Multiple Institutional Review Board participants provided written informed consent The investigation conducted open label single dose pharmacokinetic study healthy African American volunteers years age Participants prospectively screened enrolled based CYP2C8 genotype i e CYP2C8 1 1 CYP2C8 2 carriers Participants excluded following presence CYP2C8 3 and or CYP2C8 4 alleles body mass index kg m2 ³35 kg m2 current past history cardiovascular hepatic renal endocrine gastrointestinal hematologic immunologic neurologic diseases active malignancy self reported HIV positivity active drug alcohol abuse pregnancy Laboratory exclusion criteria included fasting plasma glucose ³ mg dL serum potassium mEq L mEq L serum creatinine mg dL liver function tests ³ times upper limit normal hematocrit men women platelets _ 109 L white blood cell count _ 109 L _ 109 L laboratory abnormalities classified grade higher per published grading criteria 11 Medication exclusions antidiabetic agents systemic glucocorticoids agent known inhibit induce CYP2C8 and or CYP3A4 metabolizing enzymes e g gemfibrozil trimethoprim rifampin grapefruit juice A description participant reported concomitant medications provided Supporting Information Study Protocol The pharmacokinetic study took place University Colorado Hospital Clinical Translational Research Center CTRC Participants admitted CTRC overnight fast A single dose mg pioglitazone administered mouth A M ml water Participants received calorie controlled breakfast calories carbohydrate protein fat hours pioglitazone ingestion Meals also given hours pioglitazone intake Participants asked abstain smoking caffeine study time period Blood samples measurement pioglitazone M III M IV plasma concentrations collected predose hours post pioglitazone dose Plasma harvested within minutes blood draw stored 80 C later bioanalytical processing Genetic analyses For genetic screening process buccal cell sample collected participant using published mouthwash method 12 Genomic DNA isolated buccal cells using QIAamp DNA Mini Kit Qiagen Valencia CA USA Subjects genotyped CYP2C8 2 Ile269Phe rs11572103 CYP2C8 3 Arg139Lys rs11572080 Lys399Arg rs10509681 CYP2C8 4 Ile264Met rs1058930 using PCR pyrosequencing assays PSQ MA Qiagen Valencia CA USA according standard manufacturer protocol Genotype allele frequencies screening population provided Supporting Information Drug Concentration Analyses Plasma concentrations pioglitazone M III M IV measured using validated LC MS MS assay A detailed description plasma sample preparation chromatography mass spectrometry MS conditions quality control data provided Supporting Information Briefly pioglitazone hydrochloride hydroxy pioglitazone keto pioglitazone pioglitazone d4 internal standard purchased Toronto Research Chemicals Inc North York Ontario Canada Plasma samples prepared using protein precipitation method acetonitrile methanol water 13 Chromatographic separation conducted _ mm micron Zorbax extended C18 column Agilent Technologies Santa Clara CA USA equipped guard column The two mobile phases consisted A mM ammonium acetate formic acid water B acetonitrile methanol delivered flow rate ml min The retention times M IV M III pioglitazone min min min respectively For MS analysis Applied Biosystems Sciex Applied Biosystems Foster City CA USA used ESI positive ion mode The lower limit quantification ng ml pioglitazone M III M IV The assays linear range ng ml ng ml lower limit quantification extracted plasma ng ml pioglitazone M III M IV The method accuracies within pioglitazone M IV M III respectively Interday precision pioglitazone M III M IV respectively Sample Size Calculation Sample size calculated statistical power analysis using NCSS PASS software assuming two tailed _ The study powered expected difference pioglitazone AUC0 individuals CYP2C8 1 1 genotype CYP2C8 2 allele carriers A two sample two tailed test sample size subjects n 9 CYP2C8 1 1 genotype n 9 CYP2C8 2 carriers would provide power detect difference mean pioglitazone AUC0 two genotype groups assuming coefficient variation Pharmacokinetic Statistical Analyses Plasma concentration time curves pioglitazone M III M IV generated Maximum plasma concentrations Cmax time maximum plasma concentration Tmax taken curves Noncompartmental analysis WinNonlin version Pharsight Corporation Mountain View CA USA used determine pharmacokinetic parameters The terminal elimination rate constant _Z obtained regression log linear portion pioglitazone plasma concentration time curves Half life t1 2 calculated divided _Z Pioglitazone area plasma concentration time curve infinity AUC0 hours AUC0 48 M III AUC0 48 M IV AUC0 48 calculated using linear log trapezoidal rule Weight adjusted AUC0 calculated AUC0 _ divided subjectÕs weight kg The primary endpoint study difference pioglitazone AUC0 CYP2C8 genotype groups CYP2C8 1 1 versus CYP2C8 2 carriers Secondary endpoints compared CYP2C8 genotype groups included pioglitazone M III M IV pharmacokinetic parameters e g pioglitazone AUC0 48 M III pioglitazone AUC0 48 M IV pioglitazone AUC0 48 M III M IV AUC0 48 Baseline demographics compared CYP2C8 1 1 homozygotes CYP2C8 2 carriers Fisher exact test categorical data independent tests continuous data Data follow normal distribution log transformed prior analysis back transformed data presentation Pharmacokinetic data compared CYP2C8 genotype groups versus carriers using independent tests Mann Whitney U tests time data generalized linear model analysis assessment covariates Statistical analyses conducted using SPSS version software A p value used level significance\n",
      "Material Methods Volunteers Inclusion criteria required volunteers healthy males years age body mass index kg m2 able understand read French language Candidates ineligible smokers hypersensitive prasugrel ritonavir constituents tablets consumed alcohol regularly concomitant disease used drug food grapefruit month prior study either affect metabolized CYP3A 2C19 2B6 2C9 Volunteers used drugs associated increased risk bleeding days preceding start study excluded familial history clotting disorders antecedent haemorrhagic disease previous active gastrointestinal ulcer Study design This open label cross over study conducted healthy volunteers clinical research unit Geneva University Hospitals This study conducted accordance Good Clinical Practice Guidelines Declaration Helsinki The Geneva University Hospital Ethics Committee Institutional Review Board Swissmedic approved protocol study began This clinical trial registered http www clinicaltrials gov NCT01346800 Written informed consent obtained participant study Volunteers received single oral dose mg prasugrel first day After least one week received mg ritonavir followed mg prasugrel hr later At session also received ÔmicrococktailÕ containing mg bupropion mg flurbiprofen mg omeprazole mg midazolam phenotyping CYP2B6 CYP2C9 CYP2C19 CYP3A respectively hr micrococktail administration Adverse events assessed study Each individual participated study approximately weeks initial screening final session Analysis DBS samples Capillary blood samples pharmacokinetic analysis collected prior hr administration single dose prasugrel After small finger prick using disposable lancet BD Microtainer Contact Activated Lancet United Kingdom _l blood spotted onto filter paper Protein Saver Card Whatman previously soaked _l 2 bromo 3Õ methoxyacetophenone BMAP mM This pre treatment allows unstable thiol group prasugrel AM form disulphide bond BMAP Samples stored _20 C analysis The DBS concentrations prasugrel AM midazolam omeprazole bupropion flurbiprofen measured LC MS MS platform consisting QTtrap triple quadrupole linear ion trap mass spectrometer equipped TurboIon Sprayª interface AB Sciex Darmstadt Germany Ultimate RS pump Dionex LC system Data acquired processed using Analyst software version AB Sciex Analytical method description Before analysis discs i d mm covering entire DBS punched placed bottom individual LC vials containing _L inert insert BGB Analytik Germany Samples extracted adding _L methanol containing ng ml derivatized prasugrel AM d3 Sirius Fine Chemicals Germany After min _L supernatant injected LC MS MS system The analytes separated Kinetex Phenomenex Brechb hler Switzerland RP C18 column _ mm _m particles i d using gradient elution mode running waterÐacetonitrile v v waterÐacetonitrile v v min The total run time min including column wash equilibration After electrospray ionization ESI MS MS detection carried multiple reactions monitoring MRM unit resolution operating dual mode positive negative time settling ms The instrument parameters manually optimized follows curtain gas psi ion source gas GS1 GS2 psi respectively ion source voltage V positive ESI mode _4500 V negative ESI mode temperature 650 C entrance potential collision cell exit potential V positive ESI mode _10 V negative mode The MRM transitions analytes relevant study summarized table Validation The method fully validated according guidelines European Medicines Agency validation bioanalytical methods based three non consecutive days testing A typical validation day consisted DBS calibrators Cal injected duplicate n  DBS quality controls QC injected quadruplicate n  Cal QC DBS samples prepared independently way using fresh human EDTA blood supplied University Hospitals Geneva The calibration curves linear standard concentration ranges 0 1Ð50 ng ml midazolam 0 5Ð250 ng ml prasugrel AM omeprazole bupropion 50Ð10 000 ng ml flurbiprofen Based calibration curves trueness expressed relative bias intermediate precision QCs calculated The values within expected criteria analytes The selectivity method investigated injecting DBS pre treated BMAP obtained volunteers recruited study No interfering peaks observed retention window analytes matrix effects To ensure DBS specimens collected study could shipped stored ambient temperature short period analytesÕ stability investigated days three different temperatures i e _20 C 4 C room temperature The assay showed compounds stable tested temperatures back calculated concentrations comprised corresponding 1 day old DBS samples As significant difference observed storage room temperature _20 C DBS cards could collected shipped stored ambient temperature Moreover reinjection study DBS samples stored _20 C months showed similar results previously obtained Phenotyping plasma samples A blood sample approximately ml obtained hr administration ÔmicrococktailÕ session phenotyping Blood samples immediately centrifuged separated plasma stored _20 C analysis We used validated extraction methods routinely used laboratory Omeprazole flurbiprofen midazolam metabolites extracted described previously Bupropion extracted liquidÐliquid extraction procedure All probes metabolites analysed LCÐMS MS method described previous section Size calculation To detect inhibition prasugrel AM formation ritonavir least  power _  eight volunteers needed Two additional volunteers recruited case volunteer withdrawal Statistics The pharmacokinetic parameters prasugrel AM midazolam bupropion flurbiprofen omeprazole calculated using non compartmental method WinNonLin version Pharsight Mountain View CA USA All statistical tests performed spss version Chicago IL USA According regulatory guidelines results presented mean values S D mean ratios confidence intervals The values tmax presented median range The effect ritonavir pharmacokinetic variables prasugrel estimated Wilcoxon signed rank test using spss version All statistical tests interpreted significance level two sided\n",
      "Methods Patient selection Eligibility recruitment patients initial diagnosis locally advanced pancreatic carcinoma treated University Nebraska Medical Center UNMC This study approval Institutional Review Board IRB 441 07 FB UNMC All patients gave written informed consent Treatment plan Patients initially received females males mg mÐ2 gemcitabine i v 30_min 50_mg mÐ2 leucovorin i v 30_min 2700_mg mÐ2 5 FU IV 24_h day weekly 3_weeks three cycles days 1Ð63 Oral nelfinavir given 625_mg 1250_mg twice daily 3_weeks starting 2_weeks prior initiation radiation days 56Ð75 We chose 625_mg low dose dose shown better tolerated preferred patients We chose 1250_mg high dose standard dose nelfinavir HIV patients 1250_mg twice daily given orally The drugs required study obtained commercial sources Because duration nelfinavir therapy limited planned dose modification grade 1Ð2 toxicities attributed nelfinavir In event grade worse toxicity attributed nelfinavir drug withheld toxicity grade less severity drug resumed 625_mg oral administration daily 625_mg orally twice daily Participants instructed take nelfinavir food The study conducted compliance ethical principles compliance local laws regulations Pharmacokinetic studies After patients received least 10_days nelfinavir serial blood samples collected following time points steady state 0_h measure trough concentration nelfinavir dosing 12_h latter prior next planned dose nelfinavir twice daily regimen Blood collected 10_ml green top tubes BD Franklin Lakes NJ containing sodium heparin The collected heparinized blood placed ice immediately The tube centrifuged 10_min 800___g 4_ C Plasma removed tube placed labelled cryovial 1 8_ml aliquots frozen _80_ C time analysis A total samples patients collected pharmacokinetic analysis average approximately nine samples per patient Quantification nelfinavir M8 concentrations performed using Waters HPLC system consisting pump autosampler photodiode array detector Milford MA USA Chromatographic separation obtained isocratic conditions room temperature analytical C8 Nova Pak column 250___3 9_mm 3 0_µm The mobile phase contained 20_m acetate buffer acetonitrile v v pH_4 88 The u v spectrum monitored 255_nm detection nelfinavir M8 268_nm detection internal standard amprenavir The flow rate 1_ml minÐ1 A standard curve generated every analytical run Stock solutions nelfinavir M8 metabolite amprenavir internal standard prepared dissolving weighed amounts 2_ml glass vials methanol separately The solutions stored _20_ C For preparation calibration standards working solutions nelfinavir M8 amprenavir prepared diluting appropriate volumes stock solutions methanol Calibration concentrations 0 1562Ð10_µg mlÐ1 nelfinavir M8 obtained spiking human blank plasma Calibration standards prepared daily new batch samples added blank plasma quality control samples prepared plasma divided small aliquots stored _20_ C use Individual primary methanol stock solutions nelfinavir M8 amprenavir prepared concentrations high enough combined secondary dilution 1_ml volume methanol resulted free base concentration 200_µg mlÐ1 This standard non serially diluted concentrations 1 532_µg mlÐ1 A µl addition solutions 180_µl human bank plasma resulted standard curve concentrations 0 1532_µg mlÐ1 Calibration curves fitted least squares linear regression analysis using 1 concentration2 weighting factor On day analysis patientsÕ plasma thawed room temperature A 0 2_ml patient plasma sample taken 2_ml Eppendorf tube spiked internal standard mixed 0 3_ml precipitating solvent mixture acetonitrile 0 1_ orthophosphoric acid  v v It vortex mixed 30_s incubated ice 10_min vortexed 30_s The mixture centrifuged 000_rev minÐ1 10_min refrigerated microcentrifuge 4_ C The supernatant transferred borosilicate glass tube evaporated Zymark TurboVap evaporator dryness flow nitrogen 40_min 40_ C residue re suspended µl mixture acetonitrile 0 1_ orthophosphoric acid  v v It filtered _ syringe filter labeled autosampler tube 20_µl injected The current HPLC u v assay method certain advantages reported assays quantification nelfinavir M8 metabolite The sample preparation simple utilizing efficient rapid liquidÐliquid extraction The assay entirely isocratic involving two stable solvent components low volatility pH adjusted acetate buffer solution acetonitrile The background blank baseline clear little interference endogeneous peaks In addition equilibration rapid absorbance 255_nm transparent run time less 20_min Non compartmental analysis performed obtain pharmacokinetic parameters nelfinavir M8 including elimination half life t1 2 total body clearance CLT F apparent volume distribution VD F using WinNonlin Pro version Pharsight Corporation Mountain View CA USA Pharmacogenetic studies Venous blood 20_ml collected pharmacogenetic analysis Genomic DNA isolated buffy coat using QIAamp DNA Blood Kit Qiagen Valencia CA USA per manufacturerÕs instructions Genotyping polymerase chain reaction restriction fragment length polymorphism PCR RFLP conditions performed previously described Goldstein  Blaisdell The primers used amplification CYP2C19 exon forward 5 CAGAGCTTGGCATATTGTATC 3 reverse 5 GTAAACACACAACTAGTCAATG 3 The primers used amplification CYP2C19 exon forward 5 AAATTGTTTCCAATCATTTAGCT 3 reverse 5 ACTTCAGGGCTTGGTCAATA 3 A mixture 2_µl 10___PCR buffer Fisher BioReagents 0 8_µl 2 5_m deoxyneocleotide triphosphate 1 6_µl 25_m magnesium chloride 0 5_µl forward reverse primer pmol µlÐ1 40_ng genomic DNA 0 1_µl Taq polymerase U µlÐ1 sterile water final volume 20_µl used The PCR settings follows step 94_ C 5_min step 94_ C 20_s step 53_ C 10_s step 72_ C 10_s Steps repeated 37_cycles followed 72_ C 5_min To detect CYP2C19 2 allele Sma I restriction enzyme used detect CYP2C19 3 allele BamH I restriction enzyme used Following addition respective restriction enzyme PCR product reaction incubated 37_ C overnight The stop buffer containing EDTA glycerol bromophenol blue added reactions analyzed gel electrophoresis agarose gel After ethidium bromide staining gel sizes digested DNA fragments determined manual visualization Statistical analysis StudentÕs unpaired t test used compare mean values individual groups A P value considered statistically significant\n",
      "METHODS AND MATERIALS Study Design This open label randomized crossover study Subjects assigned receive carvedilol mg Coreg orally without paroxetine coadministration random order The paroxetine regimen consisted mg immediate release paroxetine orally daily two days twice daily five days twice daily day carvedilol dosing daily four days afterward titrated safety reasons On carvedilol dosing days paroxetine mg carvedilol mg given orally concurrently morning second dose paroxetine mg given orally hours later All paroxetine doses taken home except carvedilol dosing days dosing times recorded dosing diaries Dosage regimens chosen yield quantifiable carvedilol concentrations blood minimize fluctuations paroxetine exposure across measurement period representing lower doses typical clinical practice minimize potential toxicity There minimum day washout period carvedilol doses last previous paroxetine dose off paroxetine carvedilol doses Subjects healthy volunteers required fast p m night prior admission Water allowed ad lib except hour hours carvedilol dose Carvedilol administration phases carried supervision General Clinical Research Center Michigan Clinical Research Unit The University Michigan Hospital Study medications dispensed hospital pharmacy given oz water Subjects received standardized lunch dinner prepared monitored research center The study protocol approved Institutional Review Board University Michigan Hospital Subjects Prospective subjects eligible study inclusion nonsmoking healthy adults Ð years age inclusive regularly taking medications including natural products supplements willing abstain non study medications study period willing adhere dietary restrictions required willing comply study requirements including documenting medication ingestion adverse effects Potential subjects excluded study clinically significant abnormal findings history physical exam including blood pressure less mmHg resting heart rate less beats per minute significantly abnormal findings screening electrocardiogram abnormal laboratory values baseline follow up laboratories Other exclusion criteria included allergy serious adverse reaction medications used study including heparin presence condition investigator felt would interfere successful completion study participation study study period Women breastfeeding pregnant childbearing potential reliable contraception excluded Sample Collection Subjects intravenous catheter placed antecubital forearm vein a m carvedilol dosing days Blood samples mL sample collected tubes containing ethylene diaminetetracetic acid immediately prior carvedilol administration time hours administration The catheter withdrawn hour blood sample final blood sample mL drawn venipuncture Catheter patency maintained 3mL heparin units mL solution Three milliliters blood withdrawn catheter deadspace discarded immediately prior blood sample All blood samples centrifuged C approximately rpm within one hour collection Plasma collected stored _70 C analysis After blood draw heart rate rhythm measured 3 lead electrocardiogram Next sitting blood pressure BP measured automated blood pressure machine Blood pressures taken minimum three times per sample difference greater mmHg systolic readings Bioanalytical Methods Plasma carvedilol enantiomer concentrations quantified independent outside laboratory NSF International Ann Arbor MI To summarize mL plasma extracted mL diethyl ether mL diethyl ether alkalization Britton Robinson buffer The organic phase evaporated residue reconstituted mL acetic acid R S enantiomers analyzed high pressure liquid chromatography system Agilent Technologies Santa Clara California The method employed mm chiral cellobiohydrolase column mobile phase consisting 2 propanol M sodium acetate buffer pH _M disodium EDTA flow rate mL min A _L injection volume used Column effluent measured using fluorescence detector Hitachi High Technologies Corporation Tokyo Japan using nm excitation wavelength nm emission wavelength The lower limit quantification LLOQ determined ng mL Data Analysis PK Analysis PK parameters R S carvedilol calculated noncompartmental methods Winnonlin version Pharsight Corp Mountain View CA Concentrations LLOQ removed including pre dose concentrations PK variables evaluated included AUC time infinity AUC0Ð calculated linear trapezoidal rule maximum concentration Cmax time reach Cmax Tmax apparent oral clearance Cl F terminal elimination rate _z Area curve extrapolated infinity dividing last measureable concentration _z Statistical Analysis PK variables reported geometric mean  standard deviation except Tmax reported median range Demographic variables reported arithmetic mean  standard deviation Differences PK pharmacodynamic PD parameters study phases evaluated analysis variance ANOVA controlling study phase order subject post hoc analysis appropriate TukeyÕs studentized range test using R version Vienna Austria Ninety percent confidence intervals CIs around carvedilol AUC geometric mean ratios GMRs paroxetine without paroxetine also given A sample size subjects calculated detect increase AUC paroxetine coadministration power significance level A significance level used statistical testing\n",
      "Methods Study design This open label randomized two period two treatment two way crossover study Subject screening assessments included medical history physical examination haemodynamics including blood pressure heart rate 12 lead electrocardiogram ECG genotyping CYP2D6 status known laboratory screening Eligible subjects admitted Pfizer Clinical Research Unit New Haven CT evening study period Twenty eight subjects aged years received single dose fesoterodine mg alone treatment A single dose fesoterodine mg co administered fluconazole mg treatment B The crossover treatments separated day washout period Specifically treatment periods single dose fesoterodine mg administered orally fasted state day During treatment B fluconazole mg administered h approximately h fesoterodine mg administration day also day approximately h fesoterodine mg administration day Subjects completed two treatment periods randomized order The study conducted compliance Declaration Helsinki International Conference Harmonization Good Clinical Practice Guidelines local regulatory requirements The protocol approved appropriate Institutional Review Board study centre All subjects provided written informed consent entering study Subjects Eligible subjects included healthy men women years age body mass index BMI kg mÐ2 total body weight kg Subjects excluded severe acute chronic medical psychiatric condition laboratory abnormality current previous urinary retention bladder obstruction micturition disturbance urinary tract infections nocturia prostatic hyperplasia urethral stricture uncontrolled narrow angle glaucoma regular alcohol consumption exceeding seven drinks per week women drinks per week men within months screening 12 lead ECG demonstrating corrected QT interval QTc ms screening Assessment pharmacokinetics safety Blood samples 5 HMT PK analysis collected pre dose h fesoterodine dosing The total volume blood samples collected subject approximately ml Blood samples placed immediately ice water bath centrifuged g min 4 C resultant plasma samples minimum ml stored approximately _20 C within h collection Plasma samples analyzed 5 HMT concentrations Advion Bioservices Inc Ithaca NY using validated liquid chromatography tandem mass spectrometry LC MS MS method previously described Plasma 5 HMT PK parameters included AUC time zero infinity AUC 0 AUC time time last quantifiable concentration AUC 0 tlast maximum plasma concentration Cmax time Cmax tmax half life t1 2 determined plasma concentrationÐtime data using standard noncompartmental methods Safety assessed via adverse event AE monitoring laboratory evaluations vital sign measurements Safety data analyzed descriptively included subjects received least one dose study drug Statistics A sample size subjects required provide confidence intervals CIs difference treatments   natural log transformed scale ratio treatments range non transformed scale AUC 0 Cmax respectively coverage probability This estimate based estimates within subject standard deviations ln AUC 0 ln Cmax or coefficient variation CV AUC 0 Cmax respectively obtained results previous studies A total subjects enrolled The additional subjects enrolled anticipating discontinuation four subjects based prior experience studies similar design conducted clinical research unit Log transformed AUC 0 AUC 0 last Cmax analyzed using analysis variance anova sequence period treatment fixed effects subject within sequence random effect yield estimated adjusted means PK parameters corresponding CIs fesoterodine reference fesoterodine plus fluconazole test groups The adjusted mean differences CIs differences exponentiated provide point estimates ratio adjusted geometric means test  reference CIs ratios All subjects least one concentration measurement least one treatment period included concentration summaries All subjects least one PK parameter interest least one treatment included statistical analysis PK parameters Physiologically based pharmacokinetic PBPK methodology A PBPK model SimCYP V7 1 5 HMT generated incorporating physico chemical properties log P  base pKa  fraction unbound plasma blood  plasma ratio absorption steady state volume distribution l kgÐ1 together intrinsic clearances CYPs 3A4 2D6 µl min_1mg_1 microsomal protein renal clearance l hÐ1 The contributions CYP 3A4 2D6 clearance 5 HMT calculated knowing total clearance l hÐ1 renal clearance 5 HMT l hÐ1 The difference total renal clearance assumed metabolic clearance The drugÐdrug interaction DDI studies CYP3A4 inhibitor CYP2D6 EMs PMs indicated CYPs 3A4 2D6 contributed equally metabolic clearance Thus intrinsic clearance inputs CYPs 3A4 2D6 back calculated well stirred model hepatic clearance assuming equal contribution two enzymes used PBPK model The model validated comparing clinical PK data PBPK simulations The trial design PBPK simulations used _ trial subjects aged years individuals female The population selected composed standard Caucasian population CYP2D6 PM subjects For fluconazole ketoconazole DDI simulations single dose mg fesoterodine administered day following administration fluconazole mg twice daily ketoconazole mg twice daily doses used clinical studies\n",
      "Materials Methods This open label randomized three period DDI study GXR LDX healthy adults aged 18Ð45 years Written informed consent obtained subject accordance International Conference Harmonisation ICH Good Clinical Practice GCP Guideline E6 applicable regulations At screening inclusion criteria body mass index kg m2 inclusive satisfactory medical assessment significant relevant abnormalities medical history physical examination vital signs laboratory evaluation considered reasonably likely interfere subjectÕs participation ability complete study normal clinically insignificant electrocardiogram ECG findings screening Subjects excluded study current recurrent disease could affect clinical laboratory assessments history seizure disorder history presence known cardiac abnormalities syncope cardiac conduction problems exercise related cardiac events clinically significant bradycardia history controlled uncontrolled hypertension resting sitting SBP greater mmHg DBP greater mmHg symptomatic clinically meaningful orthostatic hypotension assessed investigator On day first treatment period subjects randomly assigned one six possible treatment sequences i e ABC ACB BAC BCA CAB CBA Fig During studyÕs three treatment periods subjects administered one three medication regimens regimen A consisted single 4 mg dose GXR regimen B consisted single 50 mg dose LDX regimen C consisted coadministration single doses GXR mg LDX mg Subjects confined clinical research center treatment period i e day _1 day The total confinement study days Washout periods least days separated treatment periods Pharmacokinetic Assessments Guanfacine lisdexamfetamine d amphetamine levels measured plasma produced blood samples collected predose within min administration h treatment Blood samples centrifuged approximately rpm min C within min blood draw Plasma concentrations measured using liquid chromatography LC tandem mass spectrometry LCÐMS MS methods validated quantitation guanfacine lisdexamfetamine d amphetamine human K3 EDTA plasma For guanfacine LCÐMS MS analysis carried Sciex mass spectrometer coupled Shimadzu LC pump model LC 10AT Perkin Elmer series autosampler The internal standard used guanfacine 13C15N3 Guanfacine internal standard extracted _L human plasma liquidÐliquid extraction prior LCÐMS MS analysis The chromatographic separation achieved XBridge phenyl _m _ mm LC column Waters Corporation mobile phase flow rate mL min The mass spectrometer operated positive electrospray ionization mode resolution settings used unit Q1 low Q3 The multiple reaction monitoring MRM transition m z _ guanfacine MRM transition m z _ internal standard guanfacine 13C15N3 On basis sample volume _L assay ranged ng mL guanfacine Samples limit quantitation diluted range control plasma For d amphetamine lisdexamfetamine LCÐMS MS analysis carried Sciex API mass spectrometer coupled Shimadzu LC pump model LC 10AT Perkin Elmer series autosampler The internal standards used amphetamine D5 d amphetamine lisdexamfetamine D8 lisdexamfetamine Plasma samples containing d amphetamine lisdexamfetamine internal standards extracted liquidÐliquid extraction prior LCÐMS MS analysis The chromatographic separation achieved Phenosphere NEXT CN _m _ mm column Phenomenex mobile phase flow rate mL min The mass spectrometer operated positive mode resolution setting used unit Q1 Q3 The MRM transitions m z _ d amphetamine m z _ amphetamine D5 m z _ lisdexamfetamine m z _ lisdexamfetamine D8 On basis plasma sample volume _L assay ranged ng mL d amphetamine ng mL lisdexamfetamine Safety Assessments Safety evaluations included AEs vital signs 12 lead ECGs physical examination findings clinical laboratory parameters Pulse blood pressure BP assessed supine standing positions predose within min administration h treatment ECGs recorded h treatment administered TEAEs defined AEs occurred worsened on treatment period TEAEs assigned treatment received time onset AE Because crossover study reported AE considered TEAE periods crossover h last administration within period unless partial date time showed TEAE occurred identified period Statistical Analysis The primary analysis pharmacokinetic analysis performed using data pharmacokinetic population The pharmacokinetic population consisted subjects received least one dose study medication least one postdose safety assessment evaluable concentrationÐtime profiles guanfacine LDX d amphetamine Pharmacokinetic parameters determined plasma concentrationÐtime data noncompartmental analysis included maximum plasma concentration Cmax time Cmax tmax area plasma concentrationÐtime curve AUC last measurable concentration time AUC0Ðt AUC extrapolated infinity AUC0Ð apparent terminal half life t1 2 apparent oral dose clearance CL F apparent volume distribution Vz F CL F Vz F corrected body weight Summary statistics including numbers observations means standard deviations SDs coefficients variation medians maximums minimums geometric means determined pharmacokinetic parameters treatment regimens The means log transformed pharmacokinetic parameters compared among treatments using analysis variance ANOVA sequence period treatment fixed effects subject nested within sequence random effect crossover study design To estimate magnitude treatment differences Cmax AUC0Ð geometric mean ratio GMR defined least squares mean difference log transformed parameters back transformed original scale  confidence intervals CIs also calculated If  CIs GMR GXR  LDX GXR GXR  LDX LDX guanfacine LDX following coadministration GXR LDX analyte following GXR LDX alone fall within reference interval 0 80Ð1 25 hypothesis DDI GXR LDX would rejected If CIs entirely contained within interval clinical significance mean ratio estimates confidence limits would interpreted within context therapeutic index The available within subject estimates SDs log transformed parameters AUC0Ð SD  Cmax SD  GXR pooled previous studies GXR A previous study LDX reported within subject SD log transformed parameters Cmax AUC0Ð A total subjects six per sequence required demonstrate equivalence using bioequivalence reference interval 0 80Ð1 25 allowing  difference treatment means achieve  power\n",
      "Methods The study approved Competent Authority Germany BfArM EudraCT Ethics Committee Medical Faculty University Heidelberg It conducted Department Clinical Pharmacology Pharmacoepidemiology accordance standards Good Clinical Practice defined ICH E6 Guideline Good Clinical Practice agreement Declaration Helsinki specific legal requirements Germany Study population Fourteen healthy male n female n Caucasian participants stratified according CYP2C19 genotype enrolled study seven poor metabolizers PM seven ultrarapid metabolizers UM They years old average age  years All participants mentally physically healthy defined medical history physical examination electrocardiogram routine laboratory analyses included haematology blood chemistry serology urine drug screening With exception oral contraceptives none participants took continuous medication months prior study All participants nonsmokers Women required nonpregnant nonlactating agreed use appropriate barrier contraception throughout study Further exclusion criteria included intake substance known induce inhibit drug metabolizing enzymes transport system enzymes within period less times respective elimination half life condition could modify absorption distribution metabolism excretion drug regimen investigation allergies except mild forms hay fever history hypersensitivity reactions smoking excessive alcohol drinking approximately g alcohol per day blood donation within last months participation study within last months positive drug screening known admitted drug abuse inability communicate well investigator All participants gave written informed consent study measures carried Study design blood sampling urine collection A randomized double blind placebo controlled cross over study conducted The randomization scheme generated using website Randomization com _http www randomization com_ Each subject received ritonavir mg Norvir mg Abbott Wiesbaden Germany placebo P Tabletten wei mm Lichtenstein Winthrop F rstenfeldbruck Germany every h starting evening day _19 00 h morning day total six doses One hour intake second ritonavir placebo dose day single oral dose mg tilidineÐnaloxone solution ml Valoron N Pfizer Pharma GmbH Karlsruhe Germany given together ml table water On days blood samples ml collected intake tilidine h administration tilidine Blood samples immediately centrifuged 2500g 4 C separated plasma stored _20 C analysis Urine collected h three fractions study days aliquot ml kept frozen _20 C analysis After washout period days procedure repeated ritonavir placebo interchanged During study day standardized lunch dinner meals served Alcohol grapefruit juice caffeinated beverages allowed throughout study Determination tilidine metabolites ritonavir plasma For determination ritonavir plasma µl reconstituted extracts injected onto analytical column different mobile phase different mass spectrometry conditions mobile phase consisted acetonitrile 0 1 ammoniumacetat v v The mass spectrometer adjusted admit protonated molecules M  H m z ritonavir internal standard via first quadrupole Q1 collision induced fragmentation Q2 monitoring product ions via Q3 m z ritonavir m z internal standard Calibration ritonavir linear range 10Ð10 ng ml_1 The coefficient correlation r2 always greater The lower limit quantification ng ml_1 The day to day within day results quality control samples given Table The extraction recovery ritonavir 90Ð109 three quality control concentrations The extraction recovery internal standard concentration ng ml_1 Determination tilidine metabolites urine Urine samples µl calibration samples calibration range 10Ð500 ng ml_1 quality control samples transferred µl borate buffer pH containing internal standard tramadol ng ml_1 µl water added For cleavage glucuronides water substituted glucuronidase solution units per µl samples placed water bath 37 C h For liquid liquid extraction ml tert butyl methyl ether added tubes placed overhead shaker min After centrifugation min 3000g ml supernatant transferred glass tubes organic phase reduced dryness using nitrogen 40 C The residues reconstituted µl mm ammonium acetate acetonitrile v v Ten microlitres solution injected LC MS MS system The conditions LC MS MS described plasma samples Calibration compounds tilidine nortilidine bisnortilidine linear range 10Ð500 ng ml_1 The coefficient correlation r2 always greater The lower limit quantification ng ml_1 compound The day to day within day results quality control samples given Table The extraction recovery three drugs ranged three different quality control concentrations The extraction recovery internal standard concentration ng ml_1 Calculation statistic analysis A power calculation performed using PS Power Sample Size Calculations Owing low frequency CYP2C19 PMs priori sample size seven UM PM subjects fixed With anticipated difference tilidine clearance genotypes known variability low power detect difference population means PM UM groups However conditions CYP3A4 inhibition thereby considerable reduction variability power increase given sample size Data presented means  SD In addition confidence intervals given tables Noncompartmental analysis performed use WinNonlin software version Pharsight Mountain View CA USA determine following pharmacokinetic parameters tilidine nortilidine bisnortilidine maximal observed plasma concentration Cmax time reach maximal observed plasma concentration tmax terminal elimination half life t1 2 area concentrationÐtime curve AUC h AUC0Ð72 AUC infinity AUC0Ð extrapolated use linear trapezoidal rule Ritonavir AUC_ _ h determined second ritonavir dose The renal clearances CLren tilidine nortilidine bisnortilidine determined amount tilidine nortilidine bisnortilidine excreted urine h Ae0Ð72 divided corresponding AUC0Ð72 values Partial metabolic clearances calculated sum metabolites formed via metabolic pathway interest excreted urine h Ae0Ð72 divided AUC0Ð72 parent drug Differences pharmacokinetic parameters placebo ritonavir treatment assessed use nonparametric Wilcoxon matched pairs signed rank test CYP2C19 genotypes MannÐWhitney U test GraphPad Instat GraphPad Inc San Diego CA USA A P value less considered significant Study plasma samples µl calibration samples range 1Ð250 ng ml_1 tilidine metabolites 10Ð10 ng ml_1 ritonavir quality control samples transferred µl acetonitrile contained internal standard tramadol ng ml_1 cyclopropyl ritonavir ng ml_1 The samples vortexed subsequently centrifuged min 000g 10 C From clear supernatant µl transferred glass tubes The organic phase blown dryness gentle stream nitrogen water bath 40 C residues reconstituted µl mm ammoniumacetate acetonitrile v v Ten microlitres solution injected LC MS MS liquid chromatography tandem mass spectrometry Details LC MS MS instruments previously described The mass spectrometer programmed admit protonated molecules M  H m z tilidine nortilidine bisnortilidine tramadol via first quadrupole Q1 collision induced fragmentation Q2 monitoring product ions via Q3 m z tilidine nortilidine bisnortilidine m z tramadol Peak area ratios obtained monitored ions used construction calibration curves using weighted linear least squares regression Each analytical run included seven calibration samples concentrations 1Ð250 ng ml_1 tilidine nortilidine bisnortilidine respectively three quality control samples concentrations ng ml_1 exact concentrations specified Table The quality control samples measured duplicate Data collection peak integration calculations performed using Analyst version software Applied Biosystems Darmstadt Germany Prior quantification study samples method validated accordance US Food Drug Administration guidelines Calibration three drugs tilidine nortilidine bisnortilidine linear range 1Ð250 ng ml_1 The coefficient correlation r2 always greater The lower limit quantification ng ml_1 drugs The day to day within day results quality control samples given Table The extraction recovery three drugs ranged three quality control concentrations The extraction recovery internal standard concentration ng ml_1\n",
      "MATERIALS AND METHODS Subjects Blood obtained unrelated Japanese patients men women mean age range 47Ñ72 years treated thalidomide Shinshu University Hospital DNA analysis approved Institutional Review Board Clinical Trials Shinshu University Hospital Ethical Committee Human Genome Analysis Shinshu University Written consent obtained participant informed experimental procedure purpose study The patients received thalidomide therapy treatment MM AL amyloidosis POEMS syndrome fixed thalidomide dosages least week blood samples obtained Biochemical hematological tests performed taking blood showed evidence hepatic renal impairment subjects Some patients treated concurrent medications vincristine doxorubicin dexamethasone VAD therapy Study Protocol Patients taking mg thalidomide capsules Sauramide Penn Pharmaceuticals Corporation Gwent U K Thaled Fujimoto Pharmaceutical Corporation Osaka Japan daily night week Patients stopped taking thalidomide 2d blood sample collection A thalidomide capsule taken orally breakfast day sampling day At time measurement day venous blood samples obtained h administration thalidomide In patients poor general condition blood samples obtained h 24h administration thalidomide Whole blood samples collected tubes ethylenediaminetetraRegular Article To correspondence addressed e mail somori shinshu u ac jp Vol No acetic acid EDTA 2K The concentrations R and S thalidomide serum determined genetic variations CYP2C19 identified follows Whole blood samples immediately mixed volume 25mM citrate buffer pH stored _80 C analysis The R and S thalidomide concentrations plasma determined 200_L aliquots thawed samples Determination R and S Thalidomide Concentrations Plasma R and S thalidomide concentrations plasma determined high performance liquid chromatography HPLC Briefly 20_L 1 56mM phenacetin internal standard 100_L 25mM citrate buffer pH 1mL ethyl acetate added 100_L whole blood The mixture shaken 1min followed centrifugation 1500_g 5min The upper layer 0 84mL evaporated dryness reduced pressure 40 C The residue reconstituted 100_L 5mM citrate buffer pH 3 0 acetonitrile v v 2_L solution injected HPLC system Hitachi ELITE LaChrom Hitachi Tokyo Japan composed Hitachi L 2100 pump Hitachi L 2200 auto sampler Hitachi L 2300 column oven Hitachi L 2400 UV detector The column CHIRALPAK AD RH column 150mm_2 0mm i d Daicel Chemical Industries Osaka Japan guard column type 10mm_4mm i d The mobile phase consisted water acetonitrile Column temperature 40 C flow rate 0 1mL min The wavelength detector 220nm The areas curve AUC approximated trapezoidal method Polymerase Chain Reaction PCR Amplification CYP2C19 2 Regions Genomic DNA whole blood amplified using KOD FX 40U mL KOD FX polymerase 12 5_L 2_PCR buffer KOD FX 5_L 2mM deoxyribonucleotide triphosphates dNTPs Toyobo Osaka Japan containing nuclease free water total volume 25_L PCR primers concentration 0 32_M Genotyping procedures identifying CYP2C19 2 performed PCR restriction fragment length polymorphism RFLP using allele specific primers minor modifications Primers follows CYP2C19 2 forward primer 5_ AATTACAACCAGAGCTTGGC 3_ reverse primer 5_ TATCACTTTCCATAAAAGCAAG 3_ CYP2C19 3 forward primer 5_ TATTATTATCTGTTAACTAATATGA 3_ reverse primer 5_ ACTTCAGGGCTTGGTCAATATAG 3_ Amplification two regions performed separate tubes using MyCycler thermal cycler Bio Rad Hercules CA U S A PCR conditions follows CYP2C19 2 initial denaturation step 94 C 2min followed cycles 98 C 10s 60 C 68 C 15s CYP2C19 3 initial denaturation step 94 C 2min followed cycles 98 C 53 C 68 C 20s Restriction enzyme cleavage performed 37 C 3h addition units SmaI CYP2C19 2 units BamHI CYP2C19 3 The digested PCR products analyzed electrophoresis agarose gels stained ethidium bromide Statistical Analysis The correlations among CYP2C19 genotype age sex concurrent interacting medications evaluated _2 test compare allele frequency variant p values corrected according BonferroniÕs method Results presented means S D In analyses p 0 05 taken indicate statistical significance\n",
      "In total healthy individuals enrolled The study conducted accordance principles enshrined Declaration Helsinki well Good Clinical Practice All participants given mg single oral dose oseltamivir Tamiflu Roche Korea Seoul Korea Blood samples collected scheduled times study period prior dosing hours hours drug administration Blood samples collected fluoride oxalate tubes Plasma separated centrifugation g 4 C minutes stored _70 C drug concentration analysis performed A blood sample drawn individual genetic analysis stored ethylenediaminetetraacetic acid EDTA _20 C DNA extraction performed The plasma concentrations oseltamivir oseltamivir carboxylate analyzed validated liquid chromatography coupled tandem mass spectrometry LC MS MS method protein precipitation acetonitrile In brief plasma samples mL spiked internal standard _L oseltamivir d3 ng mL _L oseltamivir d3 carboxylate _g mL _L methanol After vigorous vortex mixing _L deionized water added _L supernatant A _L aliquot solution injected LC Shimadzu Prominence LC Shimadzu Co Kyoto Japan detected MS MS API5000 AB SCIEX Foster city CA USA system Chromatographic separation compound conducted using T3 column _m _ mm mobile phase consisting acetonitrile including formic acid The mass spectrometer electrospray source run positive mode m z _ oseltamivir _ oseltamivir d3 _ oseltamivir carboxylate _ oseltamivir d3 carboxylate The lower limits quantification oseltamivir oseltamivir carboxylate ng mL ng mL Linearity calibration curves established within ranges 1_200 ng mL oseltamivir 10_2 000 ng mL oseltamivir carboxylate coefficients determination r2 ³ The respective accuracy levels oseltamivir oseltamivir carboxylate ranged 84 1 _121 4 91 4 _114 4 The respective precision levels oseltamivir oseltamivir carboxylate expressed coefficients variation DNA extracted using standard methods QIAamp DNA Blood Mini Kit Qiagen Hilden Germany ABCB1 polymorphisms c 1236C T c 2677G T A c 3435C T genotyped subjects pyrosequencing methods using Pyrosequencer Biotage Uppsala Sweden referenced previous study The validity method confirmed direct sequencing The pharmacokinetic variables oseltamivir estimated non compartmental methods using Phoenix version Certara USA Inc St Louis MO USA The peak drug concentrations Cmax time reach Cmax Tmax obtained The area plasma concentration time curve AUC time zero infinity AUCinf calculated using formula AUCinf  AUClast  Ct ke Ct final recorded plasma concentration ke elimination rate constant determined linear regression log linear part plasma concentration time curve AUClast AUC time zero final measurable time derived using linear trapezoidal rule hours oseltamivir hours oseltamivir carboxylate The elimination half life t1 2 calculated 0 693 ke Statistical comparisons pharmacokinetic variables performed using Kruskal Wallis tests followed Mann Whitney U test involving post hoc comparisons Bonferroni correction Differences considered statistically significant P value Kruskal Wallis test P value Mann Whitney U test involving post hoc comparisons Bonferroni correction The data analyzed using IBM SPSS Windows IBM Corp Chicago IL USA\n",
      "Materials methods Subjects Sixteen healthy male subjects age  years height  cm weight  kg BMI  fasting plasma glucose  mmol l recruited study Exclusion criteria anaemia haemoglobin g dl history drug abuse symptomatic coronary heart disease significant elevation hepatic enzyme levels aspartate aminotransferase AST alanine aminotransferase ALT  IU l serum creatinine  mg dl fasting plasma glucose  mmol L presenting one criteria metabolic syndrome Subjects consuming alcoholic drinks one time twice week smoking cigarettes day taking medication also excluded Study design A randomized crossover study two phases washout period weeks carried The study approved Ethics Committee Institute Clinical Pharmacology Central South University Project No CTXY 140007 1 registered Chinese Clinical Trial Registry ChiCTR IPR 14005491 All participants signed informed consent clinical trial Once enrolled participants advised maintain stable activity levels without periods strenuous exercise days formal study Approximately days prior study subjects met dietitian create 3 day meal plan maintained carbohydrate intake 200Ð250 g day The volunteers recorded food intake 3 day food diary The last meal admission eaten Clinical Trials Centre Xiangya Hospital All subjects divided two groups group one n  group two n  randomly The volunteers took mg telmisartan Boehringer Ingelheim Pharma GmbH  Co KG Germany placebo orally daily h days At h day participants received mg oral dose metformin Shenzhen Neptunus Pharmaceutical Co Ltd China After overnight fast h day subjects given another dose mg metformin Shenzhen Neptunus Pharmaceutical Co Ltd China together telmisartan placebo Two hours metformin administration oral glucose tolerance test OGTT immediately conducted following ingestion 75 g glucose load Chongqing Heping Pharmaceutical Co Ltd China Carbohydrate controlled meals provided h second dose metformin After washing period weeks subjects entered study next phase In stage two one participant experienced vomiting ingestion g glucose The OGTT data participant excluded pharmacokinetic data metformin kept Sample collection In period indwelling catheter inserted forearm h predose Day To determine metformin concentrations plasma blood samples collected h second dose metformin For OGTT analysis blood samples collected immediately ingestion glucose min ingestion Blood samples centrifuged separated All samples frozen _80 C pending assaying Metformin insulin concentration analysis The detection metformin performed Shimadzu LC 2010C HPLC system Kyoto Japan autosampler ultraviolet detector The Class VP software Shimadzu used data analysis processing Compounds separated Hypersil BDS C18 column mm 200 mm _m particle size Phenomenex Security GuardTM guard column Phenomenex US quantified UV detection nm The mobile phase composed M phosphate buffer triethylamine sodium dodecyl sulfate acetonitrile  V V delivered flow rate ml min Metformin used external standard Sample prepared following procedure _l plasma mixed _l acetonitrile ml plastic tube mixture vortexed min After centrifugation min r min supernatants transferred injection vial _l injected HPLC The good linear relationship metformin obtained range 25 0Ð5000 ng ml regression equation Y  Ð  1 08618325 X r2  The limit metformin detection ng mL The intraday interday coefficients variation The sample recovery ranged RSD Glucose insulin concentration analysis The pharmacodynamics metformin characterized plasma insulin blood glucose responses Serum insulin blood glucose concentrations measured fully automatic biochemical detector immediately sampling The plasma insulin response characterized determining fasting insulin concentration FINS threshold value insulin resistance HOMA IR threshold value insulin secretion HOMA IS The threshold value insulin resistance HOMA IR threshold value insulin secretion HOMA IS calculated following equations HOMA IR FINS _ FPG 22 5 HOMA IS  _ FINS FPG 3 5 The blood glucose response AUC0 3 maximum concentration The AUC values calculated linear trapezoidal rule Pharmacokinetics The Pharmacokinetic parameters calculated noncompartmental analysis using DAS Maximum metformin concentration Cmax time maximum concentration Tmax determined area metformin concentrationÐtime curves time period 0Ð12 h AUC0 12 calculated using linear trapezoidal rule The elimination rate constant ke estimated slope best fit line determined linear regression analysis log transformed concentrationÐtime curve The elimination half life t1 2 calculated equation t1 2  ln 2 ke Statistical analysis Measurements subjects telmisartan placebo treatment compared using paired samples test Data expressed mean values  standard deviation SD The data analyzed using SPSS v 19 0 IMB Corp Armonk NY USA P  considered significant The associated drugÐdrug interaction assessed based CIs geometric mean ratios metformin  telmisartan metformin  placebo primary pharmacokinetic parameters Cmax AUC0 12 It concluded significant pharmacokinetic interaction existed two drugs CI values fall within range 0 80Ð1 25 13\n",
      "Methods Study design This randomized open label two way crossover multiple dose within subject dose escalation study healthy subjects identified CYP2D6 EMs n  PMs n  genotyping This study conducted compliance ethical principles Declaration Helsinki International Conference Harmonization Good Clinical Practice guidelines The protocol approved institutional review board investigational centre participating study subjects provided written informed consent entering study Subjects Subjects included healthy adults ages years inclusive body mass index BMI kg m_2 total bodyweight kg Key exclusion criteria evidence history clinically significant diseases clinical findings screening condition possibly affecting drug absorption 12 lead ECG demonstrating QTc ms screening Subjects genotyped CYP2D6 status enrolment The alleles genotyped duplication Subjects homozygous combination classified PMs Other genotypes classified EMs Study procedures Screening evaluation occurred within days first dose period Day defined day first day dosing day period Subjects admitted Clinical Research Unit CRU day morning days evening remained ECG measurement h post dose day day last scheduled assessment day respectively Subjects required return CRU mornings days dose administration able leave CRU Subjects received tolterodine ER mg daily days followed tolterodine ER mg daily days treatment A fesoterodine mg daily days followed fesoterodine mg daily days treatment B Treatment order randomized least 3 day washout period treatments Subjects received study medication daily morning days 4 mg dose days 8 mg dose study period Doses administered breakfast days days least 10 h overnight fast days Subjects required fast 4 h period clinical laboratory measurements Subjects also fasted overnight two occasions period minimum h evening time dosing days On study day lunch dinner served approximately h respectively breakfast The meal schedule menu followed two treatment periods Blood urine sample collection analysis In period pharmacokinetic PK blood samples ml collected pre dose days day h post dose day h post dose Following tolterodine ER blood samples collected tubes contained serum separator additives kept room temperature clotted Following fesoterodine blood samples collected tubes containing sodium heparin Samples centrifuged approximately g min 4 C Samples stored screw capped polypropylene tubes approximately _20 C within h collection Serum samples analysed tolterodine 5 HMT Eurofins AvTech Laboratories Inc Portage MI USA plasma samples analysed 5 HMT Advion BioSciences Inc Ithaca NY USA Urine collected h post dose days Voided volume collected 1 l polyethylene containers stored approximately 4 C At end collection period urine output subject pooled total volume recorded 10 ml sample stored polypropylene tubes _70 C Urine samples analysed 5 HMT Advion BioSciences Inc Ithaca NY USA All plasma serum urine samples analysed using validated analytical methods described previously conducted compliance Pfizer standard operating procedures All concentration calculations based peak area ratios tolterodine 5 HMT internal standard The calibration curves 0 10Ð60 ng ml_1 0 10Ð10 ng ml_1 0 02Ð20 ng ml_1 1 00Ð1000 ng ml_1 tolterodine serum 5 HMT serum 5 HMT plasma 5 HMT urine respectively characterized regression coefficient slope intercept using 1 x2 weighted except 5 HMT plasma 1 x weighted used linear regression Concentrations tolterodine 5 HMT quality control study samples determined inverse prediction calibration curve The mean precision estimates expressed coefficient variation back calculated calibration curve concentrations ²10 6 serum tolterodine ²7 1 serum 5 HMT ²5 6 plasma 5 HMT ²3 3 urine 5 HMT The corresponding accuracy expressed  difference theoretical concentration ranged _1 3 serum tolterodine _0 8 serum 5 HMT _0 5 plasma 5 HMT _4 3 urine 5 HMT The precision estimates quality control samples ²8 1 serum tolterodine ²7 2 serum 5 HMT ²3 3 plasma 5 HMT ²6 3 urine 5 HMT The corresponding accuracy ranged serum tolterodine _3 0 serum 5 HMT _7 1 _4 5 plasma 5 HMT _1 5 urine 5 HMT Pharmacokinetic analysis The pharmacokinetic parameters calculated comparison active moieties fesoterodine tolterodine ER area plasma concentration vs time curve pre dose h post dose AUC 0 24 h maximum observed plasma concentration Cmax time maximum plasma concentration tmax terminal phase half life t1 2 Additionally 5 HMT amount excreted urine Ae renal clearance CLr determined tolterodine ER fesoterodine administration Concentrations converted nm units using molecular weights tolterodine 5 HMT respectively PK calculations comparisons active moieties two treatments 5 HMT fesoterodine doses 5 HMT plus tolterodine tolterodine doses Statistical analysis Assuming dropout rate approximately subjects enrolled study ensure subjects completed study The sample size completed subjects empirically selected provide sufficient number subjects enable meaningful pharmacokinetic variability characterization two treatments Based previous between study comparisons active moiety variability associated specifically high tolterodine exposures CYP2D6 PMs Therefore precise characterization range active moiety exposures PM EM subjects enrolled ratio The PK parameters summarized descriptively moiety treatment dose genotype EMs PMs Plots median predose concentrations treatment dose level visually examined assess attainment steady state Clinical laboratory safety assessment Safety evaluations included clinical monitoring subject reported AEs including serious AEs vital signs heart rate blood pressure 12 lead ECGs clinical laboratory tests\n",
      "Methods Twelve healthy subjects entered study Written informed consent obtained subjects approval granted Phase Clinical Trials Unit Ethical Review Committee The debrisoquine hydroxylase cytochrome P 450 2D6 phenotype determined subject approximately years start current investigation using oral debrisoquine substrate probe Urine debrisoquine hydroxy debrisoquine concentrations assayed GC Debrisoquine metabolic ratios ranges poor extensive metabolisers respectively Of individuals six poor metabolisers two male four female aged years six extensive metabolisers two male four female aged years A single dose ondansetron mg hydrochloride dihydrate given intravenous infusion min Blood samples plasma ondansetron assay taken dosing min h start infusion Plasma ondansetron concentrations measured using h p l c procedure limit quantification ml plasma sample ng ml The coefficient variation assay limit quantification The maximum measured plasma drug concentration Cmax obtained directly concentration time data The terminal elimination rate constant Qi determined linear least squares regression using logarithmically transformed points terminal phase corresponding terminal half life ln 2 IX The AUC zero last quantifiable concentration calculated combiCorrespondence Dr E I L Ashforth Department Clinical Pharmacokinetics Glaxo Group Research Ltd Greenford Middlesex UB6 OHE E I L Ashforth et al Table Pharmacokinetic parameters describing fate ondansetron mg i v poor extensive metabolisers debrisoquine Data presented geometric means confidence intervals All P values quoted comparison poor extensive metabolisers The treatment comparisons presented ratio results poor extensive metabolisers together confidence intervals Treatment comparisonGroup I Group P Group IGroup Parameter Poor metabolisers Extensive metabolisers value  Cmax ng ml AUC ng mlh CL ml min t 2 h nation linear logarithmic trapezoidal methods The linear model used plasma drug concentrations rising logarithmic method concentrations declining The area extrapolated infinite time using Cz lz Cz last quantifiable plasma drug concentration Plasma clearance CL calculated Dose AUC Statistical comparisons parameters made using one way analysis variance allowing effect study group poor extensive metabolisers The variance associated pharmacokinetic parameters increases mean value increases Therefore log transformation applied data order satisfy constant variance assumption analysis variance All statistical tests carried level significance comparisons made respect group extensive metabolisers\n",
      "MATERIALS AND METHODS Chemicals Omeprazole two metabolites 59 hydroxyomeprazole omeprazole sulfone obtained July Notes Biol Pharm Bull 923Ñ927 _ To correspondence addressed e mail okumurak kobe u ac jp  Pharmaceutical Society Japan Optimal Dose Omeprazole CYP2C19 Extensive Metabolizers Anti Helicobacter pylori Therapy Pharmacokinetic Considerations Tomoko KITA Toshiyuki SAKAEDA Nobuo AOYAMA b Toshiyuki SAKAI c Yuko KAWAHARA Masato KASUGA c Katsuhiko OKUMURA a Department Hospital Pharmacy School Medicine Kobe University b Department Endoscopy School Medicine Kobe University c Division Diabetes Digestive Kidney Diseases Department Clinical Molecular Medicine Graduate School Medicine Kobe University Chuo ku Kobe 650Ð0017 Japan Received January accepted April In anti Helicobacter pylori therapy using omeprazole antimicrobials efficacy related CYP2C19 genotype groups eradication rates extensive metabolizers poor metabolizers The present study undertaken help predict optimal dosage omeprazole extensive metabolizers therapy Seven healthy Japanese subjects classified based CYP2C19 genotype extensive metabolizers n54 poor metabolizers n53 participated study Each subject received single oral dose omeprazole mg least 1 week washout period dose Plasma concentrations omeprazole two metabolites monitored h dose medication After dose administered pharmacokinetic profiles omeprazole two metabolites significantly different extensive metabolizers poor metabolizers The area plasma concentrationÐtime curve AUC omeprazole extensive metabolizers disproportionally increased 3 2or 19 2 fold dose escalation mg omeprazole respectively In contrast AUC omeprazole proportionally increased higher dose poor metabolizers The AUC omeprazole mg administration poor metabolizers almost equal AUC extensive metabolizers mg administration In anti H pylori therapy recommended dose omeprazole extensive metabolizers suggested maximum mg32 d based pharmacokinetic considerations Key words CYP2C19 genotype nonlinear kinetics omeprazole Fig Metabolic Pathways Omeprazole The thickness arrows indicates approximate contribution CYP isoforms metabolic pathways AstraZeneca Ltd London U K All chemicals reagent grade obtained commercially Subjects Seven unrelated H pylori negative males agreed participate study The CYP2C19 genotype determined using polymerase chain reaction restriction fragment length polymorphism PCR RFLP 13 14 They classified two groups subjects extensive metabolizers CYP2C19 1 CYP2C19 1 remaining subjects poor metabolizers CYP2C19 2 CYP2C19 2 n51 CYP2C19 2 CYP2C19 3 n52 The demographics age weight extensive metabolizers poor metabolizers different years mean6S D kg respectively None subjects hepatic renal dysfunction taken medication including alcohol over the counter drugs least week study Written informed consent obtained subjects study commenced The protocol study approved advance Institutional Review Board Kobe University School Medicine Kobe Japan Study Protocol Each subject received single oral dose omeprazole Omepral tablet AstraZeneca Ltd mg least 1 week washout period dose Each dose taken h breakfast lunch served h drug ingestion Venous blood samples collected prior h taking medication Plasma samples separated centrifugation 9003g min stored C analysis It confirmed alteration concentrations omeprazole two metabolites storage Concentration Measurements Plasma concentrations omeprazole two metabolites 59 hydroxyomeprazole omeprazole sulfone measured described previously 11 12 Briefly ml mg phenacetin ml methanol internal standard ml diethyl etherdichloromethane  v v added ml plasma sample They extracted twice shaking min mixture centrifuged 9003g min Then ml propylene glycol added supernatant solvent evaporated nitrogen stream C The residue dissolved ml mobile phase filtered using 0 2 mm filter HPLC Sample Prep LCR4 LG Nihon Millipore Ltd Tokyo Japan Fifty microliter aliquots injected HPLC system Pharmacokinetic Analysis The maximum plasma concentration Cmax obtained graphically The areas plasma concentrationÐtime curve AUC omeprazole two metabolites calculated using linear trapezoidal rule h According rational pharmacokinetic notation AUC 59 hydroxyomeprazole omeprazole sulfone depended omeprazole AUC metabolite corrected dividing omeprazole consider metabolic processes appropriately Statistical Analysis Equivalence variance tested using F test Statistical comparisons performed using unpaired t test p values less considered significant\n",
      "METHODS This study phase I open label parallel 2 arm drug interaction study investigate effects EFV DRV r PK pitavastatin This study performed healthy adult HIV 1 seronegative volunteers avoid potential development drug resistance HIV infected persons exposed DRV r EFV monotherapy The primary objective study investigate effect EFV DRV r PK pitavastatin Secondary objectives investigate effects pitavastatin PK EFV DRV r describe nonÐsteady state changes serum LDL C due pitavastatin presence EFV DRV r Subjects The study population consisted male female HIV seronegative healthy volunteers 18Ð60 years age Subjects chronic underlying illnesses could taking chronic medications Subjects weigh within normal body weight body mass index 18Ð25 minimum weight kg All enrolled volunteers required baseline laboratory values including hemogram renal function within normal limits aspartate aminotransferase AST alanine aminotransferase ALT 1 5_ upper limit normal Both male female subjects except documented reproductive potential agree practice adequate birth control using combination accepted birth control methods Females childbearing potential negative pregnancy test within days study entry day entry PK visit Subjects could participated investigational drug studies within days study entry Subjects enrolled August January The final study visit last subject completed February Study Design Subjects recruited participate parallel study arms The study design previously described 5 schematic outline shown Figure For first days subjects took pitavastatin mg daily On fourth day pitavastatin administered direct observation From day subjects self administered tablet EFV mg arm A tablets DRV mg tablet ritonavir mg arm B daily followed directly observed dosing day From day subjects took pitavastatin mg EFV mg arm A pitavastatin mg DRV r mg arm B followed directly observed dosing day Blood samples collected drug administration minutes hours postdose days In arm A pitavastatin EFV administered night PK sampling scheduled begin night whereas arm B drug dosing PK sampling completed morning Serum aliquots stored _70 C within minutes collection Compliance study medications measured pill counts adherence questionnaire In addition PK blood samples fasting lipid profiles collected days subjects The protocol approved New York University School Medicine University Buffalo Institutional Review Board Informed consent obtained subjects Drug Assays Day day samples subjects arms A B assayed pitavastatin primary metabolite pitavastatin lactone PPD Bionalytical Laboratories Middleton WI Liquid chromatography tandem mass spectrometry used measure drug concentrations according validated PPD Method P1097 01 The lower limit quantitation values ng mL pitavastatin pitavastatin lactone respectively Incurred sample reproducibility within accepted standard ²20 relative difference original repeated sample values Day day samples subjects arms A arm B assayed quantify concentrations EFV DRV Translational Pharmacology Research Core Laboratory University Buffalo EFV DRV quantified using previously published simultaneous high performance liquid chromatography assay slight modification 9 Briefly method involved liquidÐliquid extraction plasma sample followed separation C8 Symmetry column Waters Associates Milford MA detection using Model photodiode array detector Waters Associates assure specificity The lower limit quantitation value ng mL During course assay application interassay variation ²15 Verification accuracy EFV DRV concentrations performed conjunction Clinical Pharmacology Quality Assurance CPQA Quality Control Program 10 Serum total cholesterol triglycerides high density lipoprotein concentrations assayed Bellevue Hospital Laboratory using standard enzymatic assays Calculated LDL C determined using Friedewald equation Concentration data used calculate steady state plasma PK parameters pitavastatin lactone metabolite pitavastatin EFV DRV PK parameters included maximum plasma concentration Cmax area plasma concentration curve time last measurable concentration AUC0 _ time achieve maximum plasma concentration Tmax Actual sample times used rather scheduled sampling times AUCs estimated according linear trapezoidal rule without extrapolation beyond dosing interval Statistical Analyses Statistical analyses performed using Minitab software Minitab Inc State College PA Using linear mixed effects model treatment fixed effect subject random effect mean log transformed Cmax AUC0 _ pitavastatin alone without EFV DRV r day compared pitavastatin coadministered EFV DRV r day study arms A B respectively Similarly using model mean log transformed PK parameters EFV alone DRV r alone day compared EFV DRV r coadministered pitavastatin day study arms A B respectively The confidence intervals CIs geometric mean ratio test to reference treatments day vs day day vs day calculated evaluate potential DDI No formal sample size calculation performed A sample size subjects per study arm considered adequate detect possible interaction steady state EFV DRV r pitavastatin Subjects complete PK evaluation visits replaced achieve required sample size\n",
      "Methods Design The study registered European Clinical Trials Database EudraCT No2005 004717 15 The protocol approved Regional Ethics Committee Swedish Medical Products Agency The study conducted accordance Good Clinical Practices Helsinki declaration Previously genotyped volunteers recruited database former study participants Human Pharmacology Unit Clinical Pharmacology Karolinska University Hospital Huddinge All CYP2C19 17 17 subjects database ten asked participate CYP2C19 1 1 subjects recruited random fashion blinded previous phenotypic data Sample size calculations based primary outcome represented differences AUC CYP2C19 1 1 CYP2C19 17 17 using prior estimate difference omeprazole AUC groups It estimated true difference could detected given one sided level significance _ power _ using six CYP2C19 17 17 CYP2C19 1 1 subjects Twelve volunteers previously genotyped CYP2C19 1 1 included five CYP2C19 17 17 volunteers could participate The study conducted open label one phase trial volunteers given single oral dose mg omeprazole two 20 mg tablets Losec Mups AstraZeneca Sweden Peripheral blood samples drawn i v cannula forearm vein ml sodium heparin collection tubes prior drug administration following times omeprazole ingestion h After centrifugation min g plasma separated stored _20 C analysis Subjects After oral written explanation study subjects gave written informed consent Prior starting study blood obtained clinical chemistry genotype confirmation along urine drug screening urinalysis No medications paracetamol allowed within weeks omeprazole administration drugs prohibited within h omeprazole administration Additional exclusion criteria included use Saint John s wort within months foods containing poppy seeds within days foods drinks containing grapefruit within days omeprazole administration Female volunteers required abstain hormonal contraceptives minimum weeks Subjects excluded based clinically significant abnormal ECG blood chemistry urine analysis urine drug detection positive pregnancy test The subjects sex age weight smoking status presented Table The volunteers fasted h h omeprazole administration Genotyping Subjects genotyped CYP2C19 17 using novel nested polymerase chain reaction PCR approach introduce allele specific restriction site restriction fragment length polymorphism analysis Briefly DNA obtained peripheral blood using commercially available kit DNeasy Qiagen West Sussex UK A base pair bp fragment containing CYP2C19 17 Ð806C_T mutation site PCR amplified using ng genomic DNA U Taq DNA polymerase ABgene Epsom UK _l 10_ Buffer IV mM MgCl2 mM dNTPs _M 2C19 1 forward primer 5_GCCCTTAGCACCAAATTCTC 2C19 1 reverse primer 5_ATTTAACCCCCTAAAAAAACACG The thermoprofile consisted initial denaturation step 95 C min followed cycles 95 C 52 C 72 C followed 72 C min A 143 bp fragment allele specific NsiI restriction site created following _l initial PCR amplification U Taq DNA polymerase ABgene Epsom UK _l 10_ Buffer IV mM MgCl2 mM dNTPs _M 2C19 2 forward primer 5_AAATTTGTGTCTTCTGT TCTCAATG 2C19 2 reverse primer 5_AGACCCTGG GAGAACAGGAC The thermoprofile consisted 95 C min followed cycles 95 C 51 C 72 C followed 72 C min Restriction digestion resultant PCR product performed 37 C h contained following _l PCR reaction _l 10_ NEB reaction buffer _l NsiI New England BioLabs Ipswich MA USA Agarose gel electrophoresis revealed fragments either bp bp CYP219 17 CYP2C19 1 alleles respectively Subjects genotyped CYP2C19 2 allele using TaqMan Allelic Discrimination Assay Applied Biosystems Foster City CA USA ABI PRISM according manufacturer s recommendations Chemicals Omeprazole 5 hydroxyomeprazole omeprazole sulphone internal standard H supplied AstraZeneca M lndal Sweden All stock solutions prepared methanol sodium carbonate buffer M pH stored _20 C Unless otherwise stated reagents purchased commercial vendors reagent analytical grade Sample analysis Omeprazole two metabolites 5 hydroxyomeprazole omeprazole sulphone quantified using reversed phase high performance liquid chromatography R HPLC method based previously published methodologies 11Ð13 Duplicate 100 _l plasma samples combined _l methylene chloride acetonitrile  v v _l mM disodium phosphate buffer pH containing nmol internal standard For samples near limit quantification _l plasma combined ml methylene chloride acetonitrile _l internal standard All samples extracted min using vortex mixer followed centrifugation g min aspiration plasma aqueous phase The organic phase transferred new tube evaporated dryness 60 C Samples reconstituted _l methanol followed _l mM disodium phosphate buffer pH To minimize potential particulate carryover R HPLC analysis reconstituted samples filtered using 0 2 _m microcentrifuge spin column Ultrafree MC Millipore N dinge Sweden _l resultant filtrate injected R HPLC system Chromatography performed using Varian Prostar R HPLC system consisting Model solvent delivery module Model UV Vis detector Model autosampler combined LiChrospher RP select B _ mm _m particle column identical _ mm precolumn Merck Whitehouse Station NJ USA The mobile phases mM ammonium acetate pH A acetonitrile B The solvent gradient follows initially A 20 B linear ramp A 45 B min min linear return initial condition min min followed 5 min equilibration injection next sample The flow rate ml min_1 Absorbance monitored nm peak areas determined using Varian Star version software package Retention times min 5 hydroxyomeprazole internal standard omeprazole sulphone metabolite respectively Standard curves generated spiking drug free plasma omeprazole two metabolites concentration range 10Ð2500 nmol l_1 combined internal standard followed extraction quantification described The limit quantification three analytes nmol l_1 The intraday interday coefficients variation omeprazole two major metabolites respectively Pharmacokinetic statistical analysis Pharmacokinetic parameters determined using noncompartmental analysis WinNonlin version Pharsight Mountain View CA USA The area concentrationÐtime curve infinity calculated using linear trapezoid rule extrapolation infinity using log linear terminal elimination phase __ Total body clearance calculated CL  molar dose AUC without normalization fraction administered dose reaching central compartment bioavailability Data reported mean confidence interval CI Statistical calculations performed using Graphpad Prism Microsoft Excel The pharmacokinetic parameters CYP2C19 17 17 CYP2C19 1 1 subjects compared using unpaired two tailed heteroscedastic t test\n",
      "Methods Study design The study protocols approved German authorities BfArM regional ethics committee Rhineland Palatinate Healthy male volunteers 23Ð47 years body mass index 19 2Ð29 9 kg m_2 included given informed written consent The trials conducted accordance guidelines Good Clinical Practice Declaration Helsinki Human Pharmacology Centre Ingelheim Boehringer Ingelheim Germany Subjects good general health according routine medical history physical examination vital signs 12 lead ECG laboratory data Two open label randomized two way crossover studies similar design performed healthy male volunteers one assessing interactions paroxetine one ketoconazole Treatment A studies consisted single oral dose mg tamsulosin HCl modified release capsule Alna Source BI Austria GmbH Austria Treatment B paroxetine study consisted mg paroxetine daily Seroxat Source GlaxoSmithKline Germany days mg paroxetine daily days achieve steady state full CYP2D6 inhibition finally mg paroxetine daily days taper regimen On day mg paroxetine treatment subjects additionally received single dose mg tamsulosin HCl To maintain full CYP2D6 inhibition pharmacokinetic PK sampling period tamsulosin paroxetine mg administered day Treatment B ketoconazole study consisted mg ketoconazole daily Source Pliva East Hanover NJ USA days order achieve steady state full CYP3A4 inhibition day additionally single dose mg tamsulosin HCl To maintain full CYP3A4 inhibition PK sampling period tamsulosin ketoconazole mg administered day In studies blood samples PK withdrawn h tamsulosin HCl administration Paroxetine sparse sampling performed h tamsulosin HCl administration Ketoconazole sparse sampling performed h tamsulosin HCl administration Safety tolerability Safety tolerability assessed measurement vital signs blood pressure pulse rate including forced orthostatic stress testing well 12 lead ECGs Orthostasis assessed measuring blood pressure min rest supine position min rest standing position Safety assessments carried h tamsulosin HCl administration orthostasis assessed h tamsulosin HCl administration Safety laboratory haematology serum chemistry urinalysis testing performed screening end of trial visit assessed adverse events recorded Genotyping Extensive metabolizers regard CYP2D6 identified based genotyping subjects carried external provider Epidauros Biotechnology AG Am Neuland Bernried Germany utilizing assays based TaqMan sequencing methodology For participants paroxetine ketoconazole studies genotypes nine two two two one subjects respectively Bioanalytical methods Tamsulosin The bioanalytical method quantification tamsulosin HCl human plasma based high performance liquid chromatography tandem mass spectrometry HPLC MS MS After addition AB 289 internal standard provided Yamanouchi Europe B V Leiderdorp Netherlands plasma tamsulosin internal standard extracted plasma using liquid liquid extraction ethylacetate  cyclo hexane v  v alkaline conditions The organic phase evaporated residue reconstituted ammonium acetate mm  acetonitrile v  v A sample injected HPLC MS MS system separate tamsulosin internal standard matrix constituents using Symmetry C18 material Waters Saint Quentin en Yvelines France mean size µm stainless steel column mm _ mm acetonitrile  ammonium acetate mm v  v mobile phase A constant flow rate µl min_1 employed Detection performed using triple stage quadrupole mass spectrometer API Applied Biosystems Courtaboeuf Cedex France APCI atmospheric pressure chemical ionization interface positive ion mode Tamsulosin parent daughter ions detected m z  internal standard AB 289 parent daughter ions m z  This method suitable quantification tamsulosin tamsulosin HCl human plasma concentrations ranging ng ml_1 In study inaccuracy imprecision values tamsulosin within  respectively Ketoconazole The bioanalytical method quantification ketoconazole human plasma based HPLC MS MS validated SGS Cephac Europe France After addition itraconazole internal standard LGC PROMOCHEM Molsheim France plasma ketoconazole internal standard extracted plasma using liquid liquid extraction heptane  3 methylbutanol v  v alkaline conditions The organic phase evaporated residue reconstituted methanol  aqueous ammonium acetate mm v  v The sample injected HPLC MS MS system separate ketoconazole internal standard matrix constituents using BDS Hypersil C18 material mean size µm column mm _ mm supplied Thermo Electron Corporation Courtaboeuf France methanol  aqueous ammonium acetate mm v  v mobile phase A constant flow rate µl min_1 employed Detection performed using triple stage quadrupole mass spectrometer API Applied Biosystems Courtaboeuf Cedex France APCI interface positive ion mode Ketoconazole parent daughter ions detected m z  internal standard itraconazole parent daughter ions m z  This method suitable quantification ketoconazole human plasma concentrations ranging ng ml_1 In study inaccuracy imprecision values ketoconazole within  respectively Paroxetine The bioanalytical method quantification paroxetine human plasma based HPLC MS MS validated SGS Cephac Europe France After addition d4 paroxetine internal standard Toronto Research Chemicals Inc North York Ontario Canada plasma paroxetine internal standard extracted plasma using Solid Phase Extraction Oasis HLB cc mg cartridges Waters Saint Quentin en Yvelines France The cartridges eluted methanol containing formic acid The sample extract evaporated dryness residue reconstituted H2O containing formic acid The sample injected HPLC MS MS system separate paroxetine internal standard matrix constituents using Zorbax SB C18 material mean size µm column _ mm supplied Agilent Massy France water  acetonitrile v  v containing formic acid mobile phase A constant flow rate µl min_1 employed Detection performed using triple stage quadrupole mass spectrometer API Applied Biosystems Courtaboeuf Cedex France TurboIonSpray interface positive ion mode Paroxetine parent daughter ions detected m z  internal standard itraconazole parent daughter ions m z  This method suitable quantification paroxetine human plasma concentrations ranging ng ml_1 In study inaccuracy imprecision values paroxetine within  respectively The lower limit quantification ng ml_1 tamsulosin ng ml_1 paroxetine ng ml_1 ketoconazole Pharmacokinetic data analysis Pharmacokinetic parameters calculated non compartmental analyses using WinNonlin professional version Pharsight Corporation Mountain View CA Only concentrations within validated concentration range actual sampling times used calculation pharmacokinetic parameters Individual Cmax tmax values directly determined plasma concentration time profiles subject The apparent terminal rate constant _z estimated regression ln C vs time terminal log linear disposition portion concentrationÐtime profiles Terminal half life t1 2 calculated ln 2 _z Area concentrationÐtime curve tamsulosin HCl plasma time interval last quantifiable data point AUC 0 tlast calculated using linear up log algorithm Area concentrationÐtime curve time interval extrapolated infinity AUC 0 calculated An external file holds picture illustration etc Object name bcp0072 0247 mu1 jpg An external file holds picture illustration etc Object name bcp0072 0247 mu2 jpgis predicted concentration time tlast last time point plasma concentration quantification limit Apparent clearance CL F apparent volume distribution calculated Dose AUC 0 CL F _z respectively Statistical methods AUC 0 Cmax AUC 0 tlast statistically analyzed analysis variance anova models logarithmic scale including effects accounting following sources variation model ÔsequenceÕ Ôsubjects nested within sequencesÕ ÔperiodÕ ÔtreatmentÕ The effect Ôsubjects within sequencesÕ considered random whereas effects considered fixed The pharmacokinetic parameters log transformed natural logarithm prior fitting anova model The difference expected means log test _ log reference estimated difference corresponding Least Square Means point estimate two sided confidence intervals based t distribution computed These quantities back transformed original scale give point estimator geometric mean interval estimates median intra subject ratio response test tamsulosin  ketoconazole tamsulosin  paroxetine response reference tamsulosin All subjects provided least one observation least one primary pharmacokinetic PK endpoint without important protocol violations relevant evaluation pharmacokinetics included analysis primary PK endpoints All pharmacokinetic parameters geometric mean geometric coefficient variation median range adverse events frequencies subjects adverse events vital signs mean SD laboratory data evaluated descriptively\n",
      "Methods The study AC 055 106 followed principles Declaration Helsinki Good Clinical Practice protocol approved independent Ethics Committee Ethik Kommission der Medizinischen Universit t Wien und des Allgemeinen Krankenhauses der Stadt Wien AKH Vienna Austria Written informed consent obtained subjects prior study start Study design subjects This single centre open label randomized three way crossover study healthy male subjects received following oral treatments A loading dose 30_mg macitentan day followed 10_mg daily days B sildenafil 20_mg three times daily days single 20_mg dose day C loading dose 30_mg macitentan day followed 10_mg daily days sildenafil 20_mg three times daily days single 20_mg dose day Both macitentan sildenafil indicated chronic use therefore mutual pharmacokinetic interactions investigated steady state conditions Because long t1 2 ACT 132577 loading dose macitentan administered reduce time steady state days days Subjects assigned one six possible treatment sequences treatments separated washout phase least days Selection doses dosing regimens macitentan 10_mg daily sildenafil 20_mg three times daily based approved dosing recommendations Twelve healthy male subjects aged years body mass index 28_kg_m_2 included study Subjects included medical examination showing clinically significant abnormalities Subjects could participate smoked prior history drug alcohol abuse allergic drug using medication participated another clinical trial month period preceding screening examination Based coefficient variation CV variable AUC_ macitentan sildenafil study power reject null hypothesis one limits confidence interval CI ratio geometric mean treatment C vs geometric mean treatment A B outside interval 0 80Ð1 25 Study conduct The screening examination performed within weeks study start The subjects hospitalized evening day _1 treatments B C day treatment A last blood sample pharmacokinetic purposes withdrawn treatment period Assessments study days done ambulatory basis On day treatment period subjects consumed standardized light breakfast study drug intake On days drug intake done irrespective food intake Smoking drinking alcoholic beverages xanthine containing beverages permitted time clinic intake water ad libitum Tolerability safety monitored recording treatment discontinuations adverse events vital signs ECG physical examination clinical laboratory testing The end study examination took place least days last blood sample withdrawn treatment period Sampling bioanalytics During treatments A C study days predose 2_ml blood sample measurement macitentan active metabolite ACT 132577 collected prior morning drug administration After administration study drug morning day blood samples 2_ml collected EDTA containing tubes indwelling catheter antecubital vein 24_h measurement macitentan ACT 132577 treatment A 8_h measurement sildenafil N desmethylsildenafil treatment B During treatment C 2_ml blood samples withdrawn time points listed treatments A B However time points 8_h common treatments two 2_ml blood samples withdrawn After collection tubes centrifuged 10_min 1500_g 4 C plasma separated stored _20 C pending analysis Plasma concentrations macitentan sildenafil respective metabolites ACT 132577 N desmethylsildenafil determined using validated liquid chromatography coupled tandem mass spectrometry methods LC MS MS The macitentan ACT 132577 assay linear concentration range 0 5Ð1000_ng_ml_1 limit quantification 1 0_ng_ml_1 analytes The method measure sildenafil metabolite validated range 750_ng_ml_1 sildenafil 300_ng_ml_1 N desmethylsildenafil limits quantification 2_ng_ml_1 respectively The performance methods monitored using quality control samples Precision CV ²6 8 macitentan ²6 5 ACT 132577 ²3 1 sildenafil ²7 6 N desmethylsildenafil whereas bias ²2 3 ²3 3 ²12 3 ²9 8 macitentan ACT 132577 sildenafil N desmethylsildenafil respectively Data analysis statistics The pharmacokinetic variables Cmax tmax AUC_ macitentan sildenafil respective metabolites determined non compartmental methods Cmax time Cmax tmax read directly concentration_time data whereas area plasma concentration_time curve one dosing interval AUC_ estimated linear trapezoidal rule Log transformed Cmax AUC_ values analyzed linear mixed effect models tested advance period carry over effects A potential carry over effect considered corresponding compound given preceding period If neither period carry over effect present treatment included mixed effect model If period and or carry over effect present corresponding factor included addition treatment Geometric mean ratios confidence limits calculated corresponding back transformed contrasts mixed effect models\n",
      "Methods This two arm double blind placebo controlled randomized crossover study healthy subjects 18Ð60 years age Subjects randomized two sequence groups Group received sitaxentan sodium mg daily days followed 14 day washout placebo days Group received placebo days followed days later sitaxentan sodium mg days On day treatment period participants received sildenafil mg concurrently sitaxentan dose BP PK analysed day treatment period The protocol approved Institutional Review Board site Bio Kinetic Clinical Applications Inc Springfield MO USA study conducted accordance Declaration Helsinki Good Clinical Practice guidelines according International Conference Harmonization Technical Requirements Registration Pharmaceuticals Human Use Harmonized Tripartite Guideline applicable federal state local laws rules regulations Written informed consent obtained subjects Blood samples determination sitaxentan concentrations collected prior dosing days sitaxentan sildenafil N desmethylsildenafil predose day h post dose day treatment period Seated systolic diastolic BP measurements taken predose baseline h post dose day treatment periods All measurements performed triplicate time point mean values reported Blood samples collected tubes containing ethylenediamine tetraaceticacid processed plasma centrifugation stored Ð20 C analysis using liquid chromatography tandem mass spectrometry methods sitaxentan MDS Pharma Services Montreal Canada sildenafil N desmethylsildenafil CEDRA Corp Austin TX USA validated meet specifications set Food Drug Administration Bioanalytical Method Validation guidance Analytes extracted organic solvent extraction using isotopic internal standardization The mass transitions monitored m z 475_58 sildenafil m z 461 5_283 N desmethylsildenafil m z 453_417 sitaxentan The analytical range within study assay precision coefficient variation accuracy 5 00Ð750 ng ml_1 3 5Ð4 4 93 1Ð101 0 sildenafil 2 00Ð300 ng ml_1 4 9Ð7 6 98 3Ð105 8 N desmethylsildenafil 0 005Ð2 0 µg ml_1 3 8Ð6 7 100 0Ð111 5 sitaxentan Interference evaluations conducted prior analysis ensured analyte adversely influence quantification analytes Routine laboratory tests haematology clinical chemistry urinalysis physical examinations vital signs ECG readings conducted screening day treatment period At baseline additional physical examination vital signs check performed latter repeated multiple times throughout day Adverse events AEs use concomitant medications recorded PK parameters Cmax Tmax _z first order rate constant associated terminal log linear portion curve estimated via linear regression time vs log concentration t1 2 AUC 24 h dosing interval steady state AUC0Ð24 sitaxentan AUC0Ðt AUC sildenafil N desmethylsildenafil calculated using noncompartmental analysis AUC0Ðt calculated using linear trapezoidal method time last measurable concentration AUC0Ð calculated AUC0Ð AUC0Ðt Ct _ Pharmacodynamic PD parameters maximum positive change Emax maximum negative change EmaxÐ mean change Eavg seven time points seated systolic diastolic BP values PK calculations statistical analyses used SAS Windows Version SAS Institute Inc Cary NC USA Comparisons sildenafil N desmethylsildenafil PK parameters respect placebo sitaxentan treatments used analysis variance anova model sequence subject within sequence treatment period classification variables Confidence intervals CI constructed treatment ratios sitaxentan placebo parameters using log transformed data two one sided t tests procedure The PD parameters Emax EminÐ Eavg change baseline predose day systolic diastolic BP compared sitaxentan placebo treatments using anova model data original scale CIs constructed treatment ratios sitaxentan placebo using two one sided t tests procedure\n",
      "Methods The final protocol reviewed approved Independent Ethics Committee according specifications outlined applicable regulations e g International Conference Harmonisation Good Clinical Practice US Code Federal Regulations The trial performed accordance principles Good Clinical Practice All volunteers gave written consent prior trial related procedure Trial population Eighteen healthy HIV 1 negative volunteers enrolled trial randomized six panels different treatment sequences determined randomization schedule A minimum least evaluable subjects per treatment arm considered sufficient allow relevant conclusions With minimum evaluable subjects expected within subject variability logarithmic scale AUClastfor etravirine range confidence interval CI least squares means LSmeans ratio estimated _0 79 All volunteers able comply protocol requirements aged 18Ð55 years body mass index BMI kg m_2 Because significant effect CYP2C19 pharmacokinetics omeprazole volunteers known poor metabolizer status CYP2C19 volunteers Asian ethnicity due high incidence poor metabolizers CYP2C19 excluded smokers Women non child bearing potential could included All volunteers needed good health determined medical history physical examination clinical laboratory assessments They needed test HIV antibody negative participated previous trials investigational drugs within past days Volunteers history suspicion current alcohol and or drug abuse suspected allergy trial medications excluded Volunteers abnormalities might effect absorption drugs chronic diarrhoea gastric stasis etc well consuming solely plant based diets allowed participate Volunteers allowed use concomitant medication including over the counter products dietary supplements days first administration trial medication The use grapefruit juice beverages containing alcohol quinine prohibited days h respectively prior drug administration Volunteers advised refrain strenuous activities day Ð1 last day session Screening volunteers took place within days first administration trial medication For treatment A etravirine alone volunteers admitted research unit day Ð1 remained confined day Both treatment B ranitidine treatment C omeprazole started visit unit Drug intake continued home recorded well intake relevant meals subject s diary Volunteers readmitted research unit day discharged day Etravirine co administered day Both ranitidine omeprazole intakes continued day Daily safety visits pharmacokinetic sampling took place treatment days discharge There wash out period minimally days administration etravirine start next period Additional safety visits planned days administration etravirine The last follow up visit performed day last administration etravirine Etravirine treatment A administered single 100 mg tablet Phase formulation ingested within min completion standardized breakfast In treatment B ranitidine Zantac administered current recommended oral dose regimen mg twice daily h breakfast dinner In treatment C omeprazole administered one 40 mg tablet controlled release formulation Losec MUPS h breakfast All drug intakes took place approximately ml water Safety assessments Adverse events AEs evaluated throughout trial During drug administration home volunteers requested record AEs diary Severity drug relationship AEs etravirine ranitidine and or omeprazole assessed Laboratory assessments ECG vital signs assessments physical examinations performed specific time points AEs coded according Medical Dictionary Regulatory Activities dictionary version laboratory data evaluated using National Institute Allergy Infections Diseases Division AIDS toxicity scale Pharmacokinetic statistical analyses Etravirine Plasma samples bioanalysis etravirine collected days 1Ð5 treatment A days 8Ð12 treatment B C dosing h dose administration Plasma samples stored ²_18 C assayed Plasma concentrations etravirine determined using validated liquid chromatography mass spectrometry mass spectrometry LC MS MS methods The internal standard IS used stable isotope labelled etravirine d4 Plasma extracted using tertiary butyl methyl ether alkaline conditions Isocratic chromatographic separation achieved C 3 5 µm Symmetry Shield RP18 Waters Milford MA USA i d _ mm ml min_1 The elution mixture consisted formic acid solution acetonitrile v v ratio Detection done tandem MS API3000 instrument Applied Biosystems Foster City CA USA electrospray positive multiple reaction monitoring MRM mode MRM transitions m z m z etravirine IS respectively The effective linear range 2 00Ð5000 ng ml_1 lower limit quantification ng ml_1 Intrabatch precision varied CV intrabatch accuracy varied Metabolites etravirine M8 M12 Pharmacokinetic samples taken treatment etravirine alone treatment A co administration omeprazole treatment C time points predose h analysed post hoc using LC MS MS methodology Fifty microlitre aliquots plasma precipitated using methanol followed acetonitrile After thorough vortex mixing centrifugation µl clear supernatant injected onto high performance liquid chromatography MS MS system API4000 Applied Biosystems Chromatographic separation done 3 5 µm X bridge C18 column Waters mm i d _ mm ml min_1 applying gradient elution The elution mixture consisted formic acid water v v acetonitrile Quantification based MRM mass spectrometric detection M8 m z M12 m z The linear range set 2 00Ð2000 ng ml_1 metabolite Study samples preceded calibration curve every analytical batch bracketed sets quality control QC samples independently prepared four different concentration levels An analytical batch accepted least QC results least concentration within respective nominal value Intrabatch accuracy precision results level QC samples 92 7Ð112 6 0 4Ð10 1 CV M8 84 7Ð115 3 2 1Ð16 9 CV M12 respectively Pharmacokinetic statistical analyses plasma concentrations etravirine planned metabolites post hoc statistical analysis pharmacokinetic parameters performed using WinNonlin Professional version Pharsight Corp Mountain View CA USA Microsoft Excel Microsoft Redmond WA USA SAS SAS Institute Inc Cary NC USA Noncompartmental analysis model extravascular input plasma data applied pharmacokinetic analysis The maximum plasma concentration Cmax time reach Cmax tmax obtained inspection plasma concentrationÐtime profiles The value area plasma concentrationÐtime curve time administration last time point measurable plasma concentrations AUClast determined using linear trapezoidal rule Descriptive statistics calculated plasma concentrations pharmacokinetic parameters etravirine metabolites Statistical analyses performed etravirine using co administration ranitidine omeprazole test treatment B C treatment etravirine alone treatment A reference The primary pharmacokinetic parameters used statistical analysis Cmax AUClast logarithmic scale All available observations included statistical analysis The least squares means LSmeans primary parameters treatments estimated linear mixed effects model controlling treatment sequence period fixed effect subject random effect A CI constructed around difference LSmeans test reference Both difference LSmeans confidence limits retransformed original scale Safety pharmacodynamic parameters evaluated means descriptive statistics frequency tabulations\n",
      "Methods This open label randomized three way crossover study 13 conducted single Swedish center accordance ethical principles standards described Declaration Helsinki International Conference Harmonisation ICH Good Clinical Practice GCP guidelines Written informed consent obtained participating subjects prior commencement study Study Aims The aims study assess pharmacokinetic interaction lesogaberan esomeprazole steady state vice versa healthy subjects via assessment area plasma concentration time curve AUC dosing interval AUC_ hours lesogaberan hours esomeprazole maximum observed plasma concentration Cmax lesogaberan esomeprazole administered alone concomitantly Additional study evaluations included assessment AUC time zero last quantifiable concentration AUCt time reach maximal plasma concentration tmax terminal elimination half life t1 2 oral clearance CL F The potential lesogaberan induce CYP3A4 measured analysis plasma 4 _ hydroxy cholesterol 4 _OH cholesterol concentrations The safety tolerability lesogaberan administered alone concomitantly esomeprazole also assessed Study Population Healthy male female subjects aged 18Ð45 years body mass index 19Ð30 kg m2 body mass 50Ð100 kg eligible inclusion Only surgically sterilized female subjects included study reproductive toxicology lesogaberan currently unknown In order ensure safety subject exclusion criteria included clinically significant illness within weeks prior first dose study medication s ii history allergy hypersensitivity clinically significant orthostatic reactions syncope cardiovascular respiratory renal hepatic neurologic mental gastrointestinal disease iii ongoing allergy hypersensitivity iv concomitant condition medication could potentially modify pharmacokinetics study drug s Study Design Treatments The study flow presented figure Following pre study screening visit study consisted three 7 day treatment periods separated washout periods least days On day first treatment period subjects block randomized random order treatment following three treatment regimens hard capsule modified release formulation lesogaberan mg twice daily dosing interval hours dosed morning afternoon days 1Ð6 morning day ii esomeprazole capsules mg daily formulated esomeprazole magnesium trihydrate mg dosed morning days 1Ð7 iii two regimens combined dosed described Study medications administered standardized volume mL water fasted subjects Food restricted pm evening prior administration study medication hour post morning dose days 1Ð6 hours morning dose day fluids restricted hour pre dose hour post morning dose days 1Ð6 hours morning dose day Standardized meals provided hour morning dosing days 1Ð6 hours dosing day All study subjects required stay study center overnight day Additional study procedures included daily monitoring adverse events via self reporting direct questioning ii orthostatic testing standardized breakfast day pre dose days hours post dose day iii physical examination supine blood pressure pulse measurements electrocardiography follow up visit Sample Collection Analysis Plasma concentration time profiles lesogaberan esomeprazole day generated blood samples mL collected pre dose hours post dose hours post dose Additional blood samples taken determination pre dose lesogaberan plasma concentrations days relevant treatment periods In order evaluate potential CYP3A4 induction blood samples also collected pre dose days determination 4 _OH cholesterol plasma concentrations subjects receiving lesogaberan alone Plasma samples prepared centrifugation relative centrifugal force g immediately frozen _20 C lesogaberan esomeprazole _70 C 4 _OH cholesterol Samples analyzed accredited laboratory PRA International Assen Netherlands using reverse phase liquid chromatography mass spectrometry methods lesogaberan 4 _OH cholesterol normal phase liquid chromatography ultra violet detection esomeprazole The lower limits quantification lesogaberan esomeprazole _mol L _mol L 14 Statistical Analysis A total least subjects randomized treatment ensure least evaluable subjects end study The calculations determine sample size based data previous studies 14 For lesogaberan assumed within subject standard deviation SD ln AUC ln Cmax would approximately within subject SD difference ln AUC ln Cmax would approximately With evaluable subjects probability confidence interval CI ratio would wider For esomeprazole expected within subject SD ln AUC ln Cmax approximately With evaluable subjects probability CIs geometric mean ratio AUC would wider geometric mean ratio Cmax would wider Analysis Sets The pharmacokinetic analysis set included subjects received lesogaberan esomeprazole either alone concomitantly evaluable pharmacokinetic data major protocol deviations The safety population defined subjects received least one dose lesogaberan esomeprazole either alone concomitantly post dose data available Methods Statistical Analysis The pharmacokinetic analyses performed using standard non compartmental methods WinNonlin Professional 4 1 b later software Phase I Services Quintiles AB Uppsala Sweden The log transformed variables AUC_ Cmax analysed using mixed model ANOVA fixed effects sequence period treatment random effect subject within sequence The evaluation effect lesogaberan pharmacokinetic variables esomeprazole vice versa performed calculating symmetrical t distribution CIs mean differences log AUC_ log AUCt log Cmax lesogaberan esomeprazole administered concomitantly versus alone The CIs antilog transformed generate CIs ratios geometric means coefficients variation Here report wider CIs A similar transformation calculate ratio geometric means corresponding CIs 4 _OH cholesterol plasma concentration following administration lesogaberan alone performed\n",
      "Methods Subjects A total subjects enrolled ensure least subjects would complete study Subjects eligible participate healthy adult male female non childbearing potential 18Ð55 years age body weight ³60 kg body mass index BMI within 19Ð30 kg m2 range Subjects excluded study pregnant smoked liver disease active latent tuberculosis coeliac disease positive serologic test tissue transglutaminase tTG hepatitis B hepatitis C human immunodeficiency virus HIV Subjects also excluded drug alcohol problems blood pressure abnormalities mental legal incapacities sensitivities medical conditions judged principal investigator unsuitable study consumed red wine citrus fruits fruit juices vegetables mustard green family charbroiled meats within days prior first dose study medication No alcohol caffeine concomitant medications allowed clinic All subjects provided written informed consent study specific procedures performed The study conducted accordance good clinical practice applicable regulatory requirements Declaration Helsinki single site Buffalo Clinical Research Center Buffalo NY USA A local Institutional Review Board reviewed approved study Study design treatments This open label single sequence repeat dose study CCX114671 ClinicalTrials gov identifier NCT01489943 designed evaluate effect repeat doses vercirnon PK probe substrates three CYP enzymes two transporter proteins healthy subjects The probes used investigate enzyme transporter activity midazolam CYP3A4 pioglitazone CYP2C8 omeprazole CYP2C19 rosuvastatin BCRP OATP1B1 All probe substrates administered orally doses would provide adequate concentrations parent and or metabolite assessment potential interactions vercirnon The probe compounds administered morning study days outlined Table Vercirnon mg administered twice day BID meal days 5Ð14 Eligible subjects admitted clinical unit day day first dose remained in house day On days received single doses probe compounds midazolam mg oral syrup pioglitazone mg tablet omeprazole mg capsule rosuvastatin mg tablet respectively This followed vercirnon x 250 mg capsules BID days 5Ð10 On days addition vercirnon mg BID subjects also received probe compound order days 1Ð4 For morning dose subjects required fast overnight Subjects served moderate fat breakfast i e fed state consisting approximately  fat cal Thirty minutes breakfast served study medication administered mL water For evening dose vercirnon subjects also served standard meal min prior dosing Serial blood samples collected 24 h period following administration probe substrates except rosuvastatin samples collected h Full details sample collection probe substrate analysis including validation precision accuracy ranges provided Online Resource Systemic levels probe substrates co administered vercirnon compared systemic levels probes administered alone On study days 5Ð10 single trough concentrations collected immediately prior dosing Additionally subset subjects volunteered serial blood samples collected h study days analysis vercirnon metabolites GSK2635622 GSK2656694 All subjects returned unit follow up visit within 7Ð10 days last dose study medication discharged study The total duration subjectÕs participation study including screening _30 days treatment follow up visit approximately days Sample size considerations The potential effect vercirnon probe substrates evaluated study assessed comparing ratio area concentration curve zero infinity AUC0Ð probe substrate combination vercirnon test AUC0Ð probe substrate alone reference The precision comparison interest estimated using sample size subjects based largest average estimate within subject variability CVw CYP450 substrates studied  rosuvastatin AUC0Ð GlaxoSmithKline data file Point estimates corresponding  confidence intervals CIs constructed differences mean test reference treatments comparison interest The estimated precision  observed point estimate precision expressed half width  CI For point estimate one corresponding  CI ratio geometric means would 0 84Ð1 19 This calculation based loge scale two tailed procedure type I error rate  A total subjects enrolled ensure patients would complete study A sensitivity analysis conducted event CVw estimates greater expected For CVw upper range  estimated precision comparisons interest would  observed point estimate i e  CI ratio geometric means would 0 81Ð1 23 point estimate one This calculation based loge scale two tailed procedure Type I error rate  Study population The Ôsafety populationÕ consisted subjects received least one dose study medication The ÔPK populationÕ included subjects Ôsafety populationÕ PK samples adequate calculation PK parameters The Ôday day populationÕ excluded subjects PK population multiple PK samples collected day day The ÔPGx populationÕ excluded subjects predicted poor metabolisers potentially reduced transporter activity based genotyping Pharmacokinetic analysis Plasma concentration time data probe substrates vercirnon metabolites analysed non compartmental methods using WinNonlin v5 3 PharSight Certara Company St Louis MO From concentration time data probe compound AUC0Ð AUC time curve time zero pre dose last time quantifiable concentration AUC0Ðt Cmax time occurrence Cmax tmax apparent terminal phase half life t1 2 data available determined following administration without vercirnon For vercirnon two metabolites AUC time curve dosing interval AUC0Ð_ Cmax tmax determined subset six subjects serial PK sampling days Vercirnon accumulation following repeat dosing determined calculating accumulation ratio Ro AUC0Ð_ comparing Cmax day day The ratio metabolite AUC0Ð_ vercirnon AUC0Ð_ day day calculated converting AUC0Ð_ values appropriate molar units Statistical analysis Probe assessment The potential effect vercirnon probe substrates evaluated study assessed comparing ratio AUC0Ð probe substrate without concomitant vercirnon The primary endpoint probe substrates except omeprazole ratio AUC0Ð probe substrates administered without concomitant vercirnon Due high interand intra subject variability associated omeprazole PK metabolite 5 OH omeprazole also quantified plasma ratio omeprazole metabolite parent calculated normalise variability associated absorption metabolism omeprazole The statistical endpoint omeprazole calculated AUC0Ð ratio metabolite parent without concomitant vercirnon Following loge transformation primary endpoints separately analysed using mixed effects model Treatment fitted fixed effect subject random effect Point estimates associated  CI constructed ratios back transforming respective difference treatment least squares LS means associated  CI Vercirnon steady state analysis Trough concentration C_ samples collected subjects study days 6Ð11 used assess attainment steady state Individual plasma vercirnon pre dose concentrations obtained mean  standard deviation SD median range plotted summarised day A mixed effects model subject random effect day fixed effect performed loge transformed C_ data Day treated continuous variable model Achievement plasma vercirnon steady state assessed calculating  CI slope linear regression pre dose C_ versus day To claim steady state reached slope estimate needed close zero  CI slope estimate needed include zero Safety Safety tolerability parameters assessed measurement vital signs cardiac monitoring adverse event AE assessments clinical laboratory tests The two vercirnon metabolites GSK2635622 GSK2656694 assayed molar ratio metabolite vercirnon parent concentrations determined Pharmacogenetic analyses To account potential inter patient variability result genetic polymorphisms exploratory PGx evaluations also conducted Exploratory analyses included PK parameters sub population subjects common genetic variations CYP enzymes BCRP OATP1B1 transporters could negatively impact activity PGx population The ÔAffymetrix DMET PlusÕ genotyping array used genotype common genetic variants CYP3A4 3A5 CYP2C8 CYP2C19 SLCO1B1 OATP1B1 ABCG2 BCRP Subjects carrying genetic variants predicted poor metabolism reduced activity respective CYP enzymes transporters excluded relevant exploratory PGx analysis thereby creating sub populations fewer confounding factors\n",
      "Methods Study Population Design This single center phase I open label fixed sequence DDI study healthy adult volunteers male female individuals aged years systolic diastolic blood pressure pulse rate body temperature within normal ranges body weight kg body mass index kg m2 recruited Subjects excluded study used consumed substances known interfere CYP enzymes investigated The study consisted two treatment periods In period day subject received single dose probe drug cocktail modified Cooperstown cocktail orally contained caffeine mg omeprazole mg dextromethorphan mg midazolam mg After washout period days period day subjects received single 50 mg dose osilodrostat orally followed single dose probe drug cocktail min later Blood samples collected administration cocktail study periods following time points pre dose h post dose Plasma concentrations cocktail probe substrates assayed using validated methods WuXi AppTec Co Ltd The analytes extracted plasma samples analysis performed validated liquid chromatography tandem mass spectrometry assay The limits quantitation different analytes ng mL caffeine ng mL dextromethorphan ng mL omeprazole ng mL midazolam ng mL osilodrostat Plasma concentrations osilodrostat assayed using validated liquid chromatography tandem mass spectrometry assay limit quantitation ng mL Analysis Sets The safety set included subjects received least one dose study medication Five separate pharmacokinetic analysis sets evaluated one probe drug substrate one osilodrostat For probe substrate pharmacokinetic analysis set included subjects received planned amount probe substrate period planned amount probe substrate plus osilodrostat period vomit within h study drug administration sufficient pharmacokinetic concentration data determine least one evaluable primary pharmacokinetic parameter The pharmacokinetic analysis set osilodrostat included subjects received planned amount osilodrostat period vomit within h study drug administration least one evaluable pharmacokinetic parameter Pharmacokinetic Assessment The primary objective assess effect osilodrostat pharmacokinetic parameters CYP1A2 CYP2C19 CYP2D6 CYP3A4 5 probe substrates caffeine omeprazole dextromethorphan midazolam using modified Cooperstown cocktail healthy adult subjects Secondary objectives included determination key pharmacokinetic parameters area concentration time curve AUC time zero last measureable concentration AUClast AUC time zero extrapolated infinity AUCinf maximum plasma concentration C max metabolites probe substrates i e paraxanthine caffeine dextrorphan dextromethorphan 5 hydroxyomeprazole omeprazole hydroxymidazolam midazolam pharmacokinetic exposure single 50 mg dose osilodrostat safety tolerability osilodrostat co administered probe substrates All pharmacokinetic parameters osilodrostat cocktail probe substrates determined non compartmental analysis using Phoenix WinNonlin version Safety Tolerability Safety assessment based mainly frequency adverse events AEs reported investigator time informed consent days last dose osilodrostat administered number laboratory values fell outside pre determined ranges Laboratory tests performed screening end of treatment visit study day All AEs coded according Common Terminology Criteria Adverse Events version Treatment emergent AEs defined started study drug administration days date study drug administration started study drug administration worsened afterwards Statistical Analyses Statistical analyses pharmacokinetic parameters primary objective performed using pharmacokinetic analysis set probe drug The single dose pharmacokinetics probe drugs administered without single 50 mg dose osilodrostat compared using model based statistical analysis The single dose pharmacokinetic parameters AUClast AUCinf C max CYP1A2 CYP2C19 CYP2D6 CYP3A4 5 substrates caffeine dextromethorphan omeprazole midazolam log transformed analyzed separately probe drug linear mixed effects model For DDI analysis point estimate treatment difference least squares means log pharmacokinetic parameters corresponding confidence intervals CIs calculated obtain point estimate CI ratio geometric means pharmacokinetic parameters test compared reference probe plus osilodrostat mg probe alone The CIs ratio geometric means AUClast AUCinf C max substrates without osilodrostat co administration determined Descriptive statistics reported secondary pharmacokinetic analyses Physiologically Based Pharmacokinetic Modeling Osilodrostat Pharmacokinetics DrugÐDrug Interactions A physiologically based pharmacokinetic PBPK model developed osilodrostat within framework Simcyp Simulator version release Certara Inc The model incorporated physiochemical clinical pharmacokinetic parameters vitro vivo enzyme phenotyping information vitro CYP perpetrator inhibition induction characteristics osilodrostat The Supplemental Information contains details methods results vitro CYP inhibition Supplemental Table CYP induction Supplemental Tables CYP enzyme reaction phenotyping studies Supplemental Table input parameters PBPK model Supplemental Table The model developed simulate concentration time profiles pharmacokinetic parameters osilodrostat 30and 50 mg single doses In addition model developed simulate pharmacokinetic parameters geometric mean AUC C max ratios CYP probe substrates co administered single 50 mg dose osilodrostat according actual clinical trial design described The qualified model used predict pharmacokinetics osilodrostat multiple 30 mg twice daily doses days predict DDIs CYP probe substrates dosed day multiple doses osilodrostat mg twice daily dosed days 1Ð16\n",
      "Methods This five arm randomized double blind double dummy crossover placebo controlled study approved institutional ethical committee Anaesthesiology Pharmacology Intensive care Department Geneva University Hospitals notified Swiss Agency therapeutic products Swissmedic performed according Good Clinical Practices Ten healthy non smoking male volunteers included history illicit drugs consumption opioid contraindications normal medical examination ECG liver kidney functions taking medications The Latin squares method used randomization The five crossover phases separated least week washout period The fasting volunteers received single oral dose CYP2D6 blocker quinidine mg CYP3A4 blocker ketoconazole mg matching placebos Microdoses midazolam µg dextromethorphan mg given orally h later A single oral dose oxycodone hydrochloride Oxynorm Mundipharma mgákg_1 drops matching placebo given h later Naloxone mg injected intravenously h oxycodone placebo Pharmacokinetic measurements Blood samples mL plasma concentration oxycodone oxymorphone noroxycodone noroxymorphone drawn indwelling catheter left forearm vein oxycodone administration h dosing Blood samples divided two ethylenediamine tetraacetic acid EDTA tubes centrifuged 3350_g min 6 C frozen _20 C analysis Plasma concentrations analytes determined validated assay using online column switching liquid chromatography coupled tandem mass spectrometric detection CS LC MS MS Shortly plasma proteins precipitated adding µL plasma sample µL acetonitrile ethanol solution containing internal standard ISTD oxycodone d3 ngámL_1 The mixture vortexed centrifuged min 4 C 000_g µL supernatant transferred mL Eppendorf tube evaporated dryness The solid residue reconstituted µL formic acid water acetonitrile váv_1 injected CS LC MS MS system The online column switching performed Prospekt system Spark Emmen Netherlands First analytes trapped Hysphere Resin GP Ð 10_12 µm cartridge Then transferred trapping column analytical column XTerra MS _ mm µm Waters separated gradient mode water acetonitrile 0 1 formic acid mLámin_1 Mass spectrometric detection performed Q TRAP AB MDS Sciex Concord ON mass spectrometer selected reaction monitoring mode dwell time  ms The following transitions collision energies selected oxycodone m z 316 1_m z eV oxymorphone m z 302 3_m z eV noroxycodone m z 302 3_m z 30e noroxymorphone m z 288 1_m z eV oxycodone d3 m z 319 3_m z eV Precision accuracy quality control samples found better The lower limit quantification LLOQ using plasma aliquot mL found pgámL_1 oxycodone oxymorphone pgámL_1 noroxycodone noroxymorphone respectively Phenotyping During pre study screening visit conventional dose mg dextromethorphan given determine CYP2D6 activity Microdoses dextromethorphan mg midazolam µg given determine CYP2D6 CYP3A activities respectively five study sessions avoid pharmacodynamic interaction oxycodone For CYP2D6 deconjugated dextromethorphan metabolites assayed urine collected h described Daali et al metabolic ratio deconjugated dextromethorphan dextrorphan calculated CYP3A phenotypes measured using previously validated method Eap et al The min total unconjugated conjugated 1 OHmidazolam midazolam ratios determined single plasma sample using gas chromatography negative chemical ionization mass spectrometry GC NCIMS Genotyping Genomic DNA extracted whole blood genetic variants CYP2D6 alleles identified gene AmpliChipª CYP450 DNA microarray Roche previously described Rebsamen et al CYP2D6 alleles associated normal absent decreased increased enzyme activity http www imm ke se CYPalleles In study following CYP2D6 alleles identified associated normal enzyme activity displaying decreased enzyme activity associated absence activity 2xN gene duplication resulting increased enzyme activity According alleles combinations observed CYP2D6 phenotype individual predicted follows poor metabolizer PM carrying two non functional alleles intermediate IM carrying one non functional allele one associated reduced activity extensive EM carrying least one functional allele ultra rapid UM carrying least three copies functional allele see detailed predicted phenotype Table Data analysis Pharmacokinetic analysis The maximum concentration Cmax time Cmax Tmax terminal elimination half life T1 2z area concentration curve AUC extrapolated infinity AUC using linear trapezoidal method AUC dose partial areas AUC90 AUC360 AUC1440 oxycodone oxymorphone noroxycodone noroxymorphone estimated plasma concentration time values use non compartmental methods WinNonLin Pharsight Mountainview California The software package SPSS Windows Chicago Illinois used statistical analysis The normality data assessed descriptive analysis data normalized log transformation allow use parametric tests necessary Mean values standard deviations SD used summarize continuous variables Multiple repeated analyses variance anova used test treatment differences depending genotype whereas one way anova used test impact genotype oxycodone treatment Spearman correlation coefficients used correlations pharmacokinetics CYP2D6 3A activities Two tailed tests significance level used statistical analyses\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Methods Subjects A total healthy White volunteers men women participated study giving written informed consent The participants recruited pool subjects genotyped SLCO1B1 CYP2C8 CYP2C9 SNPs All genotyping performed TaqMan allelic discrimination Applied Biosystems Real Time Polymerase Chain Reaction System Applied Biosystems Foster City CA USA according manufacturer s instructions reaction volume µl Genotyping SLCO1B1 SNPs carried described previously Genotyping CYP2C9 2 c 430C_T CYP2C9 3 c 1075A_C alleles performed using TaqMan Pre Developed Assay Reagents Allelic Discrimination Applied Biosystems Genotyping CYP2C8 3 allele c 416G_A c 1196A_G carried using Custom TaqMan SNP genotyping assays Applied Biosystems CYP2C8 genotyping validated previously described method Only noncarriers CYP2C8 3 CYP2C9 2 CYP2C9 3 alleles recruited The participants selected basis SLCO1B1 c 521T_C SNP well g 11187G_A g 10499A_C c 388A_G SNPs allocated one three groups according genotype Haplotypes assigned described previously The control group comprised participants five women men homozygous reference genotype position c 521TT group Their mean  SD age  years height  cm weight  kg The second group included participants six women six men heterozygous c 521T_C SNP c 521TC group Their mean  SD age  years height  cm weight  kg Four c 521TC participants haplotype three 1A 15 one 1B 15 diplotype four haplotype one 1A 16 three 1B 16 four haplotype two 1A 17 two 1B 17 The third group consisted four participants one woman three men homozygous c 521CC genotype c 521CC group Their mean  SD age  years height  cm weight  kg The SLCO1B1 diplotypes participants c 521CC genotype The subjects ascertained healthy medical history physical examination routine laboratory tests enrolment None subjects tobacco smoker taking continuous medication including oral contraceptives Use drugs prohibited week use grapefruit products days use alcohol day day administration rosiglitazone pioglitazone Study design The study protocol approved Coordinating Ethics Committee Helsinki Uusimaa Hospital District National Agency Medicines Helsinki Finland Following overnight fast subjects ingested single 4 mg dose rosiglitazone one Avandia 4 mg tablet GlaxoSmithKline Brentford UK wash out period least week single 15 mg dose pioglitazone one Actos 15 mg tablet Takeda London UK The study drugs administered ml water h Subjects received standardized warm meal h administration study medication standardized snack h Timed blood samples 5Ð10 ml drawn cannulated forearm vein tubes containing ethylenediamine tetraaceticacid administration rosiglitazone pioglitazone min h subjects discharged clinical research unit In addition blood samples drawn venepuncture h rosiglitazone h pioglitazone administration Plasma stored _70 C analysis Determination drug concentrations Plasma rosiglitazone N desmethylrosiglitazone measured use API Q TRAP liquid chromatography tandem mass spectrometry system Sciex Division MDS Inc Toronto Ontario Canada The reversed phase chromatographic separation achieved XBridge C18 column internal diameter _ mm particle size µm Waters Corp Milford MA USA using mobile phase consisting mmol l_1 ammonium acetate pH adjusted ammonium hydroxide solution acetonitrile ratio  v v A 10 µl aliquot injected mobile phase delivered flow rate µl min_1 yielding total chromatographic run time min Pioglitazone served internal standard analytes The mass spectrometer operated positive TurboIonSpray mode samples analysed via selected reaction monitoring use transition M H precursor ion product ionfor analyte internal standard The selected ion transitions monitored follows m z m z rosiglitazone m z m z N desmethylrosiglitazone m z m z pioglitazone The limit quantification plasma rosiglitazone ng ml_1 day to day coefficient variation CV ng ml_1 ng ml_1 ng ml_1 ng ml_1 n  The plasma concentrations pioglitazone metabolites determined described previously The limit quantification plasma pioglitazone M3 metabolite ng ml_1 M4 ng ml_1 The day to day CV ng ml_1 ng ml_1 ng ml_1 pioglitazone ng ml_1 ng ml_1 ng ml_1 M3 ng ml_1 ng ml_1 M4 n  Because authentic reference compounds available concentrations N desmethylrosiglitazone M5 metabolite pioglitazone given arbitrary units relative ratio peak area metabolite internal standard The detector response metabolites confirmed linear relevant concentration range means sample dilution 1Ð125 fold dilutions r  signal noise ratio S N  used determination limit Pharmacokinetic analysis The pharmacokinetics rosiglitazone pioglitazone characterized peak concentration plasma Cmax time Cmax tmax elimination half life t1 2 area plasma concentrationÐtime curve AUC rosiglitazone h pioglitazone AUC time infinity AUC0Ð The terminal log linear part concentrationÐtime curve identified visually elimination rate constant ke determined natural log transformed data linear regression analysis The t1 2 calculated equation t1 2  ln2 ke AUC calculated combination linear increasing concentrations log linear decreasing concentrations trapezoidal rules extrapolation infinity appropriate division last measured concentration ke Weight adjusted AUC0Ð calculated follows AUC0Ð á weight kg 70 kg The apparent formation rate constant kf N desmethylrosiglitazone metabolites pioglitazone determined method residuals ascending part metabolite concentrationÐtime curve Statistical analysis Results expressed mean  SD text tables Statistical comparisons pharmacokinetic variables rosiglitazone pioglitazone metabolites subjects SLCO1B1 c 521TT c 521TC c 521CC genotypes performed using analysis variance anova post hoc testing Tukey test equal variances GamesÐHowell test unequal variances Equality group variances tested Levene statistics compatibility residuals normal distribution ShapiroÐWilk test AUC Cmax data logarithmically transformed analysis The confidence intervals CI calculated geometric mean ratio Cmax AUC values c 521TC c 521TT c 521CC c 521TT pairs mean difference t1 2 kf values The tmax data analysed KruskalÐWallis test The number subjects genotype group estimated sufficient detect greater mean AUC0Ð rosiglitazone pioglitazone subjects c 521TC genotype c 521TT genotype well greater mean AUC0Ð rosiglitazone pioglitazone subjects c 521CC genotype c 521TT genotype power least _ level All data analysed statistical program SPSS Windows SPSS Inc Chicago IL USA Differences considered statistically significant P \n",
      "MATERIALS METHODS The protocol study approved Ethics Committee University Medicine Wroc_aw Poland The verbal written informed consent obtained study Patients Eleven patients women men aged 45Ð64 years mean age years diagnosed depression according ICD 10 criteria Ð F32 0 n  F32 1 n  F33 1 n  F33 2 n 2 Ð included study ICD 10 Polish translation version Normal health status confirmed basis physical examination blood analysis urinalysis hepatic function test electrocardiogram Exclusion criteria treatment substrates inhibitors CYP2D6 half life longer h baseline measurement washout period study study liver kidney dysfunction hematologic disorders medical contraindication tricyclic antidepressants Phenotyping procedure CYP2D6 activity measured twice estimation sparteine MR one week wash out period MR1 2 weeks fixed dose doxepin treatment MR2 Each patients ingested one tablet containing mg sparteine sulfate All patients treated simultaneously Urine excrected following h collected The volume urine recorded 50 ml aliquot stored Ð20 C analyzed Sparteine metabolites 2and 5 dehydrosparteine determined urine gas chromatographic method Eichelbaum et al The MR calculated  dose excreted sparteine dose excreted 2and 5 dehydrosparteine Based MR value patients classified CYP2D6 extensive metabolizers EM MR  poor metabolizers PM MR  Precision specifity method Quantitation done use peak area ratios sparteine metabolites internal standard A linear relationship obtained range tested 0 05Ð200 g ml The precision method determination sparteine metabolites good coefficient variation With sample volume ml urine concentrations low g ml could detected The specificity method assessed recording mass spectra sparteine metabolites GC MS Varian MAT CH Doxepin treatment The dose doxepin established individually according clinical status tolerability treatment The daily fixed doses doxepin time second phenotyping mg n  mg n  mg n  mg n  Statistical analysis Exact one sided Wilcoxon signed ranks test used probability level p  considered statistically significant The statistical analysis performed using SPSS version Windows\n",
      "Materials methods Study design This Phase I randomized open label three period four sequence four treatment study healthy volunteers Subjects randomized one four treatment sequences Fig All subjects received three treatments washout period least days administration period The duration administration period days exception PPI treatment days including 6 day follow up glasdegib administration Glasdegib administered mL water water withheld h administration The primary study objective determine bioequivalence new ICH glasdegib formulation di HCl glasdegib formulation determined periods using two way crossover study design Subjects received 100 mg single dose di HCl glasdegib ICH glasdegib administered overnight fast least h No food allowed least h glasdegib dosing The effects food PK ICH glasdegib determined period subset subjects n_ _12 using one way crossover study design Following 10 h fast subjects consumed recommended high fat _50 total caloric content meal high calorie meal _800 calories 500Ð600 calories protein carbohydrate fat respectively Subjects received 100 mg single dose ICH glasdegib_ _5 min meal consumed The reference evaluation ICH glasdegib administered fasted conditions periods The effect PPI rabeprazole PK ICH glasdegib determined period subset subjects n_ _12 using one way crossover study design Following 7 day washout period rabeprazole mg administered daily days On day PK sample collection day rabeprazole administration rabeprazole glasdegib administered fasted state Rabeprazole administered h glasdegib No food allowed h following glasdegib administration The reference objective ICH glasdegib administered fasted conditions periods The primary PK endpoints AUCinf Cmax glasdegib Additional PK endpoints AUC time last quantifiable concentration AUClast time Cmax Tmax plasma elimination half life t_ apparent oral clearance CL F apparent volume distribution following oral dose Vz F Subjects Eligible subjects healthy females non childbearing potential males 18_55 years age body mass index BMI 17 5_30 5 kg m2 Subjects good health based medical history physical examination including blood pressure pulse rate measurements 12 lead electrocardiogram ECG clinical laboratory tests Subjects excluded meet entry criteria including known sensitivity PPIs donated blood within days prior dosing condition possibly affecting drug absorption e g gastrectomy achlorhydria used prescription non prescription drugs dietary supplements within days five half lives whichever longer exception acetaminophen paracetamol abnormal clinical laboratory tests liver function Subjects also excluded ECG demonstrating time beginning Q wave end T wave corresponding electrical systole QT corrected heart rate interval_ _450 ms time ECG Q wave end S wave corresponding ventricle depolarization QRS interval_ _120 ms family history myocardial infarction congenital long QT syndrome torsades de pointes clinically significant ventricular arrhythmias Ethical approval The study protocol approved independent institutional review board conducted accordance Declaration Helsinki Good Clinical Practice guidelines Informed consent obtained individual participants included study This trial registered ClinicalTrials gov identifier NCT03130556 Pharmacokinetic assessments analysis Blood samples PK analysis collected h following glasdegib administration using dipotassium ethylenediaminetetraacetic acid tubes Glasdegib plasma concentrations determined Covance Bioanalytical Services Shanghai China using validated sensitive specific high performance liquid chromatographyÐtandem mass spectrometric HPLCÐMS MS method A 50 µL plasma aliquot spiked deuterated internal standard glasdegib d4 followed addition NH4OH aq extraction µL ethyl acetate centrifugation A 400 µL aliquot organic layer evaporated dryness stream nitrogen residue reconstituted µL formic acid acetonitrile water v v injected HPLCÐMS MS system Chromatographic separation achieved Zorbax XDB C18 50___2 1 mm µm Agilent Technologies Santa Clara CA HPLC column heated C mobile phase gradient flow rate µL min Mobile phase A consisted formic acid water mobile phase B consisted formic acid acetonitrile The mobile phase composition started B min increased linearly B min Detection glasdegib internal standard MS MS Sciex API Applied Biosystems Foster City CA multiple reaction monitoring mode using positive ion electrospray IonSpray voltage V temperature C The monitored ion transitions m z _ glasdegib m z _ internal standard Calibration curves linear range 3Ð3000 ng mL glasdegib plasma using weighted 1 concentration2 linear regression The lower limit quantification LLOQ glasdegib ng mL PK plasma samples stored __70 C assayed within days established frozen plasma stability Inter assay accuracy percent relative error ng mL glasdegib quality control samples ranged __0 4 Inter assay precision percent coefficient variation CV ²_6 1 across quality control levels Glasdegib PK parameters calculated using noncompartmental analysis plasma concentrationÐtime data Samples LLOQ set analysis Actual sample collection times used PK analysis Cmax Tmax observed values AUClast determined using linear log trapezoidal method AUCinf calculated AUClast  Clast Kel Clast predicted plasma concentration last quantifiable time point estimated log linear regression analysis Kel terminal phase rate constant calculated linear regression log linear concentration time curve The t_ calculated loge 2 Kel CL F calculated dose AUCinf Vz F calculated dose AUCinf _ Kel Safety assessments All subjects received glasdegib treatment included safety analyses Safety tolerability glasdegib assessed adverse event AE monitoring changes clinical laboratory results ECGs physical examination findings AEs graded according Medical Dictionary Regulatory Activities version Sample size determination For bioequivalence sample size subjects provided power confidence interval CI ratio test to reference treatment glasdegib AUCinf would within acceptance range 80_125 ii power CI ratio test to reference treatment Cmax would within acceptance range 80_125 This estimate based assumption true ratio test to reference AUCinf Cmax within subject standard deviations loge AUCinf logeCmax respectively obtained mean three prior studies glasdegib The sample size subjects per group assessment effect food PPI glasdegib PK chosen empirically assessments estimation purposes A sample size subjects provided CIs difference treatments _0 1323 _0 1645 natural log scale AUCinf Cmax respectively coverage probability Statistical analysis To determine bioequivalence ICH glasdegib di HCl glasdegib natural log transformed AUCinf AUClast Cmax glasdegib analyzed using mixed effects model sequence period treatment fixed effects subject within sequence random effect To estimate effects food PPIs bioavailability glasdegib natural log transformed AUCinf AUClast Cmax glasdegib analyzed using mixed effects model treatment fixed effect subject random effect Adjusted mean differences CIs differences models exponentiated provide estimates adjusted geometric mean ratio CIs Test Reference\n",
      "Materials methods Study population This study designed panel study including healthy volunteers All volunteers drawn database approximately individuals phenotyped sparteine Six poor six extensive metabolizers sparteine fulfilled requirements inclusion exclusion criteria included study Persons included years age passed physical examination normal clinical chemistry haematology immunology electrocardiogram Volunteers excluded history liver disease severe allergic reactions deviated ideal weight forheight abused alcohol donated ml blood within last months None volunteers allowed take medication except oral contraceptives throughout entire study period allowed drink alcohol day fluoxetine administration The volunteers consented participate basis written verbal information The study protocol approved regional Ethics Committee Danish National Board Health Study procedure Fluoxetine Fontex Eli Lilly A S Denmark administered single oral dose mg day study period As baseline reference blood sample drawn immediately volunteer took fluoxetine O h subsequently blood sampled hand days In poor metabolizers additional blood samples drawn days The volunteers confined research facility first day blood samples drawn using indwelling intravenous catheter Venflon ii 2 Ohmeda Sweden possible On occasions blood drawn venous puncture The blood samples centrifuged plasma stored C analysis When volunteers finished study plasma samples transferred ice analytical laboratory Lausanne Switzerland Rand S fluoxetine Rand S norfluoxetine assayed gas chromatography mass spectroscopy The limit quantification ng ml enantiomers fluoxetine Stereoselective metabolism fluoxetine ng ml enantiomers norfluoxetine coefficients variance range Eap et al All volunteers agreed report adverse effect taking fluoxetine These reports registered case report forms During study volunteers also carried sparteine tests week In short volunteer selfadministered mg sparteine Depasan1 Giulini Pharma Germany hand collected urine next h hon day new blood test The first test performed day fluoxetine administered Sparteine tests thus performed days volunteers additionally days poor metabolizers Urine volume measured ml specimen stored C analysis The urine analysed gas chromatography Vinks et al  Plwrmacokinetics statistics The apparent oral clearance enantiomer fluoxetine determined use trapezoidal rule calculating area curve AUC The elimination half life enantiomers fluoxetine norfluoxetine determined according equation Finally AUC ratio norfluoxetine fluoxetine determined enantiomer This ratio reflects relationship nf norfluoxetine f fluoxetine With respect phenotype pharmacokinetic parameter compared Rand S enantiomer Wilcoxon s matched pair sign test enantiomer result extensive poor metabolizers compared Mann Whitney U test Calculations performed SPSS Windows statistical significance level Table I Calculated pharmacokinetic data racemic fluoxetine corresponding P values intake mg racemic fluoxetine six poor PM six extensive EM metabolizers sparteine Cleam11ce Eli111i11atio11 1alf life days AUC1 11g 1r l Plle11otype S J111oxeti11e R j111oxeti11e S j111oxeti11e R J111oxeti11e S Jluoxeti11e R fluoxeti11e PMl PM2 PM3 PM4 PMS PM6 Median Wilcoxon Rversus S enantiomer P value EMl EM2 EM3 EM4 58 h EMS EM6 Median 40 l Wilcoxon Rversus enantiomer P valuc Mann Whitney PM versus EM P values From urine data concentrations sparteine 2and 5 dehydrosparteine obtained metabolic ratio sparteine divided dehydrosparteines calculated Extensive metabolizers defined according metabolic ratio lower poor metabolizers according metabolic ratio greater The metabolic ratios calculated urine data compared calculating confidence limits median differences Calculations performed Medstat Herlev University Hospital \n",
      "Original Article Published December Correlation Cytochrome P450 CYP 1A2 Activity Using Caffeine Phenotyping Olanzapine Disposition Healthy Volunteers Kara Lee Shirley Yuen Y Hon Scott R Penzak YW Francis Lam Vicky Spratlin  Michael W Jann Neuropsychopharmacology volume pages961Ð966 2003 Cite article Accesses Citations Altmetric Metricsdetails Abstract Olanzapine previously shown predominant metabolism cytochrome CYP P450 1A2 Caffeine shown provide accurate phenotypic probe measuring CYP1A2 activity The purpose study determine significant correlation exists olanzapine disposition caffeine metabolic ratios Subjects phenotyped CYP1A2 activity caffeine probe methodology After 200 mg caffeine administration blood 4_h saliva 10_h urine 8_h total collected high performance liquid chromatography HPLC analysis caffeine metabolites CYP1A2 activity measured plasma PMR4_h saliva SMR6_h SMR10_h three urinary metabolic UMR18_h UMR28_h UMR38_h ratios Each healthy nonsmokers male received single 10_mg olanzapine dose blood collected HPLC determination olanzapine concentrations predose 120_h postdose Olanzapine pharmacokinetic parameters study similar previously published All caffeine metabolic ratios PMR4_h SMR6_h SMR10_h UMR18_h UMR28_h significantly correlated p 0 001 except UMR38_h correlate A significant correlation p 0 05 also found olanzapine clearance PMR4_h r 0 701 SMR6_h r 0 644 SMR10_h r 0 701 UMR18_h r 0 745 UMR28_h r 0 710 A negative correlation observed olanzapine clearance UMR38_h r _0 029 p NS A significant correlation found olanzapine clearance various caffeine metabolic ratios Interpatient variability CYP1A2 activity may explain wide interpatient variability olanzapine disposition Compounds modulate CYP1A2 activity may expected alter olanzapine pharmacokinetics accordingly INTRODUCTION Caffeine 1 3 7 trimethylxanthine 137X one commonly ingested compounds throughout world The metabolic pathways caffeine complex involve formation three principal metabolites theobromine 3 7 dimethyl xanthine 37X theophylline 1 3 dimethylxanthine 13X paraxanthine 1 7 dimethylxanthine 17X Each metabolites primarily formed cytochrome CYP P450 1A2 Carrillo et al Conversion 17X metabolite comprises metabolic pathway caffeine The metabolic pathways 37X 13X metabolites also influenced CYP2E1 Sinues et al Caffeine become popular metabolic probe CYP1A2 activity humans Carrillo et al one major P450 cytochromes liver accounts total P450 content In addition caffeine clinically important psychotropic medications olanzapine clozapine haloperidol thioridazine imipramine clomipramine fluvoxamine tacrine completely partially metabolized enzyme Carrillo et al Callaghan et al Bertilsson et al Spigset et al 1999a Otani Aoshima Thus interindividual variability CYP1A2 activity may alter pharmacokinetics medications influence response therapy including toxicities tardive dyskinesia older typical antipsychotics Carrillo et al Kelly et al Basile et al Ou Yang et al Olanzapine atypical antipsychotic agent used treatment schizophrenia bipolar disorders psychotic conditions Olanzapine metabolized 10and 4_ N glucuronide 4_ N desmethylolanzapine via CYP1A2 olanzapine N oxide flavin monooxygenase Callaghan et al Conversion 2 hydroxymethylolanzapine CYP2D6 minor pathway olanzapine Ring et al Clozapine like olanzapine metabolized variety CYP isozymes including CYP1A2 CYP3A4 CYP2D6 flavin monooxygenase Jann et al Otani Aoshima Clozapine disposition found covary CYP1A2 activity healthy volunteers reciprocal clozapine s area plasma concentrationÐtime curve AUC significantly correlated urinary caffeine N 3 demethylation index conversion 17X metabolite r 0 84 p 0 0024 Clozapine clearance also found correlate significantly caffeine 37X 13X indexes r 0 89 p 0 0013 r 0 85 p 0 0023 Bertilsson et al Olanzapine disposition evaluated seventeen healthy volunteers concentrations caffeine 17X measured saliva 10_h postcaffeine dosing Hagg et al A significant correlation caffeine activity caffeine 17X ratio olanzapine clearance found r 0 19 p 0 56 However studies used one biological matrix assess caffeine metabolism urine saliva concentrations The purpose study examine relation olanzapine disposition CYP1A2 activity determined caffeine phenotyping plasma saliva urine concentrations caffeine 17X 13X metabolites METHODS Subjects The Mercer University Institutional Review Board approved study participant provided written informed consent In healthy nonsmokers male one female participated study Subjects included investigation met following inclusion criteria medically healthy volunteers men women years age women childbearing potential medically acceptable birth control excluding oral contraceptives hormonal implants depo injections Subjects also excluded met following exclusion criteria presence chronic medical condition pregnancy and or breastfeeding history alcohol tobacco drug abuse use prescription over the counter medications herbal remedies metabolized CYP P450 1A2 system inability comply diet free caffeine ethanol grapefruit juice products 48_h overnight stay prior study day The health status subjects assessed thorough health medication history physical examination complete metabolic hematologic blood profile prior study protocol initiation Study Design Subjects asked comply diet free caffeine ethanol grapefruit juice products 48_h come Center Clinical Research CCR overnight stay approximately 12_h prior initiation study day The investigator confirmed compliance protocol specified diet via detailed subject interviews After eating standardized breakfast subjects received 200_mg caffeine No Doz Previously standardized procedures used obtaining plasma saliva urine samples established previous investigators Carrillo et al Spigset 1999b Each subject two 10_ml blood samples drawn one sample obtained prior caffeine administration second sample 4_h postcaffeine dosing All samples collected EDTA vacutainer tubes centrifuged 3200_g 10_min plasma harvested stored Ð80 C analyzed caffeine paraxanthine Immediately caffeine administration subjects began collect urine continued next 8_h All urine samples measured individually total volume aliqoted smaller samples subsequently acidified pH 0 1_M hydrochloric acid storage Ð80 C preservation caffeine metabolites At 10_h caffeine administration subjects asked chew piece paraffin wax film stimulate saliva production 2_ml sample saliva collected stored Ð80 C time analysis Each subjects received single 10_mg olanzapine dose Venous blood samples collected high performance liquid chromatography HPLC determination olanzapine concentrations predose 120_h postdose All samples stored _80 C assayed One male subject withdrew study personal reasons participate olanzapine dosing Analytic Methods Olanzapine plasma concentrations assayed Bioanalytical Services BAS west Lafayette IN published HPLC method developed drug s manufacturer Eli Lilly Pharmaceuticals Indianapolis IN HPLC Catlow et al Plasma urine salivary caffeine 137X metabolites 17X 13X 5 acetylamino 6 amino 3 methyluracil AAMU 1 methylxanthine 1X 1 methyl uric acid 1U dimethyl uric acid 17U analyzed using validated HPLC methodology El Yazigi et al Fuhr Rost CYP1A2 activity measured plasma PMR salivary SMR urinary metabolite UMR caffeine metabolic ratios validated previous phenotypic studies Fuhr et al Spigset et al Carrillo et al Data Statistical Analysis Olanzapine pharmacokinetic parameters values subject determined use noncompartmental methods displayed Table Maximal plasma concentrations Cmax time reach Cmax Tmax determined visual inspection concentrationÐtime profiles The elimination rate constant _z estimated absolute value slope linear regression natural logarithm concentration vs time Half life calculated ln_2 _z The area plasma concentrationÐtime curve AUC0Ð determined linear trapezoidal rule extrapolation infinity AUC0Ð dividing last concentration measured elimination rate constant _z Oral clearance CL F determined dividing dose administered AUC0Ð apparent volume distribution V F calculated ratio CL F _z The confidence intervals CIs differences means log transformed pharmacokinetic parameter values transformed back original scale give CIs geometric means Table Olanzapine Single Dose Pharmacokinetics Caffeine PMR4_h Presented N 14 Full size table CYP1A2 activity determined molar ratios MRs caffeine metabolites plasma P 4_h PMR4_h calculated 17X 137X saliva S 10_h SMR6_h SMR10_h calculated 17X 137X The urinary U MR 8_h UMR8_h determined three different calculations different metabolite concentrations UMR18_h 17X 137X UMR28_h 17X 17U 137X UMR38_h AAMU 1X 1U 17U Fuhr et al Spigset et al Carrillo et al Olanzapine clearance data caffeine metabolic ratios tested normality ShapiroÐWilk tests Olanzapine clearance covariation CYP1A2 activity PMR4_h SMR6_h SMR10_h UMR18_h UMR28_h UMR38_h tested Pearson s correlation coefficient Statistical significance defined p 0 05 calculations performed Statistica\n",
      "P ATIENTS AND M ETHODS Study Population Treatment Patients cancer treated gefitinib part biologic effects study evaluate relationships among gefitinib dose exposure tissue pharmacodynamic activity    A secondary objective study focus work reported develop population model gefitinib assess relationship CYP3A activity gefitinib exposure toxicity Patients histologically confirmed malignant solid tumor susceptible gefitinib therapy determined treating physician lesions amenable serial tumor biopsies enrolled study Additional eligibility criteria included age years Eastern Cooperative Oncology Group performance status less adequate marrow function leukocyte count ³ _ L absolute neutrophil count ³ _ L platelet count ³ _ L adequate liver kidney functions total bilirubin ² mg dL aspartate aminotransferase alanine aminotransferase ² times institution upper limit normal serum creatinine ² mg dL anticancer treatment days previous enrollment concomitant use drugs would induce CYP3A including phenytoin carbamazepine rifampicin phenobarbital St John s wort Gefitinib provided AstraZeneca Wilmington DE mg brown film coated tablets Cohorts patients treated daily mg gefitinib additional patients treated cohort assessable serial tumor skin biopsies treatment days daily treatment After cycle one patients underwent additional cycles treatment treatment discontinued upon disease progression unacceptable unmanageable drug related adverse events All patients treated The Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Baltimore MD The Institutional Review Board The Sidney Kimmel Comprehensive Cancer Center Johns Hopkins approved protocol written informed consent obtained patient Gefitinib Pharmacokinetics Serial blood samples obtained patient baseline treatment gefitinib hours following administration first dose gefitinib day Additional blood samples obtained administration gefitinib days Blood samples collected heparinized tubes placed ice processed within hour collection Plasma isolated centrifugation g C minutes divided two aliquots stored _20 C analysis Total gefitinib plasma concentrations determined one aliquot plasma using validated high performance liquid chromatography HPLC tandem mass spectrometric method LC MS MS described previously    Because unbound drug concentrations believed relevant pharmacologic toxicologic responses total drug concentrations unbound gefitinib pharmacokinetics also evaluated Unbound gefitinib plasma concentrations determined second aliquot plasma 96 well equilibrium dialyzer 5 kDa cutoff regenerated cellulose membrane Harvard Apparatus Holliston MA using validated equilibrium dialysis method described previously    Oral Midazolam Test Within hours beginning gefitinib treatment patients given single 3 mg dose oral midazolam Versed Syrup Roche Basel Switzerland Serial blood samples collected treatment minutes hours administration midazolam Blood samples collected tubes containing EDTA placed ice processed within hour collection Plasma isolated centrifugation g C minutes stored _70 C analysis Midazolam quantif_ied using validated HPLC tandem mass spectrometric method Samples prepared liquid chromatography solvent extraction procedure recovery exceeded Briefly _L plasma extracted adding mL ethyl ether containing temazepam _g mL internal standard followed vortex mixing centrifugation g minutes ambient temperature The top organic layer withdrawn evaporated dryness C gentle stream nitrogen The residue reconstituted _L acetonitrile water 50_ _50 vol vol aliquot _L applied Waters Model separations system Milford MA The compound interest separated Waters X Terra MS C18 analytical column _ mm i d _m eluted acetonitrile 0 1 formic acid 70_ _30 vol vol isocratic flow rate mL min minutes The effluent monitored Micromass Quattro LC triple quadrupole mass spectrometric detector Beverly MA using electrospray positive ionization mode The linear calibration curve midazolam generated range 0 2Ð100 ng mL coefficient determination greater withinand between day precision accuracy period days validation within Pharmacokinetic Analysis Noncompartmental analysis Individual total unbound gefitinib concentrations midazolam plasma concentrations analyzed standard noncompartmental methods using software program WinNonlin version Pharsight Corporation Cary NC Gefitinib pretreatment trough concentration  Cmin  considered evaluable sample obtained hours previous dose within hours next dose Gefitinib Cmin steady state  Css min  determined average pretreatment concentrations days obtained Apparent oral clearance midazolam calculated dose divided area concentrationÐtime curve AUC Population pharmacokinetic analysis The population pharmacokinetic model gefitinib developed two stages structural covariate free model development followed covariate model development All analyses performed first order conditional estimation method interaction using NONMEM program software version V University California San Francisco CA Xpose S PLUS   software used graphic diagnostics covariate screening The structure model built fit total  Cp  unbound  Cu  gefitinib plasma concentrations patients simultaneously Because vitro vivo data shown binding gefitinib plasma proteins linear therapeutic concentration range 1Ð5000 ng mL    unbound fraction  Fu  used link unbound total concentrations model When model intended predict total gefitinib pharmacokinetic parameters expression Cu  Cp _ Fu used link total unbound concentrations model model intended predict unbound gefitinib pharmacokinetics expression Cp  Cu  Fu used link unbound total concentrations model Oneand two compartment models first order absorption without lag time first order elimination two compartment model sequential zero order input mimicking dissolution first order absorption first order elimination tested fit multiple dose plasma concentration versus time profiles Model selection nonhierarchic models guided decrease Akaike Information Criterion AIC graphic goodness of fit analyses Xpose AIC calculated AIC  _2LL  _ p  _2LL NONMEM objective function value OFV _2log likelihood p number pharmacokinetic parameters model Interindividual variability pharmacokinetic parameters included exponential function Residual error modeled combination method including additive proportional part could excluded estimated negligible A screen potentially statistically significant covariates performed using S PLUS 6 2 Xpose software Uppsala University Uppsala Sweden generalized additive model GAM stepwise multiple regression method allows covariates entered model either linear nonlinear fashion according natural cubic spline function one internal break point    The following covariates screened pharmacokinetic parameters structural model sex age body size i e weight height body surface area hematocrit serum albumin alpha 1 acid glycoprotein concentration liver function indicated levels alanine aminotransferase aspartate transaminase total bilirubin kidney function indicated serum creatinine midazolam apparent oral clearance Potentially statistically significant covariates selected GAM analysis introduced covariate model linear exponential power functions according following discrimination criteria decrease objective function value greater  P forward full covariate model building increase objective function value greater  P stepwise backward model reduction    minimization relative standard error parameter estimates minimization model estimated parameter interindividual variability improvement precision parameter estimate random scatter points around horizontal line identity plots weighted residue versus predicted concentrations Assessment Toxicity Diarrhea skin rash two common drug related toxicities caused gefitinib treatment graded scored point scale 0Ð4 accordance National Cancer Institute Common Toxicity Criteria version Cancer Therapy Evaluation Program Division Cancer Treatment  Diagnosis National Cancer Institute National Institutes Health Bethesda MD The grade diarrhea skin rash assigned patient worst grade diarrhea skin rash experienced first 28 day cycle treatment ExposureÐToxicity Analysis Relationships pharmacokinetic parameters incidence principal toxicities diarrhea rash examined Pharmacokinetic parameters assessed parameters total unbound gefitinib exposure calculated noncompartmental analysis AUC Cmax day observed Css min  gefitinib apparent oral clearance estimated final model midazolam apparent oral clearance Because worst grade diarrhea rash scored categorical variable i e probability individual score diarrhea rash might linked drug exposure use logistic regression model described previously    However based data small population patients statistically significant association drug exposure individual scores diarrhea rash observed Hence final model diarrhea rash treated dichotomous categorical variables representing absence toxicity first cycle treatment representing occurrence toxicity including grade first cycle treatment A logistic regression model applied predict probability toxicity  P  single predictor  x  i e observed gefitinib Css min  The probability diarrhea expressed P P y 1 x ¹ x Odds P1_P ¹ x 1_¹ x Log odds expressed linear function single predictor  g  x  logit g x ln P1_P ln ¹ x 1_¹ x _ _x Thus probability diarrhea  P  determined P P y 1 x ¹ x exp _ _x 1 exp _ _x _ represents logit baseline probability _ represents drug effect introduced model either linear function i e slope _ Css  maximum effect model i e Emax_Css EC50 Css  The exposureÐtoxicity model analyzed using NONMEM program An increase objective function value greater  P exclusion drug effect model i e slope Emax set adopted indicate statistically significant association drug exposure incidence diarrhea rash Statistical Analysis Interindividual variation gefitinib exposure parameters AUC Cmax  Css min  midazolam clearance CL F_MDZ derived noncompartmental analysis described fold difference determined ratio maximum minimum value parameter Bivariate correlations examined Pearson test P regarded statistically significant Pearson correlation Statistical analyses performed SPSS version SPSS Inc Chicago IL All P values based two sided statistical tests R ESULTS\n",
      "Methods Ethics subjects This study conducted compliance ethical principles originating derived Declaration Helsinki _Revised Edinburgh accordance International Conference Harmonization Good Clinical Practice guidelines The protocol informed consent documentation reviewed approved Ethics Committee Hamamatsu University Hospital Each patient received information scientific aim study Written informed consent obtained healthy male subjects Study design This study open label randomized 3 period crossover trial _UMIN CTR UMIN000002708 conducted single site _Translational Research Center Hamamatsu University Hospital Shizuoka Japan There minimum 21 day washout period treatments In treatment arms participants received single oral dose mg gabapentin _GabapenÂ Tablet Pfizer Japan Inc Tokyo Japan overnight fast h Gabapentin treatment alone mg gabapentin without concomitant drug Concomitant MgO treatment consisted single oral administration g MgO _MagmittÂ Tablet Kyowa Chemical Industry Co Ltd Kagawa Japan together mg gabapentin concomitant omeprazole treatment consisted oral administration mg omeprazole _OmepralÂ Tablet AstraZeneca K K Osaka Japan h min mg gabapentin To standardize conditions subjects allowed eat drink h following dosing required drink least mL natural water _hardness mg L within h To ensure full compliance doses study medication administrated medical supervision Sample collection Blood samples _5 mL determination gabapentin omeprazole drawn EDTA tubes h single administration gabapentin treatment arm Twenty four hour cumulative urine gabapentin administration collected day blood sampling Bioanalytical methods Gabapentin purchased Toronto Research Chemicals Inc _North York Ontario Canada Baclofen internal standard fluoro 7 nitro benzofurazan fluorescent derivatization reagent obtained Wako Pure Chemicals _Osaka Japan Dojindo Laboratories _Kumamoto Japan respectively Plasma urine specimens obtained centrifugation blood urine respectively  g 4 C min stored 80 C sample preparation Gabapentin concentrations plasma urine determined isocratic fluorometric HPLC previously described 13 Calibration curves human plasma urine linear concentration ranges µg mL respectively Intraand inter assay precision accuracy values plasma within within respectively urine within within respectively Plasma concentrations omeprazole determined using HPLC UV method previously described 14 Calibration curves human plasma linear concentration range µg mL Intraand inter assay precision accuracy values plasma within within respectively Safety Adverse reaction monitoring vital sign measurements physical examination findings clinical laboratory tests performed treatment arm The severity grade adverse reaction categorized using Common Terminology Criteria Adverse Events _CTCAE version The relationship adverse event treatment determined investigator Pharmacokinetic analysis Pharmacokinetic parameters gabapentin omeprazole calculated using non compartmental pharmacokinetic method using Phoenix WinNonlin _v Pharsight Corporation Mountain View CA based individual concentration time profiles The Cmax time _Tmax estimated directly experimental data The AUCs gabapentin omeprazole h infinity _AUC0 W determined linear trapezoidal method The apparent elimination half life _T1 2 calculated _ln ke  ke slope log linear regression terminal phase concentration versus time curve BA gabapentin estimated equation BA _  amount gabapentin _cumulative urine 200 mg gabapentin  Renal clearance gabapentin _CLGP calculated equation CLGP  amount gabapentin 24 h urine AUC0 W gabapentin Creatinine clearance _CLCR calculated using values measured 24 h urine collection Statistical analysis All statistical analyses performed using SPSS _15 0J SPSS Japan Inc Tokyo Japan The pharmacokinetic parameters urine pH three treatments compared using one way repeated measures analysis variance post hoc paired t test The relationships adverse reactions treatment tested using Fisher s exact test Pharmacokinetic data urine pH expressed mean  standard deviation _SD Statistical data expressed mean difference confidence interval _95 CI The pharmacokinetic data omeprazole expressed median interquartile range _IQR normal distribution could assumed interindividual variation A p g considered indicate statistical significance\n",
      "2 _Patients methods Patient eligibility treatment Patients years younger receiving cyclophosphamide part standard clinical treatment B cell NHL eligible participate trial The study approved UK Trent Multicentre Research Ethics Committee registered appropriate clinical trial registries PK Ð REC 04 MRE04 68 CTA EUDRACT prior patient recruitment Participating centres obtained written informed consent either patients parents appropriate patients entered onto study Patients required central venous access form double lumen central venous catheters order participate pharmacokinetic study Baseline toxicity data prior cyclophosphamide treatment including baseline haemoglobin white blood cell platelet counts obtained patients notes details concomitant medications prior and or combination cyclophosphamide recorded Additional patient characteristics clinical parameters including glomerular filtration rate serum creatinine alanine transaminase ALT bilirubin measurements also collected post study analysis Cyclophosphamide mg m2 administered min infusion twice daily days treatment six doses total part COPADM regimen This consisted cyclophosphamide g m2 total dose described hydration continued ml m2 day h final dose vincristine mg m2 bolus intravenous infusion day prednisolone mg m2 day days 1Ð7 doxorubicin mg m2 1Ð6 h infusion day high dose methotrexate g m2 intravenous infusion h day folinic acid mg m2 orally every h beginning h start methotrexate required intrathecal methotrexate hydrocortisone 8Ð15 mg days Toxicity following cyclophosphamide treatment assessed National Cancer Institute Common Toxicity Criteria version Progression free survival data obtained monthly follow up visits centre treatment undertaken Blood sampling analysis Blood samples ml pharmacokinetic analysis obtained central line prior administration first dose cyclophosphamide day end infusion h start infusion Additional samples obtained prior administration first dose cyclophosphamide day treatment dose end infusion h start infusion dose All samples taken different lumen used drug administration following standardised procedure Plasma separated whole blood samples centrifugation 1200g C min stored _20 C prior analysis Samples sent overnight courier dry ice insulated container Northern Institute Cancer Research Newcastle University Concentrations cyclophosphamide stable inactivated metabolites KetoCP DCCP CXCP measured plasma using validated LC MS method previously described Cyclophosphamide obtained Sigma Poole Dorset The inactive metabolites internal standard deuterated cyclophosphamide D4CP obtained IIT University Bielefeld Germany The assay limit quantification _g ml cyclophosphamide _g ml metabolites exhibited withinand between run coefficients variation bias QC samples analyte included assay Standard curves linear 0 5Ð10 _g ml cyclophosphamide 0 05Ð1 _g ml CXCP DCCP KetoCP r2 values ³ Samples containing concentrations cyclophosphamide metabolites linear range diluted blank plasma Pharmacokinetic analysis A population pharmacokinetic model cyclophosphamide developed using nonlinear mixed effects modelling NONMEM version based enhancement model previously published group The first order conditional estimation method _ _ interaction used together ADVAN1 TRANS2 ADVAN3 TRANS4 appropriate A composite error model appropriate describe within subject error An additive error model logarithmic scale used inter individual variability pharmacokinetic parameters As cyclophosphamide concentrations available days doses patient additional error terms included account inter occasion variation IOV clearance CL volume distribution central compartment V1 The exact timing second dose administered day doses administered day recorded Given unknown dosing history allow non zero cyclophosphamide concentrations prior start first cyclophosphamide infusion day rate controlled steady state ÔinfusionÕ central compartment assumed terminating start current infusion This effect initialising compartments appropriate amount drug The rate ÔinfusionÕ allowed vary across population Allometric scaling used population pharmacokinetic parameters approach taken scaling used previously published analysis Changes NONMEM objective function value OFV examination residual plots guided model structure development Empirical Bayes estimates pharmacokinetic parameters including CL V1 cyclophosphamide area plasma concentration time curve AUC obtained final population model The covariates body weight age gender ALT bilirubin creatinine alongside genetic variation including CYP2B6 6 genotype assessed relationship CL Plasma concentrations inactive metabolites CXCP DCCP KetoCP determined day dose day dose cyclophosphamide treatment Calculation metabolite AUCs time 0Ð6 h carried using trapezoidal rule day dose day dose Pharmacogenetics Genomic DNA obtained whole blood samples using Qiagen QIAamp DNA Blood Maxi kits according manufacturer s instructions DNA purity concentration measured using NanoDrop ND 1000 Thermo Scientific Rockford United States America USA stored _20 C prior pharmacogenetic analysis Genotyping SNPs CYP2B6 5 1459C  T rs3211371 CYP2B6 6 785A  G rs2279343  516G  A rs3745274 CYP2C19 2 681G  A rs4244285 CYP2C19 17 806C  T rs12248560 GSTP1 2 313A  G rs1695 CAR 540C  T rs2307424 PXR 25385C  T rs3814055 performed using TaqMan probes ABI Fast Real Time PCR System Applied Biosystems California USA according manufacturer s instructions Allelic discrimination performed using sequence detection software Applied Biosystems Statistical analysis For analysis pharmacogenetic data overall differences groups assessed MannÐWhitney KruskalÐWallis tests using GraphPad Prism version software GraphPad Software Inc San Diego CA USA Analysis linkage disequilibrium performed using Fisher s exact test two sided general contingency tables SPSS version software SPSS Inc Chicago IL USA Time disease progression calculated delay first day cyclophosphamide treatment first observation disease progression death Hazard ratios disease progression estimated individual covariates using univariate Cox proportional hazards regression model approach model fitted separately Potential prognostic factors tested continuous variables Statistical significance given P values \n",
      "Methods This TP_DI study conducted part sub_study within phase multicentre open_label study assess immunogenicity pharmacokinetics PK PD tolerability DAC HYP patients relapsingÐremitting multiple sclerosis main study The TP_DI sub_study registered ClinicalTrials gov identifier NCT01462318 EudraCT 2010_023856_97 conducted seven clinics three countries four clinics Hungary DRC Gy gyszervizsg l K zpont Kft Balatonf red Hungary Ken zy Gyula K rh z Rendel_int zet Debrecen Hungary Vaszary Kolos K rh z Ideggy gy szat Esztergom Hungary Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz Sz kesfeh rv r Hungary one clinic Katowice Poland NEURO_CARE SMO Gabriela Klodowska_Duda two clinics United States Neurology Specialists Inc Dayton Ohio Associates Neurology PSC Lexington Kentucky The study followed Declaration Helsinki approved ethics committees Eg szs g gyi Tudom nyos Tan cs Klinikai Farmakol giai Etikai Bizotts ga Budapest Hungary Komisja Bioetyczna przy Slaskiej Izbie Lekarskiej w Katowicach ul Katowice Poland Quorum Review IRB Seattle Washington USA All patients provided written informed consent study entry Patients study design Patients eligible enrolled TP_DI study years age inclusive confirmed diagnosis relapsingÐremitting multiple sclerosis according McDonald criteria previous cranial magnetic resonance imaging demonstrating lesion s consistent multiple sclerosis baseline Expanded Disability Status Scale score inclusive one clinical relapse s within previous years Patients excluded regimen therapeutic anticoagulation low molecular weight heparin oral anticoagulant agents used medication prescription nonprescription herbal supplement inhibits induces CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A activity within days five half_lives whichever longer first dose probe drug cocktail consumed grapefruit grapefruit_containing products caffeine_containing products within days first dose probe drug cocktail discontinued interferon IFN beta ³ week first dose probe drug cocktail history hypersensitivity midazolam caffeine warfarin vitamin K dextromethorphan omeprazole The use CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A inhibitors inducers allowed study period Twenty patients enrolled TP_DI sub_study received probe drug cocktail two sequential treatment periods days first dose DAC HYP period days third dose DAC HYP mg subcutaneous SC every weeks three doses period The probe drug cocktail consisted oral midazolam mg oral syrup parenteral formulations caffeine mg tablet warfarin mg tablet vitamin K mg tablet omeprazole mg capsule dextromethorphan mg oral syrup Oral vitamin K mg used prophylactically counteract warfarin s anticoagulant effect Midazolam oral syrup mg ml_1 used study sites United States midazolam parenteral formulation used oral administration study sites Hungary Poland due commercial availability Using parenteral formulation concentration mg ml_1 ml formulation diluted ml water entire preparation administered The dose midazolam used study mg based standard dosing range 2Ð5 mg oral dosing used drug cocktail study Furthermore higher dose midazolam used ensure measurable concentrations period event DAC HYP decreased midazolam concentrations To detect potential effects DAC HYP activities CYP isoenzymes probe drug cocktail administered days third dose DAC HYP mg SC every weeks clinical dose investigated phase studies based following PK PD considerations steady_state exposure would achieved three doses DAC HYP based terminal half_life 2Ð3 weeks time maximum concentration Cmax following SC dosing DAC HYP days increase serum IL_2 reached plateau weeks DAC HYP dosing The sample size study similar commonly used cocktail drug interaction studies n  15Ð21 Patients reported study clinic morning probe drug cocktail administration study periods The probe drug cocktail administered following overnight fast ³8 h ml water A standard lunch provided h following administration probe drug cocktail After receiving probe drug cocktail patients stayed clinic ³12 h  min supervision safety PK assessments Patients allowed leave clinic completely recovered potential sedative effects midazolam Patients reported back clinic     h probe drug cocktail administration collection PK samples PK sampling schedule Blood samples determination plasma concentrations midazolam caffeine S_warfarin omeprazole 5_hydroxyomeprazole collected probe drug cocktail administration h h probe drug cocktail administration Urine samples measurement dextromethorphan dextrorphan collected 12_h period immediately probe drug cocktail administration The PK sampling schedules deemed adequate used probe drug cocktail studies Blood samples measurement serum DAC HYP concentrations collected pre_dose period DNA preparation genotyping A single whole_blood sample genotyping polymorphic CYP2D6 CYP2C19 enzymes collected baseline patients Whole_blood samples screened presence star alleles 1XN 2XN 4XN 10XN 17XN 35XN 41XN CYP2D6 gene three star alleles CYP2C19 gene using AmpliChip P450 2D6 2C19 assay Roche Diagnostics Indianapolis Indiana USA Measurement plasma urine concentrations probe drugs serum concentration DAC HYP Plasma samples analysed caffeine midazolam omeprazole 5_hydroxyomeprazole S_warfarin using validated liquid chromatography LC tandem mass spectrometric detection MS MS methods developed Covance Inc Madison Wisconsin USA Regarding caffeine plasma sample volume ml combined internal standard caffeine_d9 solid_phase extraction employing Waters HLB cartridge Waters Corporation Milford Massachusetts USA Extracts evaporated dryness stream nitrogen resulting residue reconstituted methanol water v v submission analysis Chromatographic separation achieved using Genesis C18 column _ mm _m gradient acetic acid water mobile phase A methanol mobile phase B An API mass spectrometer AB Sciex Framingham Massachusetts USA employing electrospray ionization positive ion mode used monitor analyte Multiple reaction monitoring MRM transitions m z _ caffeine _ internal standard caffeine_d9 The lower limit quantification calibration range interassay precision accuracy bias 25 0Ð20 ng ml_1 3 4Ð8 6 _2 3 _0 1 respectively Regarding midazolam plasma sample volume ml combined internal standard alpha_hydroxytriazolam extracted human plasma automated liquidÐliquid extraction Following extraction samples evaporated dryness stream nitrogen The resulting residue reconstituted methanol water v v samples submitted analysis Chromatographic separation achieved using Merck Chromolith SpeedROD RP_18e column _ mm Merck KGaA Darmstadt Germany gradient conditions mobile phase A consisting trifluoroacetic acid mM ammonium formate pure methanol mobile phase B An API mass spectrometer AB Sciex Framingham Massachusetts USA employing electrospray ionization positive ion mode used monitor analyte MRM transitions m z _ midazolam _ internal standard alpha_hydroxytriazolam The lower limit quantification calibration range interassay precision accuracy bias 0 0500Ð50 0 ng ml_1 4 2Ð11 9 _4 3 respectively Regarding omeprazole plasma sample volume _l basified using ammonia combined internal standard omeprazole_d3 underwent liquidÐliquid extraction using ethyl acetate After centrifugation organic layer transferred clean plate diluted equal volume acetonitrile analysis Chromatographic separation achieved using Thermo Scientific BetaSil Silica_100 _ mm _m Thermo Fisher Scientific Waltham Massachusetts USA gradient using mobile phases consisting acetonitrile water formic acid v v v acetonitrile water formic acid v v v An API mass spectrometer AB Sciex Framingham Massachusetts USA positive ion mode used monitor analyte MRM transitions m z _ omeprazole _ internal standard omeprazole_d3 The lower limit quantification calibration range interassay precision accuracy bias 0 500Ð1000 ng ml_1 3 8Ð6 6 _6 5 respectively Regarding S_warfarin plasma sample volume ml combined internal standard S_warfarin_d6 extracted human plasma liquidÐliquid extraction using ethyl acetate hexane The organic layer evaporated dryness stream nitrogen resulting residue reconstituted acetonitrile analysis Chromatographic separation achieved using Astec __Cyclodextrin Cyclobond I column _ mm _m Phenomenex Inc Torrance California USA isocratic conditions mobile phase acetonitrile acetic acid triethylamine v v v An API mass spectrometer AB Sciex Framingham Massachusetts USA employing atmospheric pressure chemical ionization negative ion mode used monitor analyte MRM transitions m z _ S_warfarin _ internal standard S_warfarin_d6 The lower limit quantification calibration range interassay precision accuracy bias 5 00Ð1500 ng ml_1 12 8Ð18 6 _2 7 respectively Urine samples analysed dextromethorphan dextrorphan using validated assay developed Pharmaceutical Product Development LLC Middleton Wisconsin USA Dextromethorphan dextrorphan extracted _l urine incubated beta_glucuronidase solution internal standards dextromethorphan_D3 dextrorphan_D3 3_methoxymorphinan_D3 Extracts analysed LC MS MS detection The lower limit quantification calibration range interassay precision accuracy bias respectively 0 00100Ð1 00 _g ml_1 3 59Ð6 71 _12 5 _6 84 dextromethorphan 0 0200Ð20 0 _g ml_1 0 895Ð2 31 _5 88 dextrorphan A validated sandwich enzyme_linked immunosorbent assay method used determine DAC HYP concentrations human serum In assay format microtiter plates coated anti_idiotype DAC HYP antibody followed blocking washing incubation diluted calibrators controls samples A biotin_conjugated anti_human IgG added detect bound DAC HYP After another plate washing horseradish peroxidase conjugated streptavidin added bound horseradish peroxidase conjugate detected tetramethyl benzidine substrate read colorimetrically plate reader The standard curve range 500Ð7500 ng ml_1 DAC HYP human serum Samples measuring outside assay limits quantitation re_analysed appropriate dilution If sample result fell lower limit quantitation ng ml_1 sample dilution minimum required dilution result sample reported limit quantitation PK statistical analysis Plasma PK parameters probe drug cocktail determined using actual sample collection times non_compartmental method Phoenix WinNonlin Pharsight Corporation Sunnyvale California USA Pre_dose concentrations higher Cmax excluded PK evaluations The h urinary ratio dextromethorphan dextrorphan calculated Pre_specified primary PK endpoints area curve AUC infinity AUC 0Ðinf midazolam caffeine S_warfarin omeprazole h urine dextromethorphan dextrorphan ratio Considering objective study determine effect DAC HYP CYP activities using sensitive probe substrates evaluation plasma AUC probe substrates provides better accurate phenotypic measure CYP activities Cmax plasma ratio given time point Caffeine metabolites analysed impact DAC HYP CYP1A2 determined based caffeine exposure Statistical analyses conducted log_transformed PK parameters urinary ratio using linear mixed_effects model treatment fixed effect subject random effect using SAS version SAS Institute Cary North Carolina USA To evaluate effect DAC HYP probe drug PK adjusted geometric mean ratio treatment period probe drug cocktail  DAC HYP treatment period probe drug cocktail alone calculated along associated confidence interval CI\n",
      "METHODS Study Design This phase I open label parallel group 3 period fixed sequence study evaluate effect dolutegravir steady state PK metformin safety tolerability metformin The study conducted February May Eligible subjects without T2DM sequentially assigned ratio cohorts In period subjects cohorts received mg metformin IR q12h days In period subjects received mg metformin IR q12h plus either mg dolutegravir q24h cohort mg dolutegravir q12h cohort days In period subjects cohorts received mg metformin IR q12h days There washout treatment periods doses study medication taken moderate fat meal Given primary objective study examine effect dolutegravir metformin PK usual starting dose mg twice daily metformin used healthy subject study 12 Metformin administered moderate fat meal approximately fat reduce gastrointestinal side effects Study Population Before study initiation study protocol amendments consent forms reviewed approved institutional review boards study site Quintiles Early Clinical Development Overland Park KS subjects provided signed consent The study conducted accordance ethical standards Declaration Helsinki amendments consistent good clinical practices local regulatory requirements Healthy male female subjects eligible inclusion study based following criteria ages years inclusive body weight ³50 kg males ³45 kg females body mass index within range 18 5Ð31 0 kg m2 inclusive healthy judged basis physical examination medical history 12 lead electrocardiogram ECG laboratory testing alanine aminotransferase ALT alkaline phosphatase bilirubin ²1 5 times upper limit normal capable giving written informed consent Female subjects eligible nonÐchild bearing potential child bearing potential negative pregnancy test results agreed use one protocol defined contraception methods Subjects excluded study chronic history liver disease known hepatic biliary abnormalities except Gilbert s syndrome asymptomatic gallstones HIV positive current illicit drug users positive prestudy drug alcohol screen regularly used tobaccoor nicotine containing products within months screening pregnant lactating history regular alcohol consumption drinks wk males drinks wk females tested positive either hepatitis B hepatitis C virus Subjects refrain consuming red wine Seville oranges grapefruits grapefruit juice days first dose study medication final dose Subjects abstain caffeineor xanthine containing products eg coffee tea cola drinks chocolate alcohol hours start dosing collection final PK sample session The use tobacco products allowed screening final follow up visit Safety Monitoring Safety assessed throughout study included adverse event AE monitoring clinical laboratory testing vital sign measurements physical examinations ECGs Adverse events laboratory events graded according Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version December August clarification 16 Pharmacokinetic Sampling Blood samples mL metformin plasma PK collected morning dose within minutes dosing hours postdose last day dosing period Blood samples mL dolutegravir plasma PK collected predose within minutes dosing hours postdose day period Bioanalytical Methods Metformin Plasma samples analyzed metformin Pharmaceutical Product Development Richmond VA using validated analytical method based solid phase extraction followed high performance liquid chromatography tandem mass spectrometry analysis The lower upper limits quantification metformin ng mL respectively Dolutegravir Plasma samples analyzed dolutegravir Pharmaceutical Product Development Middleton WI using validated analytical method based solid phase extraction followed high performance liquid chromatography tandem mass spectrometry analysis The lower upper limits quantification dolutegravir ng mL respectively Pharmacokinetic Analysis Plasma metformin dolutegravir concentrationÐtime data analyzed noncompartmental methods using Model extravascular administration Phoenix WinNonlin version Pharsight Corporation St Louis MO Calculations based actual sampling times recorded study From plasma concentrationÐtime data following PK parameters determined data permitted metformin maximum concentration Cmax time Cmax tmax AUC dosing interval AUC 0Ð_ half life t 1 2 apparent clearance oral dosing CL F The following pharmacokinetic parameters determined dolutegravir Cmax tmax AUC 0Ð_ CL F predose concentration C0 concentration end dosing interval C_ Statistical Analysis This study designed estimate effect dolutegravir steady state PK metformin No formal hypothesis tested An analysis variance considering treatment fixed effect subject random effect performed using Statistical Analysis Software SAS Version higher Mixed Linear Models procedure compare plasma metformin PK parameters test treatment dolutegravir  metformin ie end period reference treatment metformin alone ie end period cohort The statistical analysis performed log transformed plasma PK parameters Point estimates associated confidence intervals CIs constructed differences test reference treatments cohort The point estimates associated CIs back transformed provide point estimates CIs test to reference ratio PK parameters Cmax AUC 0Ð_ t 1 2 CL F In Vitro Metformin Transport Studies Effects dolutegravir metformin transports including MATE1 MATE2 K PMAT OCT3 evaluated vitro using recombinant expression systems transport function confirmed positive control inhibitors Effects dolutegravir paracellular permeability determined confluent Madin Darby canine kidney II Caco 2 cell monolayers Cellular uptake metformin Caco 2 intestinal cell line determined absence presence metformin see Methods Supplemental Digital Content http links lww com QAI A800 describes detailed methodologies used vitro transport studies\n",
      "Methods The main objective present study evaluate potential interaction PAN bioavailability MPA MMF EC MPS intake stable renal allograft recipients Additional pharmacokinetic data main metabolite MPAG biomarker IMPDH activity evaluated The protocol approved ethics committee federal state Berlin conducted accordance Helsinki Declaration Federal Institute Drugs Medical Devices BfarM Bonn Germany Eudra CT number ClinicalTrials gov Id NCT01801280 All enrolled patients gave written informed consent Inclusion exclusion criteria Key inclusion criteria included adult ³18_years stable renal allograft recipients ³ 6_months post transplant receiving ciclosporin without glucocorticoids PPIs H2 antagonists similar medication interfering MPA absorption discontinued one month start study Exclusion criteria included patients acute rejection within 1_month start study low renal function glomerular filtration rate GFR 30_ml minÐ1 estimated Cockcroft Gault eGFR CG clopidogrel therapy HIV hepatitis C hepatitis B antigen positive gastrointestinal disorders could affect MPA absorption Study design Each patient randomized one four different sequences according computerized Latin square design simultaneously took MMF Roche Basel Switzerland EC MPS Novartis Nuremberg Germany with out PAN 40mg once in the morning o m Nycomed Konstanz Germany Figure_ Figure11 An external file holds picture illustration etc Object name bcp0080 1086 f1 jpg Figure Study design The study design four sequence four period four treatment crossover study shown It intended include five patients sequence fact five patients included sequence D four patients sequences A B C respectively Every treatment period lasted 2_weeks EC MPS enteric coated mycophenolate sodium MMF mycophenolate mofetil PAN pantoprazole PD pharmacodynamics PK pharmacokinetics MPA doses ranged 500_mg 1000_mg MMF twice daily 360Ð720_mg EC MPS Target trough levels ciclosporin Novartis Germany 75Ð115_ng mlÐ1 Study medication taken 10Ð14_days period At visit full 12_h pharmacokinetic pharmacodynamic profile determined MPA MPAG IMPDH activity LithiumÐheparin blood samples collected study medication intake 30_min 1_h 1 5_h 2_h 3_h 4_h 5_h 6_h 8_h 10_h 12_h drug administration On next day new treatment period started Routine safety parameters including vital signs clinical chemistry haematology gastrointestinal side effects determined baseline every visit Measurement pharmacokinetic data MPA MPAG Plasma MPA MPAG analysis separated stored Ð80_ C An isocratic high pressure liquid chromatography HPLC assay used simultaneous analysis MPA LGC Standards Wesel Germany MPAG TRC Inc Toronto Canada hexobarbitone LGC standards internal standard respectively A RP C18 column Phenomenex Luna 5_µm C18 2 100_A 150___4 6_mm Aschaffenburg Germany used stationary phase kept 55_ C The mobile phase consisted acetonitrile 50_mmol KH2PO4 v v pH flow rate 1 5_ml minÐ1 The pre analytical procedure collecting lithiumÐheparin plasma included protein precipitation acetonitrile Linearity assessed 0 50_µg mlÐ1 40 00_µg mlÐ1 MPA _µg mlÐ1 350 00_µg mlÐ1 MPAG The accuracy calibration standards MPA ranged lower limit quantification LLOQ 99 18Ð114 13 MPAG LLOQ 84 65Ð103 37 We either prepared quality control QC samples dilution stock solutions used external standards ChromSystems Mycophenolic Acid Glucuronide Plasma Controls lyoph placed beginning end run Intraday variation QC samples MPA ranged MPAG The relative standard deviation inter day variation QC samples MPA ranged MPAG calibration standards MPA ranged MPAG Measurement IMPDH activity IMPDH activity measured established method Glander using isocratic ion pair HPLC method Enzyme activity calculated normalizing produced xanthine 5_ monophosphate XMP internal standard adenosine 5_ monophosphate AMP Two control samples used beginning end run The within run between run precision respectively Pharmacokinetic pharmacodynamic parameters The primary endpoint study bioavailability defined AUC0Ð12_h MPA MMF EC MPS application alone combination PAN Calculation pharmacokinetic pharmacodynamic parameters MPA MPAG performed using WinNonlin Version Pharsight Corporation Mountain View CA USA using noncompartmental analysis Calculated pharmacokinetic parameters MPA AUC0Ð12_h linear up log down trapezoidal rule Cmax time Cmax tmax For MPAG AUC Cmax tmax determined For IMPDH following pharmacodynamic parameters calculated maximum activity Amax minimum activity Amin activity baseline A0 area enzyme activity curve AEC maximum inhibition Imax i e Amin Amax Data pooled treatment inhibitory maximal efficacy Emax model used calculating half maximal inhibitory concentration IC50 E  E0_Ð_ Imax___C C_ _IC50 E0 estimated baseline effect Statistical analysis sample size A possible interaction PAN bioavailability MPA Cmax analysed using linear mixed effect model LMEM sequence medication used fixed factor patient nested within sequence used random effect Natural logarithmized pharmacokinetic data AUC Cmax corresponding dose adjusted data dose adjusted Cmax dCmax dose adjusted AUC dAUC analysed WinNonLin respectively MPA pharmacokinetic parameters dose adjusted equimolar doses MPA Amax Amin A0 AEC Imax IMPDH activity analysed using LMEM For MPAG GFR added additional covariate model For statistical analysis MMF set reference treatment three treatment options analysed together using LMEM When EC MPS set reference treatment compared EC MPS_ _PAN To evaluate comparability geometric mean ratios GMRs calculated differences reference treatment treatment groups including confidence intervals CI Comparability accepted point estimates CI remained within 0 80Ð1 25 interval Tmax values transformed dose adjusted described medians minimum_Ð_maximum Statistical analysis performed using exact Wilcoxon signed rank test Demographic parameters analysed using analysis variance Friedman test descriptive methods Safety pharmacokinetic pharmacodynamic data presented proportions mean_ _95 CI mean median minimum_Ð_maximum The total sample size estimated maximum 4___4 crossover study This sample size would sufficient obtain power detect decrease bioavailability MPA PAN intake coefficient variation CV In order correct grossly estimated sample size formal power calculation proposed protocol completion evaluable pharmacokinetic profiles Contrary assumptions observed CV MPA AUC difference bioavailability MPA_ _PAN n_ _17 evaluable pharmacokinetic profiles According prespecified power calculation sample size patients would necessary obtain power detection differences MPA bioavailability PAN administration As study could enrol patients patients enrolled study final analysis performed specified protocol\n",
      "Materials Methods Study Design Treatment The protocol approved institutional review board study site initiation study study conducted accordance International Conference Harmonisation Good Clinical Practice Declaration Helsinki All participants provided written informed consent accordance Good Clinical Practice guidelines This open label randomized two period drugÐdrug interaction study conducted Clinical Pharmacology Miami Inc Miami FL USA December February consisted 28 day screening phase two single dose 5 day treatment periods separated 7 day washout period doses Before first treatment period participants randomized ratio single administration either Cooperstown cocktail alone included substrates CYP1A2 caffeine CYP2D6 dextromethorphan CYP2C19 omeprazole CYP3A midazolam enzymes Cooperstown cocktail combination mg LDX The alternate treatment administered second treatment period Randomization occurred immediately dosing day first treatment period accomplished assigning 4 digit randomization number participant randomization schedule produced held PRA International Lenexa KS USA Caffeine mg dextromethorphan mg omeprazole mg administered orally mL room temperature water On days LDX administered also given orally mL room temperature water omeprazole All orally administered agents given within 1 min period swallowed whole administration confirmed mouth check Midazolam mg kg administered intravenously 1 min period within min last orally administered agent midazolam administration immediately followed 5 mL normal saline intravenous infusion flush indwelling catheter All participants required fast approximately h dosing another h dosing Participants also required refrain taking fluids h h dosing permitted lie first h following administration A follow up telephone contact made approximately week final day last treatment period identify ongoing and or new AEs concomitant medications taken since discharge Participants Eligible participants healthy men nonpregnant nonlactating women 18Ð45 years age body mass index 18 5Ð30 0 kg m2 screening visit hemoglobin values ³12 g dL screening start treatment clinically significant relevant medical history physical examination vital signs electrocardiogram ECG laboratory evaluations In addition participants ability understand fully comply study procedures provide consent Participants excluded study participation current recurrent comorbid disease could affect either pharmacokinetics study drug clinical laboratory assessments history current medical psychiatric disorder required treatment made unlikely fully comply study requirements presented undue risk study drug procedures Participants also excluded current history significant cardiac problems including structural abnormalities conduction problems exercise related events clinically significant bradycardia cardiomyopathy transient ischemic attacks strokes problems hypertension resting sitting systolic blood pressure SBP mmHg diastolic blood pressure DBP mmHg family history sudden cardiac death ventricular arrhythmia risk suicide suicide ideation previous suicide attempts intolerance hypersensitivity study drugs history alcohol substance abuse within past year consumed excessive amounts alcohol units day men units day women consumed tobacco another investigational study drug substantially changed eating habits within days first study dose routinely consumed caffeine units day prone caffeine withdrawal headaches donated blood within days start study unable fast follow standardized diet meal schedules Pharmacokinetic Endpoints Blood samples pharmacokinetic analysis collected pre dose serially h post dose The primary endpoints Cmax area plasma concentration versus time curve infinity AUC0Ð parent compounds caffeine dextromethorphan omeprazole midazolam metabolites paraxanthine dextrorphan 5 hydroxyomeprazole 1 hydroxymidazolam administered Cooperstown cocktail alone combination LDX Other pharmacokinetic parameters calculated included time maximum observed concentration sampled dosing interval tmax terminal half life t_ total body clearance extravascular administration divided fraction dose absorbed CL F volume distribution associated terminal slope following extravascular administration divided fraction dose absorbed Vz F In addition parent to metabolite ratios Cmax AUC0Ð CYP substrate calculated treatment regimen pharmacokinetic parameters LDX d amphetamine assessed Bioanalytical Assays Cytochrome P450 Substrate Analysis Concentrations omeprazole 5 hydroxyomeprazole midazolam 1 hydroxymidazolam dextromethorphan dextrorphan caffeine paraxanthine determined using validated liquid chromatography tandem mass spectrometry LCÐMS MS methods The LCÐMS MS system Sciex API 4000 mass spectrometer AB SCIEX Framingham MA omeprazole 5 hydroxyomeprazole midazolam 1_ hydroxymidazolam caffeine paraxanthine Sciex API 5000 mass spectrometer dextromethorphan dextrorphan coupled Shimadzu high performance liquid chromatography HPLC system Shimadzu Kyoto Japan For omeprazole 5 hydroxyomeprazole µL plasma sample combined µL deuterated internal standard omeprazole d3 5 hydroxyomeprazole d3 dissolved methanol water followed addition _L acetonitrile precipitate protein After centrifugation supernatant diluted reconstitution solution methanol water µL sample injected LC MS MS system Chromatographic separation achieved Phenomenex Synergi Hydro RP  µm _ mm HPLC column Phenomenex Torrance CA mobile phase gradient For midazolam 1_ hydroxymidazolam µL plasma sample combined µL deuterated internal standard midazolam d4 _ hydroxymidazolam d4 dissolved methanol water containing N HCl followed addition mL methanol precipitate protein After centrifugation supernatant diluted reconstitution solution mM ammonium acetate µL sample injected LCÐMS MS system Chromatographic separation achieved Atlantis T3 µm _ mm HPLC column Waters Milford MA mobile phase gradient For dextromethorphan dextrorphan µL plasma sample combined µL deuterated internal standard dextromethorphan d3 dextrorphan d3 dissolved methanol After centrifugation supernatant diluted reconstitution solution  formic acid µL sample injected LCÐMS MS system Chromatographic separation achieved Hypersil GOLD aQ µm _ mm HPLC column Thermo Scientific Waltham MA isocratic condition For caffeine paraxanthine µL plasma sample combined µL internal standard solution caffeine d3 dissolved methanol water followed addition mL methanol precipitate protein After centrifugation supernatant diluted N HCl µL injected LCÐMS MS system The chromatographic separation achieved YMCbasic µm C 8 _ mm HPLC column YMC America Allentown PA mobile phase gradient The mass spectrometers operated positive electrospray ionization ESI mode The selected reaction monitoring transitions m z _ m z omeprazole m z _ m z omeprazole d3 m z _ m z 5 hydroxyomeprazole m z _ m z 5 hydroxyomeprazole d3 m z _ m z midazolam m z _ m z midazolam d4 m z _ m z 1_ hydroxymidazolam m z _ m z _ hydroxymidazolam d4 m z _ m z dextromethorphan m z _ m z dextromethorphan d3 m z _ m z dextrorphan m z _ m z dextrorphan d3 m z _ m z caffeine m z _ m z paraxanthine m z _ m z caffeine d3 Plasma concentrations calculated using 8 point curve weighted linear regression The nominal concentrations based standards prepared human plasma ranged ng mL omeprazole USP Rockville MD USA Toronto Research Chemicals Inc Toronto ON Canada 5 hydroxyomeprazole Toronto Research Chemicals Inc Toronto ON Canada 0 1Ð100 ng mL midazolam Cerilliant Round Rock TX USA 1 hydroxymidazolam Cerilliant Round Rock TX USA Lipomed Cambridge MA USA 0 05Ð50 ng mL dextromethorphan USP Rockville MD USA Toronto Research Chemicals Inc Toronto ON Canada dextrorphan TLC PharmaChem Vaughan ON Canada Cerilliant Round Rock TX USA 20Ð20 000 ng mL caffeine USP Rockville MD USA C D N Isotopes Inc Pointe Claire QC Canada paraxanthine Toronto Research Chemicals Inc Toronto ON Canada Lower limits quantification ng mL omeprazole 5 hydroxyomeprazole ng mL midazolam 1 hydroxymidazolam ng mL dextromethorphan dextrorphan ng mL caffeine paraxanthine Quality control samples omeprazole 5 hydroxyomeprazole ng mL midazolam 1 hydroxymidazolam ng mL dextromethorphan dextrorphan ng mL caffeine paraxanthine ng mL prepared separate batches stored Ð20 C Supplemental Table see electronic supplementary material summarizes performance characteristics assays Lisdexamfetamine d Amphetamine Analysis Concentrations LDX d amphetamine determined using validated LCÐMS MS method The LCÐMS MS system Sciex API 4000 mass spectrometer coupled Shimadzu HPLC system The selected reaction monitoring transitions _ m z amphetamine _ m z amphetamine d5 internal standard _ m z lisdexamfetamine _ m z lisdexamfetamine d4 internal standard A 100 µL plasma sample combined µL internal standard proteins precipitated adding µL chilled acetonitrile formic acid volume volume solution After vortexing centrifugation supernatant added µL reconstitution solution Plasma concentrations LDX d amphetamine calculated using 8 point curve weighted linear regression The nominal concentrations based standards prepared human plasma ranged ng mL LDX Cerilliant Round Rock TX USA Alsachim Illkirch Graffenstaden France ng mL d amphetamine Cerilliant Round Rock TX USA Lower limits quantification ng mL LDX ng mL d amphetamine Quality control samples LDX ng mL d amphetamine ng mL prepared stored _20 C start analysis Supplemental Table see electronic supplementary material summarizes performance characteristics assays Safety Tolerability Endpoints Safety tolerability endpoints included assessments vital signs 12 lead ECGs physical examinations clinical safety laboratory tests AEs Participant reported investigator observed AEs recorded screening day two treatment periods follow up AEs classified according severity relationship study drug Vital signs assessed screening day _1 treatment period min pre dose h post dose day period days i e h post dose i e h post dose i e h post dose treatment period Physical clinical laboratory examinations assessed screening day _1 treatment period day period ECGs assessed screening days _1 treatment period day period Data Presentation Statistical Analyses The sample size estimated determine equivalence two regimens pharmacokinetic parameter substrate Cooperstown cocktail For true mean ratio estimated participants needed complete study achieve  power 1 sided _ corresponding  CI All pharmacokinetic analyses conducted using WinNonlin Phoenix version higher Pharsight Corp Mountain View CA pharmacokinetic analysis set consisted participants safety analysis set primary pharmacokinetic data considered sufficient interpretable Analysis variance period treatment regimen fixed effects participant nested within sequence random effect used compare means log transformed Cmax AUC0Ð treatment regimens analyte To assess treatment effect magnitude Cmax AUC0Ð geometric mean ratios  CIs calculated Consistent guidelines Food Drug Administration drugÐdrug interaction studies bioequivalence test rules utilized determine  CI geometric mean ratio within interval 0 80Ð1 25 Treatments considered equivalent thus interaction concluded  CI geometric mean ratio within interval 0 80Ð1 25 If  CI wholly contained within interval 0 80Ð1 25 equivalence concluded drug interaction could excluded Descriptive statistics also determined pharmacokinetic parameters analyte treatment regimens The safety analysis set included participants received one doses study drug one post dose safety assessments Safety endpoints summarized using descriptive statistics\n",
      "METHODS Clinical Study Design Participant Recruitment Treatment Allocation CONRAD A10 114 prospective interventional randomized open label parallel assignment study The protocol approved local ethics boards CONRAD Intramural Clinical Research Center Eastern Virginia Medical School Pro00006631 University Pittsburgh Pro11100105 Profamilia Santo Domingo Dominican Republic CONABIOS registered ClinicalTrials gov NCT01421368 All study volunteers provided written informed consent study procedures We enrolled healthy 18to 50 year old women HIV 1Ðuninfected pregnant reported regular menstrual cycles use hormonal contraception DMPA past days months respectively Women excluded tested positive HIV 1 hepatitis B Trichomonas vaginalis bacterial vaginosis Neisseria gonorrhoeae Chlamydia trachomatis visit Participant flow described Figure study visits summarized Table Supplemental Digital Content http links lww com QAI B219 Genital serum samples collected tenofovir gel use luteal follicular phases visit visit respectively These samples obtained assess secondary objective effect menstrual cycle phase tenofovir mucosal PK Follicular phase visits took place menstrual cycle calendar days 5Ð10 whereas luteal phase visits occurred menstrual cycle calendar days 20Ð25 After sample collection visit follicular phase participants chose either OCPs DMPA We obtained samples approximately weeks week contraceptive initiation tenofovir gel use visit assess primary objective study effect exogenous contraceptive hormones mucosal tenofovir PK compared baseline concentrations follicular luteal phases FIGURE FIGURE Study flow description CONRAD A10 114 Study We asked participants refrain vaginal intercourse hours sampling visits At sampling visit vaginal speculum inserted genital specimens obtained according study manual Specifically cervicovaginal fluid obtained direct aspirate posterior vaginal fornix 2 5 mL vaginal fluid aspirator CarTika Medical Maple Grove MN immediately transferred cryovial stored _80 C Vaginal tissue biopsies obtained _ 5 mm Tischler forcep placed cryovial snap frozen liquid nitrogen stored _80 C A cytobrush placed endocervical canal rotated times obtain endocervical cells The cytobrush transferred Falcon tube containing mL normal saline This tube centrifuged 4 C cell pellet stained Trypan blue viable endocervical cells cell pellet counted lysed methanol normal saline solution This article reports PK data obtained visits performed tenofovir gel use visits bolded visits see Table Supplemental Digital Content http links lww com QAI B219 Allocation Drug Treatments Participants randomized contraceptive method could instead self select preferred product Participants chose receive either 150 mg intramuscular dose DMPA commence OCP containing days µg ethinyl estradiol µg levonorgestrel visit For OCP users first pill ingested clinic participants told take subsequent pills time day For DMPA users intramuscular injection administered clinic Tenofovir gel manufactured current good manufacturing practices either Patheon Pharmaceuticals Cincinnati OH DPT Laboratories San Antonio TX Tenofovir gel supplied CONRAD clear transparent viscous gel packaged prefilled single use polypropylene applicators Each applicator contained mL tenofovir gel equal gm concentration weight weight formulated purified water edetate disodium citric acid glycerin methylparaben propylparaben hydroxyethylcellulose pH adjusted The active pharmaceutical ingredient supplied Gilead Sciences Inc Foster City CA This study involved administration tenofovir manner meant mimic typical use pericoital dosing regimen CAPRISA study 25 Participants inserted applicator tenofovir vaginal gel vaginally repeated dose hours later Sex take place modified regimen reduce confounding factors Following confirmation eligibility visit participants randomized ratio genital sampling hours hours second dose tenofovir vaginal gel Randomization stratified center anticipated contraceptive product used random permuted blocks method block sizes All randomizations conducted FHI360 qualified statistician otherwise involved study using validated randomization program There allocation errors The 11 hour collection meant replicate midpoint regimen used CAPRISA study 25 whereas 3 hour collection performed closer second gel dose maximize possibility drug would present types samples blood genital samples It possible blind participants center staff contraceptive method sampling assignments However laboratory staff data analysts remained blinded participant s contraceptive product choice sample analysis analysis decisions made Protocol treatment compliance measured participant report return empty used gel applicators The study center recorded date time collection PK blood genital sampling The time sampling considered protocol deviation fell hours outside 11 hour time point hour outside 3 hour time point Compliance OCP use self report participant diary entries Tenofovir Pharmacokinetic Assessment All PK samples stored _80 C study sites batch shipment dry ice University North Carolina Kashuba laboratory PK analyses All analytes quantified liquid chromatographyÐtandem mass spectrometry LC MS MS assays intraday interday precision accuracy within Tenofovir concentrations plasma CV aspirate samples determined validated methods using protein precipitation followed LC MS MS analysis For plasma samples µL plasma mixed µL methanol containing isotopically labeled internal standard 13C5 tenofovir Moravek Biochemicals Brea CA Following vortex centrifugation steps supernatant evaporated dryness The extracts reconstituted µL 1 mM ammonium phosphate pH LC MS MS analysis Using high performance liquid chromatography system Shimadzu Columbia MD LC separation achieved using Waters Atlantis T3 _ mm µm particle size analytical column Waters Milford MA gradient conditions water formic acid acetonitrile formic acid mobile phases Tenofovir 13C5 tenofovir detected AB Sciex API 5000 triple quadrupole mass spectrometer AB Sciex Foster City CA operated negative ion electrospray mode Data collected using AB Sciex Analyst Chromatography Software The dynamic range assay 0 25Ð250 ng mL Calibrators matching spiked quality control samples within nominal value analysis The extraction LC MS MS conditions used CV aspirates plasma samples dynamic range 2Ð5000 ng mL The dynamic range 6Ð6000 ng mL tissue homogenate tenofovir 0 3Ð300 ng mL tenofovir diphosphate The molecular ratio tissue tenofovir diphosphate tissue tenofovir expressed ratio multiplied Endocervical cell samples analyzed tenofovir diphosphate validated LC MS MS assay Calibration standards quality control samples prepared human peripheral blood mononuclear cell PBMC diluent consisting million PBMCs per mL methanol water solution The cytolysates methanol water initially mixed internal standard 13C5 tenofovir diphosphate centrifuged evaporated dryness gentle stream nitrogen The extracts reconstituted 1 mM ammonium phosphate pH LC MS MS analysis Tenofovir diphosphate analyzed using anion exchange chromatography Thermo BioBasic AX _ mm 5 µm particle size analytical column detected positive ion electrospray conditions AB Sciex API 5000 triple quadrupole mass spectrometer The composition mobile phase A water 750 mM ammonium acetate mobile phase B 75 25 5 mM ammonium acetate acetonitrile pH The dynamic range 0 250Ð250 pmol mL cytolysate Tissue biopsies initially homogenized solution acetonitrile 1 mM ammonium phosphate pH Aliquots resulting homogenates extracted acetonitrile containing isotopically labeled internal standards 13C5 tenofovir 13C5 tenofovir diphosphate Moravek Biochemicals Brea CA Following vortex centrifugation steps extracts evaporated dryness reconstituted 1 mM ammonium phosphate pH Final extracts transferred identical plates LC MS MS analysis Tenofovir analyzed reverse phase conditions Waters Atlantis T3 _ mm µm particle size analytical column Thermo Fisher Scientific Waltham MA followed detection negative ion electrospray conditions Tenofovir diphosphate analyzed using anion exchange chromatography Thermo BioBasic AX _ mm 5 µm particle size analytical column Waters Milford MA Tenofovir diphosphate 13C5 tenofovir diphosphate detected positive ion electrospray conditions Data assays collected using AB Sciex API 5000 triple quadrupole mass spectrometer dynamic range 0 3Ð300 ng mL homogenate tenofovir tenofovir diphosphate Sample Size The goal women contraceptive product group complete study Assuming tenofovir tenofovir diphosphate similar previous CONRAD phase I protocol 26 study would power detect decrease doubling tenofovir levels used given contraceptive product Analysis Populations The full analysis population consisted women underwent baseline genital sampling visit Subset populations defined separately evaluation effect exogenous hormones contraceptive population primary objective endogenous hormones menstrual cycle population secondary objective Specifically contraceptive population consisted women initiated one contraceptive methods visit contributed endpoint data visit The menstrual cycle population consisted women contributed endpoint data visits Statistical Analysis Drug concentration measurements fell analytic limit detection censored Where lower limit quantification LLOQ defined measurements LLOQ imputed one half LLOQ otherwise imputation performed Evaluations contraceptive effect controlled baseline characteristics differing women choosing OCPs versus DMPA using propensity score The propensity score subject s predicted probability choosing given method given baseline data 27 The final propensity score included age required priori per analysis plan weight body mass index race white versus current tobacco use history Cesarean section The propensity score effective controlling method group imbalance variables demonstrated fact adding propensity score logistic regression model substantially reduced group differences P ² P ³ Because PK data normally distributed log transformation applied avoid violating normality assumption Linear models generalizing estimation equations used evaluate effect tenofovir tenofovir diphosphate concentrations menstrual cycle secondary objective hormonal contraception exogenous hormones primary objective Generalizing estimation equation models evaluating use hormonal contraception compared drug concentrations versus method start controlling method group center sampling time point hours hours propensity score We used SAS STAT software version SAS Institute Inc Cary NC analysis GraphPad PRISM version San Diego CA graphs\n",
      "Materials methods The study conducted open label single dose 24 hour pharmacokinetic study healthy Caucasian men women years age Race determined patient self report Subjects required race parents grandparents Subjects prospectively screened enrolled stratified study based SLCO1B1 T  C genotype The clinical study approved University Colorado Multiple Institutional Review Board subjects provided written informed consent Subjects excluded study body mass index ³ kg m2 and or current past clinical history liver kidney cardiovascular gastrointestinal endocrine neurological haematological disease Patients active malignancy self reported human immunodeficiency virus positivity active alcohol abuse pregnancy and or lactation also excluded study In terms laboratory tests subjects excluded study metabolic renal hepatic haematological laboratory tests outside normal limits Exclusionary medications included gemfibrozil trimethoprim phenobarbital primidone carbamazepine rifampin cyclosporine oral anti diabetic agents and or insulin Study design The intensive 24 hour pharmacokinetic study took place University Colorado General Clinical Research Center Inpatient Unit After overnight fast subjects administered single mg oral dose rosiglitazone ml water A standardised meal per cent carbohydrate per cent protein per cent fat administered two hours rosiglitazone ingestion Additional warm meals provided six ten hours rosiglitazone ingestion All meals caffeine free subjects required abstain smoking 24 hour period Blood samples ml ethylene diaminetetraacetic acid EDTA vacuum tubes collected pre rosiglitazone dose hours post rosiglitazone dose Plasma harvested within minutes sample collection plasma samples stored 80 C high performance liquid chromatography HPLC analysis performed Genotyping After obtaining informed consent pre screening genetic sample collected potential subject via mouthwash collection method Subjects asked vigorously swish ml Scope mouthwash Procter  Gamble Cincinnati OH USA one minute expectorate sterile collection tube Genomic DNA isolated buccal cells mouthwash expectorate using commercially available kit QIAamp DNA Mini Kit Qiagen Valencia CA USA Subjects prospectively genotyped enrolled study based SLCO1B1 T  C genotype The goal enrol equal numbers SLCO1B1 T T homozygotes SLCO1B1 521C allele carriers ie T C C C genotypes Because SLCO1B1 T  C polymorphism commonly studied haplotype form subjects also genotyped following SLCO1B1 polymorphisms G  A A  C A  G Asn130Asp In terms CYP2C8 subjects genotyped CYP2C8 3 Arg139Lys polymorphism All genotyping performed polymerase chain reaction PCR pyrosequencing analysis PCR primers pyrosequencing primers PCR annealing temperatures used genotyping procedures shown Table _Table1 1 PCR reactions performed final volume _l consisted _l HotStarTaqª Master Mix Qiagen pmol primer _l water ng genomic DNA The standard PCR cycling conditions initial denaturation 95 C minutes cycles denaturation 95 C seconds annealing designated temperature seconds extension 72 C one minute followed final extension step 72 C seven minutes Samples genotyped using PSQ 96MA genotyping system Biotage AB Uppsala Sweden according standard manufacturer protocol Genotype determinations made using automated pyrosequencing software PSQª 96MA SNP software v Biotage Table PCR primers pyrosequencing primers PCR annealing temperatures used genotyping Polymorphism Primer sequence Annealing temperature SLCO1B1 G  A PCR forward TGCTGCAACCATATCAACAAA PCR reverse Biotin TGGACATTAAGCTCTCTTCTGAAA Sequencing ATATATATGTGCATATGTG 60 C SLCO1B1 A  C PCR forward Biotin GTAAAAGCCATTCCCAAAAGTAAG PCR reverse CCACCTTATTATGTCATTGCTCTA Sequencing GTTTTAAGAGTTCACTCCAG 60 C SLCO1B1 A  G PCR forward CATTTCACTTTTACCCATC PCR reverse Biotin TACCTTTTCCCACTATCTCA Sequencing ATTCTAAAGAAACTAAT 55 C SLCO1B1 T  C PCR forward Biotin AGGAATCTGGGTCATACATGTGG PCR reverse CCCCTATTCCACGAAGCATATT Sequencing AAGCATATTACCCATGAAC 60 C CYP2C8 3 Argl39Lys PCR forward Biotin GGCGTTTCTCCCTCACAACCT PCR reverse GTCACCCACCCTTGGTTTTTCT Sequencing CGGTCCTCAATGCTC 60 C Following genotyping SLCO1B1 haplotypes computationally assigned using HelixTree Genetics Analysis Software Golden Helix Inc Bozeman MT USA SLCO1B1 haplotypes assigned follows 1A 11187G 10499A 388A 521T 1B 11187G 10499A 388G 521T 11187G 10499A 388A 521C 11187G 10499A 388G 521C 11187G 10499C 388G 521C 11187A 10499A 388G 521C 11187A 10499A 388G 521T Rosiglitazone plasma concentration analysis Rosiglitazone plasma concentrations determined HPLC fluorescence detection using adaptation previously published method The HPLC system comprised Beckman binary gradient HPLC pump Beckman Coulter Inc Fullerton CA USA Agilent series autosampler G1313A Agilent Technologies Inc Santa Clara CA USA fluorescence detector G1321A Agilent Technologies Chromatographic data analysis conducted using ChromPerfect Data Collection Analysis software version Justice Innovations Mountain view CA USA Betaxolol United States Pharmacopeia Rockville MD USA used internal standard dissolved methanol make _g ml stock solution Separation performed using Hypersil phenyl column mm _ mm _m Thermo Scientific Waltham MA USA The mobile phase consisted mM sodium acetate buffer pH  acetonitrile v v run system flow rate ml min Rosiglitazone fluorescence detected excitation wavelength nm emission wavelength nm Betaxolol fluorescence detected excitation wavelength nm emission wavelength nm Sample preparation conducted using liquid liquid extraction procedure following manner _l betaxolol ng _l methanol added _l EDTA plasma vortexed Methyl tert butyl ether ml added tube vortexed high speed ten seconds The samples centrifuged _ g five minutes room temperature After centrifugation aqueous layer frozen dry ice isopropanol bath ten minutes The organic layer decanted glass tube allowed equilibrate room temperature dried ten minutes 37 C water bath using nitrogen gas The dried samples reconstituted _l mobile phase transferred vials _l aliquot injected onto column The lower limit quantification assay ng ml Pharmacokinetic analysis Rosiglitazone pharmacokinetic parameters determined non compartmental methods using WinNonlin software Pharsight Corp Mountain View CA USA Rosiglitazone plasma concentration time curves generated maximum plasma concentration Cmax time maximum plasma concentration Tmax read curves The linear trapezoidal method used calculate area plasma concentration time curve  AUC0 The half life t1 2 calculated following equation t1 2  ln2 ke ke calculated using linear regression analysis log linear portion concentration time curve Total apparent oral clearance CL F rosiglitazone calculated dose mg AUC weight adjusted oral clearance CL F kg calculated dose mg AUC weight kg Statistical analysis A one way analysis variance used compare baseline demographics AUC0 CL F CL F kg t1 2 Cmax Tmax three SLCO1B1 diplotype groups Unpaired Student s t tests used compare baseline demographics pharmacokinetic parameters CYP2C8 3 genotype groups wild type homozygotes versus CYP2C8 3 heterozygotes A stepwise linear regression analysis used determine joint effects CYP2C8 3 genotype SLCO1B1 diplotype age sex body weight rosiglitazone AUC0 All statistical analyses conducted using SPSS version Windows SPSS Inc Chicago IL USA A p value considered statistically significant\n",
      "Materials methods Subjects Studies approved appropriate institutional national research ethics committee Aspire Institutional Review Board Santee CA USA protocol number PR 10 5001 C The study conducted Parexel Early Phase Clinical Unit Baltimore MD USA November November performed compliance ethical standards laid Declaration Helsinki including amendments effect time study conducted Guidelines International Conference Harmonization Good Clinical Practice requirements Health Insurance Portability Accountability Act privacy regulations applicable regulatory requirements Written informed consent obtained subjects enrollment study A total healthy subjects dextromethorphan n _26 tolbutamide omeprazole n _20 efavirenz n_ _20 repaglinide n_ _20 enrolled studies Inclusion criteria healthy nonsmoking male female subjects aged years body mass index BMI kg m2 weight_³_50 kg screening All subjects determined general good health based medical history physical examination vital signs Female subjects negative serum pregnancy test prior visit agree use medically accepted method birth control throughout study least days dosing All subjects required refrain caffeine consumption discontinue intake alcohol beverages foods known interfere CYP metabolic enzymes None subjects received continuous medication used nicotine products For inclusion dextromethorphan part study subjects required identified dextromethorphan normal intermediate metabolizers For inclusion studies subjects normal laboratory test results serum aminotransferase concentrations negative results human immunodeficiency virus hepatitis B virus hepatitis C virus urine drug screen serum alcohol screen screening At screening visit blood samples collected sent LabCorp Research Triangle Park North Carolina CYP2D6 genotyping dextromethorphan study CYP2C9 2C19 genotyping tolbutamide omeprazole study Subjects known relevant CYP genotype allele combination predicting phenotype poor metabolizer excluded dextromethorphan tolbutamide plus omeprazole studies obtain relatively homogenous drug sensitive populations study minimize variability PK analysis Study design These phase open label drugÐdrug interaction studies Subjects admitted study center prior study remained in house completion assessments Investigational drugs administered subjects morning day approximately mL fluid ounces room temperature water subjects fasted overnight minimum h Subjects remained semi recumbent position least h dosing Each study part consisted three dosing sample collection periods In dextromethorphan study subjects n _26 received single oral dose mg dextromethorphan days single dose mg rolapitant four mg rolapitant capsules plus mg dextromethorphan day Fig In tolbutamide omeprazole study subjects n _20 received single oral cocktail mg tolbutamide mg omeprazole days single dose mg rolapitant 4___45 mg rolapitant capsules plus drug cocktail day Blood samples PK analysis rolapitant collected pre dose multiple time points h post dose days An external file holds picture illustration etc Object name 520_2018_4331_Fig1_HTML jpg Fig DrugÐdrug interaction study cohorts healthy subjects orally administered CYP probe substrates part A mg dextromethorphan part B mg tolbutamide plus mg omeprazole part C mg efavirenz part D mg repaglinide absence presence single oral dose mg rolapitant free base ROL rolapitant In efavirenz study subjects n _20 received single oral dose mg efavirenz days single dose mg rolapitant four mg rolapitant capsules mg efavirenz day Blood samples PK analysis rolapitant collected pre dose multiple time points h post dose days In repaglinide study subjects n _20 received single oral dose mg repaglinide days single dose mg rolapitant four mg rolapitant capsules mg repaglinide day Blood samples PK analysis rolapitant collected pre dose multiple time points h post dose days Determination plasma drug concentrations Following collection K2 EDTA tubes blood samples immediately placed ice Plasma separated centrifugation C transferred appropriately labeled polypropylene specimen containers frozen __20 C analysis XenoBiotic Laboratories Plainsboro NJ USA Plasma samples analyzed using fully validated liquid chromatography coupled tandem mass spectrometry detection LC MS MS method determination concentrations dextromethorphan tolbutamide omeprazole efavirenz repaglinide rolapitant ESI positive ion mode API 4000 Applied Biosystem MA except tolbutamide negative ion mode applied The LC columns Luna _ HILIC 200A 100___2 0 mm dextromethorphan Luna PFP 50___2 0 mm tolbutamide omeprazole efavirenz Luna C8 _ 50___2 0 mm repaglinide ACE Milford MA C18 AR column 2 1___50 mm 3_m rolapitant The multiple reaction monitoring MRM transitions dextromethorphan tolbutamide omeprazole efavirenz repaglinide rolapitant SCH619734 The MRM transitions respective internal standards dextromethorphan d3 tolbutamide d9 omeprazole d3 efavirenz d4 repaglinide ethyl d5 13C3 SCH619734 The validated ranges ng mL dextromethorphan ng mL tolbutamide ng mL omeprazole ng mL efavirenz ng mL repaglinide ng mL rolapitant Pharmacokinetic evaluations The following pharmacokinetic parameters calculated maximum observed concentration Cmax time observed maximum concentration Tmax area plasma concentrationÐtime curve time time last quantifiable concentration AUC0Ðlast area plasma concentrationÐtime curve time extrapolated infinity AUC0Ðinf terminal elimination half life t1 2 Safety assessments Safety tolerability assessed physical examinations vital signs laboratory safety tests reported AEs throughout studies The following safety parameters recorded clinical laboratory tests clinical chemistry hematology urinalysis glucose monitoring subjects receiving tolbutamide 12 lead electrocardiograms ECGs vital signs supine orthostatic blood pressure heart rate body temperature physical examination concomitant medication monitoring Pharmacokinetic statistical analysis Individual plasma analyte concentrationÐtime data used derive drug PK parameters using noncompartmental analyses performed Phoenix WinNonlin Pharsight Certara Sunnyvale CA USA SAS SAS Institute Cary NC software used statistical analysis To determine effect rolapitant PK investigational drugs log transformed primary endpoints AUC Cmax analyzed using repeated measures ANOVA Ninety percent confidence intervals CIs constructed ratio geometric least squares means\n",
      "Methods The study approved Ethics Committee Human Pharmacology Institute Ciba Geigy GmbH subjects gave written consent A total healthy Caucasian volunteers participated study All non smokers without history allergy bronchopulmonary disorder Group I consisted six extensive metabolisers EM debrisoquine two females age years body weight kg four males age years body weight kg Group II consisted six poor metabolisers PM debrisoquine two females age years body weight Correspondence current address Dr C H Gleiter Abteilung Klinische Pharmakologie Zentrum fur Pharmakologie und Toxikologie der Universitat Robert Koch Strasse D 37075 Gottingen Germany Current address Dr Margarete Fischer Bosch Institut fur Klinische Pharmakologie Auerbachstrasse D 70341 Stuttgart Germany L Firkusny  C H Gleiter kg four males age years body weight kg All subjects phenotyped described previously Histamine challenge All histamine challenges carried time day Histamine diphosphate Sigma Chemicals used concentrations mmol 1 l preliminary assessment All tests used two histamine concentrations first concentration effect FEVi preliminary assessment Phosphate buffered saline diluent nebulised first control Histamine nebulised according standard technique using Wiesbadener Doppelspray Lode Groningen Holland airflow min Under conditions nebuliser produced particles um output mg liquid min The aerosol inhaled min quiet tidal breathing nose pinched After inhalation FEVI Pneumoscreen Jager Wurzburg Germany measured immediately min thereafter The inhalation discontinued FEVI fell highest histamine concentration reached side effects occurred Maprotiline treatment All subjects received mg maprotiline twice daily Ludiomilg Ciba Geigy GmbH p o open manner days On day received mg morning dose Time schedule On day maprotiline treatment histamine test carried drawing blood sample h drug intake Volunteer tested day technical reasons Between days cessation drug administration histamine challenge repeated EM depending availability volunteers Table No blood samples drawn EM tests half lives maprotiline passed In two PM subjects histamine test extended days termination maprotiline treatment depending availability subjects Table In extra four PM volunteers histamine challenges carried shown Table On day blood samples measurement plasma concentration maprotiline drawn volunteers h drug intake After cessation treatment blood samples obtained PM subjects morning immediately histamine challenge indicated Table Analytical procedures Urine concentrations debrisoquine hydroxy metabolite assayed described Lennard Maprotiline concentrations plasma measured using modified h p l c method fluorometric detection excitation nm emission nm The coefficient variation assay linear range ng ml The limit quantitation ng ml limit detection ng ml 1 Pharmacokinetic analysis Cmax values noted directly data For technical reasons plasma samples beyond h available consistently subjects Therefore AUC h values dose maprotiline day calculated This done using linear trapezoidal rule Estimates terminal elimination half life t 2 Z made linear least squares regression semilogarithmically transformed terminal plasma drug concentration data EM volunteers four PM volunteers completed sample collection The trough plasma concentrations maprotiline day transformed blood concentrations described Riess et al normalised dose comparison values reported Riess et al Angst  Rothweiler Data analysis The metabolic ratio debrisoquine MRD calculated described previously Subjects MRD  considered PM MRD  EM The concentration histamine caused decrease FEVI referred PC20 provocation concentration In instances decrease FEVi exceeded PC20 calculated linear interpolation Comparisons pharmacokinetic parameters Tables made using unpaired twosided t test P values  regarded statistically significant Confidence intervals CI differences mean Cmax AUC 0 48 h ti 2 z values calculated\n",
      "RESEARCH DESIGN AND METHODS This double blind six way crossover study conducted healthy fasting volunteers The active comparators U mL insulin lispro injection Humalog Lilly insulin aspart injection NovoLog Novo Nordisk insulin glulisine injection Apidra sanofi aventis Investigational drugs prepared diluting U mL rHuPH20 final concentration _g rHuPH20 mL All study drugs injected subcutaneously units kg abdomen random sequence Eight hour euglycemic glucose clamps statistical analyses conducted previously described described detail Fig Mean duration action equivalent glucose infusion measure mean residence time PK curves measures arithmetic mean first moment glucose infusion rate GIR function time curve like mean residence time calculated area first moment curve product time GIR function time divided area GIR curve total glucose infused\n",
      "PATIENTS AND METHODS Study Design This exploratory randomized open_label multicenter prospective 52_week study designed determine pharmacokinetics MPA MPAG efficacy safety tolerability MMF following IV oral administration MMF CellCept Roche Basel combination standard reduced levels tacrolimus Prograf Astellas Pharma US corticosteroids liver transplant patients The study adhered principles outlined Guidelines Good Clinical Practice conducted concordance Declaration Helsinki The treatment protocol approved institutional review board center patients gave informed consent enrollment Patient Population Eligible patients adults ³18 years receiving first orthotopic liver transplant All women childbearing age required negative pregnancy test within week study entry women childbearing potential required use contraception participating study Patients excluded receiving multiorgan transplantation expected live least days without need retransplantation received hemodialysis liver transplantation contraindication tacrolimus corticosteroids MMF MPA Tween inactive ingredient IV MMF Patients also excluded administered following therapies study investigational immunosuppressive agents part study regimen hepatic enzyme inducers rifampin barbiturates carbamazepine phenytoin norethindrone tobacco grapefruit juice drugs known likely interact pharmacokinetics MMF eg probenecid colestipol cholestyramine Drug Regimens Patients randomized ratio treatment arms treatments aimed producing trough levels tacrolimus either ng mL tacrolimus standard_dose group n  ng mL tacrolimus reduced_dose group n  All patients started IV MMF g constant_rate infusion hours repeated every hours 8Ð20 doses within hours following transplant surgery Patients transferred oral MMF g every hours It expected patients would receive oral MMF days post_transplant later day Patients remained MMF throughout study Tacrolimus started hours post_transplant Patients remain within target levels tacrolimus week either 10Ð15 ng mL standard_dose group 5Ð8 ng mL reduced_dose group target range could adjusted according practice center yet maintained ng mL week To attain target levels tacrolimus patients tacrolimus standard_dose group initially administered mg kg day orally divided doses patients tacrolimus reduced_dose group initially administered mg kg day orally divided doses All patients also received MMF g twice daily corticosteroids according standard clinical practice center Following steroid taper patients remain least mg kg day prednisone equivalent week visit Patients could also receive cytomegalovirus prophylaxis according study center protocol Study Assessments Procedures Pharmacokinetic Assessments The primary pharmacokinetic endpoint study area concentration_time curve hours AUC0Ð12 MPA MPAG Pharmacokinetic sampling performed baseline last IV MMF dose 4Ð10 days post_transplant first oral MMF dose 5Ð11 days post_transplant weeks Sampling AUC0Ð12 mandatory last IV MMF dose first oral MMF dose week At visits end weeks 12_hour pharmacokinetic blood sampling optional In selected centers discretion investigator AUC0Ð12 tacrolimus also assessed assaying tacrolimus pre_dose minutes post_dose hours post_dose pharmacokinetic sampling days MMF In order eligible pharmacokinetic sampling patients required hemoglobin ³ g dL hours prior sampling undergone dialysis since transplantation received stable dose MMF least days tacrolimus least days severe anemic condition judged investigator On last morning IV MMF dose blood samples collected pre_dose minutes post_dose hours post_dose During oral dosing phase patients took MMF dose approximately hours MMF predose sampling pharmacokinetic visit Patients required fast least hours prior taking dose day pharmacokinetic sampling Water allowed ad libitum Following oral MMF doses weekly schedules described previously blood samples collected pre_dose minutes post_dose hours post_dose Blood sampling collected peripheral central line dedicated drawing samples venipuncture arterial line port drug administration Blood samples mL venous blood measurement MPA MPAG collected lithium heparinized tubes Clinical Assessments The primary clinical endpoint proportion patients biopsy_proven acute rejection BPAR requiring treatment pulse immunosuppression therapy graft loss defined death retransplantation first weeks post_transplant Secondary variables proportion patients BPAR requiring treatment graft loss weeks patient graft survival weeks post_transplant renal function calculated creatinine clearance end weeks In addition treatment failure defined BPAR requiring treatment pulse immunosuppression therapy graft loss change tacrolimus trough concentration outside specified range either lack efficacy need maintain adequate immunosuppression dose MMF decreased account toxicity Biopsies performed discretion investigator rejection suspected histologic confirmation required prior treatment rejection Laboratory Assessments Tacrolimus trough levels taken administration tacrolimus dose also monitored daily first week dosing clinical visit days following dose adjustment times according clinical practice Renal function estimated calculated creatinine clearance Cockcroft_Gault equation end weeks For first weeks every effort made maintain patients dose g MMF twice daily Dose interruption adverse events followed stepwise dose reductions g MMF twice daily Dose reductions tacrolimus permitted provided levels remained within designated range treatment arm Drug Analysis MPA MPAG isolated plasma solid phase extraction levels measured reverse_phase high_performance liquid chromatography ultraviolet detection The lower limits quantification MPA MPAG _g mL respectively The precision assay MPA MPAG respectively The overall accuracy assay MPA MPAG data file Following extraction whole blood samples using liquid liquid extraction tacrolimus concentrations measured liquid chromatographyÐmass spectrometry mass spectrometry The lower limit quantification ng mL The overall precision assay accuracy assay ranged data file Pharmacokinetics Pharmacokinetic parameters derived noncompartmental methods WinNonLin Pharsight Corp Actual times used calculate AUCs For MPA MPAG following parameters calculated observed maximum plasma concentration Cmax time Cmax AUC0Ð12 area concentration_time curve hours last measurable concentration AUClast mean predose 12_hour plasma concentrations Cmin If mandatory visits 12_hour sample unavailable Cmin reported concentration beginning dosing interval predose trough concentration At optional week visits patients missing 12_hour samples Therefore AUClast calculated visits MMF systemic exposure Cmax Cmin AUC dose_normalized g MMF Pharmacokinetic parameters presented descriptive summary statistics treatment Statistics No formal statistical comparisons groups planned However although formal sample size calculation performed basis previous experience sample size evaluable patients group week deemed sufficient allow adequate characterization pharmacokinetics experimental group Therefore study aimed recruit patients order ensure least evaluable patients week would available It prospectively defined efficacy data would presented descriptively The primary efficacy analyses conducted intention_to_treat population comprised randomized patients received least dose study drug least follow_up data point The effect tacrolimus mean effect ratio reduced dose standard dose estimated analysis variance log_transformed dose_adjusted AUC performed separately treatment period Renal function also compared groups In addition AUC MPA rejectors nonrejectors compared retrospectively\n",
      "Materials Methods This open label randomized single center three period crossover drugÐdrug interaction study conducted May July Healthy adults randomized receive single doses GXR Intuniv Shire Development LLC Wayne PA USA mg MPH extended release Concerta McNeil Pediatrics Titusville NJ USA mg combination GXR mg MPH mg Institutional review board approval received conduct study informed consent provided subjects The study conducted accordance current applicable regulations International Conference Harmonisation ICH Good Clinical Practice GCP Guideline E6 local ethical legal requirements principles 18th World Medical Assembly amendments Subjects The study subjects healthy volunteers aged 18Ð45 years exhibited significant relevant abnormalities medical history physical examination vital signs laboratory evaluation reasonably likely interfere subjectÕs participation ability complete study Normal clinically insignificant electrocardiogram ECG findings also required inclusion study The study exclusion criteria included current recurrent disease cardiovascular renal liver gastrointestinal diseases malignancy conditions could affect clinical laboratory assessments action absorption disposition investigational agents Cardiac conditions including history hypertension known family history sudden cardiac death ventricular arrhythmia also exclusionary Other exclusion criteria included current use medication exception hormone replacement therapy hormonal contraceptives use tobacco form routine consumption units caffeine per day presence medical psychiatric disorder may required treatment made subject unlikely comply studyÕs requirements complete study Study Design The study subjects randomly assigned one six administration sequences consisting three treatment periods separated washout period least days duration The subjects allocated 4 digit randomization number starting immediately prior predose pharmacokinetic blood draw eligibility determined At least six subjects randomized six possible treatment sequences GXR MPH GXR  MPH GXR GXR  MPH MPH MPH GXR GXR  MPH MPH GXR  MPH GXR GXR  MPH GXR MPH GXR  MPH MPH GXR The study medication administered clinical research center supervised clinical staff The subjects required fast approximately h prior administration dose study medication All study medication given water morning A moderate fat lunch provided h dose administration The subjects confined center treatment period remained discharge procedures completed approximately h subjects received treatment Pharmacokinetic Safety Assessments Vital signs monitored blood samples collected ECG data obtained administration study medication treatment period Guanfacine dexmethylphenidate d MPH l methylphenidate l MPH levels measured plasma produced blood samples collected predose h postdose Immediately blood collection blood samples kept ice centrifuged within min following blood draw Plasma concentrations guanfacine d MPH l MPH measured using liquid chromatography tandem mass spectrometry LCÐMS MS detection methods validated quantitation guanfacine d MPH l MPH human K3 EDTA plasma The method utilized liquid liquid extraction procedure prior LCÐMS MS analysis The stable isotope labeled compounds guanfacine 13C15N3 MPH D9 used internal standards guanfacine d l MPH respectively For guanfacine LCÐMS MS analysis carried Sciex mass spectrometer coupled Shimadzu liquid chromatography LC pump model LC 10AT Perkin Elmer series autosampler The chromatographic separation achieved XBridge phenyl _m _ mm LC column mobile phase The mass spectrometer operated positive electrospray ionization mode resolution settings used unit Q1 low Q3 The multiple reaction monitoring MRM transition m z _ guanfacine MRM transition m z _ internal standard guanfacine 13C15N3 For d l MPH LCÐMS MS analysis carried Sciex mass spectrometer coupled Shimadzu LC pump model LC 10AT Perkin Elmer series autosampler The chromatographic separation achieved ChiralPak AD H _ mm _m LCÐMS column mobile phase The mass spectrometer operated positive mode resolution setting used unit Q1 Q3 The MRM transition m z _ MPH MRM transition m z _ internal standard MPH D9 The assay ranges ng mL guanfacine analysis based plasma sample volume _L ng mL d MPH l MPH analysis based plasma sample volume _L Safety evaluated collecting data reported AEs physical examination findings vital signs 12 lead ECGs At end treatment period biochemical hematologic assessments performed urinalysis conducted Staff contacted subjects days last dose last investigational agent collect data new onset AEs treatment related concerns Statistical Methods The primary analysis pharmacokinetic analysis performed using data pharmacokinetic population This population consisted subjects received least one dose study medication least one postdose safety assessment evaluable concentrationÐtime profiles guanfacine d MPH l MPH Pharmacokinetic parameters determined plasma concentrationÐtime data noncompartmental analysis included Cmax time Cmax tmax AUCt AUC apparent elimination half life t_ apparent oral dose clearance CL F apparent volume distribution terminal phase oral administration V_z F CL F V_z F corrected bodyweight Summary statistics including numbers observations means standard deviations SDs medians maximums minimums geometric means determined pharmacokinetic parameters treatment regimens The means log transformed pharmacokinetic parameters compared among treatments using analysis variance ANOVA sequence period treatment fixed effects subject nested within sequence random effect crossover study design To estimate magnitude treatment differences Cmax AUC geometric mean ratio GMR defined least squares mean difference log transformed parameters back transformed original scale  confidence intervals CIs also calculated The hypothesis drug interaction GXR MPH would rejected either following fall within interval 0 80Ð1 25  CIs GMR guanfacine following GXR alone guanfacine following GXR combination MPH ii  CIs GMR d MPH following MPH alone d MPH following MPH combination GXR If CIs entirely contained within interval 0 80Ð1 25 clinical significance mean ratio estimates CIs would interpreted within context therapeutic index The available within subject estimates SDs log transformed parameters AUC SD  Cmax SD  GXR pooled previous studies GXR Data ÔSummary Basis Approvable ApprovalÕ letter MPH indicated intrasubject coefficient variation MPH  based AUC approximates within subject SD log transformed AUC A previous study MPH reported within subject SD Cmax AUC To demonstrate equivalence allowing  difference true means true within subject SD based higher AUCs GXR MPH subjects six per sequence required achieve  power\n",
      "Methods Study design This open label two treatment single sequence drug interaction study This study coordinated Clinical Trial Center Samsung Medical Center Seoul Republic Korea Healthy male subjects ages years years body mass index BMI 19Ð27 kg m2 extremes included eligible enrollment On day subjects received single dose VPA mg Depakote Abbott Laboratories mL water After washout 5Ð9 days subjects received AMC mg Augmentin GlaxoSmithKline plc three times daily days On day subjects received single dose VPA confined center morning day The highest approved dosage drug used study maximize ability detect significant pharmacokinetic interaction This AMC dose considered sufficient affecting intestinal microbiota based previous study 6 The study approved Institutional Review Board Samsung Medical Center The study conducted accordance Good Clinical Practice Declaration Helsinki The study registered cris nih go kr cris KCT0001165 Written informed consent obtained participants prior screening evaluations Blood sampling Venous blood samples collected hour predose hours hours hours hours hours hours hours hours hours hours hours study drug administration two subjects samples obtained hour hours instead hours hours respectively Samples placed heparinized tubes centrifuged 2 000_ g minutes 4 C Plasma samples stored _70 C bioanalysis Drug analysis Assays plasma VPA concentrations performed validated fluorescence polarization immunoassay COBAS INTEGRA Roche Diagnostics Mannheim Germany duly licensed laboratories Assays conducted compliance applicable standard operating procedures place time analysis Clinical Chemistry Laboratory Samsung Medical Center The assay coefficient variation lower sensitivity mg L The lower limit quantification mg L calibration ranged mg L mg L Safety analysis Safety evaluations included observations clinically significant changes physical examinations clinical laboratory tests blood chemistry hematology urinalysis vital signs systolic diastolic blood pressure pulse rate Blood pressure values obtained seated position upper arm using semi automated cuff oscillometric sphygmomanometer Adverse events AEs monitored evaluated frequency severity relationship treatment recorded using MedDRA Version Maintenance Support Services Organization Chantilly VA USA Pharmacokinetic analysis The pharmacokinetic parameters VPA calculated noncompartmental analysis individual plasma concentrationÐtime data using Phoenix WinNonlin software Certara St Louis MO USA The maximum concentration Cmax time Cmax tmax obtained observed data The area plasma concentrationÐtime curve time last quantifiable concentration AUClast partial AUC hours hours AUC4Ð12 estimate EHC determined using linear log trapezoidal method The elimination half life t1 2 calculated t1 2 ln 2 kel kel elimination rate constant kel calculated linear regression log linear concentrationÐtime curve Statistical methods All statistical analyses conducted using SAS Enterprise Guide software SAS Institute Inc Cary NC USA The Cmax AUClast estimates log transformed analyzed generalized linear model Back transformed summary statistics includes geometric least squares means geometric mean ratio GMR between treatment comparisons confidence intervals CIs The analysis tmax based untransformed data using non parametric methods Wilcoxon signed rank test A sample size calculated sufficient power significance level assuming difference exposure VPA without AMC intrasubject coefficient variation VPA\n",
      "MATERIAI S AND METHODS Study Design This study employed parallel group design healthy male volunteers The subjects classified two groups I II subjects subjects assigned Group I subjects assigned Group II On study days subjects Group I received 1 mg alprazolam tablet every hours q8h TRT subjects Group II received X 5 mg buspirone tablets q8h TRT On days subjects received combination 1 mg alprazolam tablet X 5 mg buspirone tablets q8h TRT Serial blood samples pharmacokinetic evaluation collected dosing interval hours postdose study days Additional blood samples collected morning dose study days monitor attainment steady state groups subjects Subjects A total male volunteers completed study The mean age years mean body weight kg The subjects judged healthy based physical examination clinical laboratory evaluations The subjects confined clinical facility entire duration study hours administration last dose monitor withdrawal reactions abruptly stopping alprazolam dosing Drug Administration On day morning dose administered overnight fast AM Additional doses administered PM PM Each dose administered mL water The meal times kept constant study days The subjects received light breakfast hours lunch hours dinner hours receiving morning dose Collection Processing Plasma Samples Serial blood samples pharmacokinetic evaluation collected study days The samples collected O pre dose hours morning dose Additional blood samples collected mornCNS AGENTS ing dose study days monitor attainment steady state subject groups All venous blood samples mL collected Becton Dickinson Vacutainers containing K3 ethylenediaminetetra acetic acid anticoagulant Immediately collection sample gently inverted complete mixing anticoagulant centrifuged minutes 1000g 5 C separate plasma The separated plasma transferred screw capped tubes kept frozen 20 C analysis Analysis Plasma Samples The plasma samples group I subjects analyzed alprazolam a HO alprazolam GC electron capture detector method modified previously published method 9 Alprazolam a HO alprazolam triazolam internal standard extracted plasma using toluene isoamyl alcohol derivatized acetic anhydride The sample injected onto gas chromatograph equipped DB wide bore column The column temperature maintained 265 C The standard curves fitted linear regression equation range ng mL Quality control samples containing alprazolam a HO alprazolam analyzed analytical run evaluate accuracy precision sample stability storage The plasma samples group II subjects analyzed buspirone 1 PP using previously published GC MS method 10 The standard curves fitted linear regression equation concentration range ng mL buspirone ng mL 1 PP using software developed BristolMyers Squibb Co Syracuse New York 11 Quality control samples containing buspirone 1 PP analyzed analytical run evaluate accuracy precision sample stability storage The standard curves alprazolam buspirone metabolites showed high correlation coefficients betweenand within day variability quality control values generally less These data indicated assays precise accurate Pharmacokinetic Analyses The pharmacokinetic parameters buspirone PP alprazolam a HO alprazolam calculated plasma concentration time profile using noncompartmental methods 12 The highest observed plasma concentration sampling prefile corresponding sampling time de1105 BUCH ET AL fined Cmax Tmax respectively The area plasma concentration versus time curve AUC calculated using combination linear log trapezoidal rules Trough Cmin concentrations morning dose days session used assessing attainment steady state The plasma concentra tions determined sample collected hours morning dose study days defined Cmin ss used treatment comparison Statistical Analyses Statistical comparisons pharmac okinetic parameters made within group For Group I subjects statistical analyses day data performed pharmacokinetic parameters alprazolam a HO alprazolam Similarly Group Il subjects parameters buspirone 1 PP subjected statistical analyses Attainment steady state assessed evaluation CMIN data obtained AM days session For Group I subjects attainment steady state evaluated respect alprazolam a HO alprazolam For Group II subjects Cmin values 1 PP used subjects buspirone levels less lower limit quantitation Because 1 PP longer elimination half life buspirone steady state respect 1 PP would also indicate buspirone A randomized block analysis variance model used assess attainment steady state Paired t tests used compare Cmax Cmin ss AUCo a obtained days within group subjects The paired Wilcoxon signed rank test14 used compare Tmax day day group subjects\n",
      "Methods Inclusion exclusion criteria Eligible subjects n  included healthy adults aged 18Ð55 years PT International Normalized Ratio INR partial thromboplastin time plasma protein C S activity functional within normal range Subjects excluded receiving warfarin treatment active thromboembolic events history coagulation abnormalities presence occult blood stool history evidence clinically significant urological disease narrow angle glaucoma condition affecting drug absorption Additional key exclusion criteria positive urine drug test alcohol consumption i e consumption exceeding drinks week females drinks week males within months screening drink defined oz ml wine oz ml beer oz ml hard liquour tobacco use i e use tobaccoor nicotine containing products excess equivalent cigarettes day_1 consumption grapefruit grapefruit related cranberry cranberry related juice within days receiving study drug Study design This open label randomized crossover study consisted two treatment periods During one period subjects received single dose warfarin mg alone day treatment A period subjects received fesoterodine mg daily days 1Ð9 single supratherapeutic dose warfarin mg co administered day treatment B Subjects randomized one two treatment sequences treatment A followed treatment B treatment B followed treatment A There least 10 day washout warfarin doses two treatment periods This study conducted compliance Declaration Helsinki compliance International Conference Harmonization Good Clinical Practice Guidelines The final protocol approved appropriate Institutional Review Board All subjects provided written informed consent prior entering study The drug molecular target nomenclature included conforms British Journal Pharmacology s Guide Receptors Channels Pharmacokinetic evaluations Blood samples determination R warfarin S warfarin concentrations plasma collected warfarin dose h post dose Plasma samples analysed WuXi AppTec Shanghai China using validated sensitive specific high performance liquid chromatography tandem mass spectrometry method compliance sponsor s standard operating procedures Plasma samples stored approximately _20 C analysis assayed within days established stability data generated validation Calibration standard responses linear ng ml_1 active enantiomers Clinical specimens lower limit quantification ng ml_1 recorded ng ml_1 analysis The between day assay accuracy expressed per cent relative error quality control QC concentrations ranged R warfarin _1 3 S warfarin low medium low medium high high diluted QC concentrations Assay precision expressed between day coefficient variation CV  mean estimated concentration QC samples R warfarin S warfarin low ng ml_1 medium low ng ml_1 medium high ng ml_1 high ng ml_1 dilution ng ml_1 QC concentrations Pharmacokinetic parameters Sand R warfarin calculated plasma concentrationÐtime data using standard non compartmental methods Primary PK endpoints Sand R warfarin area plasma concentrationÐtime curve time zero infinity AUC 0 maximum plasma concentration Cmax Secondary endpoints Sand R warfarin area plasma concentrationÐtime profile time time last quantifiable concentration AUC 0 last time Cmax tmax half life t1 2 Pharmacodynamic evaluations Warfarin PD anticoagulation activity monitored assessment INR corresponds PT ratio corrected individual thromboplastin reagent using International Sensitivity Index ISI Although INR replaced PT clinical practice monitoring patients receiving warfarin PT also used PD analysis study PT less variable INR Blood samples R warfarin S warfarin PD analyses collected warfarin dose h post dose Primary PD endpoints area INR vs time curve AUCINR maximal INR INRmax Secondary endpoints area PT vs time curve AUCPT maximal PT PTmax Safety evaluations Safety assessed adverse event AE monitoring laboratory evaluations physical examinations 12 lead ECG testing vital sign evaluations Statistics Study populations Twelve completed subjects would provide ³90 power show equivalence warfarin PK PD without fesoterodine assuming within subject CV true ratio The PK concentration population included subjects randomized treated ³one concentration measurement ³one treatment period The PK parameter analysis population defined subjects randomized treated ³one primary PK endpoint measured ³one treatment period The safety population consisted subjects received ³one dose study drug PK PD analyses Natural log transformed PK analyses AUC 0 Cmax PD analyses AUCINR INRmax analysed using mixed effect model sequence period treatment fixed effects subject within sequence random effect Estimates adjusted mean differences warfarin co administered fesoterodine test treatment warfarin alone reference treatment corresponding confidence intervals CIs obtained Adjusted mean differences CIs differences exponentiated provide estimates ratio test  reference adjusted geometric means CIs ratios Lack treatment interaction concluded CIs ratio adjusted geometric means AUC 0 Cmax AUCINR INRmax fell within bioequivalence acceptance range AUC 0 Cmax AUC 0 last tmax t1 2 AUCINR INRmax AUCPT PTmax summarized descriptively treatment Safety analyses Adverse events occurring within days treatment discontinuation including temporary cessations recorded treatment emergent Events occurring non treatment periods washout follow up also counted treatment emergent attributed previous treatment\n",
      "Methods Study design This phase randomized open_label three_period crossover study healthy adults received following three treatments single oral dose mirogabalin 15_mg tablet day treatment A mirogabalin mg day plus probenecid 500_mg tablet every h days treatment B mirogabalin mg day plus cimetidine 400_mg tablet every h days treatment C separated ³5_day washout period Figure Subjects fasted overnight least h prior mirogabalin administration least h dosing Mirogabalin administered approximately ml water Subjects received one six possible treatment sequences i e ABC ACB BAC BCA CAB CBA The study approved Institutional Review Board performed accordance Declaration Helsinki International Conference Harmonization guidelines All subjects provided written informed consent participation Study population Healthy participants eligible enroll aged years body mass index BMI kg mÐ2 Healthy participants determined medical history physical examinations vital signs 12_lead electrocardiograms ECGs clinical laboratory tests screening Women either nonchildbearing potential childbearing potential using nonhormonal methods contraception least months prior study Men agreed use barrier contraception spermicide donate sperm All subjects agreed abstain caffeinated drinks foods alcohol grapefruit apple orange juice vegetables mustard green family charbroiled meats days prior first dose end study Exclusion criteria included history surgical treatment may impair oral absorption drugs creatinine clearance ml minÐ1 use tobacco_ nicotine_containing products within preceding months Sample collection bioanalytic methods Blood samples collected assess PK mirogabalin inactive lactam metabolite days treatment period predose h h postdose Urine samples collected assessment mirogabalin lactam metabolite days treatment period predose h h h h h h postdose Blood samples collected assess PK cimetidine probenecid day prior morning dose prior doses h day prior morning dose h morning dose prior doses h days prior morning dose prior doses h day h last dose Plasma concentrations free_base mirogabalin analyzed Celerion Lincoln NE USA using validated liquid chromatographyÐtandem mass spectrometry LCÐMS MS method Plasma samples containing analyte internal standard d5_mirogabalin A206Ð04632 Daiichi Sankyo Pharma Development Basking Ridge NJ USA extracted using Oasis HLB solid_phase extraction plate Waters Inc Milford MA USA Extracted samples analyzed Zorbax 300_SCX column mm length mm internal diameter _m particle size Agilent Technologies Santa Clara CA USA ambient temperature mobile phase v v acetonitrile mmol lÐ1 ammonium formate pH formic acid flow rate ml minÐ1 Mirogabalin internal standard detected using AB Sciex API 4000ª triple quadrupole mass spectrometer Sciex Framingham MA USA The calibration curves mirogabalin 1 concentration squared_weighted linear regression ranged ng mlÐ1 The intra_ interassay precision coefficient variation CV values validation within respectively intra_ interassay accuracy values Ð16 3 Ð7 1 respectively Dilution integrity verified concentration 20_000 ng mlÐ1 The plasma concentrations probenecid analyzed using validated LCÐMS MS method Worldwide Clinical Trials Austin TX USA Plasma samples _l mixed internal standard probenecid_d14 SynFine Research Richmond Hill ON Canada Samples extracted via methanol_mediated protein precipitation The _l sample removed diluted ml acetonitrile water Up _l extracted sample injected onto Onyx C_18 _ mm Phenomenex Inc Torrance CA USA connected API triple quadrupole mass spectrometer Sciex Analyte eluted using gradient mobile phase comprised water formic acid ammonium acetate 2_propanol acetonitrile formic acid ammonium acetate The flow rate ml minÐ1 total run time min Quantitation performed using weighted linear least squares LS regression analyses generated calibration standards prepared fresh daily The method validated range _g mlÐ1 probenecid The intra_ interassay precision accuracy CV values within respectively lower limit quantification LLOQ intra_ interassay accuracy values within respectively concentrations The plasma concentrations cimetidine also analyzed using validated LCÐMS MS method Worldwide Clinical Trials Austin TX USA Plasma samples _l mixed internal standard cimetidine_d3 SynFine Research Richmond Hill ON Canada Samples extracted via acetonitrile_mediated protein precipitation Up _l extracted sample injected onto Kinetex PFP _m _ mm Phenomenex Inc connected API triple quadrupole mass spectrometer Sciex The analyte eluted using gradient mobile phase comprised mmol lÐ1 ammonium formate water acetonitrile water The flow rate ml minÐ1 total run time min Quantitation performed using weighted linear LS regression analyses generated calibration standards prepared fresh daily The method validated range 10_000 ng mlÐ1 cimetidine The intra_ interassay precision accuracy CV values within respectively LLOQ intra_ interassay accuracy values within respectively concentrations The plasma concentrations lactam metabolite mirogabalin analysed Celerion using validated LCÐMS MS method Plasma samples containing analyte internal standard d5_labeled analyte A212Ð6230 Daiichi Sankyo Pharma Development mixed equal_volume ammonium acetate mmol lÐ1 extracted n_butyl chloride 96_well plate Extracted samples analyzed ACE C18 column mm length mm internal diameter _m particle size Advanced Chromatography Technologies Aberdeen UK ambient temperature mobile phase v v acetonitrile water formic acid flow rate ml minÐ1 The lactam metabolite mirogabalin internal standard detected using AB Sciex API 4000ª triple quadrupole mass spectrometer The calibration curve analyte 1 concentration2 weighted linear regression ranged ng mlÐ1 The intra_ interassay precision CV values validation respectively intra_ interassay accuracy values Ð9 2 Ð4 7 respectively Dilution integrity verified concentration ng mlÐ1 Pharmacokinetic assessments Pharmacokinetic parameters computed using Phoenixª WinNonlin version Certara Princeton NJ USA PK assessments included maximum observed plasma concentration Cmax time maximum observed plasma concentration tmax area plasma concentration_time curve time last quantifiable dose AUC 0_t terminal elimination half_life t_ apparent total body clearance CL F fraction administered dose excreted urine fe percentage dose excreted urine Ae  dose renal clearance CLR Safety assessments Safety assessments included treatment_emergent adverse events TEAEs physical examination findings vital signs 12_lead ECGs clinical laboratory tests TEAEs coded using Medical Dictionary Regulatory Activities MedDRA coding dictionary version McLean VA USA Statistical analysis planned sample size Differences treatments mirogabalin administered alone probenecid cimetidine calculated ratios geometric LS mean confidence intervals CIs For PK parameters Cmax AUC 0_t AUC analysis variance model treatment sequence period subject nested within sequence fixed effects model performed natural log transformed data Assuming equal randomization ratio type I error rate no_effect equivalence limits expected ratio geometric LS mean intrasubject CV total subjects i e four subjects per treatment sequence provided power conclude absence interaction Therefore total subjects planned enrolled study i e five subjects per treatment sequence Nomenclature targets ligands Key protein targets ligands article hyperlinked corresponding entries http www guidetopharmacology org common portal data IUPHAR BPS Guide PHARMACOLOGY permanently archived Concise Guide PHARMACOLOGY\n",
      "Methods Patients blood sampling This prospective study conducted adult patients epilepsy stable LTG treatment least months Department Neurology University Medical Centre Ljubljana Slovenia regular ambulatory visits Patients genders older years confirmed epilepsy oral LTG treatment either mono_ combination therapy eligible study Chronic renal hepatic diseases pregnancy exclusion criteria study All enrolled patients previously informed purpose study provided written informed consent The study approved National Medical Ethics Committee Republic Slovenia 25p 04 12 carried according Declaration Helsinki Demographic data age weight height gender smoking status adverse event data duration current AED therapy concomitant drug therapy co_morbidities LTG dosing regimen collected time enrolment study Biochemical parameters including serum creatinine Crs aspartate aminotransferase AST alanine transaminase ALT obtained patient s charts Patient compliance LTG treatment assessed attending neurologist subjects suspected non_compliance excluded study Patients asked record time last dose ambulatory visit Two blood samples drawn approximating trough immediately dosing peak 2Ð4 h steady_state concentrations Exact blood sampling times recorded laboratory personnel The collected blood samples immediately centrifuged g min transported central storage facility stored _80 C analysis Drug assay For plasma concentration measurements LTG LTG_glu h p l c method u v detection Saracino et al adapted The assay calibrated concentration range 0 25Ð20 mg l_1 r  LTG 0 25Ð15 mg l_1 r  LTG_glu The accuracy method expressed bias better precision RSD The lower limit quantification mg l_1 analytes Genotyping Isolation genomic DNA peripheral blood leukocytes performed using Qiagen FlexiGene kit Qiagen Hilden Germany The genotyping UGT1A4 70C  A rs 6_755_571 UGT2B7Ð161C  T rs7668258 A  G rs28365063 performed real_time PCR genotyping using Taqman Allelic Discrimination Assays Applied Biosystems Foster City CA USA assay ABI instrument Applied Biosystems Foster City California USA Genotyping SLC22A1 1222G  A rs628031 ABCB1 3435C  T rs1045642 1236C  T rs1128503 polymorphisms carried using fluorescence_based competitive allele_specific KASPar assay KBiosciences Herts UK ABCB1 2677G  T A rs2032582 polymorphism determined using PCR amplification followed analysis PCR fragments agarose gel previously described The genotype distributions evaluated HardyÐWeinberg equilibrium HWE _2 test applying Yates correction Meta_analysis previous population pharmacokinetic studies LTG Since pharmacokinetic data study provide information structural variability parameters used prior information population pharmacokinetic studies LTG stabilize model For calculation priors performed literature search MEDLINE database studies published December The search strategy lamotrigine tw AND pharmacokinetics tw AND nonmem tw OR population tw Searching limited studies adults published English language From identified studies extracted information typical values geometric means pharmacokinetic parameters population patients interindividual variability IIV relative standard errors RSE estimates Before analysis data IIV parameters transformed log_domain i e _2 calculated reported coefficient variation CV values Meta_analysis parameters performed using random effects model approach taking consideration heterogeneity studies Normal inverse Wishart distribution fixed effects interindividual variability used Degrees freedom DF inverse Wishart distribution _2 calculated using equation DF 2_ _2SE_2 2 1 Model development Population pharmacokinetic analysis performed non_linear mixed effects modelling approach using nonmem software ver Icon Development Solutions Ellicott City MD USA Model building steps graphical presentations managed using Perl_speaks_nonmem PsN ver http psn sourceforge net Xpose ver http xpose sourceforge net Pharmacokinetic analysis performed two steps Initially measurements LTG concentration parent drug taken analysis The structural model used one compartment model first order absorption elimination ADVAN2 TRANS2 PREDPP subroutine Since absolute bioavailability cannot estimated based oral data estimated parameters absorption rate constant K apparent volume distribution V apparent clearance oral dosing CL A log_normal distribution individual parameter values assumed exponential model used estimate IIV Additive proportional combination additive  proportional error models evaluated describe residual intra_individual variability LTG concentration Prior information meta_analyses incorporated model using nonmem prior functionality The first order conditional method interaction FOCE_I used parameter estimation Stepwise covariate modelling procedure used build final model Categorical covariates including patient s gender smoking status co_therapy inducers carbamazepine oxcarbazepine phenytoin phenobarbital oral contraceptives inhibitors valproic acid VPA sertraline LTG metabolism genetic polymorphisms UGTs SLC22A1 ABCB1 tested Association genetic polymorphisms tested using co_dominant model This model compares heterozygous homozygous variant genotypes homozygous wild_type Additionally dominant recessive models evaluated Moreover effect ABCB1 haplotype tested Continuous covariates considered inclusion patient s weight ideal body weight IBW calculated using Devine equation age Crs CockroftÐGault estimate creatinine clearance CLcr liver enzymes AST ALT LTG daily dose Continuous covariates centred population mean covariate values incorporated using linear power models Missing covariate data substituted mean covariate value continuous frequent value categorical covariates In forward addition step criteria covariate inclusion model set P  A difference objective function value OFV approximately _2 distributed degrees freedom equal difference number parameters two hierarchical models The final model determined backward elimination covariates full model using stringent criterion P  compensate multiple comparisons An additional criterion retention covariate reduction unexplained IIV The model adequacy checked standard diagnostic plots predicted vs observed concentration weighted residuals vs observed concentration time The final pharmacokinetic model evaluated precision bootstrap procedure The bootstrap re_sampling method replacement using replications applied calculate parameter standard errors non_parametric confidence intervals CI Internal predictive ability evaluated visual predictive check VPC applying prediction variability correction Multiple imputation analysis described Johansson et al used evaluate influence missing covariate data smoking status To get insight disposition LTG data LTG_glu concentration measurements included analysis second step An additional compartment introduced LTG_glu plasma concentration We assumed LTG completely converted LTG_glu This assumption seems reasonable mass balance studies LTG indicate renal elimination unchanged LTG insignificant accounts less conversion LTG_N_5_glucuronide minor route LTG metabolism The model coded differential equations employing nonmem s ADVAN subroutine Pharmacokinetic parameters estimated apparent LTG_glu volume distribution V LTG_glu LTG_glu elimination clearance CLLTG_glu addition parameters related disposition LTG Covariate effects pharmacokinetic parameters CL V CLLTG_glu V LTG_glu tested described Sensitivity analysis Sensitivity model parameters specification priors evaluated re_estimation final model variation prior mean variance _50 Additionally evaluated sensitivity parameters informativeness prior using less informative prior For purpose altered precision prior changing standard errors _50\n",
      "Methods We study accordance ICH Guideline Good Clinical Practice The Brent Medical Ethics Committee designated North London REC approved study subjects gave fully informed written consent Subject population We studied healthy volunteers men women aged 18Ð39 years mean SD  years body mass index 18Ð28 kg mÐ2 mean SD  kg mÐ2 weight 53 8Ð98 8 kg mean SD  kg Twenty three Europid one Afro Caribbean All non smokers taking medicines We deemed healthy basis medical history examination 12 lead ECG h ambulatory ECG safety tests blood including electrolytes urine We excluded subject corrected QT QTc using Bazett s correction heart rate interval ³450 ms women ³430 ms men 12 lead ECG resting heart rate outside range 50Ð100 beats min_1 ³50 premature ventricular contractions significant arrhythmia h ECG Study design The study randomized placebo controlled double blind double dummy crossover using Williams balanced design Each subject received four treatments placebo domperidone mg four doses daily h intervals ketoconazole mg every h combination domperidone ketoconazole The active drugs matching placebo supplied tablets Janssen Cilag Each treatment period days day washout periods Subjects resident h dosing h last dose period While resident subjects received standard meals scheduled times allowed alcohol grapefruit juice quinine caffeine containing beverages Subjects returned follow up assessment days final dose Assay domperidone ketoconazole In period took blood samples assay domperidone ketoconazole morning dose days h morning dose day We separated plasma within h sampling stored _18 C assay domperidone Janssen Research Foundation Beerse Belgium using validated HPLC method PPD Development Richmond Virginia USA assayed ketoconazole using validated LC MS MS method Limits reliable quantitation ng mlÐ1 µg mlÐ1 respectively Intraand inter assay coefficients variation ²7 Pharmacokinetic analysis We used standard non compartmental methods actual elapsed sampling times calculate pharmacokinetic parameters domperidone ketoconazole We determined maximum minimum observed concentrations steady state Cmax ss Cmin ss time maximum concentration tmax directly observed data day We used linear trapezoidal method calculate area plasma concentrationÐtime curve 0Ð24 h steady state day AUC 0 24 hss We defined average steady state plasma concentration Cavg ss h AUC 0 24 hss 24 We calculated elimination half life steady state t1 2 z ss terminal portion log plasma concentrationÐtime curve day Pharmacodynamics We recorded 12 lead ECGs GE Marquette MAC day _1 follow up following times relative scheduled time day morning dose h We also recorded 12 lead ECGs morning dose days h morning dose day From 12 lead ECGs Quintiles Cardiac Alert UK calculated average RR QT interval measurements 3Ð5 consecutive beats nearly always lead II using calibrated electronic calipers resolution ms The analyst measured ECG intervals individual subject We corrected QT interval heart rate using Bazett s QTcB  QT RR 1000 0 5 Fridericia s QTcF  QT RR 1000 0 33 Sagie s QTLc  QT  1000ÐRR _ formulae Safety tolerability assessments We continuous cardiac monitoring via telemetry h dosing day h last dose day vital signs screening day _1 h dose days 1Ð7 follow up laboratory safety tests screening days _1 follow up medical examination screening days _1 follow up We recorded three lead h ambulatory ECGs days _1 follow up using ACS model Holter recorders Laguna Hills USA We monitored adverse events throughout study Statistical analysis All analyses done intention treat basis data included subjects completed least one treatment period even subjects complete entire study To test bioequivalence analysis variance anova log transformed Cmax ss Cmin ss AUC 0 24 hss Cavg ss t1 2 ss Initial models contained fixed effects period treatment carryover random effects subject If carryover effects significant level dropped model For pharmacokinetic parameter calculated mean treatment ratio combined therapy single therapy associated confidence interval using mean square error anova To examine relationship pharmacokinetics pharmacodynamics steady state linear regression difference placebo day QTcB QTcF QTLc _QTcB _QTcF _QTLc plasma concentrations domperidone ketoconazole To test differences treatments heart rate QTcB QTcF QTLc baseline day _1 steady state used linear mixed effects regression model repeated measurements Initial models fixed effects treatment group treatment sequence period gender timing post dose treatment timing interaction treatment gender interaction Day _1 ECG results included covariate analysis steady state Subject subject time included random effects We compared covariance structures using likelihood ratio tests determine whether complex structures led significant improvement model fit If treatment gender interaction significant stratified analyses gender All P values two sided\n",
      "METHODS Study population The study protocol approved ethics committee Medical Faculty Carl Gustav Carus Dresden Germany Before study participants informed physician aim course possible risks study written informed consent obtained Before completion study detailed physical examination laboratory tests carried The volunteers drug free least weeks study abstain alcoholor caffeine containing drinks starting hours dosing meals contained codeine morphine i e poppy seeds days drug administration Ten healthy male volunteers participated study They normal orocecal transit time hours investigated sulfasalazine prestudy Group I consisted five extensive metabolizers sparteine group II consisted five poor metabolizers sparteine CYP2D6 phenotype assessed single oral dose mg sparteine sulfate 17 subjects classified according urinary metabolic ratio sparteine 2and 5 dehydrometabolites In addition genotyping carried use polymerase chain reaction deoxyribonucleic acid peripheral leukocytes volunteers Polymerase chain reaction procedures performed detect I II alleles CYP2D6 gene Ôs 2Õ The characteristics volunteers shown Table I The genotypes listed Table I according new nomenclature human CY Ô2D6 alleles Study design The trial carried randomized double blind placebo controlled two way crossover study Codeine phosphate mg placebo identically encapsulated gelatin capsule Pharmacy Department University Dresden On two occasions least days apart volunteers received overnight fast either oral placebo oral codeine ml mineral water minutes later gm sulfasalazine powder nonsustained release tablet Azulfidine ml mineral water The volunteers remained sitting position minutes codeine administration Standardized breakfast lunch provided hours sulfasalazine administration respectively Blood samples obtained codeine placebo administration l 3 2 11 z 3 h 61 z 81 z hours Urine collected parallel hours Urine serum samples stored 20Ó C analysis Analytical methods determination sulfpyridine codeine morphine Sulfapyridine concentrations serum assayed HPLC use Shimadzu 1OA system reversed phase Nucleosil C column mm X mm guard column mm pm particle size MachereyNagel The mobile phase consisted acetonitrile phosphate buffer mol L pH The retention time minutes flow rate ml min column temperature 45Ó C The ultraviolet detector set wavelength nm The detector signal measured Kontron 450 MT2 Data System No internal standard used For precipitation proteins l acetonitrile added l l serum sample After mixing centrifugation clear supernatant transferred another tube evaporated dryness Vacuum centrifuge RC Jouan The residue solved methanol phosphate buffer l rJ injected autosampler loop Standard samples pg rnl sulfapyridine calibration curve prepared drug free serum The curves linear range coefficient correlation At pg ml limit quantification coefficient variation coefficient variation i ml Codeine morphine determined gas chromatography tandem mass spectrometry use TSQ mass spectrometer Finnigan MAT Bremen Germany coupled II gas chromatograph Hewlett Packard Waldbronn Germany described dihydrocodeine dihydromorphine 23 To ml serum ng morphine d ng codeine d added internal standards The samples extracted pH ml dichloromethane 2 propanol 9 l vol vol organic phase evaporated residue derivatized pentafluoropropionic acid minutes 60Ó C The derivatizing reagent evaporated residue dissolved acetonitrile Aliquots used gas chromatography tandem mass spectrometry analysis Gas chromatography performed DB 5 capillary column mm internal diameter km film thickness J W Scientific Fisons Maim Germany splitless mode carrier gas helium inlet pressure kPa Injections carried automatically 280Ó C A2OOS autosampler CTC Analytics Zwingen Switzerland The initial oven temperature 150Ó C held minute increased 35Ó C min 250Ó C This temperature held minutes increased 30Ó C min 300Ó C Mass spectrometry performed negative ion chemical ionization mode Mass spectrometric conditions follows source temperature 150Ó C methane chemical ionization gas pressure Pa electron energy eV emission current p A argon collision cell pressure mPa collision energy eV The M 20 ions used parent ions morphine mlz morphine d m z codeine m z codeine d mlz The daughter ions used m z morphine morphine d m z codeine codeined The limit quantification pmol ml codeine pmol ml morphine coefficient variation respectively Codeine morphine urine l l determined 1 lO dilution water described The total amounts codeine unconjugated conjugated morphine unconjugated conjugated measured 1 lO dilution l l urine water acid hydrolysis JJ hydrochloric acid 98Ó C minutes method Pharmucokinetic evaluation The pharmacokinetics codeine morphine determined use Mikus et al CLINICAL PHARMA COLOGY THERAPEUTICS APRIL Table II Orocecal transit times administration placebo mg codeine phosphate healthy volunteers Ejdensive b Mean  SD 6 9k2 3 Type II error Poor met oh Mean SD QpeIIerror 70 2zQ3 3 43 8Õ21 8 62 6k30 3 45 7t24 1 OCTT Orocecal transit time see Methods section AU area sulfapyridine time curve hours p  placebo versus codeine paired I test standard procedures Terminal elimination halflife noncompartmental analysis performed TOPFIT program 24 Partial metabolic clearance codeine morphine calculated following G let  Ae AUC Ae total amount conjugated unconjugated morphine excreted urine hours AUCc area serum codeine time curve Renal clearance CL codeine morphine derived equations Aec unconjugated amount unconjugated codeine excreted urine hours A uOcOnjugated amount unconjugated morphine excreted urine hours AUC area plasma morphine time curve The orocecal transit time defined time sulfapyridine concentration l ml Because intersubject intrasubject variability orocecal transit time quite substantiaJ4 area sulfapyridine time curve hours AUC calculated additional measure transit time Statistical analysis All data presented mean k SD Pharmacokinetic parameters extensive poor metabolizers compared nonparametric Mann Whitney U test use program INSTAT GraphPad Software San Diego Calif Differences orocecal transit time placebo codeine treatment assessed paired test extensive metabolizers poor metabolizers separately power calculations performed p Values always considered statistically significant\n",
      "Sacubitril valsartan also known LCZ696 first_in_class angiotensin receptor neprilysin inhibitor ARNI approved many countries worldwide including USA European Union treatment patients heart failure reduced ejection fraction HFrEF Sacubitril valsartan indicated reduce risk cardiovascular death hospitalization heart failure patients heart failure NYHA Class IIÐIV reduced ejection fraction 1 Following oral administration sacubitril valsartan provides exposure sacubitril prodrug metabolized active neprilysin inhibitor sacubitrilat LBQ657 valsartan angiotensin receptor blocker ARB 2 Neprilysin inhibition sacubitrilat increases natriuretic peptide NP levels thereby promoting natriuresis diuresis vasodilation inhibition maladaptive fibrotic remodeling via second_messenger cyclic guanosine monophosphate cGMP 3 Along neprilysin inhibition simultaneous blockade renin_angiotensin_aldosterone system RAAS valsartan inhibits deleterious cardiovascular renal effects sustained activation angiotensin II effectors 5 Sildenafil potent selective inhibitor cGMP_degrading enzyme phosphodiesterase type PDE5 increases concentration cGMP 7 Sildenafil augments nitric oxide NO _induced cGMP_dependent vasodilation corpus cavernosum indicated treatment erectile dysfunction ED 8 Given high prevalence ED _62 patients heart failure possibility coadministration sildenafil sacubitril valsartan 9 Sacubitril valsartan analytes interact drugs metabolized liver cytochrome P450 CYP enzymes constitute major metabolic pathway sildenafil 10 Although sacubitrilat weak inhibitor CYP2C9 IC50 _M impact pharmacokinetics CYP2C9 substrate warfarin observed sacubitril valsartan warfarin coadministered 13 Thus CYP_mediated pharmacokinetic drugÐdrug interaction sacubitril valsartan sildenafil expected However sacubitril valsartan sildenafil increase levels second_messenger cGMP lowers blood pressure BP effects basal vascular tone indicating potential pharmacodynamic interaction sacubitril valsartan sildenafil respect magnitude BP reduction Supplemental Figure S1 4 Therefore present study conducted investigate potential pharmacokinetic pharmacodynamic drugÐdrug interactions sacubitril valsartan sildenafil The study conducted patients mild_to_moderate hypertension account potentially greater BP reduction following coadministration sacubitril valsartan sildenafil compared administration sacubitril valsartan sildenafil alone\n",
      "Methods Enrollment The study approved investigational review board IRB University Maryland Baltimore UMB registered ClinicalTrials gov NCT01631383 All subjects gave written informed consent acutely intoxicated prior starting study procedures Participants healthy cocaine using adults recruited community media advertising screened initially telephone person comprehensive psychological medical evaluation Inclusion criteria included men non pregnant non breastfeeding women age 18Ð50 years old current CUD self reported cocaine use averaging least weekly past months positive urine test cocaine last month HIV seronegative EKG without clinically significant abnormality normal blood pressure 90Ð140 50Ð90 mmHg normal resting heart rate 60Ð90 bpm ability adhere study restrictions examination schedule contraception use weeks study women reproductive potential Exclusion criteria included participation drug trial within days prior study entry history clinically significant adverse reaction hypersensitivity L THP cocaine inability communicate cooperate investigators currently taking prescribed psychoactive medication current clinically significant medical problem might interfere safe study participation current major depressive disorder current schizophrenia current bipolar disorder score Evaluation Sign Consent ESC questionnaire 26 Study Design This study followed randomized double blind placebo controlled design Subjects participated residing days 4 nights secure medically monitored Brief Stay Unit BSU designed phase I studies Subjects randomized receive either L THP mg capsules Q12 h matching placebo doses study Days 1Ð4 starting morning day admission study Day Ninety minutes following final dose morning Day subjects received single mg intranasal dose cocaine The L THP dosing duration chosen participants reach steady state L THP plasma concentration approximately hours prior cocaine challenge based L THP half life hours 24 Subjects resided BSU morning Day evening Day returned final blood collection safety evaluation Day Table Study medications Bulk L THP purchased Wuxi Gorunjie Technology Co Ltd No Wuqiao West Road Wuxi Jiangsu CN L THP matching placebo capsules prepared UMSOP compliance Chemistry Manufacturing Controls CMC standards Cocaine hydrochloride USP obtained National Institute Drug Abuse NIDA Drug Supply Program Covidien meeting guidelines CMC standards For cocaine challenge Day mg cocaine powder weighed placed mirror front seated subject The subject divided powder approximately equal lines using spatula inhaled line different nostril using 65mm plastic straw Subjects min ingest line took  minute waited 4Ð6 minutes lines allow checking vital signs 12 lead ECG 3 minute rhythm strip Randomization Blinding The study biostatistician used permuted block method randomization generate multiple sequences blocks size four two participants assigned l THP placebo When new participant met study eligibility criteria gave informed consent study coordinator requested randomization study biostatistician responded sending code number unblinded study pharmacist identifying next randomization sequence The pharmacist prepared appropriate dose L THP placebo provided study coordinator package labeled ÒL THP Placebo mg capsules Q12 h Ó Only study biostatistician pharmacist aware actual contents package participant study personnel remained blinded L THP cocaine assays Blood samples mL obtained via indwelling peripheral venous catheter L THP dose hours cocaine administration Day every minutes hours every minutes hours every hour hours hours cocaine administration Table shows blood sampling details Samples collected Vacutainer tubes BD Diagnostics Franklin Lakes NJ containing EDTA NaF centrifuged rpm _ minutes separated plasma transferred immediately plastic Eppendorfª tubes Fisher scientific Hampton NH storage _80 C later assay within five days Plasma concentrations cocaine L THP measured University Maryland School Pharmacy UMSOP Pharmacokinetics Biopharmaceutics Laboratory PBL using previously validated ultra performance liquid chromatography fluorescence detection UPLC FL analysis method developed group 27 Assay limit quantification LOQ ng mL L THP cocaine Non compartmental Analysis L THP cocaine PK parameters initially determined using model independent approach non compartmental analysis NCA estimation AUCs linear trapezoidal method using Phoenix WinNonlin Pharsight Corporation Cary NC validated using Phoenix Validation Suite Pharsight Corporation Cary NC PK analysis performed using actual times individual blood samples obtained actual measured analyte concentrations PK parameters geometric means estimated included maximum observed plasma concentration Cmax time Cmax Tmax terminal half life t1 2 area plasma concentration time curve time time last quantifiable sample estimated AUC0Ðlast area plasma concentration time curve time infinity AUC0Ð clearance following oral intranasal administration CL F F defined bioavailability Statistical comparisons cocaine PK parameters without exposure L THP conducted two sample t tests assuming unequal variance GraphPad Prism version GraphPad Software Inc La Jolla CA Statistical significance set two tailed alpha  Safety Tolerability Assessments We measured variety safety outcomes determine short term tolerability L THP using following scales Barnes Akathisia Scale BAS assess objective subjective components akathisia 28 Simpson Angus Scale SAS assess extrapyramidal symptoms 29 Epworth Sleepiness Scale ESS 30 assess sedation Symptom ChecklistÐ90 item Revised SCL 90R 31 assess psychological symptoms analyzed terms Global Severity Index GSI subscales Depression Anxiety Paranoid Ideation Psychoticism Side Effect Checklist SEC 25 item self report scale assessing side effects associated L THP non specific side effects Each item rated 4 point Likert scale ÒnoneÓ 1 ÒmildÓ 2 ÒmoderateÓ 3 ÒsevereÓ 4 Vital signs systolic SBP diastolic DBP blood pressure heart rate HR respiratory rate 12 lead EKG assessed standard clinical technique admission BSU Day prior administration study medication baseline L THP safety tolerability analyses EKG performed hours initial L THP dose Day Pulse blood pressure measured periodically waking hours night duration residential stay Clinical laboratory tests complete blood count CBC thyroid stimulating hormone TSH blood chemistry panel performed admission BSU morning fasting next three days Days 2Ð4 On morning Day prior last dose L THP initiation cocaine challenge vital signs EKG assessed determine baseline values cocaine safety Ninety minutes L THP placebo administration participant self administered cocaine insufflation presence Advanced Cardiac Life Support ACLS certified physician nurse Heart rate EKG chest lead continuously monitored approximately minutes hours cocaine dosing values returned within baseline values whichever later Blood pressure heart rate monitored approximately every minutes minutes prior cocaine dosing hours dosing every minutes hours every hours hours 12 lead EKGs completed immediately following cocaine administration hours post administration Clinical laboratory tests performed follow Day Sample size power For Phase I study sample size determined need adequate power detect potential drug drug interaction cocaine L THP would dangerously elevate acute cardiovascular heart rate and or blood pressure response cocaine administration determined consultation FDA serious safety question posed use L THP cocaine using participants Had randomized participants completed study would power 0 80 detect standard deviation increase peak change HR SBP DBP tested two sided alpha 0 05 participants completing exposure cocaine plus l THP placebo power 0 80 detect standard deviation increase measures Data Analysis Baseline Characteristics Safety Tolerability Data Baseline participant characteristics Table two medication groups compared Wilcoxon test categorical variables t test quantitative variables The primary between group comparison cardiovascular laboratory tests SCL 90R ESS variables peak change baseline subject adjusted baseline value using ANCOVA Baseline defined morning admission Day prior first dose L THP placebo The endpoint safety tolerability data evening Day completers last measurement withdrawal Between group comparisons movement assessments side effects based proportion participants group showing increase severity baseline using Fishers exact test For BAS increase considered least 2 point increase baseline least 1 point increase higher baseline For SAS increase considered least 2 point increase total score For Day safety data relating cocaine administration used morning values prior L THP administration baseline calculated maximal change baseline compared peak change medication groups using StudentÕs test\n"
     ]
    }
   ],
   "source": [
    "#remove stopword in \"Methods section\" text files:    \n",
    "import nltk\n",
    "import re\n",
    "nltk.download('stopwords')\n",
    "from nltk.corpus import stopwords \n",
    "from nltk.tokenize import word_tokenize \n",
    "#word_tokenize accepts a string as an input, not a file. \n",
    "stop_words = set(stopwords.words('english')) \n",
    "\n",
    "import pandas as pd\n",
    "newdata = pd.read_csv(\"/Users/phuong/Downloads/NewData_Metadata.csv\",encoding='latin-1')\n",
    "\n",
    "methods_section = newdata[\"Methods_Section\"]\n",
    "filtered_methods_section = []\n",
    "\n",
    "for methods in methods_section:\n",
    "    filtered_methods = []\n",
    "    methods = methods.replace(\"- \",\"\")\n",
    "    methods = re.sub(' +', ' ',methods)\n",
    "    words = methods.split() \n",
    "    for word in words:\n",
    "        word = re.sub(r'\\W+', ' ', word)\n",
    "        word = word.lstrip()\n",
    "        word = word.rstrip()\n",
    "        if not word in stop_words: \n",
    "            if not re.match(\"^[0-9 ]+$\", word):\n",
    "                filtered_methods.append(word)\n",
    "    filtered_methods = ' '.join(filtered_methods)\n",
    "    print (filtered_methods)\n",
    "    filtered_methods_section.append(filtered_methods)\n",
    "\n",
    "newdata['Filtered_Methods_Section'] = filtered_methods_section \n",
    "\n",
    "newdata.to_csv(\"/Users/phuong/Downloads/NewData_Metadata_Filtered.csv\")\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
